Substituted pyrazoles as p38 kinase inhibitors

ABSTRACT

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R 1 , R 2 , R 3  and R 4  are as described in the specification.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. patent application Ser. No. 09/513,351 (filed Feb. 24, 2000), which, in turn, claims priority to both International Patent Application PCT/US99/26007 (filed on Nov. 17, 1999, and published as International Publication No. WO 00/31063) and U.S. patent application Ser. No. 09/196,623 (filed Nov. 20, 1998). International Patent Application PCT/US99/26007 claims priority to U.S. patent application Ser. No. 09/196,623. U.S. patent application Ser. No. 09/196,623 is a CIP of U.S. patent application Ser. No. 09/083,670 (filed May 22, 1998), which, in turn, claims priority to U.S. Provisional Patent Application No. 60/047,570 (filed May 22, 1997). The text of each of the above-referenced applications is incorporated by reference.

FIELD OF THE INVENTION

This invention relates to a novel group of pyrazole compounds, compositions and methods for treating p38 kinase mediated disorders.

BACKGROUND OF THE INVENTION

Mitogen-activated protein kinases (MAP) is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines. The p38 MAP kinase group is a MAP family of various isoforms, including p38α, p38β and p38γ, and is responsible for phosphorylating and activating transcription factors (e.g. ATF2, CHOP and MEF2C) as well as other kinases (e.g. MAPKAP-2 and MAPKAP-3). The p38 isoforms are activated by bacterial lipopolysaccharide, physical and chemical stress and by pro-inflammatory cytokines, including tumor necrosis factor (TNF-α) and interleukin-1 (IL-1). The products of the p38 phosphorylation mediate the production of inflammatory cytokines, including TNF and IL-1, and cyclooxygenase-2.

TNF-α is a cytokine produced primarily by activated monocytes and macrophages. Excessive or unregulated TNF production has been implicated in mediating a number of diseases. Recent studies indicate that TNF has a causative role in the pathogenesis of rheumatoid arthritis. Additional studies demonstrate that inhibition of TNF has broad application in the treatment of inflammation, inflammatory bowel disease, multiple sclerosis and asthma.

TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.

IL-8 is another pro-inflammatory cytokine, which is produced by mononuclear cells, fibroblasts, endothelial cells, and keratinocytes, and is associated with conditions including inflammation.

IL-1 is produced by activated monocytes and macrophages and is involved in the inflammatory response. IL-1 plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.

TNF, IL-1 and IL-8 affect a wide variety of cells and tissues and are important inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines by inhibition of the p38 kinase is of benefit in controlling, reducing and alleviating many of these disease states.

Various pyrazoles have previously been described. U.S. Pat. No. 4,000,281, to Beiler and Binon, describes 4,5-aryl/heteroaryl substituted pyrazoles with antiviral activity against both RNA and DNA viruses such as myxoviruses, adenoviruses, rhinoviruses, and various viruses of the herpes group. WO 92/19615, published Nov. 12, 1992, describes pyrazoles as novel fungicides. U.S. Pat. No. 3,984,431, to Cueremy and Renault, describes derivatives of pyrazole-5-acetic acid as having anti-inflammatory activity. Specifically, [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid is described. U.S. Pat. No. 3,245,093 to Hinsgen et al, describes a process for preparing pyrazoles. WO 83/00330, published Feb. 3, 1983, describes a new process for the preparation of diphenyl-3,4-methyl-5-pyrazole derivatives. WO 95/06036, published Mar. 2, 1995, describes a process for preparing pyrazole derivatives. U.S. Pat. No. 5,589,439, to T. Goto, et al., describes tetrazole derivatives and their use as herbicides. EP 515,041 describes pyrimidyl substituted pyrazole derivatives as novel agricultural fungicides. Japanese Patent 4,145,081 describes pyrazolecarboxylic acid derivatives as herbicides. Japanese Patent 5,345,772 describes novel pyrazole derivatives as inhibiting acetylcholinesterase.

Pyrazoles have been described for use in the treatment of inflammation. Japanese Patent 5,017,470 describes synthesis of pyrazole derivatives as anti-inflammatory, anti-rheumatic, anti-bacterial and anti-viral drugs. EP 115640, published Dec. 30, 1983, describes 4-imidazolyl-pyrazole derivatives as inhibitors of thromboxane synthesis. 3-(4-Isopropyl-1-methylcyclohex-1-yl)-4-(imidazol-1-yl)-1H-pyrazole is specifically described. WO 97/01551, published Jan. 16, 1997, describes pyrazole compounds as adenosine antagonists. 4-(3-Oxo-2,3-dihydropyridazin-6-yl)-3-phenylpyrazole is specifically described. U.S. Pat. No. 5,134,142, to Matsuo et al. describes 1,5-diaryl pyrazoles as having anti-inflammatory activity.

U.S. Pat. No. 5,559,137 to Adams et al, describes novel pyrazoles (1,3,4-substituted) as inhibitors of cytokines used in the treatment of cytokine diseases. Specifically, 3-(4-fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole is described. WO 96/03385, published Feb. 8, 1996, describes 3,4-substituted pyrazoles, as having anti-inflammatory activity. Specifically, 3-methylsulfonylphenyl-4-aryl-pyrazoles and 3-aminosulfonylphenyl-4-aryl-pyrazoles are described.

Laszlo et al., Bioorg. Med. Chem. Letters, 8 (1998) 2689-2694, describes certain furans, pyrroles and pyrazolones, particularly 3-pyridyl-2,5-diaryl-pyrroles, as inhibitors of p38 kinase.

The invention's pyrazolyl compounds are found to show usefulness as p38 kinase inhibitors.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows Scheme B-1, which illustrates the parallel array reaction blocks that were utilized to prepare compounds of Examples B-0001 through B-1574.

FIG. 2 shows Scheme B-3, which illustrates the modular robotics laboratory environment that was utilized to prepare compounds of Examples B0001 through B-1574.

DESCRIPTION OF THE INVENTION

A class of substituted pyrazolyl compounds useful in treating p38 mediated disorders is defined by Formula IA:

wherein

R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbbnylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl)carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

-   —(CR²⁰²R²⁰³)_(y)—; -   —C(O)—; -   —C(O)—(CH₂)_(y)—; -   —C(O)—O—(CH₂)_(y)—; -   —(CH₂)_(y)—C(O)—; -   —O—(CH₂)_(y)—C(O)—; -   —NR²⁰²—; -   —NR²⁰²—(CH₂)_(y)—; -   —(CH₂)_(y)—NR²⁰²—; -   —(CH₂)_(y)—NR²⁰²—(CH₂)_(z)—; -   —(CH₂)_(y)—C(O)—NR²⁰²—(CH₂)_(z)—; -   —(CH₂)_(y)—NR²⁰²—C(O)—(CH₂)_(z)—; -   —(CH₂)_(y)—NR²⁰²—C(O)—NR²⁰³—(CH₂)_(z)—; -   —S(O)_(x)—(CR²⁰²R²⁰³)_(y)—; -   —(CR²⁰²R²⁰³)_(y)—S(O)_(x)—; -   —S(O)_(x)—(CR²⁰²R²⁰³)_(y)—O—; -   —S(O)_(x)—(CR²⁰²R²⁰³)_(y)—C(O)—; -   —O—(CH₂)_(y)—; -   —(CH₂)_(y)—O—; -   —S—; -   —O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkoxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, or alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R² is —NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R² is —C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl, aryl and aralkyl; or

R² has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is —CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; and

further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and

further provided that R⁴ is not methylsulfonylphenyl or aminosulfonylphenyl; and

further provided that R¹ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

In a subclass of interest, R² is as defined above, and

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

In the various embodiments of the present invention, the novel compounds generically disclosed herein preferably do not include those substituted pyrazoles disclosed in WO98/52940 published on Nov. 26, 1998.

A subclass of compounds useful in treating p38 mediated disorders is defined by Formula I:

wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl)carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is —CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,

wherein R⁴³ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of any disorder or disease state in a human, or other mammal, which is excacerbated or caused by excessive or unregulated TNF or p38 kinase production by such mammal. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula I and/or 1A or a pharmaceutically acceptable salt thereof.

Compounds of Formula I and/or IA would be useful for, but not limited to, the treatment of inflammation in a subject, as an analgesic in the treatment of pain including but not limited to neuropathic pain, and for use as antipyretics for the treatment of fever. Compounds of the invention would be useful to treat arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, gouty arthritis and other arthritic conditions. Such compounds would be useful for the treatment of pulmonary disorders or lung inflammation, including adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, and chronic pulmonary inflammatory disease. The compounds are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC(AIDS related complex), pneumonia, and herpesvirus. The compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs. host reaction and allograft rejections, cardiovascular diseases including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure, and cardiac reperfusion injury, renal reperfusion injury, liver disease and nephritis, and myalgias due to infection.

The compounds are also useful for the treatment of influenza, multiple sclerosis, leukemia, lymphoma, diabetes, systemic lupus erthrematosis (SLE), neuroinflammation, ischemia including stroke and brain ischemia, brain trauma, brain edema, skin-related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, scar tissue formation, and angiogenic disorders. Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis. The compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue. Compounds of the invention also would be useful for treatment of angiogenesis, including neoplasia; metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemaginomas, including invantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone; diabetic nephropathy and cardiomyopathy; and disorders of the female reproductive system such as endometriosis. The compounds of the invention may also be useful for preventing the production of cyclooxygenase-2.

Compounds of the invention would be useful for the prevention or treatment of benign and malignant tumors/neoplasia including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamus cell and basal cell cancers, prostate cancer, renal cell carcimoma, and other known cancers that affect epithelial cells throughout the body.

The compounds of the invention also would be useful for the treatment of certain central nervous system disorders such as Alzheimer's disease and Parkinson's disease.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, DMARD's, immunosuppressive agents, NSAIDs, 5-lipoxygenase inhibitors, LTB₄ antagonists and LTA₄ hydrolase inhibitors.

As used herein, the term “TNF mediated disorder” refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.

As used herein, the term “p38 mediated disorder” refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.

As TNF-β has close structural homology with TNF-α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as “TNF” unless specifically delineated otherwise.

A preferred class of compounds consists of those compounds of Formula I wherein

R¹ is selected from hydrido, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower heterocyclyl, lower cycloalkylalkylene, lower haloalkyl, lower hydroxyalkyl, lower aralkyl, lower alkoxyalkyl, lower mercaptoalkyl, lower alkylthioalkylene, amino, lower alkylamino, lower arylamino, lower alkylaminoalkylene, and lower heterocyclylalkylene; or

R¹ has the formula

wherein:

i is 0, 1 or 2; and

R²⁵ is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclylalkyl, lower alkoxyalkylene, lower phenoxyalkylene, lower aminoalkyl, lower alkylaminoalkyl, lower phenoxyaminoalkyl, lower alkylcarbonylalkylene, lower phenoxycarbonylalkylene, and lower heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxycarbonylalkylene, and lower alkylaminoalkyl; and

R²⁷ is selected from lower alkyl, lower cycloalkyl, lower alkynyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower cycloalkylalkylene, lower cycloalkenylalkylene, lower cycloalkylarylene, lower cycloalkylcycloalkyl, lower heterocyclylalkylene, lower alkylphenylene, lower alkylphenylalkyl, lower phenylalkylphenylene, lower alkylheterocyclyl, lower alkylheterocyclylalkylene, lower alkylheterocyclylphenylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl, lower alkoxyheterocyclyl, lower alkoxyalkoxyphenylene, lower phenoxyphenylene, lower phenylalkoxyphenylene, lower alkoxyheterocyclylalkylene, lower phenoxyalkoxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylheterocyclyl, lower alkoxycarbonylheterocyclylcarbonylalkylene, lower aminoalkyl, lower alkylaminoalkylene, lower phenylaminocarbonylalkylene, lower alkoxyphenylaminocarbonylalkylene, lower aminocarbonylalkylene, arylaminocarbonylalkylene, lower alkylaminocarbonylalkylene, lower phenylcarbonylalkylene, lower alkoxycarbonylphenylene, lower phenoxycarbonylphenylene, lower alkylphenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylphenylcarbonylphenylene, lower alkoxycarbonylheterocyclylphenylene, lower alkoxycarbonylalkoxylphenylene, lower heterocyclylcarbonylalkylphenylene, lower alkylthioalkylene, cycloalkylthioalkylene, lower alkylthiophenylene, lower phenylalkylthiophenylene, lower heterocyclylthiophenylene, lower phenylthioalklylphenylene, lower phenylsulfonylaminoalkylene, lower alkylsulfonylphenylene, lower alkylaminosulfonylphenylene; wherein said lower alkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower heterocyclylalkylene, lower alkylheterocyclylphenylene, lower alkoxyphenylene, lower phenoxyphenylene, lower phenylaminocarbonylalkylene, lower phenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylthiophenylene, lower heterocyclylthiophenylene, lower phenylthioalklylphenylene, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR⁴⁶R⁴⁷ wherein R⁴⁶ is lower alkoxycarbonyl, and R⁴⁷ is selected from lower phenylalkyl, lower phenylalkoxyalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower alkoxycarbonylalkylene, lower alkylthioalkylene, and lower phenylalkylthioalkylene; wherein said phenylalkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from lower alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, heterocyclyl, heterocyclylalkylene, lower alkylheterocyclylalkylene, lower phenoxyalkylene, lower alkoxyphenylene, lower alkylphenoxyalkylene, lower alkylcarbonyl, lower alkoxycarbonyl, lower phenylalkoxycarbonyl, lower alkylamino and lower alkoxycarbonylamino; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclylalkylene and lower phenoxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, lower alkyl and lower alkoxy; and

R² is selected from hydrido, halogen, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, lower haloalkyl, lower hydroxyalkyl, 5- or 6-membered heterocyclyl, lower alkylheterocyclyl, lower heterocyclylalkyl, lower alkylamino, lower alkynylamino, phenylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkylaminoalkylamino, lower cycloalkyl, lower alkenyl, lower alkoxycarbonylalkyl, lower cycloalkenyl, lower carboxyalkylamino, lower alkoxycarbonyl, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, lower alkoxycarbonylheterocyclylcarbonyl, alkoxycarbonylalkyl, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylsulfonyl, lower heterocyclyloxy, and lower heterocyclylthio; wherein the aryl, heterocylyl, heterocyclylalkyl, cycloalkyl, and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, lower alkynyl, phenyl, 5- or 6-membered heterocyclyl, lower phenylalkyl, lower heterocyclylalkyl, lower epoxyalkyl, carboxy, lower alkoxy, lower aryloxy, lower phenylalkoxy, lower haloalkyl, lower alkylamino, lower alkylaminoalkylamino, lower alkynylamino, lower amino(hydroxyalkyl), lower heterocyclylalkylamino, lower alkylcarbonyl, lower alkoxycarbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, and phenylsulfonyl; or

R² has the formula:

wherein:

j is 0, 1 or 2; and

m is 0;

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵ is selected from alkyl, cycloalkyl, haloalkyl, alkenyl, aryl, heterocyclyl, aralkyl, arylcycloalkyl, cycloalkenylalkylene, heterocyclylalkylene, alkylarylene, alkylheterocyclyl, arylarylene, arylheterocyclyl, alkoxy, alkenoxy, alkoxyalkylene, alkoxyaralkyl, alkoxyarylene, aryloxyalkylene, aralkoxyalkylene, cycloalkyloxyalkylene, alkoxycarbonyl, heterocyclylcarbonyl, alkylcarbonyloxyalkylene, alkylcarbonyloxyarylene, alkoxycarbonylalkylene, alkoxycarbonylarylene, aralkoxycarbonylheterocyclyl, alkylcarbonylheterocyclyl, arylcarbonyloxyalkylarylene, and alkylthioalkylene; wherein said aryl, heterocyclyl, aralkyl, alkylarylene, arylheterocyclyl, alkoxyarylene, aryloxyalkylene, cycloalkoxyalkylene, alkoxycarbonylalkylene, and alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

R³⁵ is CHR⁴⁸R⁴⁹ wherein R⁴⁸ is arylsulfonylamino or alkylarylsulfonylamino, and R⁴⁹ is selected from aralkyl, amino, alkylamino, and aralkylamino; or

R³⁵ is —NR⁵⁰R⁵¹ wherein R⁵⁰ is alkyl, and R⁵¹ is aryl; and

wherein R³⁶ is selected from alkyl, haloalkyl, aryl, heterocyclyl, cycloalkylalkylene, alkylarylene, alkenylarylene, arylarylene, aralkyl, aralkenyl, heterocyclylheterocyclyl, carboxyarylene, alkoxyarylene, alkoxycarbonylarylene, alkylcarbonylaminoarylene, alkylcarbonylaminoheterocyclyl, arylcarbonylaminoalkylheterocyclyl, alkylaminoarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, alkylsulfonylaralkyl, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, cycloalkylalkylene, aralkyl, alkylcarbonylaminoheterocyclyl, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷ is selected from hydrogen and alkyl; and

wherein R³⁸ is selected from hydrogen, alkyl, alkenyl, aryl, heterocyclyl, aralkyl, alkylarylene, arylcycloalkyl, arylarylene, cycloalkylalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, aryloxyarylene, arylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkylene, alkoxycarbonylarylene, alkylcarbonylcarbonylalkylene, alkylaminoalkylene, alkylaminoaralkyl, alkylcarbonylaminoalkylene, alkylthioarylene, alkylsulfonylaralkyl, and aminosulfonylaralkyl; wherein said aryl, heterocyclyl, aralkyl, and heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

R³⁸ is —CR⁵²R⁵³ wherein R⁵² is alkoxycarbonyl, and R⁵³ is alkylthioalkylene; or

R³⁷ and R³⁸ together with the nitrogen atom to which they are attached form a heterocycle; and

R³⁹ and R⁴⁰ have the same definition as R²⁶ and R²⁷ in claim 1; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; or

R² is selected from the group consisting of

wherein

k is an integer from 0 to 3; and

R⁵⁶ is hydrogen or lower alkyl; and

R⁵⁷ is hydrogen or lower alkyl; or

R⁵⁶ and R⁵⁷ form a lower alkylene bridge; and

R⁵⁸ is selected from hydrogen, alkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, alkoxycarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, —C(O)R⁵⁹, —SO₂R⁶⁰, and —C(O)NHR⁶¹;

wherein R⁵⁹ is selected from alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, alkylarylene, aralkyl, alkylheterocyclyl, alkoxy, alkenoxy, aralkoxy, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰ is selected from alkyl, aryl, heterocyclyl, alkylarylene, alkylheterocyclyl, aralkyl, heterocyclylheterocyclyl, alkoxyarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶¹ is selected from alkyl, aryl, alkylarylene, and alkoxyarylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, and

wherein R⁴³ is selected from hydrogen, lower alkyl, lower aminoalkyl, lower alkoxyalkyl, lower alkenoxyalkyl and lower aryloxyalkyl; and

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, aminosulfonyl, halo, lower alkyl, lower aralkyl, lower phenylalkenyl, lower phenylheterocyclyl, carboxy, lower alkylsulfinyl, cyano, lower alkoxycarbonyl, aminocarbonyl, lower alkylcarbonylamino, lower haloalkyl, hydroxy, lower alkoxy, amino, lower cycloalkylamino, lower alkylamino, lower alkenylamino, lower alkynylamino, lower aminoalkyl, arylamino, lower aralkylamino, nitro, halosulfonyl, lower alkylcarbonyl, lower alkoxycarbonylamino, lower alkoxyphenylalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylheterocyclylamino, lower alkylaminocarbonyl, lower alkoxyphenylalkylamino, hydrazinyl, lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; and

R⁴ is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, aryl selected from phenyl, biphenyl, and naphthyl, and 5- or 6-membered heterocyclyl; wherein the lower cycloalkyl, lower cycloalkenyl, aryl and 5-10 membered heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, halo, lower alkyl, lower alkynyl, lower alkoxy, lower aryloxy, lower aralkoxy, lower heterocyclyl, lower haloalkyl, amino, cyano, nitro, lower alkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of particular interest consists of these compounds of Formula I wherein

R¹ is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R² is selected from hydrido, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-n-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, piperadinylamino, N-benzylamino, N-propargylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, N,N-dimethylaminoethylamino, N,N-dimethylaminopropylamino, morpholinylethylamino, morpholinylpropylamino, carboxymethylamino, methoxyethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 1,1-dimethylethoxycarbonyl, 1,1-dimethylethoxycarbonylaminoethylamino, 1,1-dimethylethoxycarbonylaminopropylamino, piperazinylcarbonyl, and 1,1-dimethylethoxycarbonylpiperazinylcarbonyl; wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, isopropyl, tert-butyl, isobutyl, benzyl, carboxy, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, dimethylamino, methoxycarbonyl, ethoxycarbonyl, and 1,1-dimethylethylcarbonyl; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R³ is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylcarbonylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethenyl, chlorophenylethenyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy, methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbonyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, ethylaminocarbonyl, methylcarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methyl-hydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl, ethyl or phenylmethyl; and

R⁴ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of particular interest consists of these compounds of Formula I wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, methoxycarbonylethyl, N,N-dimethylamino, N-phenylamino, piperidinyl, piperazinyl, pyridinyl, N-methylpiperazinyl, and piperazinylamino; wherein the phenyl, piperidinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and trifluoromethyl;

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of specific interest consists of those compounds of Formula I wherein

R¹ is hydrido or methyl;

R² is selected from hydrido, methyl or ethyl;

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R⁴ is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein

R¹ is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloroethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R² has the formula:

wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰ and R³¹ are independently selected from hydrogen and lower alkyl;

R³² is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclylalkyl, lower alkoxyalkylene, aryloxyalkylene, aminoalkyl, lower alkylaminoalkyl, lower phenylaminoalkyl, lower alkylcarbonylalkylene, lower phenylcarbonylalkylene, and lower heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, lower alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵ is selected from lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower phenylcycloalkyl, lower cycloalkenylalkylene, lower heterocyclylalkylene, lower alkylphenylene, lower alkylheterocyclyl, phenylphenylene, lower phenylheterocyclyl, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower alkoxyphenylalkyl, lower alkoxyphenylene, lower phenoxyalkylene, lower phenylalkoxyalkylene, lower cycloalkyloxyalkylene, lower alkoxycarbonyl, lower heterocyclylcarbonyl, lower alkylcarbonyloxyalkylene, lower alkylcarbonyloxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower phenylalkoxycarbonylheterocyclyl, lower alkylcarbonylheterocyclyl, lower phenylcarbonyloxyalkylphenylene, and lower alkylthioalkylene; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylheterocyclyl, lower alkoxyphenylene, lower phenoxyalkylene, lower cycloalkoxyalkylene, lower alkoxycarbonylalkylene, and lower alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R³⁵ is CHR⁴⁸R⁴⁹ wherein R⁴⁸ is phenylsulfonylamino or lower alkylphenylsulfonylamino, and R⁴⁹ is selected from lower phenylalkyl, amino, lower alkylamino, and lower phenylalkylamino; or

R³⁵ is —NR⁵⁰R⁵¹ wherein R⁵⁰ is lower alkyl, and R⁵¹ is aryl selected from phenyl, biphenyl and naphthyl; and

wherein R³⁶ is selected from lower alkyl, lower haloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower alkylphenylene, lower alkenylphenylene, phenylphenylene, lower phenylalkyl, lower phenylalkenyl, lower heterocyclylheterocyclyl, carboxyphenylene, lower alkoxyphenylene, lower alkoxycarbonylphenylene, lower alkylcarbonylaminophenylene, lower alkylcarbonylaminoheterocyclyl, lower phenylcarbonylaminoalkylheterocyclyl, lower alkylaminophenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonylphenylene, lower alkylsulfonylphenylalkyl, and lower phenylsulfonylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkylcarbonylaminoheterocyclyl, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷ is selected from hydrogen and lower alkyl; and

wherein R³⁸ is selected from hydrogen, lower alkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylcycloalkyl, phenylphenylene, lower cycloalkylalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower phenoxyphenylene, phenylcarbonyl, lower alkoxycarbonyl, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower alkylcarbonylcarbonylalkylene, lower alkylaminoalkylene, lower alkylaminophenylalkyl, lower alkylcarbonylaminoalkylene, lower alkylthiophenylene, lower alkylsulfonylphenylalkyl, and lower aminosulfonylphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, and lower heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R³⁸ is —CR⁵²R⁵³ wherein R₅₂ is lower alkoxycarbonyl, and R₅₃ is lower alkylthioalkylene; or

R³⁷ and R³⁸ together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle;

R³⁹ and R⁴⁰ have the same definition as R²⁶ and R²⁷ in claim 2; or

R² is selected from the group consisting of

wherein

k is an integer from 0 to 2; and

R⁵⁶ is hydrogen or lower alkyl; and

R⁵⁷ is hydrogen or lower alkyl; and

R⁵⁸ is selected from hydrogen, lower alkyl, lower phenylalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower heterocyclylalkyl, lower alkoxycarbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, lower phenylsulfonyl, —C(O)R⁵⁹, —SO₂R⁶⁰, and —C(O)NHR⁶¹;

wherein R⁵⁹ is selected from lower alkyl, lower haloalkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower alkoxy, lower alkenoxy, lower phenylalkoxy, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰ is selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower alkylheterocyclyl, lower phenylalkyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonylphenylene, and lower phenylsulfonylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶¹ is selected from lower alkyl, aryl selected from phenyl, biphenyl and napthyl, lower alkylphenylene, and lower alkoxyphenylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

R³ is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R³ is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylcarbonylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethenyl, chlorophenylethenyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy, methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbonyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, ethylaminocarbonyl, methylcarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methyl-hydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl, ethyl or phenylmethyl; and

R⁴ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² has the formula:

wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰ is hydrogen; and

R³¹ is selected from hydrogen and lower alkyl; and

R³² is selected from hydrogen and lower alkyl; and

R³³ is selected from lower alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰;

wherein R³⁵ is selected from lower alkyl, lower cycloalkyl, phenyl, lower heterocyclyl, lower alkylphenylene, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower phenoxyalkylene, and lower phenylalkoxyalkylene; wherein said phenyl and lower phenoxyalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, and lower haloalkyl; and

wherein R³⁶ is selected from lower alkyl, phenyl, lower heterocyclyl, lower alkylphenylene, phenylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, and lower alkylamino; wherein said phenyl and lower heterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷ is hydrogen; and

wherein R³⁸ is selected from lower alkyl, phenyl, and lower alkylphenylene;

wherein R³⁹ and R⁴⁰ have the same definition as R²⁶ and R²⁷ in claim 2; or

R² is selected from the group consisting of

wherein

k is an integer from 0 or 1; and

R⁵⁶ is hydrogen; and

R⁵⁷ is hydrogen; and

R⁵⁸ is selected from —C(O)R⁵⁹ and —SO₂R⁶⁰;

wherein R⁵⁹ is selected from lower alkyl, lower cycloalkyl, phenyl, lower alkylphenylene, and lower alkoxyalkylene; wherein said phenyl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R⁶⁰ is selected from lower alkyl; and

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and

R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of specific interest consists of those compounds of Formula I wherein

R¹ is hydrido or methyl; and

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and

R⁴ is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

In one embodiment of the present invention, the compounds of Formula I and/or 1A satisfy one or more of the following conditions:

R¹ is hydrido or lower alkyl; more preferably, R¹ is hydrido or methyl; and still more preferably, R¹ is hydrido;

R² is hydrido or lower alkyl; more preferably, R² is hydrido or methyl; and still more preferably, R² is hydrido;

R² comprises a piperidinyl, piperazinyl or cyclohexyl moiety;

R³ is substituted or unsubstituted pyridinyl; and preferably, the pyridinyl is a 4-pyridinyl; or

R⁴ is substituted or unsubstituted phenyl; and preferably, R⁴ is phenyl substituted with halo.

In addition, where R³ is substituted pyrimidinyl, preferably at least one R³ substitutent is attached to the carbon atom positioned between two nitrogen atoms of the pyrimidinyl ring.

A family of specific compounds of particular interest within Formula I and/or 1A consists of compounds, tautomers and pharmaceutically-acceptable salts thereof as follows:

-   4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-methyl-3-[4-(methylthio)phenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorohpenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-[(1,1′-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine; -   2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol; -   3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol; -   1-hydroxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium; -   5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine; -   4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine; -   4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-methylphenyl)-3-propyl-1H-pyrazol-4-yl]pyridine; -   4-[(3-methyl-5-phenyl-1H-pyrazol-4-yl)methyl]pyridine; -   4-[3,5-bis(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[4-methyl-2-(2-trifluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(2-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-methyl-3-(2,4-dimethylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-fluoro-2-methylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3,5-dimethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3,5-dimethoxyphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl]pyridine; -   N,N-dimethyl-4-[5-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]benzenamine; -   4-[3-(2,3-dihydrobenzofuran-5-yl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-bromophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(2-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine; -   4-(3-ethyl-4-phenyl-1H-pyrazol-4-yl)pyridine; -   4-[5-(3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-ethyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(3,4-difluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-ethoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine; -   4-[3-methyl-5-(3-thienyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(2,4-dichlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   ethyl-3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-5-propanoate; -   4-[3-(4-fluorophenyl)-1-methyl-pyrazol-4-yl]pyridine; -   5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine; -   5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine; -   5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine; -   2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine; -   2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine; -   4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine; -   2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol; -   1-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine; -   5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide; -   4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(1-cyclohexyen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine; -   4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-furyl)-3-methyl-1H-pyrazol-4-yl]pyridine; -   2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate; -   4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide; -   1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone; -   N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine; -   3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxylate; -   4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide; -   1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone; -   3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine; -   N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-3-amine; -   2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine; -   4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine; -   2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine; -   4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine; -   N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine; -   4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole; -   3-methyl-5-phenyl-4-(3-thienyl)-1H-pyrazole; -   4-(3-furyl)-3-methyl-5-phenyl-1H-pyrazole; -   3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole; -   4-(2-furyl)-3-methyl-5-phenyl-1H-pyrazole; -   4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole; -   4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole; -   4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole; -   4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole; -   3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole; -   3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine; -   4-(3-phenyl-1H-pyrazol-4-yl)pyridine; -   2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine; -   4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine; -   4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine; -   5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine     dihydrate; -   5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine; -   5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine     hydrate (2:1); -   5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine     monohydrate; -   1,1-dimethylethyl     4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine     trihydrochloride; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine; -   1,1-dimethylethyl     4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine     trihydrochloride; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine; -   N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine,     trihydrochloride; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine; -   4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine,     dihydrochloride; -   1,1-dimethylethyl     [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate; -   N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine,     trihydrochloride monohydrate; -   1,1-dimethylethyl     [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate; -   1,1-dimethylethyl     4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   1,1-dimethylethyl     4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   1,1-dimethylethyl     [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine; -   4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine; -   4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol; -   3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol; -   4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone; -   1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone; -   Ethyl-2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate; -   2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic     acid; -   3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol; -   4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid; -   5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol; -   1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine; -   1,1-dimethylethyl     4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate; -   4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine; -   4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine; -   4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine; -   3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol; -   3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol; -   4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol; -   4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile; -   4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine; -   3-(4-fluorophenyl)-1-methyl-α-phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine; -   4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide; -   Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid; -   4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine; -   4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine; -   4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   2-methyl-4-[1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   2-methyl-4-[1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine; -   4-(3-phenyl-1H-pyrazol-4-yl)pyridine; -   4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine; -   4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine; -   4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine; -   4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   (E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethenyl)pyridine; -   (S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine; -   4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxy-phenyl)methyl]-2-pyridinamine; -   N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine; -   N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine; -   2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine; -   N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine; -   N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine; -   4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-methylhydrazino)pyridine; -   2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoro-pyridine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine; -   4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methyl-pyridine; -   4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine; -   3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine; -   2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine; -   N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine; -   2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine; -   N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-morpholineethanamine; -   3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine; -   4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine; -   (E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine; -   3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine; -   4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine; -   3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine; -   N-[(4-fluorophenyl)methyl]-4-[3(or     5)-(4-fluorophenyl)-1-[[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperadinyl-2-pyridinamine; -   N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanamine; -   4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine; -   2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol; -   2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol; -   3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-propanol; -   3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine; -   N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine; -   N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine; -   5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol; -   4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl     ester; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine; -   4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine; -   4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine; -   4,4′-(1H-pyrazole-3,4-diyl)bis[pyridine]; -   4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine; -   2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine; -   N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine; -   N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide; -   Ethyl     [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate; -   4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine; -   4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine; -   4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine,     dihydrate; -   methyl-4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate,     monohydrate; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic     acid, dihydrate; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic     acid, monosodium salt dihydrate; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine,     monohydrate; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine,     trihydrochloride monohydrate; -   4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine; -   4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine; -   N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine; -   1-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine,     trihydrochloride; -   N-[5-(4-fluorophenyl)-4-(pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine; -   ethyl     4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate,     monohydrate; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)piperazine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-phenylpiperazine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine; -   1,1-dimethylethyl     [3-[[5-(4-chlorophenyl)-4-(2-[(phenylmethyl)amino]-4-pyridinyl-1H-pyrazol-3-yl]amino]propyl]carbamate; -   1,1-dimethylethyl     4-[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   ethyl     4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate; -   1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone; -   4-[3-(4-fluorophenyl)-5-[(1-methyl-4-piperidinyl)methyl]-1H-pyrazol-4-yl]pyridine; -   1,1-dimethylethyl     4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate; -   1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine; -   1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine; -   4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-3H-pyrazol-3-yl]-4-piperidineamine,     trihydrochloride, monohydrate; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine,     dihydrate; -   1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine; -   1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine; -   1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine; -   1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine; -   1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methylpiperazine; -   1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine; -   4-[5-[4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine; -   5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine; -   5-(4-chlorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine; -   5-(4-fluorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine; -   1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine; -   5-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   5-(4-fluorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine; -   N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine; -   4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine; -   4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine; -   1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperidinol; -   1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl-4-piperidinol; -   4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine; -   4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl[pyrimidine; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic     acid; -   ethyl     4-[5[-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic     acid; -   ethyl     4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide; -   4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic     acid; -   ethyl     4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic     acid; -   ethyl     4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-ethyl-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)-4-piperidinamine; -   1-acetyl-N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(2-propynyl)-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-cyclopropyl-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine; -   N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine; -   ethyl     4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate; -   5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine; -   (βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene     ethanol; -   (βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene     propanol; -   (βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene     ethanol; -   (βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene     propanol; -   N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine; -   N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine; -   N-(1-ethyl-4-piperidinyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine; -   2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol; -   (2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-1-pentanol; -   N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-1,4-pentanediamine; -   (2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol; -   N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine; -   (2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol; -   1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]-2-pyridinamine; -   N,N-diethyl-N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,2-ethanediamine; -   4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl]pyridine,     monohydrochloride; -   8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-dioxa-8-azaspiro[4.5]decane; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinone; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine,     trihydrochloride; -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine,     trihydrochioride; -   4-[3-(4-fluorophenyl)-5-[4-(1-pyrrolidinyl)-1-piperidinyl]-1H-pyrazol-4-yl]pyridine,     trihydrochloride; -   ethyl     4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate; -   1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine; -   1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine; -   4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine; -   N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine; -   4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-methyl-1-piperidinyl)propyl]-2-pyridinamine; -   ethyl     4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate; -   N,N-diethyl-N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine; -   N1,N1-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine; -   N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-1-piperazinepropanamine(2E)-2-butenedioate     (1:1); -   N-(2-[1,4′-bipiperidin]-1′-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine; -   N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N′,N′-trimethyl-1,3-propanediamine; -   N,N,N″-triethyl-N′-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine; -   3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1,2-propanediol; -   trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol; -   4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone;     and -   1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine,     trihydrochloride.

Within Formula I there is another subclass of compounds of high interest represented by Formula IX:

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower heterocycyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R⁴ is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, lower cycloalkyldienyl, 5- or 6-membered heterocyclyl, and aryl selected from phenyl, biphenyl, naphthyl; wherein R⁴ is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R⁵ is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethylethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R⁴ is selected from cyclohexyl, cyclohexenyl, cyclohexadienyl, phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula X:

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R⁴ is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R⁵ is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula X

R¹ is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, piperadinylamino, dimethylaminoethylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, N-methylpiperazinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, propargylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula XI:

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R⁴ is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R⁵ is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula XI

R¹ is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds consists of those compounds of Formula IX wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxycarbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkynylamino, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxycarbonylheterocyclyl, and lower alkoxycarbonylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is —CR⁵⁴R⁵⁵ wherein R⁵⁴ is phenyl and R⁵⁵ is hydroxy; and

R⁴ is phenyl that is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R⁵ is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, iower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of specific interest consists of those compounds of Formula IX wherein

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl;

R² is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

R⁴ is phenyl that is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

R² is selected from hydrido and lower alkyl; and

R⁴ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

R⁵ is selected from hydrido, halo and alkylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Still another class of compounds of specific interest consists of those compounds of Formula IX

wherein;

Z represents a carbon atom; and

R¹ is selected from hydrido, methyl, hydroxyethyl, propargyl; and

R² is hydrido; and

R⁴ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R⁵ is selected from hydrido, fluoro, and 1-methylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A preferred class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom; and

R¹ is selected from hydrido and methyl; and

R² is hydrido; and

R⁴ is selected from phenyl that is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R⁵ is selected from hydrido and fluoro; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula IXA:

wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkynyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkylamino, lower alkynylamino, arylamino, lower aralkylamino, lower heterocyclylalkylamino, lower aminoalkylamino, lower alkylaminoalkylamino, lower hydroxyalkylamino, lower carboxyalkylamino, and lower alkoxyalkylamino, lower alkoxycarbonylaminoalkylamino, wherein the aryl group is optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl, aralkyl, carboxy, lower alkoxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

R² is R²⁰⁰-heterocyclyl-R²⁰¹ or R²⁰⁰-cycloalkyl-²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_(y)—;

—(CH₂)_(y)—NR²⁰²—;

—O—(CH₂)_(y)—;

—(CH₂)_(y)—O—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, aryl, heterocyclyl, lower aralkyl, lower heterocyclylalkylene, lower alkylcarbonyl, lower hydroxyalkylcarbonyl, lower cycloalkylcarbonyl, arylcarbonyl, haloatylcarbonyl, lower alkoxy, lower alkoxyalkylene, lower alkoxyarylene, lower alkoxycarbonyl, lower carboxyalkylcarbonyl, lower alkoxyalkylcarbonyl, lower heterocyclylalkylcarbonyl, lower alkylsulfonyl, lower alkylsulfonylalkylene, amino, lower aminoalkyl, lower alkylamino, lower aralkylamino, lower alkylaminoalkylene, aminocarbonyl, lower alkylcarbonylamino, lower alkylcarbonylaminoalkylene, lower alkylaminoalkylcarbonyl, lower alkylaminoalkylcarbonylamino, lower aminoalkylcarbonylaminoalkyl, lower alkoxycarbonylamino, lower alkoxyalkylcarbonylamino, lower alkoxycarbonylamincalkylene, lower alkylimidocarbonyl, amidino, lower alkylamidino, lower aralkylamidino, guanidino, lower guanidinoalkylene, and lower ilkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, lower alkyl, aryl and lower aralkyl; and

y is 0, 1, 2 or 3; and

R⁴ is selected from aryl selected from phenyl, biphenyl, naphthyl, wherein said aryl is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, and hydroxy; and

R⁵ is selected from hydrido, halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower hydroxyalkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower hydroxycycloalkylamino, lower alkoxycarbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

When the substituent at the 4-position of the pyrazole ring is a substituted pyridinyl, at least one of the substituents preferably is attached to a ring carbon atom adjacent the nitrogen heteroatom of the pyridine ring. When the substituent at the 4-position of the pyrazole ring is a substituted pyrimidinyl, at least one of the substituents preferably is attached to the carbon ring atom-between the nitrogen heteroatoms of the pyrimidine ring. When R² comprises a substituted piperidinyl or piperazinyl moiety, at least one of the substituents preferably is attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine or piperazine ring.

A subclass of compounds of specific interest consists of those compounds of Formula IXA wherein;

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-butylamino, N-propargylamino, N-phenylamino, N-benzylamino, aminoethylamino, aminopropylamino, aminobutylamino, methylaminoethylamino, dimethylaminoethylamino, ethylaminoethylamino, diethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, piperidinylmethylamino, piperidinylethylamino, piperidinylpropylamino, piperazinylmethylamino, piperazinylethylamino, piperazinylpropylamino, carboxymethylamino, carboxyethylamino, methoxyethylamino, ethoxyethylamino, ethoxymethylamino, (1,1-dimethyl)ethylcarbonylaminopropylamino, and (1,1-dimethyl)ethylcarbonylaminoethylamino, wherein the phenyl, morpholinyl, piperidinyl, and piperazinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, ethyoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R² is R²⁰⁰-piperidinyl-R²⁰¹, R²⁰⁰-piperazinyl-R²⁰¹, or R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, iodo, hydroxy, methyl, ethyl, propyl, benzyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, ethylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or —NR⁶²R⁶³ wherein R⁶² is methylcarbonyl or amino, and R⁶³ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:

wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-butylamino, N-propargylamino, N-phenylamino, N-benzylamino, aminoethylamino, aminopropylamino, aminobutylamino, methylaminoethylamino, dimethylaminoethylamino, ethylaminoethylamino, diethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, piperidinylmethylamino, piperidinylethylamino, piperidinylpropylamino, piperazinylmethylamino, piperazinylethylamino, and piperazinylpropylamino, wherein the phenyl, morpholinyl, piperidinyl, and piperazinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, and methoxy; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is selected from hydrido, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, morpholinylpropylamino, wherein the phenyl and morpholinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and methoxy; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:.

R¹ is hydrido; and

R² is selected from hydrido, methylaminopropylamino, dimethylaminopropylamino, ethylaminopropylamino, diethylaminopropylamino, morpholinylmethylamino, morpholinylethylamino, and morpholinylpropylamino; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is selected hydrido; and

R² is selected from hydrido, dimethylaminopropylamino, diethylaminopropylamino, morpholinylethylamino, and morpholinylpropylamino; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula XA:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

R²⁰⁰ selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl) ethyl, chioromethyl, chioroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluororoethyl, fluoropropyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, methylsulfonyl, ethyl sulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, ethoxycarbonylamino, or methylsulfonylamino; and

R²⁰² is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, hydroxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, propoxypropyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, methylsulfonyl, ethylsulfonyl, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, and ethoxycarbonylamino; and

R²⁰² is selected from hydrido, methyl phenyl and benzyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamiho, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-piperidinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, methyl, methoxyethyl, methylcarbonyl, hydroxymethylcarbonyl, methoxymethylcarbonyl, methylsulfonyl, amino, N,N-dimethylamino, and N,N-diethylamino; and

R²⁰² is selected from hydrido and methyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethyl amino; or

a pharmaceutically-accepiable salt or tautomer thereof.

Within Formula IXA there is another subclass of compounds of interest represented by Formula XA:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperazinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl; fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, idimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperazinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethylene, methoxyethylene, ethoxyethylene, methoxyphenylene, ethoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, and methylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-piperazinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethynyl, propynyl, propargyl, phenyl, benzyl, piperidihyl, piperazinyl, and morpholinyl; and

R²⁰² is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy) ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethyl aminobutyl amino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropyl amino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-piperazinyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, methyl, cyclopropyl, propargyl, and benzyl; and

R²⁰² is selected from hydrido and methyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or mrore radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, and diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA there is another subclass of compounds of interest represented by Formula XA:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, iodo, hydroxy, carboxy, keto, methyl, ethyl, propyl, butyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, propargyl, butynyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, butoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, ethoxycarbonylaminomethylene, methylimidocarbonyl, ethylimidocarbonyl, amidino, methylamidino, methylamidino, benzylamidino, guanidino, guanidinomethylene, guanidinoethylene, and methyl sul fonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, propyl, butyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of particular interest consists of those compounds of Formula XA wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, chloro, fluoro, bromo, hydroxy, carboxy, keto, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-dimethyl)ethyl, chloromethyl, chloroethyl, chloropropyl, fluoromethyl, fluoroethyl, fluoropropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, benzyl, piperidinyl, piperazinyl, morpholinyl, piperidinylmethylene, piperazinylmethylene, morpholinylmethylene, methoxy, ethoxy, propoxy, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hyd-oxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonyl, ethylsulfonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylamino -carbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, and ethoxycarbonylaminomethylene; and

R²⁰² and R²⁰³ are independently selected from hydrido, methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and ethoxy; and

R⁵ is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino, methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of specific interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminomethylene, ethylcarbonylaminomethylene, aminomethylcarbonylaminocarbonylmethylene, methoxycarbonylamino, ethoxycarbonylamino, methoxymethylcarbonylamino, methoxyethylcarbonylamino, ethoxymethylcarbonylamino, ethoxyethylcarbonylamino, methoxycarbonylaminomethylene, and ethoxycarbonylaminomethylene; and

R²⁰² is selected from hydrido, methyl, phenyl and benzyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, dimethylaminoethylamino, dimethylaminopropylamino, dimethylaminobutylamino, dimethylaminopentylamino, diethylaminoethylamino, diethylaminopropylamino, diethylaminobutylamino, and diethylaminopentylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

A subclass of compounds of high interest consists of those compounds of Formula XA wherein:

R¹ is hydrido; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

methylene;

—NR²⁰²—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of amino, aminomethyl, N,N-dimethylamino, and N-isopropylamino; and

R²⁰² is selected from hydrido and methyl; and

R⁴ is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido; hydroxypropylamino, hydroxycyclohexylamino, and diethylaminoethylamino; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene,. cycloalkenyialkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, . aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthicarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from mercapto, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, N-alkyl-N-alkynyl-amino, aminocarbonylalkylene, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, Ialkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—C(O)—;

—C(O)—(CH₂)_(y)—;

—C(O)—O—(CH₂)_(y)—;

—(CH₂)_(y)—C(O)—;

—O—(CH₂)_(y)—C(O)—;

—NR²⁰²—;

—NR²⁰²(CH₂)_(y)—;

—(CH₂)_(y)—NR²⁰²—;

—(CH₂)_(y)—NR²⁰²—(CH₂)_(z)—;

—(CH₂)_(y)—C(O)—NR²⁰²—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²C(O)—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²—C(O)—NR²⁰³—(CH₂)_(z)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—;

—(CR²⁰²R²⁰³)_(y)—S(O)_(x)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—O—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y—C(O)—;)

—O—(CH₂)_(y)—;

—(CH₂)_(y)—O—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkcxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, or alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R² is —NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R² is —C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl, aryl and aralkyl; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylo ulfinylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkyl ee, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylam nocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—C(O)—;

—C(O)—(CH₂)_(y)—;

—C(O)—O—(CH₂)_(y)—;

—(CH₂)_(y—C(O)—;)

—O—(CH₂)_(y)—C(O)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_(y)—;

—(CH₂)_(y)—NR²⁰²—;

—(CH₂)_(y)—NR²⁰²(CH₂)_(z)—;

—(CH₂)_(y)—C(O)—NR²⁰²—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²—C(O)—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²—C(O)—NR²⁰³—(CH₂)_(z)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—;

—(CR²⁰²R²⁰³)_(y)—S(O)_(x)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—O—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—C(O)—;

—O—(CH₂)_(y)—;

—(CH₂)_(y)—O—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkoxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, or alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6

wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R² is —NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R² is —C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl, aryl and aralkyl; or

R² has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, is aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵,

—C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein

R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is —CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are substituted with one or more radicals independently selected from keto, haloarylamino, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxyarylamino, alkylsulfonylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, alkylheterocyclylalkylamino, heterocyclylheterocyclylalkylamino, and alkoxycarbonylheterocyclylamino; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula IA is another subclass of compounds of interest wherein:

R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydrbxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, mercapto, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy, heterocyclyloxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy, alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl, aralkythio, heterocyclylalkylthio, aminoalkoxy, cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy, alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² is R²⁰⁰-heterocyclyl-R²⁰¹, R²⁰⁰-aryl-R²⁰¹, or R²⁰⁰-cycloalkyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

—(CR²⁰²R²⁰³)_(y)—;

—C(O)—;

—C(O)—(CH₂)_(y)—;

—C(O)—O—(CH₂)_(y)—;

—(CH₂)_(y)—C(O)—;

—O—(CH₂)_(y)—C(O)—;

—NR²⁰²—;

—NR²⁰²—(CH₂)_(y)—;

—(CH₂)_(y)—NR²⁰²—;

—(CH₂)_(y)—NR²⁰²—(CH₂)_(z)—;

—(CH₂)_(y)—C(O)—NR²⁰²—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²—C(O)—(CH₂)_(z)—;

—(CH₂)_(y)—NR²⁰²—C(O)—NR²⁰³—(CH₂)_(z)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—;

—(CR²⁰²R²⁰³)_(y)—S(O)_(x)—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—O—;

—S(O)_(x)—(CR²⁰²R²⁰³)_(y)—C(O)—;

—O—(CH₂)_(y)—;

—(CH₂)_(y)—O—;

—S—;

—O—;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkoxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, or alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido, alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y+z is less than or equal to 6; and

z is 0, 1 or 2; or

R² is —NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R² is —C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl, aryl and aralkyl; or

R² has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, Alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminqalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵,

—C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein

R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is —CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups are optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloarylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided that R³ is other than maleimidyl or pyridonyl having the structures:

respectively, wherein R⁴³ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Another group of compounds of interest consists of compounds of Formula IB:

wherein:

R¹ has the same definition as previously set forth in the description of compounds of Formula IA. In another embodiment, R¹ is selected from hydrido, alkyl, hydroxyalkyl and alkynyl. In still another embodiment, R¹ is hydrido;

R² is selected from at least one of the following four categories:

(1) piperidinyl substituted with one or more substituents selected from hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl, wherein said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl substitutents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or one or more substituents selected from hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl, wherein said hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl substitutents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R² is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl; or one or more substituents selected from optionally substituted hydroxycycloalkyl and hydroxycycloalkylcarbonyl. In still another embodiment, R² is piperidinyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, hydroxyalkenyl, alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl, and hydroxycycloalkylcarbonyl. In still another embodiment, R² is piperidinyl substituted with at least one substituent selected from optionally substituted lower hydroxyalkyl, lower hydroxyalkylcarbonyl and hydroxycycloalkylcarbonyl. In still another embodiment, R² is piperidinyl substituted with 2-hydroxyacetyl, 2-hydroxy-proprionyl, 2-hydroxy-2-methylpropionyl, 2-hydroxy-2-phenylacetyl, 3-hydroxyproprionyl, 2-hydroxy-3-methylbutyryl, 2-hydroxyisocapropyl, 2-hydroxy-3-phenylproprionyl, 2-hydroxy-3-imidazolylproprionyl, 1-hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclohexylacetyl, 3-hydroxy-1-cyclohexylacetyl, 4-hydroxy-1-cyclohexylacetyl, 1-hydroxy-1-cyclopentylacetyl, 2-hydroxy-1-cyclopentylacetyl, 3-hydroxy-1-cyclopentylacetyl, 2-hydroxy-2-cyclohexylacetyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, methoxymethylene, methoxyethylene, methoxypropylene, methoxyisopropylene, ethoxymethylene, ethoxyethylene, ethoxypropylene, and ethoxyisopropylene. In each of the above embodiments, when R² is piperidinyl, the piperidinyl ring may be substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine ring. In each of the above embodiments, the piperidinyl ring may be monosubstituted at the distal nitrogen; and

(2) cyclohexyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, alkylaminoalkylene and cycloalkylamino. In another embodiment, R² is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower alkylaminoalkylene and cycloalkylamino. In still another embodiment, R² is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower dialkylaminoalkylene and cycloalkylamino. In still another embodiment, R² is cyclohexyl substituted with one or more substituents selected from hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, methylaminomethylene, methylaminoethylene, methylaminopropylene, ethylaminomethylene, ethylaminoethylene, ethylaminopropylene, propylaminomethylene, propylaminoethylene, propylaminopropylene, dimethylaminomethylene, dimethylaminoethylene, dimethylaminopropylene, diethylaminomethylene, and di-isobutylamino. In each of the above embodiments, when R² is cyclohexyl, the cyclohexyl ring may be substituted with at least one substituent attached to the 4-position carbon atom of the cyclohexyl ring heteroatom of the piperidine ring. In each of the above embodiments, the cyclohexyl ring may be monosubstituted at the 4-position carbon atom; and

(4) piperidinylamino substituted with one or more alkynyl substituents. In another embodiment, R² is piperidinylamino substituted with optionally substituted lower alkynyl. In still another embodiment, R² is piperidinylamino substituted with optionally substituted ethynyl, propynyl and butynyl. In still another embodiment, R² is piperidinylamino substituted with optionally substituted propargyl. In still another embodiment, R² is 4-propargylpiperidinylamino. In each of the above embodiments, when R² is piperidinylamino, the piperidinyl ring may be substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine ring. In each of the above embodiments, the piperidinyl ring may be monosubstituted at the distal nitrogen; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

groups may be optionally substituted with one or more substituents independently selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R³ is optionally substituted pyridinyl or pyrimidinyl. In still another embodiment, R³ is unsubstituted pyridinyl or pyrimidinyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more substituents independently selected from halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy. In another embodiment, R⁴ is selected from optionally substitutend cycloalkyl, cycloalkenyl, aryl, and heterocyclyl. In still another embodiment, R⁴ is optionally substituted phenyl. In still another embodiment, R⁴ is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo. In still another embodiment, R⁴ is phenyl optionally substituted at the meta or para position with one or more chloro radicals; or

a pharmaceutically-acceptable salt or tautomer thereof. Within each of the above embodiments, R² may be located at the 3-position of the pyrazole ring with R⁴ located at the 5-position of the pyrazole ring. Alternatively, R² may be located at the 5-position of the pyrazole ring with R⁴ located at the 3-position of the pyrazole ring.

Still another group of compounds of interest consists of the compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of:

The term “hydrido” denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (—CH₂—) radical. Where used, either alone or within other terms such as “haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl” and “hydroxyalkyl”, “cyanoalkyl” and “mercaptoalkyl”, the term “alkyl” embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. The term “alkenyl” embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are “lower alkenyl” radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The terms “alkenyl” and “lower alkenyl”, embrace radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations. The term “alkynyl” embraces linear or branched radicals having at least one carbon-carbon triple bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are “lower alkynyl” radicals having two to about six carbon atoms. Examples of alkynyl radicals include propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butynyl and 1-pentynyl. The term “cycloalkyl” embraces saturated carbocyclic radicals having three to about twelve carbon atoms. The term “cycloalkyl” embraces saturated carbocyclic radicals having three to about twelve carbon atoms. More preferred cycloalkyl radicals are “lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “cycloalkylalkylene” embraces alkyl radicals substituted with a cycloalkyl radical. More preferred cycloalkylalkylene radicals are “lower cycloalkylalkylene” which embrace lower alkyl radicals substituted with a lower cycloalkyl radical as defined above. Examples of such radicals include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl. The term “cycloalkenyl” embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. Cycloalkenyl radicals that are partially unsaturated carbocyclic radicals that contain two double bonds (that may or may not be conjugated) can be called “cycloalkyldienyl”. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl and cyclohexenyl. The term “halo” means halogens such as fluorine, chlorine, bromine or iodine. The term “haloalkyl” embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. “Lower haloalkyl” embraces radicals having one to six carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term “hydroxyalkyl” embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are “lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms “alkoxy” and “alkyloxy” embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term “alkoxyalkyl” embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term “aryl” embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkylene, acyl, carboxy, and aralkoxycarbonyl. The term “heterocyclyl” embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called “heterocyclyl”, “heterocycloalkenyl” and “heteroaryl” correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals. The term “heteroaryl” embraces unsaturated heterocyclyl radicals. Examples of heteroaryl radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term “heterocycle” also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said “heterocyclyl group” may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino, alkylthio and alkylamino. The term “heterocyclylalkylene” embraces heterocyclyl-substituted alkyl radicals. More preferred heterocyclylalkylene radicals are “lower heterocyclylalkylene” radicals having one to six carbon atoms and a heterocyclyl radicals. The term “alkylthio” embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are “lower alkylthio” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term “alkylthioalkylene” embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkylene radicals are “lower alkylthioalkylene” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkylene radicals include methylthiomethyl. The term “alkylsulfinyl” embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms, attached to a divalent —S(═O)— radical. More preferred alkylsulfinyl radicals are “lower alkylsulfinyl”, radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term “sulfonyl”, whether used alone or linked to other terms such as “alkylsulfonyl”, “halosulfonyl” denotes a divalent radical, —SO₂—. “Alkylsulfonyl” embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are “lower alkylsulfonyl” radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The “alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The term “halosulfonyl” embraces halo radicals attached to a sulfonyl radical. Examples of such halosulfonyl radicals include chlorosulfonyl, and bromosulfonyl. The terms “sulfamyl”, “aminosulfonyl” and “sulfonamidyl” denote NH₂O₂S—. The term “acyl” denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and radicals formed from succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, mandelic, pantothenic, β-hydroxybutyric, galactaric and galacturonic acids. The term “carbonyl”, whether used alone or with other terms, such as “alkoxycarbonyl”, denotes —(C═O)—. The terms “carboxy” or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, denotes —CO₂H. The term “carboxyalkyl” embraces alkyl radicals substituted with a carboxy radical. More preferred are “lower carboxyalkyl” which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term “alkoxycarbonyl” means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are “lower alkoxycarbonyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term “alkoxycarbonylalkyl” embraces alkyl radicals substituted with a alkoxycarbonyl radical as defined above. More preferred are “lower alkoxycarbonylalkyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonylalkyl radicals include substituted or unsubstituted methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonyl-ethyl and ethoxycarbonylethyl. The term “alkylcarbonyl”, includes radicals having alkyl, hydroxylalkyl, radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl. The term “aralkyl” embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with one or more substituents selected independently from halo, alkyl, alkoxy, halokoalkyl, haloalkoxy, amino and nitro. The terms benzyl and phenylmethyl are interchangeable. The term “heterocyclylalkylene” embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals (also can be called heterocycloalkylalkylene and heterocycloalkenylalkylene correspondingly), such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals (also can be called heteroarylalkylene), such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halokoalkyl and haloalkoxy. The term “aryloxy” embraces aryl radicals attached through an oxygen atom to other radicals. The term “aralkoxy” embraces aralkyl radicals attached through an oxygen atom to other radicals. The term “aminoalkyl” embraces alkyl radicals substituted with amino radicals. More preferred are “lower aminoalkyl” radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like. The term “alkylamino” denotes amino groups which are substituted with one or two alkyl radicals. Preferred are “lower alkylamino” radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N-alkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term “arylamino” denotes amino groups which are substituted with one or two aryl radicals, such as N-phenylamino. The “arylamino” radicals may be further substituted on the aryl ring portion of the radical. The term “aminocarbonyl” denotes an amide group of the formula —C(═O)NH₂. The term “alkylaminocarbonyl” denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are “N-alkylaminocarbonyl” and “N,N-dialkylaminocarbonyl” radicals. More preferred are “lower N-alkylaminocarbonyl” and “lower N,N-dialkylaminocarbonyl” radicals with lower alkyl portions as defined above. The term “alkylcarbonylamino” embraces amino groups which are substituted with one alkylcarbonyl radicals. More preferred alkylcarbonylamino radicals are “lower alkylcarbonylamino” having lower alkylcarbonyl radicals as defined above attached to amino radicals. The term “alkylaminoalkylene” embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical.

The “hydrocarbon” moieties described herein are organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Preferably, these moieties comprise 1 to 20 carbon atoms.

The heterosubstituted hydrocarbon moieties described herein are hydrocarbon moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, sulfur, or a halogen atom. These substituents include lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; ethers; acetals; ketals; esters; heterocyclyl such as furyl or thienyl; alkanoxy; hydroxy; protected hydroxy; acyl; acyloxy; nitro; cyano; amino; and amido.

The additional terms used to describe the substituents of the pyrazole ring and not specifically defined herein are defined in a similar manner to that illustrated in the above definitions. As above, more preferred substituents are those containing “lower” radicals. Unless otherwise defined to contrary, the term “lower” as used in this application means that each alkyl radical of a pyrazole ring substituent comprising one or more alkyl radicals has one to about six carbon atoms; each alkenyl radical of a pyrazole ring substituent comprising one or more alkenyl radicals has two to about six carbon atoms; each alkynyl radical of a pyrazole ring substituent comprising one or more alkynyl radicals has two to about six carbon atoms; each cycloalkyl or cycloalkenyl radical of a pyrazole ring substituent comprising one or more cycloalkyl and/or cycloalkenyl radicals is a 3 to 8 membered ring cycloalkyl or cycloalkenyl radical, respectively; each aryl radical of a pyrazole ring substituent comprising one or more aryl radicals is a monocyclic aryl radical; and each heterocyclyl radical of a pyrazole ring substituent comprising one or more heterocyclyl radicals is a 4-8 membered ring heterocyclyl.

The present invention comprises the tautomeric forms of compounds of Formulae I and IX (as well as the compounds of Formulae (IA and IXA). As illustrated below, the pyrazoles of Formula I and I′ are magnetically and structurally equivalent because of the prototropic tautomeric nature of the hydrogen:

The present invention also comprises compounds of Formula I, IA, IX, IXA, X, XA and XI having one or more asymmetric carbons. It is known to those skilled in the art that those pyrazoles of the present invention having asymmetric carbon atoms may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention. More specifically, the present invention includes enantiomers, diastereomers, racemic mixtures, and other mixtures thereof.

The present invention comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula I and/or IA, or a therapeutically-acceptable salt or tautomer thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention further encompasses substituted pyrazoles that specifically bind to the ATP binding site of p38 kinase. Without being held to a particular theory, applicants hypothesize that these substituted pyrazoles interact with p38 kinase as set forth below. As the substituent at the 3-position of the pyrazole ring approaches the ATP binding site of p38 kinase, a hydrophobic cavity in the p38 kinase forms around the 3-position substitutent at the binding site. This hydrophobic cavity is believed to form as the 3-position substituent binds to a specific peptide sequence of the enzyme. In particular, it is believed to bind to the sidechains of Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄, Leu₁₀₁ and the methyl group of the Thr₁₀₃ sidechain of p38 kinase at the ATP binding site (wherein the numbering scheme corresponds to the numbering scheme conventionally used for ERK-2). Where the 3-position substituent is aryl or heteroaryl, such aryl or heteroaryl may be further substituted. It is hypothesized that such ring substituents may be beneficial in preventing hydroxylation or further metabolism of the ring.

The substituent at the 4-position of the pyrazole ring is one that is a partial mimic of the adenine ring of ATP, although it may be further elaborated. Preferably, it is a planar substituent terminated by a suitable hydrogen bond acceptor functionality. It is hypothesized that this acceptor hydrogen bonds to the backbone N—H of the Met₁₀₆ residue while one edge of this substituent is in contact with bulk solvent.

Substitution at the 5-position of the pyrazole ring is well tolerated and can provide increased potency and selectivity. It is hypothesized that such substituents extend out in the direction of the bulk solvent and that suitable polar functionality placed at its terminus can interact with the sidechain of Asp¹⁰⁹, leading to increased potency and selectivity.

Similarly, substitution on the nitrogen atom at the 1- or 2-position of the pyrazole ring is well tolerated and can provide increased potency. It is hypothesized that a hydrogen substituent attached to one of the ring nitrogen atoms is hydrogen bonded to Asp₁₆₅. Preferably, the nitrogen atom at the 2-position is double bonded to the carbon atom at the 3-position of the pyrazole while the nitrogen atom at the 1-position of the pyrazole is available for substitution with hydrogen or other substituents.

The 5-position substitutent and the 1- or 2-position substituent of the pyrazole can be selected so as to improve the physical characteristics, especially aqueous solubility and drug delivery performance, of the substituted pyrazole. Preferably, however, these substituents each have a molecular weight less than about 360 atomic mass units. More preferably, these substituents each have a molecular weight less than about less than about 250 atomic mass units. Still more preferably, these substituents have a combined molecular weight less than about 360 atomic mass units.

A class of substituted pyrazoles of particular interest consists of those compounds having the formula:

wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with p38 kinase at said ATP binding site of p38 kinase; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality; and

R⁴ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl iring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

In this embodiment of the invention, one or more of R¹, R², R³ and R⁴ preferably are selected from the corresponding groups of the compounds of Formula I and/or IA. More preferably, R³ is an optionally substituted pyridinyl or pyrimidinyl, R⁴ is a halo substituted phenyl, and R¹ and R² have the definitions set forth immediately above.

A class of substituted pyrazoles of particular interest consists of those compounds of Formula XI wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical wherein said radical binds with Lys₅₂, Glu₆₉, Leu₇₃, Ile₈₂, Leu₈₄Leu₁₀₁, and Thr₁₀₃ sidechains at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N—H backbone of Met₁₀₆ of p38 kinase; and

R⁴ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units.

The present invention also comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I and/or IA.

For example, in one embodiment the present invention comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Formula I

wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R¹ has the formula

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxylarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalklylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R²⁷ is —CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocylcyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino (hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, —C(O)R³⁵, —C(O)OR³⁵, —SO₂R³⁶, —C(O)NR³⁷R³⁸, and —SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is —CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,

wherein R⁴³ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl, alkoxycarbonylamino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or —NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein

R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

The present invention also is directed to the use of the compounds of Formula I and/or IA in the preparation of medicaments useful in the treatment and/or prophylaxis of p38 kinase mediated conditions and disorders.

Also included in the family of compounds of Formulae I and/or IA are the pharmaceutically-acceptable salts and prodrugs thereof. The term “pharmaceutically-acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulae I and/or IA may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β-hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I and/or IA include metallic salts and organic salts. More preferred metallic salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metals. Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, tromethamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formulae I and/or IA by reacting, for example, the appropriate acid or base with the compound of Formulae I and/or IA.

The present invention additionally comprises a class of compounds defined by Formula XX:

wherein R³ and R⁴ are as defined for the compounds of Formulae I and/or IA. Also included in the family of compounds of Formula XX are the pharmaceutically-acceptable salts and prodrugs thereof.

The compounds of Formula XX are useful as intermediates in the preparation of the compounds of Formulae I and/or IA. In addition, the compounds of Formula XX themselves have been found to show usefulness as p38 kinase inhibitors. These compounds are useful for the prophylaxis and treatment of the same p38 kinase mediated disorders and conditions as the compounds of formulae I and/or IA. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula XX or a pharmaceutically acceptable salt or prodrug thereof.

The present invention further comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a p38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula XX, or a therapeutically-acceptable salt or prodrug thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The compounds of the invention can be prepared according to the following procedures of Schemes I-XXIX wherein R¹, R², R³, R⁴, R⁵, and Ar¹ are as previously defined for the compounds of Formula I, IX, X and XI except where expressly noted.

Scheme I shows the synthesis of pyrazole 5 by two routes. Condensation of the pyridylmethyl ketone 1 with aldehyde 2 in the presence of a base, such as piperidine, in a solvent, such as toluene or benzene, either in the absence or the presence of acetic acid at reflux, provides the α,β-unsaturated ketone 3. In route 1, ketone 3 is first converted to epoxide 4, such as by treatment with hydrogen peroxide solution at room temperature, in the presence of base such as sodium hydroxide. Treatment of epoxide 4 with hydrazine in ethanol or other suitable solvent at a temperature ranging up to reflux, yields pyrazole 5. In route 2, ketone 3 is condensed directly with tosyl hydrazide in the presence of an acid such as acetic acid, at reflux, to provide pyrazole 5. Alternatively, the intermediate tosyl hydrazone 6 may be isolated, conversion of it to pyrazole 5 is effected by treatment with a base, such as potassium hydroxide, in a suitable solvent, such as ethylene glycol, at a temperature ranging from 25° C. up to 150° C.

Scheme II shows the synthesis of pyrazole 12 of the present invention. The treatment of pyridine derivative 7 with ester 8 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent, such as tetrahydrofuran, gives ketone 9. Treatment of ketone 9 or a hydrohalide salt of ketone 9 with a halogenating agent, such as bromine, N-bromosuccinimide or N-chlorosuccinimide, in suitable solvents, such as acetic acid, methylene chloride, methanol, or combinations thereof, forms the α-halogenated ketone 10 (wherein X is halo). Examples of suitable hydrohalide salts include the hydrochloride and hydrobromide salts. Reaction of haloketone 10 with thiosemicarbazide 11 (where R⁶ and R⁷ can be hydrido, lower alkyl, phenyl, heterocyclyl and the like or where R⁶ and R⁷ form a heterocyclyl ring optionally containing an additional heteroatom) provides pyrazole 12. Examples of suitable solvents for this reaction are ethanol and dimethylformamide. The reaction may be carried out in the presence or absence of base or acid at temperatures ranging from room temperature to 100° C.

Thiosemicarbazides which are not commercially available may be conveniently prepared by one skilled in the art by first reacting an appropriate amine with carbon disulfide in the presence of a base, followed by treatment with an alkylating agent such as methyl iodide. Treatment of the resultant alkyl dithiocarbamate with hydrazine results in the desired thiosemicarbazide. This chemistry is further described in E. Lieber and R. C. Orlowski, J. Org. Chem., Vol. 22, p. 88(1957). An alternative approach is to add hydrazine to appropriately substituted thiocyanates as described by Y. Nomoto et al., Chem. Pharm. Bull., Vol. 39, p. 86 (1991). The Lieber and Nomoto publications are incorporated herein by reference.

Where Compound 12 contains a second derivatizable nitrogen atom, a wide range of substituents may be placed on that atom by methods known to those skilled in the art. For example, in cases where R⁶ and R⁷ together with the nitrogen atom to which they are attached comprise a piperazine ring, the distal nitrogen of that ring may be, for example, (i) methylated by reaction with formic acid and formaldehyde; (ii) propargylated by reaction with propargyl bromide in a suitable solvent such as dimethylformamide in the presence of a suitable base such as potassium carbonate; (iii) acylated or sulfonylated by reaction with a suitable acyl or sulfonyl derivative in pyridine; or (iv) cyclopropanated by reaction with [1(1-ethoxycyclopropyl)oxy]trimethylsilane using sodium cyanoborohydride in the presence of acetic acid.

Additionally, one of the nitrogen atoms of the pyrazole ring optionally may be alkylated by reaction with an alkyl halide, such as propargyl bromide, in the presence of a strong base such as sodium hydride.

Scheme III shows the synthesis of pyrazole 19 in more general form by three routes. In Route 1, ketone 13 is condensed with hydrazine 14 to give the substituted hydrazide 16, which is then reacted with acyl halide or anhydride 17 at low temperature to provide acyl hydrazone 18. Upon heating at a temperature up to 200° C., acyl hydrazone 18 is converted to pyrazole 19. In Route 2, acyl hydrazone 18 is formed directly by reaction of ketone 13 with acyl hydrazide 15, formed by reaction of hydrazine with a carboxylic acid ester, at room temperature. Heating acyl hydrazone 18 as above then provides pyrazole 19. In Route 3, ketone 13 is treated with acyl hydrazide 15 at a suitable temperature, ranging from room temperature to about 200° C., to give pyrazole 19 directly. Alternatively, this condensation may be carried out in an acidic solvent, such as acetic acid, or in a solvent containing acetic acid.

Synthetic Scheme IV describes the preparation of pyrazole 19.

Scheme V shows the two step synthesis of the 3-substituted 4-pyridyl-5-arylpyrazoles 33 of the present invention by cyclization of hydrazone dianions with carboxylates. In step 1, the reaction of substituted pyridylmethyl ketones 31 (prepared, for example, as later described in Scheme IX) with hydrazines in the presence of solvents such as ethanol gives ketohydrazones 32. Examples of suitable hydrazines include, but are not limited to, phenylhydrazine and p-methoxyphenylhydrazine. In step 2, the hydrazones 32 are treated with two equivalents of a base such as sodium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran to generate dianions. This reaction may be carried out at temperatures of about 0° C. or lower. In the same step, the dianions then are condensed with esters such as methyl isonicotinate, methyl cyclopropanecarboxylate, to give the desired pyrazoles 33. It may be necessary to treat the product from this step with a dehydrating agent, such as a mineral acid, to produce the target pyrazole in some instances.

Scheme VI shows an alternative method for synthesizing pyrazoles which are unsubstituted at the 5 position of the ring. In accordance with this method, a heteroarylmethyl ketone 34 is synthesized by first treating a heteroarylmethane with a strong base such as lithium hexamethyldisilazide or lithium diisopropylamide. Examples of suitable heteroarylmethanes are 4-methylpyridine, 4-methylpyrimidine, 2,4-dimethylpyridine, 2-chloro-4-methylpyrimidine, 2-chloro-4-methylpyridine and 2-fluoro-4-methylpyridine. The resulting heteroarylmethyl lithium species is then reacted with a substituted benzoate ester to produce ketone 34. Examples of suitable benzoate esters are methyl and ethyl p-fluorobenzoate and ethyl and methyl p-chlorobenzoate. Ketone 34 is converted to the aminomethylene derivative 35 by reaction with an aminomethylenating agent such as dimethylformamide dimethyl acetal or tert-butoxybis(dimethylamino)methane. Ketone 35 is converted to pyrazole 36 by treatment with hydrazine.

A modification of this synthetic route serves to regioselectively synthesize pyrazole 38 which contains a substituted nitrogen at position 1 of the ring. Ketone 34 is first converted to hydrazone 37 by reaction with the appropriate substituted hydrazine. Examples of suitable hydrazines are N-methylhydrazine and N-(2-hydroxyethyl)hydrazine. Reaction of hydrazone 37 with an aminomethylenating agent produces pyrazole 38. Examples of suitable aminomethylenating agents include dimethylformamide dimethyl acetal and tert-butoxybis(dimethylamino)methane.

In cases where the R³ substituent of pyrazoles 36 and 38 bears a leaving group such as a displaceable halogen, subsequent treatment with an amine produces an amino-substituted heteroaromatic derivative. Examples of such amines include benzylamine, cyclopropylamine and ammonia. The leaving group may also be replaced with other nucleophiles such as mercaptides and alkoxides. Examples of substitutable R³ groups include, but are not limited to, 2-chloropyridinyl and 2-bromopyridinyl groups.

Scheme VII describes the preparation of derivatives from pyrazole 5 (prepared in accordance with Scheme I) when R²=CH₃. Oxidation of pyrazole 5 gives carboxylic acid 39, which is then reduced to hydroxymethyl compound 40, or coupled with amine NR¹⁰R¹¹ (wherein R¹⁰ and R¹¹ are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur) to form amide 41 followed by reduction to generate amine derivative 42.

Scheme VIII illustrates the synthesis of pyrazoles 44 and 45 from pyrazole 43. The alkylation of the ring nitrogen atoms of pyrazole 43 can be accomplished using conventional techniques. Treatment of pyrazole 43 with an appropriate base (for example, sodium hydride) followed by treatment with an alkyl halide (for example, CH₃I) yields a mixture of isomers 44 and 45.

Scheme IX illustrates the synthesis of 3-aryl-4-pyridyl-pyrazoles of the present invention. Benzoate 46 is reacted with pyridine 47 in the presence of a strong base, such as an alkali metal hexamethyldisilazide (preferably sodium hexamethyldisilazide or lithium hexamethyldisilazide), in a suitable solvent, such as tetrahydrofuran, to give desoxybenzoin 48. Desoxybenzoin 48 is then converted to ketone 49 by treatment with an excess of dimethylformamide dimethyl acetal. Ketone 49 is then reacted with hydrazine hydrate in a suitable solvent such as ethanol to yield pyrazole 50. In Scheme IX, R¹² represents one or more radicals independently selected from the optional substituents previously defined for R⁴. Preferably, R¹² is hydrogen, alkyl, halo, trifluoromethyl, methoxy or cyano, or represents methylenedioxy.

The 3-aryl-4-pyrimidinyl-pyrazoles of the present invention can be synthesized in the manner of Scheme IX by replacing pyridine 47 with the corresponding pyrimidine. In a similar manner, Schemes X through XVII can be employed to synthesize 3-aryl-4-pyrimidinyl-pyrimidines corresponding to the 3-aryl-4-pyrimidinyl-pyrazoles shown in those schemes.

Scheme X illustrates one variation of Scheme IX that can be used to synthesize 3-aryl-4-pyridyl-pyrazoles that are further substituted on the nitrogen atom at position 1 of the pyrazole ring. If desoxybenzoin 48 (prepared in accordance with Scheme IX) instead is first converted to hydrazone 51 by treatment with hydrazine and hydrazone 51 is then treated with dimethylformamide dimethyl acetal, then the resulting product is pyrazole 52.

Schemes XI through XVIII illustrate further modifications that can be made to Scheme IX to synthesize other 3-aryl-4-pyridyl-pyrazoles having alternative substituents.

In Scheme XII, X is chloro, fluoro or bromo; R¹³ is, for example, hydrogen, alkyl, phenyl, aralkyl, heteroarylalkyl, amino or alkylamino; and R₂₀ is, for example, hydrogen or alkyl.

In Scheme XV, n is 1, 2, 3, 4 or 5; and R¹⁴ and R¹⁵ are independently selected from, for example, hydrogen, alkyl or aryl, or together with the nitrogen atom to which they are attached form a 4-7 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.

In Scheme XVI, R¹⁶ is selected, for example, from hydrogen, alkyl and phenyl.

In Scheme XVII, R¹⁷ is selected, for example, from alkyl, phenylalkyl and heterocyclylalkyl.

Compounds where in the 2-position of the pyridine ring is substituted by a carboxyl group or a carboxyl derivative may be synthesized according to the procedures outline in Scheme XVIII. The starting pyridyl pyrazole 67 is converted to the 2-cyano derivative 68 by first conversion to its pyridine N-oxide by reaction with an oxidizing agent such as m-chloroperoxybenzoic acid. Treatment of the pyridine N-oxide with trimethylsilyl cyanide followed by dimethylcarbamoyl chloride produces the 2-cyano compound 68. Compound 68 is converted to its carboxamide 69 by reaction with hydrogen peroxide in the presence of a suitable base. Examples of suitable bases include potassium carbonate and potassium bicarbonate. Carboxamide 69 is converted to its methyl ester 70 by reaction with dimethylformamide dimethyl acetal in methanol. The ester 70 is converted to its carboxylic acid 71 by saponification. Typical saponification conditions include reaction with a base such as sodium hydroxide or potassium hydroxide in a suitable solvent such as ethanol or ethanol and water or methanol and water or the like. Ester 70 is also convertible to substituted amide 72 by treatment with a desired amine, such as methylamine at a suitable temperature. Temperatures may range from room temperature to 180° C. In Scheme XVIII, R¹⁸ and R¹⁹ are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.

The synthesis of compound 77, wherein the amino group is extended two methylene units from the pyrazole ring is illustrated in Scheme XIX above. Reaction of pyrazole 73 with a protecting reagent such as 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) in the presence of a base such as sodium hydride yields protected pyrazole 74. This reaction results in a mixture of regioisomers wherein the 2-(trimethylsilyl)-ethoxymethyl (SEM) group may be attached to either of the nitrogen atoms of the pyrazole ring. Alternatively, protecting reagents such as 2-methoxyethoxymethyl chloride (MEMCl) also may be used.

Reaction of compound 74 with a suitable derivative of dimethyl formamide, followed by exposure to water, leads to aldehyde 75. Examples of suitable derivatives of dimethylformamide include tert.-butoxybis(dimethylamino)methane and dimethylformamide dimethyl acetal. One skilled in the art will understand that this leads to the formation of a reactive vinyl amine as an intermediate. The reaction may be carried out in the reagent itself or in the presence of dimethylformamide as solvent. Suitable reaction temperatures range from about 50° C. to about 153° C. The contacting of the intermediate vinyl amine with water may be carried out in solution in a suitable solvent such as methanol, ethanol, acetone, or dioxane. Alternatively, a solution of the vinyl amine in a suitable solvent may be contacted with hydrated silica gel.

Aldehyde 75 may be reductively aminated to amine 76 by reaction with the desired amine in the presence of a reducing agent. Typical reducing agents include sodium cyanoborohydride, sodium borohydride or hydrogen in the presence of a catalyst, such as a palldium/carbon catalyst or a Raney nickel catalyst, either at atmospheric pressure or in a pressurized system. An acid catalyst such as acetic acid or dilute hydrochloric acid may also be employed. The reaction may be run at ambient temperature or may be heated.

Pyrazole 77 is obtained by removal of the pyrazole nitrogen protecting group. The deprotection reaction employed will depend upon the specific protecting group removed. A 2-(trimethylsilyl)ethoxymethyl group can be removed, for example, by reaction of amine 76 with tetrabutylammonium fluoride while a 2-methoxyethoxymethyl group can be removed, for example, by acid hydrolysis.

Scheme XX shows the syntheses of pyrazole 82 and its derivatives 83 and 85. A substituted 4-picoline 78 is condensed with ethyl ester derivative 79 in the presence of a base such as lithium diisopropylamide to give ketone derivative 80. An example of a suitable picoline is 4-picoline. Suitable ethyl ester derivatives include ethyl 4-piperidinylacetate (Compound 79, n=1). Ester 79 may be synthesized, for example, by hydrogenation of ethyl 4-pyridylacetate and protection of the resulting piperidine nitrogen as the tert.-butoxycarbonyl (Boc) derivative by reaction with tert.-butoxycarbonyl chloride. The hydrogenation may be carried out, for example, at pressures from atmospheric to 100 psi. Suitable catalysts include 5% platinum on carbon. The presence of an acid such as hydrochloric acid may also improve reaction performance.

Treatment of 80 with a substituted benzaldehyde provides unsaturated ketone 81. Pyrazole 82 may be synthesized by treatment of 81 with p-toluenesulfonylhydrazide in the presence of acetic acid. During this reaction, the protecting tert.-butoxycarbonyl group is removed. Derivatization of pyrazole 82 by appropriate methods as described in Scheme II for analogous piperazine derivatives gives various pyrazole derivatives 83.

Alternatively, unsaturated ketone 81 can be converted to pyrazole 84 by first reaction with hydrogen peroxide in the presence of sodium or postassium hydroxide, followed by reaction with hydrazine. Using trifluoroacetic acid, the tert.-butoxycarbonyl group may be removed from pyrazole 84 to give pyrazole 62.

Alternatively, the tert.-butoxycarbonyl group of 84 may be reduced with a reagent such as lithium aluminum hydride to provide the methyl derivative 85.

Scheme XXI shows the synthesis of pyrazoles 92. Treatment of compound 86 with ester 87 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent such as tetrahydrofuran, gives ketone 88. Substituent R³ is typically heteroaryl, preferably pyridinyl or pyrimidinyl, and more preferably 4-pyridinyl. Substituent R⁴ is typically aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkyl or aralkyl, and is preferably a substitued phenyl. R¹⁰³ can be, for example, lower alkyl.

Treatment of ketone 88 with carbon disulfide, dibromomethane, and a base such as potassium carbonate in a suitable solvent such as acetone gives dithietane 89. Other suitable bases include, but are not limited to, carbonates such as sodium carbonate, tertiary amines such as triethylamine or diazabicycloundecane (DBU), and alkoxides such as potassium tert-butoxide. Other suitable solvents include, but are not limited to, low molecular weight ketones, methyl ethyl ketone, tetrahydrofuran, glyme, acetonitrile, dimethylformamide, dimethylsulfoxide, dichloromethane, benzene, substituted benzenes and toluene.

Dithietane 89 may be reacted with an appropriate amine, with or without heating, in an acceptable solvent such as toluene or acetonitrile to make thioamide 90. Thioamide 90 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 and/or its tautomer.

Alternatively, thioamide. 90 can be reacted with an alkyl halide or a sulphonic acid ester to yield substituted thioamide 91. Substituted thioamide 91 is treated with hydrazine or a substituted hydrazine in an appropriate solvent such as tetrahydrofuran or an alcohol, with or without heating, to produce pyrazole 92 or its tautomer.

R¹⁰⁴ and R¹⁰⁵ can be independent radicals or can form a heterocyclyl ring that is optionally substituted and/or contains an additional heteroatom.

Scheme XXII shows the synthesis of substituted 5-amino pyrazoles 98 and 99. Desoxybenzoin 93 (prepared, for example, as illustrated in Scheme IX, supra, or Example C-1, infra) is reacted with an aminomethylenating agent, such as N,N-dimethylformamide dimethyl acetal, to form aminomethylene ketone 94. Aminomethylene ketone 94 is converted to isoxazole 95 by treatment with a hydroxylamine in a suitable solvent such as ethanol. Isoxazole 95 is treated with a base, such as dilute aqueous sodium hydroxide, to form cyanoketone 96. Cyanoketone 96 is then reacted with a chlorinating agent, such as phosphorous trichloride, to form a vinyl chloride which is then treated with hydrazine hydrate (or a substituted hydrazine hydrate) to form amino pyrazole 97. Amino pyrazole 97 can be reacted further with a variety of alkyl halides, such as methyl bromoacetate, bromoacetonitrile, and chloroethylamine, to form the appropriate mono- or disubstituted, cyclic or acyclic amino pyrazole 98. Typical R¹⁰⁶ and R¹⁰⁷ substituents include, for example, hydrogen and alkyl. In addition, amino pyrazole 97 can be reacted further with a variety of acylating agents, such as benzyliminodiacetic acid and N,N-dimethylglycine, to give the corresponding mono- or disubstituted, cyclic or acyclic amide or imide 99.

Typical R¹⁰⁸ and R¹⁰⁹ substituents include, for example, hydrogen, alkyl and acyl.

Scheme XXIII shows the synthesis of sulfoxide/sulfone 103. Ketone 100, wherein X is preferably halo such as fluoro or chloro, in a solvent, such as tetrahydrofuran, is treated with a suitable base, such as sodium hydride or potassium t-butoxide, to yield an enolate intermediate. The enolate intermediate is reacted with carbon disulfide and then alkylated with an appropriate alkylating agent, such as methyl iodide, benzyl bromide, or trimethylsilylchloride, to form dithioketene acetal 101. Dithioketene acetal 101 can be cyclized to pyrazole 102 using hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a suitable solvent, such as tetrahydrofuran or ethanol. Pyrazole 102 is then treated with an oxidizing agent, such as potassium peroxymonosulfate, ammonium persulfate, or 3-chloroperoxybenzoic acid, to generate sulfoxide 103 (n=1) and/or sulfone 103 (n=2).

Scheme XXIV shows the synthesis of pyrazole 106. Dithioketene acetal 104 in a suitable solvent, such as toluene, is combined with a secondary amine, wherein Z is preferably S or —NCH₃, and heated to about 80-110° C. After the solution has been heated for several hours, any insoluble bis substituted material may be removed by filtration. Mono substituted product 105 is then reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in a solvent, such as tetrahydrofuran or ethanol, at ambient up to reflux temperatures, to form pyrazole 106.

Scheme XXV shows the synthesis of pyrazole 109. Dithietane 107 is added to a solution of a sodium or potassium alkoxide in tetrahydrofuran. The alkoxide may be generated by treating an alcohol, in tetrahydrofuran, with a suitable base, such as sodium hydride, sodium hexamethyldisilazide, or potassium hexamethyldisilazide. The reaction mixture is stirred from 4 to 72 hours at room temperature. The resulting thionoester 108 is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), in ethanol, methanol, or tetrahydrofuran at room temperature for about 2-18 hours to generate pyrazole 109.

Scheme XXVI shows the synthesis of pyrazole 112. To dithietane 107 in a suitable solvent, such as toluene, is added an amine, such as thiomorpholine and heated to about 80-110° C., to form thioamide 110. Thioamide 110 may be isolated or used directly in the next reaction step. To thioamide 110 in tetrahydrofuran is added a suitable base, such as potassium t-butoxide, and the resulting thiol anion alkylated with iodomethane to form alkylated thioamide 111. Alkylated thioamide 111 can be cyclized with hydrazine (or substituted hydrazine), in a solvent, such as tetrahydrofuran or ethanol, to generate pyrazole 112.

Scheme XXVII shows the synthesis of pyrazole 114. Dithietane 107 in a suitable solvent, such as tetrahydrofuran or ethanol, is reacted with hydrazine, or its hydrate (or a substituted hydrazine or its hydrate), at room temperature up to the reflux temperature of the solvent to generate thiopyrazole 113. The thiol group of thiopyrazole 113 may be alkylated with a variety of alkylating agents, such as alkyl halides or Michael acceptors, including, but not limited to, methyl chloroacetate, ethyl acrylate, and benzyl bromide, in the presence of a suitable base such as potassium carbonate, sodium ethoxide or triethylamine, in a solvent such as dimethylformamide or ethanol to generate pyrazole 114.

Scheme XXVIII shows the synthesis of pyrazole 117. Pyrazoles containing acid labile amine protecting groups, such as pyrazole 115, may be treated with a suitable acid catalyst, such as trifluoroacetic acid in dichloromethane or HCl in ethanol or dioxane to yield amine 116. Amine 116 can then be acylated or alkylated by methods known to one of ordinary skill in the art, such as reacting amine 116 with a reagent such as acetyl chloride or methyl iodide in the presence of a suitable base, such as potassium carbonate or triethylamine. In addition, N-methylation can be performed directly, using formaldehyde and formic acid in ethanol/water at reflux to give pyrazole 117 wherein R¹¹⁴ is methyl.

Scheme XXIX shows the synthesis of pyrazole 120. Pyrazoles containing base labile esters, such as pyrazole 118, may be treated with a suitable base, such as, sodium hydroxide to generate free acid 119. Acid 119 can then be aminated by methods known to one of ordinary skill in the art, such as treating acid 119 with a suitable coupling reagent, such as 1-(3-dimethylaminopropyl)3-ethylcarbodiiminde hydrochloride or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate, with or without catalysts, such as 1-hydroxybenzotriazole or N-hydroxysuccinimide, and an appropriate amine. In addition, amidation can be performed directly, by treating the methyl ester with an appropriate amine, for example N-methylpiperazine, in a suitable solvent such as dimethylformamide or methanol, at a temperature from room temperature up to reflux to generate pyrazole 120.

The following examples contain detailed descriptions of the methods of preparation of compounds of Formulas I, IA, XI, X, XI, and XX. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures. In some cases, the assigned structures were confirmed by nuclear Overhauser effect (NOE) experiments. The following abbreviations are used:

-   HCl—hydrochloric acid -   MgSO₄—magnesium sulfate -   Na₂SO₄—sodium sulfate -   NaIO₄—sodium periodate -   NaHSO₃—sodium bisulfite -   NaOH—sodium hydroxide -   KOH—potassium hydroxide -   P₂O₅—phosphorus pentoxide -   Me—methyl -   Et—ethyl -   MeOH—methanol -   EtOH—ethanol -   HOAC (or AcOH)—acetic acid -   EtOAc—ethyl acetate -   H₂O—water -   H₂O₂—hydrogen peroxide -   CH₂Cl₂—methylene chloride -   K₂CO₃—potassium carbonate -   KMnO₄—potassium permanganate -   NaHMDS—sodium hexamethyldisilazide -   DMF—dimethylformamide -   EDC—1-(3-dimethylaminopropyl)3-ethylcarbodiiminde hydrochloride -   HOBT—1-hydroxybenzotriazole -   mCPBA—3-chloroperoxybenzoic acid -   Ts—tosyl -   TMSCN—trimethylsilyl cyanide -   Me₂NCOCl—N,N-dimethylcarbamoyl chloride -   SEM-Cl—2-(trimethylsilyl)ethoxymethyl chloride -   h—hour -   hr—hour -   min—minutes -   THF—tetrahydrofuran -   TLC—thin layer chromatography -   DSC—differential scanning calorimetry -   b.p.—boiling point -   m.p.—melting point -   eq—equivalent -   RT—room temperature -   DMF DMA—dimethylformamide dimethyl acetal -   TBAF—tetrabutylammonium fluoride -   Boc—tert.-butoxycarbonyl -   DBU—diazabicycloundecane -   DMF(OMe)₂—N,N-dimethylformamide dimethyl acetal -   Et₃N—triethylamine -   TMSCl—trimethylsilylchloride -   TFA—trifluoroacetic acid -   TBTU—O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium     tetrafluoroborate -   psi—pounds per square inch -   ESHRMS—electron spray high resolution mass spectroscopy

EXAMPLE A-1

Step 1: Preparation of 4-(3-fluoro-4-methoxylphenyl) -3-pyridyl-3-butene-2-one

A solution of 4-pyridylacetone (1.0 g, 7.4 mmol), 3-fluoro-p-anisaldehyde (1.25 g, 8.1 mmol), and piperidine (0.13 g, 1.5 mmol) in toluene (50 ml) was heated to reflux. After 18 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The crude product (3.0 g) was purified by column chromatography (silica gel, 65:35 ethyl acetate/hexane) to give 4-(3-fluoro-4-methoxylphenyl) -3-pyridyl-3-butene-2-one as a pale yellow solid (1.60 g, 80%).

Step 2: Preparation of 4-[5-(3-fluoro-4-methoxyphenyl) -3-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 3-pyridyl-4-(3-fluoro-4-methoxylphenyl)-3-butene-2-one (step l) (0.99 g, 3.65 mmol) in acetic acid (25 ml), p-toluenesulfonyl hydrazide (0.68 g, 3.65 mol) was added. The reaction solution was heated to reflux for 6 hours. Acetic acid was removed by distillation from the reaction solution. The resulting residue was diluted with CH₂Cl₂ (150 ml), washed with H₂O (2×100 ml), dried (Na₂SO₄), filtered, and concentrated. The crude product (1.5 g) was purified by chromatography (silica gel, ethyl acetate) to give 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine as a pale yellow solid (213 mg, 20.7%): Anal. Calc'd for C₁₆H₁₄N₃OF.0.1H₂O: C, 67.41; H, 5.02; N, 14.74. Found: C, 67.37; H, 4.88; N, 14.35.

EXAMPLE A-2

4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine

Step 1: Preparation of 4-pyridylacetone

4-Pyridylacetone was prepared according to the method of Ippolito et al, U.S. Pat. No. 4,681,944.

Step 2: Preparation of 4-phenyl-3-(4-pyridyl)-3-butene-2-one

Using the procedure of Example A-1, step 1, 4-pyridylacetone (step 1) (1 g, 7.4 mmol) was condensed with benzaldehyde (790 mg, 7.4 mmol) in benzene (15 mL) containing piperidine (50 mg) at reflux. The desired 4-phenyl-3-(4-pyridyl)-3-butene-2-one (1.3 g, 78%) was obtained as a crystalline solid: m.p. 101-103° C. Anal. Calc'd for C₁₅H₁₃NO (223.28): C, 80.69; H, 5.87; N, 6.27. Found: C, 80.59; H, 5.79; N, 6.18.

Step 3: Preparation of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone

Using the procedure of Example A-1, step 2, a solution of 4-phenyl-3-(4-pyridyl)-3-butene-2-one (step 2) (1.25 g, 5.6 mmol) in methanol (20 ml) was treated with 30% aqueous hydrogen peroxide (1 ml) in the presence of sodium hydroxide (230 mg, 5.7 mmol). The crude product was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (270 mg, 20%).

Step 4: Preparation of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl) pyridine

Using the procedure of Example A-1, step 3, a solution of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 3) (250 mg, 1 mmol) in ethanol (15 ml) was treated with anhydrous hydrazine (50 mg, 1.5 mmol) and heated to reflux for 4 hours. The crude product was purified by chromatography (silica gel, 1:1 acetone/hexane). The product was recrystallized from ethyl acetate and hexane to give 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (81 mg, 35%) as a crystalline solid: m.p. 212-214° C. Anal. Calc'd for C₁₅H₁₃N₃ (235.29): C, 76.57; H, 5.57; N, 17.86. Found: C, 76.49; H, 5.42; N, 17.39.

EXAMPLE A-3

4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one

A solution of 4-pyrridylacetone (Example A-5, step 1) (0.75 g, 5.56 mmol), o-tolualdehyde (0.73 g, 5.56 mmol) and piperidine (100 mg) in toluene (50 ml) was heated to reflux. Water generated during the reaction was removed by a Dean-Stark trap. After heating at reflux for 5 hours, the reaction mixture was stirred at room temperature for 15 hours. The mixture was concentrated to an orange color oily residue. The crude ketone was purified by chromatography to give 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one: Anal. Calc'd for C₁₆H₁₅NO (237.30): C, 80.98; H, 6.37; N, 5.90. Found: C, 80.78; H, 6.61; N, 5.85.

Step 2: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone

To a solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one (step 1) (1.0 g, 4.2 mmol) in methyl alcohol (18 ml), a solution of H₂O₂ (30% by wt.) (0.95 g, 8.4 mmol) and sodium hydroxide (0.18 g 4.6 mmol) in water (4 ml) was added. The reaction was stirred at room temperature for 70 hours. After methyl alcohol was removed, water (25 ml) and ethyl acetate (100 ml) were added and the two phase mixture was stirred for 30 minutes. The layers were separated, and the aqueous layer was washed with ethyl acetate (100 ml). The combined organic layer was dried with Na₂SO₄, filtered and concentrated to give an oil. 4-(2-Methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone was isolated from the oil residue by chromatography.

Step 3: Preparation of 4-[5-methyl-3-(2-methylphenyl)1H-pyrazol-4-yl]pyridine

A solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 2) (0.11 g, 0.434 mmol) and hydrazine hydrate (0.043 g, 0.868 mmol) in ethyl alcohol (50 ml) was heated at reflux for 20 hours. The solvent was removed and the resulting residue was purified by chromatography to give 4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₆H₁₅N₃ (249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.66; H, 5.91; N, 16.84.

EXAMPLE A-4

4-[5-methyl-3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-3substituting p-fluorobenzaldehyde for o-tolualdehyde, the titled compound was prepared: Anal. Calc'd for C₁₅H₁₂N₃F+0.1H₂O: (249.32): C, 70.63; H, 4.82; N, 16.47. Found: C, 70.63; H, 4.78; N, 16.40.

EXAMPLE A-5

4-[5-methyl-3(4-methylphenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-3 (with one minor modification: in Step 2, the preparation of the intermediate epoxide was accomplished at 0-10° C. for 1hour, and the reaction was quenched by being partitioned between water, containing 2 eq. sodium bisulfite, and ethyl acetate) and substituting p-tolualdehyde for o-tolualdehyde, the titled product was isolated: Anal. Calc'd for C₁₆H₁₅N₃ (249.32): C, 77.08; H, 6.606; N, 16.85. Found: C, 76.97; H, 6.09; N, 16.90.

EXAMPLE A-6

4-[5-methyl-3-[4-(methylthio)phenyl]-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting 4-(methylthio)benzaldehyde for p-tolualdehyde, the titled product was prepared: Anal. Calc'd for C₁₆H₁₅N₃S (281.38): C, 68.30; H, 5.37; N, 14.93. Found: C, 68.34; H, 5.09; N, 14.78.

EXAMPLE A-7

4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting p-chlorobenzaldehyde for p-tolualdehyde, the titled product was obtained. Anal. Calc'd for C₁₅H_(12 N) ₃Cl (269.77): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.43; H, 4.44; N, 15.78.

EXAMPLE A-8

4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting m-tolualdehyde for p-tolualdehyde, the titled product was obtained: Anal. Calc'd for C₁₆H₁₅N₃+0.2H₂O: C, 75.98; H, 6.14; N, 16.61. Found: C, 76.06; H, 6.05; N, 16.38.

EXAMPLE A-9

4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

By following the method of Example A-5 and substituting 2,5-dimethylbenzaldehyde for p-tolualdehyde, the titled product was obtained: Anal. Calc'd for C₁₇H₁₇N₃+0.1H₂O: C, 77.01; H, 6.54; N, 15.85. Found: C, 76.96; H, 6.81; N, 15.51.

EXAMPLE A-10

4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine

4-Pyridylacetone (1.5 g, 12 mmol), piperonal (1.6 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature, and ethyl acetate was added to precipitate a solid, which was collected on a filter plate (1.25 g). A sample (500 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in acetic acid (5 mL) at 80° C. for 1 hour. The reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and the solvent was evaporated. The residue was dissolved in ethyl acetate, washed with 5% aqueous potassium carbonate, and water. The organic layer was dried (MgSO₄), filtered and evaporated to obtain a yellow solid. This solid was triturated with methylene chloride, yielding 4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine which was collected on a filter plate (220 mg, 42% yield). Anal. Calc'd for C₁₆H₁₃N₃O₂: C, 68.81; H, 4.69; N, 15.04. Found: C, 68.02; H, 4.54; N, 14.76. MS (M⁺H): 280 (base peak).

EXAMPLE A-11

4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine

4-Pyridylacetone (1.5 g, 12 mmol), 4-phenoxybenzoldehyde 92.1 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature and ethyl acetate was added to precipitate a solid, which was collected on a filter plate. A sample (223 mg) of this solid was heated with p-toluensulfonyl hydrazide (348 mg, 1.81 mmol) in ethylene glycol with potassium hydroxide (77 mg) at 110° C. for 0.5 hour. The work up procedure was the same as that in Example A-10. 4-[3-Methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine was obtained (100 mg, 66% yield): Anal. Calc'd for C₂₁H₁₇N₃O+0.1H₂O: C, 76.62; H, 5.27; N, 12.76. Found: C, 76.37; H, 5.19; N, 12.64. MS (M⁺H): 328 (base peak).

EXAMPLE A-12

4-[5-[[1,1-biphenyl]-4-yl]-3-methyl 1H-pyrazol-4-yl]pyridine

The same procedure as for the preparation of Example A-10 was used, substituting 4-formylbiphenyl in place of piperonal, to give 4-[5-[(1,1′-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine as a white solid: MS (M+H): 312 (base peak).

EXAMPLE A-13

4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 3-phenoxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine as a white solid.

EXAMPLE A-14

4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 3-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine as a white solid: MS (M⁺H): 342 (base peak).

EXAMPLE A-15

4-[3-methyl-5-[2-(phenylmethoxy)-phenyl]-1H-pyrazol-4-yl]pyridine

The same procedure for the preparation of Example A-10 was used, substituting 2-benzyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[2-(phenylmethyloxy)phenyl]-1H-pyrazol-4-yl]pyridine. MS (M⁺H): 342 (base peak).

EXAMPLE A-16

2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol

The same procedure for the preparation of Example A-10 was used, substituting 2-hydroxybenzaldehyde in place of piperonal, to give 2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).

EXAMPLE A-17

3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol

The same procedure for the preparation of Example A-10 was used, substituting 3-hydroxybenzaldehyde in place of piperonal, to give 3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).

EXAMPLE A-18

1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium

To a solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (Example A-2) (2.06 g, 8.76 mmol) in a mixture of CH₂Cl₂ (10 mL) and MeOH (20 mL), was added 3-chloroperoxybenzoic acid (57-86%) (2.65 g, 8.76 mmol). The reaction was stirred at room temperature for 2 h, quenched with K₂CO₃ solution (25%, 15 mL), and concentrated. The resulting residue was partitioned between EtOAc (2.0 L) and H₂O (500 mL). The organic layer was separated, washed with H₂O (500 mL), dried over MgSO₄, filtered and concentrated to give 1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium (1.12 g, 54.5%): MS (M+H) 252 (base peak).

EXAMPLE A-19

5-(4-fluorophenyl)-N,N-dimetyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

Step 1: Preparation of 1-fluoro-4-(4′-pyridylacetyl)benzene

To a solution of sodium bis(trimethylsilyl)amide (200 mL, 1.0 M in THF) at 0° C. was added a solution of 4-picoline (18.6 g, 0.20 mol) in dry THF (200 mL) over 30 minutes. The reaction mixture was stirred at 0-10° C. for another 30 minutes, then was added to a solution of ethyl 4-fluorobenzoate (16.8 g, 0.10 mol) in dry THF (200 mL) at such a rate that the internal temperature didn't exceed 15° C. After the addition, the resulting yellow suspension was stirred at room temperature for 3 hours. Water (600 mL) was added and the aqueous phase was extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give 1-fluoro-4-(4′-pyridylacetyl)benzene (19.9 g, 92%) as an oil which solidified upon standing: m.p.: 90-91° C.; Anal. Calc'd for C₁₃H₁₀FNO: C, 72.55; H, 4.68; N, 6.51. Found: C, 72.07; H, 4.66; N, 6.62.

Step 2: Preparation of 1-fluoro-4-(4-pyridylbromoacetyl)benzene

To a solution of 1-fluoro-4-(4-pyridylacetyl)benzene (step 1) (10.0 g, 0.046 mol) in acetic acid (200 mL) was added a solution of bromine (8.2 g, 0.052 mol) in acetic acid (20 mL) dropwise. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was triturated with ethyl acetate. A yellow solid formed, which was filtered and air-dried to give 1-fluoro-4-(4′-pyridylbromoacetyl)benzene (14.5 g). The compound was used in next step without further purification.

Step 3: Preparation of 5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

A mixture of 1-fluoro-4-(4′-pyridylbromoacetyl)benzene (step 2) (3.8 g, 0.01 mol) and 4,4-dimethylamino-3-thiosemicarbazide (1.2 g, 0.01 mol) in ethanol (10 mL) was heated at reflux for 30 minutes. The dark green solution was cooled and poured into water (100 mL). The aqueous phase was extracted with methylene chloride (100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The resulting residue was purified by chromatography (silica gel, ethyl acetate) to give 0.3 g 5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine (0.3 g, 11%) as a light yellow solid: m.p.: 245-247° C. Anal. Calc'd for C₁₆H₁₅FN₄: C, 68.07; H, 5.36; N, 19.84. Found: C, 68.00; H, 5.37; N, 19.61.

EXAMPLE A-20

5-(4-fluorophenyl)-N-phenyl-4-(pyridinyl)-1H-pyrazol-3-amine

5-(4-Fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine was prepared by the same procedure as described for Example A-19: m.p. 218-219° C. Anal. Calc'd for C₂₀H₁₅FN₄+0.1H₂O: C, 72.33; H, 4.61; N, 16.87. Found: C, 72.16; H, 4.56; N, 16.77.

EXAMPLE A-21

4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 1-fluoro-4-(40-pyridylacetyl)benzene N-benzoylhydrazone

To a solution of benzoic hydrazide (1.36 g, 0.01 mol) in THF (20 mL) was added 1-fluoro-4-(4′-pyridylacetyl)benzene (2.15 g, 0.011 mol) in one portion followed by a drop of conc. HCl. The reaction mixture was stirred at room temperature overnight. There was white precipitate formed, which was filtered, washed with ether and air-dried to give 1-fluoro-4-(4′-pyridylacetyl)benzene N-benzoylhydrazone (2.90 g, 79%) as a mixture of cis and trans (ratio, 1:9) isomers.

Step 2: Preparation of 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine

1-Fluoro-4-(4′-pyridylacetyl)benzene N-benzoylhydrazone (step 1) (0.50 g, 1.5 mmol) was heated at 180° C. under N₂ for 15 minutes, then cooled. The resulting solid was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine (0.25 g, 53%) as a pale yellow solid: m.p.: 265-267° C. Anal. Calc'd for C₂₀H₁₄FN₃+0.25H₂O: C, 75.10; H, 4.57; N, 13.14. Found: C, 74.98; H, 4.49; N, 12.87.

EXAMPLE A-22

4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 3-(4′-pyridylacetyl)toluene

3-(4′-Pyridylacetyl)toluene was prepared by the same method as described for Example A-19, step 1 in 70% yield.

Step 2: Preparation of trifluoroacetyl hydrazide

A mixture of ethyl trifluoroacetate (14.2 g, 0.10 mol) and hydrazine hydrate (5.54 g, 0.11 mol) in ethanol (25 mL) was heated at reflux for 6 hours. Solvent was removed and the resulting residue was dried in vacuum to give trifluoroacetyl hydrazide (12.3 g, 96%) as a clear oil which solidified upon standing.

Step 3: Preparation of 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

A mixture of 3-(4′-pyridylacetyl)toluene (2.11 g, 0.01 mol) and trifluoroacetyl hydrazide (step 2) (1.0 g, 0.01 mol) was heated at 200° C. under N₂ for 15 minutes. The crude residue was purified by chromatography (silica gel, 35:65 ethyl acetate/hexane) to give 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine (0.56 g) as a white solid: m.p. 237-239° C. Anal. Calc'd for C₁₆H₁₂F₃N₃: C, 63.36; H, 3.99; N, 13.85. Found: C, 63.6; H, 4.00; N, 13.70.

EXAMPLE A-23

4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl)pyridine

A mixture of 1-fluoro-4-(4′-pyridylacetyl)benzene (1.0 g, 4.6 mmol) and isonicotinic hydrazide (0.63 g, 4.6 mmol) in THF (25 mL) was heated to dissolution and then evaporated to dryness. The resulting solid was heated first to 140° C., which caused a phase change, and subsequently melted on further heating until 180° C. whereupon a solid crystallized out. The reaction was immediately cooled, diluted with 10% HCl (50 mL) and washed with chloroform. The aqueous layer was neutralized with bicarbonate and a tan colored solid was precipitated out. The solid was purified by treatment with activated carbon (Darco®) in boiling MeOH (100 mL), followed by filtration and concentration, to give 4-(3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine (1.05 g, 69%) as a shiny tan solid: m.p. 304° C. (DSC). Mass (MH⁺) 137 (100%). Anal. Calc'd for C₁₉H₁₃N₄F.1/4H₂O: C, 71.13; H, 4.24; N, 17.46. Found: C, 70.88; H, 3.87; N, 17.38.

EXAMPLE A-24

4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine

Step 1: Preparation of 4-cyclohexyl-3-pyridyl-3-butene-2-one

4-Cyclohexyl-3-pyridyl-3-butene-2-one was prepared by the method of Example A-1, step 1 by replacing of 3-fluoro-p-anisaldehyde with cyclohexanecarboxaldehyde.

Step 2: Preparation of 4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine

4-(5-Cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyridine was prepared by the method for Example A-1, step 2, by replacing 4-(3-fluoro-4-methoxylphenyl)-3-pyridyl-3-butene-2-one with 4-cyclohexyl-3-pyridyl-3-butene-2-one (step 1): Anal. Calc'd for C₁₅H₁₉N₃: C, 73.56; H, 7.98; N, 17.16. Found: C, 73.72; H, 7.91; N, 19.98.

EXAMPLE A-25

4-[5-(3-flouro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

4-{5-(3-Fluoro-5-methoxyphenyl)-3-methyl-3-methyl-1H-pyrazol-4-yl}pyridine was prepared by the method of Example A-1, steps 1 and 2 by replacing 3-fluoro-p-anisaldehyde with 3-fluoro-m-anisaldehyde: Anal. Calc'd for C₁₆H₁₄N₃OF: C, 67.83; H, 4.98; N, 14.83. Found: C, 67.68; H, 4.92; N, 14.92.

The following examples (No 26-55) listed in Table 1 were prepared by the procedures described above:

TABLE 1 m.p. or Anal. Calc'd No DSC Anal. Calc'd (calcd/found) A- R¹ R² R³ R⁴ (° C.) Formula C H N 26 H

185- 186 C₁₈H₁₉N₃ 77.95/ 77.51 6.90/ 6.93 15.15/ 14.73 27 H

142- 144 C₁₆H₁₅N₃ 75.71/ 75.69 6.16/ 6.11 16.55/ 16.49 28 H

240- 242 C₂₂H₁₉N₃ .0.25H₂O 80.09/ 79.74 5.96/ 5.90 12.74/ 13.01 29 H

228.8 C₁₆H₁₂N₃F₃ 63.36/ 63.28 3.99/ 3.73 13.85/ 13.69 30 H

189.6 C₁₅H₁₂N₃C .0.15H₂O 66.13/ 65.98 4.55/ 4.31 15.42/ 15.74 31 H

171.6 C₁₇H₁₇N₃ .0.2H₂O 76.49/ 76.69 6.57/ 6.53 15.74/ 15.61 32

 88.6 C₁₆H₁₄N₃Cl 67.72/ 67.35 4.97/ 5.29 14.81/ 15.02 33 H

188.8 C₁₆H₁₄N₃F 71.89/ 71.72 5.28/ 5.45 15.72/ 15.77 34 H

215.7 C₁₇H₁₇N₃ 77.54/ 77.24 6.51/ 6.80 15.96/ 15.71 35 H

201.4 C₁₇H₁₇N₃O₂ .0.25H₂O 68.10/ 67.92 5.88/ 5.65 14.01/ 13.65 36 H

210.7 C₁₅H₁₂N₄O₂ .0.25H₂O 63.26/ 63.59 4.42/ 4.39 19.67/ 19.31 37 H

252.5 C₁₇H₁₈N₄ 73.35/ 72.61 6.52/ 6.79 20.13/ 19.59 38 H

196.3 C₁₇H₁₅N₃O 73.63/ 73.43 5.45/ 5.46 15.15/ 15.19 39 H

252.8 C₁₅H₁₂N₃Br 57.34/ 57.09 3.85/ 3.79 13.37/ 13.06 40 H

198.5 C₁₅H₁₂N₃F 71.13/ 71.23 4.78/ 5.01 16.59/ 16.76 41 H

225.6 C₁₅H₁₂N₃F₃ 71.13/ 70.74 4.78/ 4.66 16.59/ 16.44 42 H

219.5 C₁₆H₁₂F₃N₃ 63.36/ 63.19 3.99/ 4.07 13.85/ 13.38 43 H

227.7 C₁₆H₁₅N₃ .0.1H₂O 76.53/ 76.53 6.10/ 6.20 16.73/ 16.49 44 H

175.6 C₁₆H₁₅N₃O .0.15H₂O 71.70/ 71.92 5.75/ 5.76 15.68/ 15.29 45 H

— C₁₇H₁₉N₃ 77.54/ 77.13 6.51/ 6.28 15.96/ 15.69 46 H

412.1 C₁₅H₁₁N₃F₂ 66.42/ 66.12 4.09/ 3.86 15.49/ 15.25 47 H

168.5 C₁₇H₁₇N₃O .0.15H₂O 72.40/ 72.39 6.18/ 5.87 14.90/ 14.50 48 H

211.2 C₁₆H₁₂N₃F₃ .0.2H₂O 62.62/ 62.64 4.07/ 4.06 13.69/ 13.35 49 H

— C₁₃H₁₁N₃S 64.71/ 64.44 4.59/ 4.58 17.41/ 17.27 50 H

189.2 C₁₅H₁₁N₃Cl₂ 59.23/ 59.22 3.65/ 3.24 13.81/ 13.81 51 H

211.7 C₁₅H₁₂N₃Cl .0.15H₂O 66.13/ 66.33 4.55/ 4.62 15.42/ 15.05 52 H

219.8 C₁₆H₁₄N₃Cl 64.11/ 63.85 4.71/ 4.69 14.02/ 13.93 53 H

163.4 C₁₉H₁₇N₃O₂Cl 64.32/ 63.98 4.83/ 5.08 11.84/ 11.80 54

H — C₁₅H₁₂N₃F .0.2H₂O 70.15/ 70.18 4.86/ 4.60 16.35/ 16.47 55 H

H — C₁₄H₁₀N₃F 70.28/ 69.97 4.21/ 3.84 17.56/ 17.53

The following pyrazoles could be prepared by the procedures described above:

EXAMPLE A-56 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-57 5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-58 5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-59 5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-60 5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-61 5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine EXAMPLE A-62 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-63 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-64 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-65 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-66 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-67 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-68 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine EXAMPLE A-69 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine EXAMPLE A-70 2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-71 2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-72 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine EXAMPLE A-73 2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-74 2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-75 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine EXAMPLE A-76 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine EXAMPLE A-77 2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-78 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-79 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-80 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-81 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-82 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-83 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-84 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol EXAMPLE A-85 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-86 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-87 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-88 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-89 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-90 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-91 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine EXAMPLE A-92 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-93 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-94 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-95 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-96 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-97 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-98 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide EXAMPLE A-99 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-100 4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-101 4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-102 4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-103 4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-104 4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-105 4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-106 4-[5-(1-cyclohexyen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-107 4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-108 4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-109 4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-110 4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-111 4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-112 4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-113 4-[5-(3-furanyl)-3-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-114 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-115 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-116 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate EXAMPLE A-117 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide EXAMPLE A-118 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone EXAMPLE A-119 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine EXAMPLE A-120 3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-121 3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-122 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxylate EXAMPLE A-123 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide EXAMPLE A-124 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone EXAMPLE A-125 3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-126 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-3-amine EXAMPLE A-127 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine EXAMPLE A-128 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine EXAMPLE A-129 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine EXAMPLE A-130 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine EXAMPLE A-131 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine EXAMPLE A-132 4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-133 3-methyl-5-phenyl-4-(3-thienyl)-1H-pyrazole EXAMPLE A-134 4-(3-furanyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-135 3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole EXAMPLE A-136 4-(2-furanyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-137 4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-138 4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-139 4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-140 4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole EXAMPLE A-141 3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole EXAMPLE A-142 3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole EXAMPLE A-143 2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-144 4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-145 4-(3-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-146 2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-147 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine EXAMPLE A-148 4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine EXAMPLE A-149 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-150 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-151 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine EXAMPLE A-152 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-153 4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; and EXAMPLE A-154 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine

The compounds of Examples A-155 through A-172 were synthesized in accordance with the chemistry described above. (particularly Scheme II) and illustrated by many of the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-155

5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 261° C. Anal. Calc'd for C₂₀H₁₅ClN₄+0.25H₂O (MW 351.32): C, 68.38, H, 4.30, N, 15.95. Found: C, 68.25, H, 4.41, N, 15.74.

EXAMPLE A-156

5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 260° C. Anal. Calc'd for C₁₅H₁₃ClN₄+0.125H₂O (MW 287.00): C, 62.77, H, 4.57, N, 19.52. Found: C, 62.78, H, 4.33, N, 19.22.

EXAMPLE A-157

5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate: DSC 230° C. Anal. Calc'd for C₁₆H₁₅ClN₄+2H₂O (MW 334.81): C, 57.40, H, 4.52, N, 16.73. Found: C, 57.72, H, 4.85, N, 16.54.

EXAMPLE A-158

5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227° C. Anal. Calc'd for C₁₆H₁₅FN₄+0.125H₂O (MW 284.57): C, 67.53, H, 5.31, N, 19.69. Found: C, 67.60, H, 5.20, N, 19.84.

EXAMPLE A-159

N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 222° C. Anal. Calc'd for C₁₇H₁₈N₄+0.25H₂O (MW 282.86): C, 72.19, H, 6.41, N, 19.81. Found: C, 71.99, H, 6.46, N, 19.90.

EXAMPLE A-160

N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 226° C. Anal. Calc'd for C₁₆H₁₆N₄+0.125H₂O (MW 266.58): C, 72.09, H, 6.05, N, 21.02. Found: C, 72.12, H, 6.12, N, 20.83.

EXAMPLE A-161

N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227° C. Anal. Calc'd for C₁₇H₁₈N₄+0.125H₂O (MW 280.61): C, 72.77, H, 6.47, N, 19.97. Found: C, 72.63, H, 6.40, N, 19.73.

EXAMPLE A-162

N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 234° C. Anal. Calc'd for C₁₉H₂₂N₄ (MW 306.41): C, 74.48, H, 7.24, N, 18.29. Found: C, 74.12, H, 7.18, N, 18.13.

EXAMPLE A-163

5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: m.p. 260-261° C. Anal. Calc'd for C₁₈H₁₉ClN₄ (MW 326.83): C, 66.15, H, 5.86, N, 17.14. Found: C, 66.03, H, 5.72, N, 17.23.

EXAMPLE A-164

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine: DSC 279° C. Anal. Calc'd for C₁₈H₁₇ClN₄O+0.25H₂O (MW 345.32): C, 62.61, H, 4.96, N, 16.23. Found: C, 62.52, H, 4.77, N, 16.52.

EXAMPLE A-165

5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 244° C. Anal. Calc'd for C₁₇H₁₇ClN₄+0.125H₂O (MW 315.06): C, 64.81, H, 5.44, N, 17.78. Found: C, 64.94, H, 5.43, N, 17.78.

EXAMPLE A-166

Isolated as 5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1): DSC 237° C. Anal. Calc'd for C₂₁H₁₇ClN₄+0.5H₂O (MW 369.86): C, 68.20, H, 4.63, N, 15.15. Found: C, 68.09, H, 4.55, N, 15.15.

EXAMPLE A-167

Isolated as 5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate: DSC 223° C. Anal. Calc'd for C₁₇H₁₇ClN₄O+H₂O (MW 346.82): C, 58.87, H, 4.94, N, 16.15. Found: C, 58.59, H, 4.79, N, 16.02.

EXAMPLE A-168

1,1-dimethylethyl-4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: DSC 251° C. Anal. Calc'd for C₂₃H₂₆ClN₅O (MW 439.95): C, 62.79, H, 5.96, N, 15.92. Found: C, 62.40, H, 5.82, N, 15.82.

EXAMPLE A-169

Isolated as 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: DSC 99° C. Anal. Calc'd for C₁₈H₁₈ClN₄+3HCl (MW 449.21): C, 48.13, H, 4.71, N, 15.59. Found: C, 47.76, H, 5.07, N, 15.51.

EXAMPLE A-170

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine: m.p. 247-249° C. Anal. Calc'd for C₁₉H₂₀ClN₅+0.75H₂O (MW 367.33): C, 62.12, H, 5.49, N, 19.06. Found: C, 62.45, H, 5.86, N, 19.32.

EXAMPLE A-171

1,1-dimethylethyl 4-[(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: m.p. 243-244° C. Anal. Calc'd for C₂₃H₂₆FN₅O₂+0.5 CH₃CH₂CO₂CH₂CH₃ (MW 467.55): C, 64.22, H, 6.47, N, 14.98. Found: C, 63.90, H, 4.61, N, 14.28.

EXAMPLE A-172

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: m.p. 204-206° C. Anal. Calc'd for C₁₈H₁₈FN₅+3HCl+0.5H₂O (MW 441.77): C, 48.94, H, 4.79, N, 15.85. Found: C, 48.66, H, 4.88, N, 15.50.

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine: m.p. 264-265° C. Anal. Calc'd for C₁₈H₁₈ClN₅+0.125H₂O (MW 342.08) C, 63.20, H, 5.30, N, 20.47. Found: C, 63.04, H, 5.36, N, 20.33.

Additional compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents further include the compounds disclosed in Table 2.

TABLE 2 General Microanalysis DSC Example Procedure Formula C calc C found H calc H found N calc N found deg C. A-173 Sch. II C24H25CIN6.3HCl.1.5H2O 50.63 50.58 4.96 5.03 14.76 14.68 182 A-174 Sch. II C25H24CIN5.0.125H2O 69.47 69.33 5.60 5.56 16.20 16.11 259 A-175 Sch. II C17H17FN6.1.25H2O 48.64 48.45 4.56 4.86 20.02 20.24 82 A-176 Sch. II C22H26CIN5O2 61.75 61.57 6.12 6.04 16.37 16.34 217 A-177 Sch. II Cl7H18CIN5.3HCl.H2O 44.85 44.96 4.65 4.87 15.38 15.17 220 A-178 Sch. II C21H24CIN5O2.0.125H2O 60.61 60.51 5.81 5.81 16.83 16.64 232 A-179 Sch. II C25H30 CIN5O3 62.04 61.76 6.25 6.25 14.47 14.37 220 A-180 Sch. II C22H25 FN6O2.0.5H2O 60.96 60.86 5.81 6.21 19.39 19.47 N.D. A-181 Sch. II C22H25 ClFN5O2 59.26 58.98 5.65 5.55 15.71 15.36 210 A-182 Sch. II C20H22CIN5.0.75H2O 62.98 62.97 5.81 5.64 18.36 17.83 271 A-183 Sch. II C16H19Cl4N5.3HCl 45.41 45.37 4.53 4.74 120

EXAMPLE A-173

N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]1-H-pyrazol-3-yl]1,3-propanediamine, trihydrochloride EXAMPLE A-174

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-(phenylmethyl)piperazine EXAMPLE A-175

Isolated as 4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride EXAMPLE A-176

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate EXAMPLE A-177

Isolated as N-[5-[4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate EXAMPLE A-178

1,1-dimethylethyl[2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate EXAMPLE A-179

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate EXAMPLE A-180

1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate EXAMPLE A-181

1,1-dimethylethyl[3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate EXAMPLE A-182

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine EXAMPLE A-183

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine

The compounds of Examples A-184 through A-189 were synthesized in accordance with the chemistry described above (particularly in Schemes I and IV) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-184

4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₅H₁₁F₂N₃: C, 66.42; H, 4.09; N, 15.49. Found: C, 66.20; H, 3.94; N, 15.16; m.p. 236.67° C.

EXAMPLE A-185

4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₇N₃: C, 77.54; H, 6.51; N, 15.96. Found; C, 77.16; H, 6.27; N, 15.69. m.p. (DSC): 189.25° C.

EXAMPLE A-186

4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine: Anal Calc'd for C₁₆H₁₄ClN₃.0.1 mole H₂O: C, 67.15; H, 4.91; N, 14.33. Found: C, 66.95; H, 5.00; N, 14.36. DSC: 176.18° C.

EXAMPLE A-187

4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine:

Anal. Calc'd for C₁₈H₁₉N₃.0.1 mole H₂O: C, 77.44; H, 6.93; N, 15.05. Found: C, 77.39; H, 6.94; N, 14.93. m.p. (DSC): 192.66° C.

EXAMPLE A-188

4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆ClN₂.0.4M EtOAc: C, 67.08; H, 5.81; N, 12.62. Found: C, 67.40; H, 6.15; N, 12.34.

EXAMPLE A-189

4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₄FN₃: C, 73.1; H, 5.05; N, 15.04. Found: C, 73.23; H, 4.89; N, 14.63; m.p.: 239-240° C.

The compound of Example A-190 was synthesized in accordance with the chemistry described above (particularly in Scheme III) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

EXAMPLE A-190

4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure as described for Example A-22 by replacing 3-(4′-pyridylacetyl)toluene with 1-fluoro-4-(4′-pyridylacetyl)benzene (prepared as set forth in Example A-19).

Anal. Calc'd for C₁₅H₉F₄N₃: C, 58.64; H, 2.95; N, 13.68. Found: C, 58.57; H, 3.07; N, 13.31. m.p. (DSC): 281.94° C.

The compounds of Examples A-191 through A-198 were synthesized in accordance with the chemistry described above (particularly in Scheme V) by selection of the corresponding starting reagents:

EXAMPLE A-191

4-(5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone

To a solution of 4-fluorobenzoyl-4′-pyridinyl methane (8.60 g, 0.04 mol) and methyl hydrazine (2.14 g, 0.044 mol) in 50 mL of ethanol was added two drops of concentrated sulfuric acid. The reaction mixture was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium carbonate solution, washed with brine, and dried over magnesium sulfate. The filtrate was concentrated and the crude product was recrystallized from diethyl ether and hexane to afford 7.5 g of a yellow solid product (77% yield), 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone.

Step 2: Preparation of 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (5.5 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 1 (0.67 g, 0.0028 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.34 g, 0.0034 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane/acetone, 10:9:1) to give 0.45 g of product, 4-[5-(cyclopropyl-3-(4-(fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine, as a light yellow solid (55% yield), mp: 129-130° C.; ¹H NMR (CDCL₃): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (m, 2H), 6.97 (m, 2H), 4.00 (s, 3H), 1.83 (m, 1H), 0.95 (m, 2H), 0.36 (m, 2H); Anal. Calc'd for C₁₈H₁₆FN₃: C, 73.70; H, 5.50; N, 14.32. Found: C, 73.63; H, 5.57; N, 14.08.

EXAMPLE A-192

5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone

To a flask containing hydroxyethyl hydrazine (3.4 g, 0.04 mol) at 80° C. was added 4-fluorobenzoyl-4′-pyridinyl methane (8.6 g, 0.04 mol) portionwise. The yellow oil was stirred at this temperature overnight. The cooled reaction mixture was dissolved with hot ethyl acetate and then triturated with hexane to give 8.9 g of product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone, as a yellow crystal (81%), mp: 122-123° C. Step 2: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone

To a solution of the 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone prepared in step 1 (2.73 g, 0.01 mol) and (1,1-dimethylethyl)dimethylsilyl chloride (1.5 g, 0.01 mol) in 25 mL of DMF was added imidazole portionwise. The reaction mixture was stirred at room temperature overnight. Water was added and extracted with ethyl acetate, the organic layer was washed with water, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 3.8 g of crude product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]hydrazone, as a yellow oil that was used in the next step without further purification. Step 3: 5-cyclopropyl-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole

5-cyclopropyl-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole

To a solution of sodium hexamethyldisilazide (4.2 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 2 (0.78 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.27 g, 0.0026 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 0.30 g of product, 5-cyclopropyl-1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,4-diphenyl-1H-pyrazole, as a light yellow oil (35% yield), ¹H NMR (CDCL₃): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (d, J=5.6 Hz, 2H), 6.97 (m, 2H), 4.47 (t, J=4.8 Hz, 2H), 4.14 (t, J=4.8 Hz, 2H), 1.93 (m, 1H), 0.95 (m, 2H), 0.87 (s, 9H), 0.41 (m, 2H); Anal. Calc'd For C₂₅H₃₂FN₃OSi: C, 68.61; H, 7.37; N, 9.60. Found: C, 68.39; H, 7.81; N, 9.23.

Step 4: Preparation of 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 3 (0.27 g, 0.00062 mol) in 5 mL of THF was added tetrabutylammonium fluoride (1.9 mL of 1.0 M THF solution) at room temperature. After 1 hour, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 9:1) to give 0.16 g of product, 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a pale yellow solid, mp: 155-157° C.; ¹H NMR (CDCL₃): δ 8.53 (br s, 2H), 7.32 (m, 2H), 7.14 (d, J=5.6 Hz, 2H), −6.97 (m, 2H), 4.42 (t, J=4.8 Hz, 2H), 4.14 (t, J=4.8 Hz, 2H), 1.83 (m, 1H), 0.93 (m, 2H), 0.35 (m, 2H); Anal. Calc'd For C₁₉H₁₈FN₃O: C, 70.57; H, 5.61; N, 12.99. Found: C, 70.46; H, 5.87; N, 12.84.

EXAMPLE A-193

3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of sodium hexamethyldisilazide (7.4 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 2 of Example A-192 (1.25 g, 0.0034 mol) in 15 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl 4-(2-methoxy)pyridinecarboxylate (0.59 g, 0.0035 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.28 g of product, 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a yellow solid, mp: 168-169° C.; ¹H NMR (CDCL₃): δ 8.42 (m, 2H), 8.20 (dd, J=0.7, 5.2 Hz, 1H), 7.37 (m, 2H), 7.02 (m, 2H), 6.95 (m, 2H), 6.71 (dd, J=1.4, 5.2 Hz, 1H), 6.66 (t, J=0.7 Hz, 1H), 4.20 (m, 2H), 4.14 (m, 2H), 3.95 (s, 3H); Anal. Calc'd for C₂₂H₁₉FN₄O₂: C, 67.86; H, 4.91; N, 14.35. Found: C, 67.46; H, 5.08; N, 14.03.

4-[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine

A second compound, 4-[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine also was isolated from the above reaction as a yellow oil by chromatography. ¹H NMR (CDCL₃): δ 8.45 (m, 2H), 8.20 (m, 1H), 7.40 (m, 2H), 7.04 (m, 2H), 6.93 (m, 2H), 6.81 (m, 2H), 4.24 (m, 2H), 4.14 (m, 2H), 3.98 (s, 3H), 0.83 (s, 9H), 0.02 (s, 6H).

EXAMPLE A-194

4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

To a solution of 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (0.28 g, 0.0006 mol) in 5 mL of acetic acid was added 3 mL of 48% hydrobromic acid. The reaction mixture was heated at reflux for 3 hour. The cooled mixture was then treated with water, basified with ammonium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (MeOH/CH₂Cl₂/NH4OH, 5:94:1) to give 0.07 g of product, 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone, as a yellow solid (32% yield), mp: 250-251° C.; ¹H NMR (DMSO-d₆): δ 11.74 (s, 1H), 8.45 (d, J=5.0 Hz, 2H), 7.35 (m, 3H), 7.16 (m, 2H), 7.03 (d, J=5.0 Hz, 2H), 6.37 (s, 1H), 6.05 (d, J=5.2 Hz, 1H), 5.0 (m, 1H), 4.13 (m, 2H), 3.81 (m, 2H); Anal. Calc'd for C₂₁H₁₇FN₄O₂.0.2H₂O: C, 66.06; H, 4.65; N, 14.67. Found: C, 66.31; H, 4.49; N, 14.27.

EXAMPLE A-195

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone was obtained as a byproduct of the reaction of Example A-194 in the form of a yellow solid (38% yield), mp: 220-221° C.; ¹H NMR (CDCl₃): δ 8.50 (m, 2H), 7.39 (m, 3H), 7.02 (m, 4H), 6.59 (m, 1H), 6.08 (dd, J=1.4, 5.2 Hz, 1H), 4.52 (t, J=6.0 Hz, 2H), 4.43 (t, J=6.0 Hz, 2H), 2.04 (s, 3H); Anal. Calc'd for C₂₃H₁₉FN₄O₃.0.3H₂O: C, 65.46; H, 4.63; N, 13.28. Found: C, 65.09; H, 4.64; N, 12.99.

EXAMPLE A-196

Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate

To a solution of sodium hexamethyldisilazide (17.0 mL, 1.0 M in THF) at 0° C. was added a solution of the compound prepared in step 1 of Example A-192 (1.37 g, 0.005 mol) in 20 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of diethyl 1,2-cyclopropanedicarboxylate (1.12 g, 0.006 mol) in 10 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 2 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.18 g of product, ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate, as a light-yellow oil (35% yield), ¹H NMR (CDCL₃): δ 8.55 (m, 2H), 7.32 (m, 2H), 7.11 (m, 2H), 6.97 (m, 2H), 4.38 (m, 2H), 4.16 (m, 4H), 2.47 (m, 1H), 1.53 (m, 2H), 1.26 (t, J=7.0 Hz, 3H), (m, 2H), 0.90 (m, 2H); Anal. Calc'd for C₂₂H₂₂FN₃O₃.0.25H₂O: C, 66.07; H, 5.67; N, 10.51 Found: C, 65.89; H, 5.80; N, 9.95.

EXAMPLE A-197

2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid

To a solution of ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate prepared in accordance with Example A-196 (0.21 g, 0.00045 mol) in 10 mL of methanol was added a solution of sodium hydroxide (0.09 g, 0.0022 mol) in 2 mL of water. The reaction mixture was stirred at reflux for 6 hours. After the solvent was removed, the residue was dissolved with 10 mL of 1N HCl and stirred for 30 minutes. The pH was then adjusted to 5-6 by addition of 1N sodium hydroxide solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium and filtered. The filtrate was concentrated and the crude was purified by recrystallization from ethanol and ether to give 0.1 g of product, 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid, as a white solid (60% yield), mp: 253-255° C.; ¹H NMR (CD₃OD): δ 8.46 (m, 2H), 7.32 (m, 2H), 7.25 (m, 2H), 7.04 (m, 2H), 4.39 (t, J=5.0 Hz, 2H), 4.03 (m, 2H), 2.60 (m, 1H), 1.51 (m, 2H), 0.97 (m, 2H); Anal. Calc'd For C₂₀H₁₈FN₃O₃: C, 65.39; H, 4.94; N, 11.44. Found: C, 64.92; H, 4.77; N, 11.20.

EXAMPLE A-198

3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

Step 1: Preparation of methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate

methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of DMF was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hours. Then SEM-Cl (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 4.0 g of the major regioisomer as a clear oil. Step 2: Preparation of 4-[1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl-5-[[(2-trimethysilyl)ethoxy]methyl-1H-imidizol-4-yl]-1H-pyrazol-4-yl]pyridine

4-[1-[2[[(1,1-dimethylethyl)dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[[2-trimethylsilyl)ethoxy]methyl]-1H-imidazol-4-yl]-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (4.5 mL, 1.0 M in THF) at 0° C. under Ar was added a solution of the compound prepared in step 2 of Example A-192 (0.8 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of the compound prepared in step 1 of the present Example (0.54 g, 0.0021 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 1 hour. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.98 g of product as a light yellow oil which solidified upon standing (91% yield), mp: 79-80° C.; ¹H NMR (CDCL₃): δ 8.48 (d, J=6.0 Hz, 2H), 7.68 (d, J=1.3 Hz, 1H), 7.38 (d, J=6.0 Hz, 2H), 7.10 (m, 2H), 7.00 (m, 2H), 6.93 (d, J=1.3 Hz, 1H), 5.25 (s, 2H), 4.53 (t, J=6.0 Hz, 2H), 4.12 (t, J=6.0 Hz, 2H), 3.84 (t, J=8.0 Hz, 2H), 0.92 (t, J=8.0 Hz, 2H), 0.84 (s, 9H), 0.021 (s, 18H); Anal. Calc'd For C₃₁H₄₄FN₅O₂Si₂: C, 62.70; H, 7.47; N, 11.79. Found: C, 62.98; H, 7.74; N, 11.88.

Step 3: Preparation of 3-(4-fluorophenyl)-5-(4-imidazoyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 2 of the present Example (0.54 g, 0.001 mol) in 10 mL of THF was added a solution of tetrabutylammonium fluoride (1.0 M in THF). After the mixture was heated at reflux for 3 hours, the solvent was removed and the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified on silica gel (methylene chloride/methanol, 95:5) to give 0.22 g of the product, 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a white solid (63% yield), mp: 227-228° C.; ¹H NMR (DMSO-d₆): δ 8.45 (m, 2H), 7.83 (s, 1H), 7.35 (m, 2H), 7.15 (m, 4H), 7.09 (s, 1H), 5.20 (br s, 1H), 4.32 (s, 2H), 3.81 (m, 2H); Anal. Calc'd For C₁₉H₁₆FN₅O: C, 65.32; H, 4.62; N, 20.05. Found: C, 64.98; H, 4.55; N, 19.79.

The compound of Example A-199 was synthesized in accordance with the chemistry described above (particularly in Scheme VI) by selection of the corresponding starting reagents:

EXAMPLE A-199

4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine

Anal. Calc'd for C₁₅H₁₂N₃Cl (269.74): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.57; H, 4.15; N, 15.54. m.p. (DSC): 198.17° C.

The compounds of Examples A-200 through A-202 were synthesized in accordance with the chemistry described above (particularly in Scheme VII) by selection of the corresponding starting reagents:

EXAMPLE A-200

5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine prepared as set forth in Example A-4 (5.83 g, 24.0909 mmol) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 ml) and tert-butanol (10 ml) was heated at reflux for 6 hours (or until all the potassium permanganate was consumed). The mixture was then stirred at room temperature overnight and then diluted with water (150 ml). Manganese dioxide was removed from the mixture by filtration. The filtrate was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to increase the pH to about 6. A white precipitate formed, was collected by filtration, washed with water, and dried in a vacuum oven to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid (isolated as the monohydrate salt) (2.9777 g, 43.7% Anal. Calc'd for C₁₅H₁₀N₃FO₂.H₂O (283+18): C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH⁺): 284 (base peak).

EXAMPLE A-201

5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol

To a suspension of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.526 g, 2.0 mmol) in dry THF (15 ml) at reflux under nitrogen, a solution of 1N lithium aluminum hydride in THF (4.0 ml, 4.0 mmol) was added dropwise over 15 minutes. A precipitate formed. The mixture was boiled for an additional hour. Excess lithium aluminum hydride was then decomposed by cautiously adding a solution of 4N potassium hydroxide in water (0.5 ml). Upon hydrolysis, a white salt precipitated. After the addition was complete, the mixture was heated at reflux for 15 minutes. The hot solution was filtered by suction through a Buchner funnel, and remaining product was extracted from the precipitate by refluxing with THF (15 ml) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, dried over MgSO₄ to give a crude product (0.45 g). Recrystallization of the crude product from methanol gave 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol (0.2808 g, 56.5%). DSC: 260.26° C.; Anal. Calc'd for C₁₅H₁₂N₃FO (269): C, 66.91; H, 4.49; N, 15.60; Found: C, 66.07; H, 4.63; N, 15.20. MS (MH⁺): 270 (base peak).

EXAMPLE A-202

1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine

Step 1: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate

To a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.9905 g, 3.5 mmol) and 1-hydroxybenzotriazole (0.4824 g, 3.57 mmol) in DMF (20 ml) at 0° C. under nitrogen, 1-(3-dimethylaminopropyl) 3-ethylcarbodiiminde hydrochloride (0.6984 g, 3.57 mmol, Aldrich Chemical Co.) was added. The solution was stirred at 0° C. under nitrogen for 1 hour then 1-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) was added followed by N-methylmorpholine (0.40 ml, 3.6 mmol). The reaction was stirred from 0° C. to room temperature overnight. After 19 hours, the solvent was removed under reduced pressure, and resulting residue was diluted with ethyl acetate, washed with saturated NaHCO₃ solution, water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure to give a crude product (1.7595 g). 1,1-Dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (1.2372 g, 78.4%) was obtained by chromatography. Anal. Calc'd for C₂₄H₂₆N₅O₃F. (451): C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH⁺) 452 (base peak)

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine bis(trifluoroacetate), monohydrate

A solution of the compound prepared in step 1 (0.1804 g, 0.4 mmol) in methylene chloride (1.0 ml) and TFA (0.3 ml) was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was dried in a vacuum oven overnight to give 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine (isolated as the bis(trifluoroacetate), monohydrate salt) (0.2400 g, 100%) as a white solid. Anal. Calc'd for C₁₉H₁₈N₅OF.2CF₃COOH.H₂O (351+228+18): C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH⁺): 352 (base peak).

The compounds of Examples A-203 through A-206 were synthesized in accordance with the chemistry described above (particularly in Scheme VIII) by selection of the corresponding starting reagents:

EXAMPLE A-203

4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine

4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine

A 60% dispersion of sodium hydride (41 mg, 0.00172 moles) (prewashed with hexane) in mineral oil (69 mg) was added with 5 ml of dioxane to a stirred solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (200 mg, 0.00086 moles) (prepared as set forth in Example A-2) in 50 ml of dioxane. After 3 hours a solution of CH₃I (122 mg, 0.00086 mole) in 10 ml dioxane was added and the mixture was stirred at room temperature for 20 hours. The mixture was concentrated to a solid. The products were partitioned between water (15 ml) and ethyl acetate (50 ml). The organic layer was dried over Na₂SO₄, filtered and concentrated to a solid. The products were purified and separated by radial chromatography. NMR (NOE experiments) showed that the first component off the column (the minor component) was 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl]pyridine, and the second material off the column was 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine.

Major isomer (4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine): m.p.: 94-99° C. Anal. calc'd for C₁₆H₁₅N₃.0.1MH₂O: C, 77.08; H, 6.06; N, 16.85. Found: C, 76.59; H, 5.70; N, 16.62.

EXAMPLE A-204

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine

4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine (the compound of Example A-32)

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine and 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-7).

Major Isomer (4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine): Anal. calc'd for C₁₆H₁₄N₃Cl (283.76): C, 67.72; H, 4.97; N, 14.81; Found: C, 67.45; H, 4.71; N, 14.63. m.p. (DSC): 190.67° C.

Minor Isomer (4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine): m.p.: 82-88° C. Anal. calc'd for C₁₆H₁₄N₃Cl: C, 67.72; H, 4.97; N, 14.81; Found: C, 67.56; H, 4.96; N, 14.73.

EXAMPLE A-205

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine and 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-methylphenyl)-5-ethyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-45).

Major Isomer (4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for C₁₈H₁₉NO₃.0.45MH₂O: C, 75.73; H, 7.03; N, 14.77. Found: C, 76.03; H, 6.87; N, 14.28.

Minor Isomer (4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for C₁₈H₁₉NO₃.0.30MH₂O: C, 76.46; H, 6.99; N, 14.86. Found: C, 76.58; H, 6.98; N, 14.63.

EXAMPLE A-206

4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆N₃Cl (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.33; H, 5.27; N, 14.08; m.p. (DSC) 164.36° C.

Example A-207

4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for C₁₇H₁₆N₃Cl (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.25; H, 5.36; N, 13.74; m.p. (DSC) 153.46° C.

The compounds of Examples A-208 and A-209 were prepared in accordance with the chemistry described above (particularly in Scheme IX):

EXAMPLE A-208

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-fluorobenzoyl-4′-pyridyl methane

To a mixture of 4-picoline (32.6 g, 0.35 moles) and ethyl-4-fluorobenzoate (50.45 g, 0.3 moles), maintained at 20° C., was added lithium bis(trimethylsilylamide) (600 mL (1M)) in a steady but rapid stream so as to maintain ambient temperature. The initial yellow solution turned into a suspension which was then stirred for an additional 2 hours. Toluene (250 mL) was added and the mixture cooled to 0° C. The reaction mixture was quenched with concentrated HCl at 0° C. to lower the pH to about 7. The organic layer was separated and the aqueous layer re-extracted with of toluene (100 mL). The organic layer was dried (sodium sulfate) and concentrated, to furnish a yellow solid which on trituration with hexanes (200 mL) provided the pure desoxybenzoin, 4-fluorobenzoyl-4′-pyridyl methane, in 90% yield (58 g). ¹H NMR was consistent with the proposed structure.

Step 2.

To a suspension of the desoxybenzoin prepared in step 1 (30 g, 0.14 moles) in tetrahydrofuran (50 mL) was added dimethylformamide dimethyl acetal (50 mL) and the mixture stirred at ambient temperature for two days. The solution was then concentrated to dryness and the solid paste obtained was triturated with hexanes (150 mL) to furnish a yellow solid which was of sufficient purity (as determined by NMR) and was used for the next step without additional purification. Yield: 33.9 g (90%). ¹H NMR was consistent with the proposed structure.

Step 3.

The vinyl amine prepared in step 2 (33.9 g, 0.1255 moles) was dissolved in 125 mL of ethanol and cooled to 0° C. Hydrazine hydrate (8.0 g of anhydrous or 16.0 g of hydrate, 0.25 moles) was then added in one portion. The mixture was stirred well and allowed to warm up to ambient temperature for a total reaction time of 3 hours. The mixture was concentrated and taken up in 200 mL of chloroform. After washing with water (100 mL), the organic layer was extracted with 150 mL of 10% HCl. The water layer was then treated with 0.5 g of activated charcoal at 70° C. for 10 minutes, filtered through celite and neutralized cautiously to pH 7-8 with vigorous stirring and cooling (20% sodium hydroxide was used). The fine off-white precipitate was filtered and dried to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine. Yield: 27.3 g. (91%). Mass spectrum: m/z=240. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₇H₁₀FN₃: C, 70.28; H, 4.21; N, 17.56. Found: C, 70.11; H, 4.33; N, 17.61.

EXAMPLE A-209

4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure described for Example A-208 using the corresponding starting reagents.

Anal. Calc'd for C₁₄H₁₀ClN₃: C, 65.76; H, 3.94; N, 16.43. Found: C, 65.22; H, 3.91; N, 16.50. m.p. (DSC): 208.46° C.

The compounds of Examples A-210 and A-211 illustrate were prepared in accordance with the chemistry described above (particularly in Scheme X):

EXAMPLE A-210

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

The desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4′-pyridyl methane, (12.7 g, 0.059 moles) was mixed with 90% hydroxyethyl hydrazine (5.3 g, 0.062 moles) in 30 mL of ethanol containing 0.5 mL of acetic acid in a 500 mL Erlenmeyer flask. After gentle boiling (1 hour), a small sample was evacuated at high vacuum and examined by ¹H NMR to confirm completion of hydrazone formation. On cooling to ambient temperature, the reaction mass solidified to a yellow cake. DMF dimethylacetal (36 mL, 0.27 moles) was then added and the mixture heated to 80 C for 10 min, at which point all the solids dissolved and a clear yellow viscous solution was obtained. The reaction mixture was immediately allowed to cool slowly to 25° C., and water (20 mL) was added dropwise with stirring, at which point a cloudy yellow oily suspension was obtained. The solution was now warmed to approximately 50-60° C., whereupon the solution turned clear yellow. Slow cooling to ambient temperature with stirring (a crystal seed if available speeds up the process) results in a copious formation of crystals. Suction filtration followed by washing with 10% ethanol-water (50 mL), followed by drying, furnishes 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol as a light yellow crystalline solid. Re-heating the filtrate to clarity as before, followed by cooling, yields additional product. The third and fourth recovery from the mother liquor on standing overnight furnishes the remaining 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol. Total yield: {12.3+3.3+0.4+0.4}=16.4 g. (97.6%). Mass spectrum, m/z=284. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₆H₁₄FN₃O+H₂O: C, 63.78; H, 5.35; N, 13.95. Found: C, 63.55; H, 5.07; N, 13.69.

EXAMPLE A-211

3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol

This compound was prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 4-methyl-pyrimidine.

The compound of Example A-212 was prepared in accordance with the chemistry of Scheme XI:

EXAMPLE A-212

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

The vinyl amine prepared in Step 2 of Example A-208 (5.0 g, 0.0185 moles) was taken up in ethanol (75 mL) and cooled to 0° C. Methyl hydrazine (1.7 g, 0.037 moles) in ethanol (75 mL) was added in one portion while maintaining the temperature at 0 to 10° C. After 3 hours at ambient temperature the solvent was removed and the residue taken up in methylene chloride (150 mL) and water (100 mL). The organic layer was separated, dried and concentrated to provide the crude regio-isomeric mixture as a light tan colored solid (80:20 by NMR in favor of the title compound). The crude isomeric mixture was taken up in 10% HCl (100 mL) and washed with methylene chloride (100 mL) and the water layer treated with activated charcoal (0.5 g). After filtration through Celite, the solution was neutralized with sodium hydroxide (20%) to pH 8 with good stirring and cooling. The cream colored precipitate was filtered, washed with water and dried. The solid (5 g) was dissolved in hot 10% heptane/toluene (70 mL) and allowed to cool slowly, first to ambient temperature and then to 15° C. Scratching the sides of the flask starts the crystallization process. After 2 hours of standing, the solids formed were filtered, washed with cold 50% toluene/heptane (25 mL) followed by hexane (25 mL) and dried to yield the pure title compound. ¹H NMR confirmed the structure (including regiochemistry using NOE experiments). Yield: 2.1 g. (45%). Mass spectrum, m/z 254 (base peak). Anal. calc'd for C₁₅H₁₂FN₃+0.2H₂O: C, 70.15; H, 4.86; N, 16.4. Found: C, 70.18; H, 4.6; N, 16.47.

The compound of Example A-213 was prepared in accordance with the chemistry of Scheme XII:

EXAMPLE A-213

2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol

An intimate mixture of 2-fluoro-pyridinyl pyrazole (0.2 g, (prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 2-fluoro-4-methylpyridine) and (R,S)-2-amino-1-butanol (4 fold molar excess) was heated to 210-220° C. in a sealed vial for 1.5 hours. After cooling to 100° C. the vial was cautiously opened and 5 mL of toluene and 5 mL of water were added and stirred well for 1 hour. The solid obtained, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol, was suction-filtered and washed with an additional 5 mL of water followed by toluene and dried. Yield: 190 mg. (71%). Mass spectrum, m/z=343. ¹H NMR was consistent with the proposed structure.

The compound of Example A-214 was prepared in accordance with the chemistry of Scheme XIII:

EXAMPLE A-214

4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (2.7 g, 10.67 mmol) (prepared in accordance with Example A-212) in acetic acid (30 mL) and DMF (13 mL) was added bromine (19.5 g, 122.0 mmol). The solution was heated at 80° C. overnight. TLC indicated that the reaction was complete. The mixture was quenched slowly with K₂CO₃ (25 g). When pH was about 5, a precipitate was formed. The precipitate was washed with water (50 mL×5) to give 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (1.24 g, 35%): mp 174.38° C.; Mass spectrum m/z=332, 334; ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₁₅H₁₁N₃FBr.0.2H₂O: C, 53.66; H, 3.42; N, 12.51. Found: C, 53.58; H, 3.12; N, 12.43.

The compound of Example A-215 was prepared in accordance with the chemistry of Scheme XIV:

EXAMPLE A-215

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

Step 1.

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (4.3 g, 17.97 mmol) (prepared in accordance with Example A-208) in methanol (100 mL) was added 3-chloroperoxybenzoic acid (5.44 g in 57% purity, 17.97 mmol). The solution was stirred at 25° C. for overnight. The mixture was concentrated. K₂CO₃ (10%, 100 mL) was added to the residue. A precipitate was formed, filtered and washed with water (30 mL×3) to give the corresponding N-oxide (3.764 g, 81.66%).

Step 2.

To a suspension of the N-oxide prepared in step 1 (0.40 g, 1.567 mmol) in DMF (5 mL) was added trimethysilyl cyanide (0.3 mL, 2.25 mmol). The mixture was stirred for 15 minutes at 25° C. Dimethylcarbamyl chloride (0.8 mL, 8.69 mmol) was added. The mixture was stirred at 25° C. for 2 hours. TLC indicated that the starting materials were gone. The mixture was partitioned into ethyl acetate:water (100 mL:20 mL). The organic layer was washed with K₂CO₃ (10%, 20 mL), water (50 mL), brine (50 mL), dried over MgSO₄, filtered and concentrated to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (0.23 g, 56% yield): mp 209.22° C.; Mass spectrum (chemical ionization) m/z=265; ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₁₅H₉N₄F.0.2H₂O: C, 67.26; H, 3.54; N, 20.92. Found: C, 67.44; H, 3.40; N, 20.69.

The compound of Example A-216 was prepared in accordance with the chemistry of Scheme XV:

EXAMPLE A-216

4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

Step 1:

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (prepared in accordance with Example A-210) (10.0 g, 0.0353 moles) was suspended in pyridine (100 mL) and cooled to 0° C. Methane sulfonyl chloride (4.4 g, 0.0388 moles) was added slowly while maintaining the temperature at 0° C. After stirring overnight at 10° C., chilled water (100 mL) and methylene chloride (150 mL) was added and the two layers separated. The water layer was re-extracted with 100 mL of methylene chloride and the organic layer dried and concentrated to a paste. After drying at high vacuum, a light tan colored cake was obtained which was triturated with ether (75 mL), filtered and dried to furnish a cream colored solid in 79% yield (10.1 g). ¹H NMR was consistent with the proposed structure. The compound was used as such for step 2.

Step 2:

The mesylate prepared in step 1 (5.0 g, 0.0138 moles) was dissolved in an eight fold excess of morpholine (9.6 g, 0.11 moles) in methanol (50 mL) and heated at reflux for 3 to 4 hours. After an NMR sample confirmed completion, the mixture was concentrated and taken up in methylene chloride (150 mL) and washed with water (100 mL) and then with 75 mL of 5% HCl. The water layer was neutralized to pH 8 and extracted with methylene chloride (100 mL). On drying and concentration a light yellow pasty solid was obtained which was triturated with 25 mL of ether to furnish a solid. Recrystallization from toluene/hexane provided 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine as a solid. Yield: 4.5 g (86%). Mass spectrum, m/z=353. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₂₀H₂₁FN₄O: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.20; H, 6.21; N, 15.80.

The compound of Example A-217 was prepared in accordance with the chemistry of Scheme XVI:

EXAMPLE A-217

3-(4-fluorophenyl)-1-methyl-α-phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol

To solid magnesium (60 mg, 5 mmol) under nitrogen was added a solution of 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (450 mg, 1.35 mmol) (prepared in accordance with Example A-214) in tetrahydrofuran (7 mL). The mixture was heated at 40° C. for 2 hours. Benzaldehyde (1 mL) was added. The mixture was heated to 45° C. for 2 hours. It was quenched with HCl (10 mL, 1N) and washed with ethyl acetate. The aqueous acid layer was basified and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over MGSO₄, filtered and concentrated to give a residue. The residue was purified with a silica gel column to give the title compound (59 mg, 12% yield). MS: m/z=360 (M+1); ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₂₂H₁₈N₂OF.0.6EtOAC: C, 71.1; H, 5.6; N, 10.2; Found: C, 70.9; H, 5.47; N, 10.2.

The compound of Example A-218 was prepared in accordance with the chemistry described above (particularly Scheme XVII):

EXAMPLE A-218

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine

The starting desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4′-pyridyl methane, (1.0 g, 0.0046 moles) was dissolved in 10 mL of DMF and cooled to −10° C. (dry ice-aqueous isopropanol). N-chlorosuccinimide (0.62 g, 0.0046 moles) was added in one portion while maintaining the temperature at −10° C. After 5 minutes the thiosemicarbazide (0.0046 moles) was added in one portion at 0° C. and allowed to warm to ambient temperature slowly over 1 hour. After stirring overnight, the solvent was removed at high vacuum and water and toluene (25 mL each) added and stirred well. The toluene layer was separated and the water layer (starting pH of 5.5) treated with bicarbonate to pH 8. The fine precipitate formed was filtered and washed with water, toluene and ether. A final trituration with ether (25 mL) furnished an off white solid, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine, which was re-filtered and dried. Yield: 0.95 g, (56%). Mass Spec. m/z: 368 (base peak). Anal. Calc'd for C₂₀H₂₂FN₅O. C, 65.38; H, 6.04; N, 19.06. Found: C, 64.90; H, 5.92; N, 18.67.

EXAMPLE A-219

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)pyridinone hydrazone

Step 1: Preparation of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine

4-Methyl-2-bromopyridine (1.0 g, 5.8 mmol) and t-butoxybis(dimethylamino)methane (5 ml) were heated to 150° C. for 16 hours. 4-Methyl-2-bromopyridine was prepared as set forth in B. Adger et al., J. Chem. Soc., Perkin Trans. 1, pp. 2791-2796 (1988), which is incorporated herein by reference. The contents were evaporated and the residue dissolved in ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate and solvent removed in vacuo to give 1.0 g of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethenamine as an oil suitable for use in step 2. Step 2: Preparation of (Z)-2-(2-bromo-4-1-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one

The product from step 1 (1.0 g, 4.4 mmol) was dissolved in methylene chloride (15 ml). Triethylamine (900 mg, 8.8 mmol) was added at 0° C., followed by the addition of 3-chlorobenzoyl chloride (350 mg, 4.5 mmol). The mixture was stirred under nitrogen for 16 hours. Solvent was evaporated in vacuo and the residue was dissolved in ether (25 ml), stirred with magnesium sulfate (500 mg) and silica gel (500 mg), and filtered. Ether was evaporated and the residue was chromatographed on silica gel using mixtures of acetone and methylene chloride as eluents to give 670 mg of the product, (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one, as a glass which was used in step 3 without further purification. Step 3: Preparation of 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine

A solution of the product from step 2 (650 mg, 1.8 mmol) and hydrazine monohydrate (100 mg) in ethanol (10 ml) was refluxed for 24 hours. Solvent was evaporated and the residue was chromatographed on silica gel using mixtures of ethyl acetate and toluene as eluents to give 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine (190 mg, 31%) as an oil: Anal. Calc'd for C₁₄H₉BrClN₃: C, 50.25; H, 2.71; N, 12.56. Found: C, 50.10; H, 2.60; N, 12.40.

Continued elution with mixtures of ethyl acetate and methanol gave 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone (190 mg, 36%) as a crystalline solid: m.p. 163-164° C.; MS (M+H)=286. Anal. Calc'd for C₁₄H₁₂N₅Cl: C, 58.85; H, 4.23; N, 24.51. Found: C, 58.53; H, 4.28; N, 24.87.

EXAMPLE A-220

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (150 mg, 0.5 mmol) in benzylamine (5 ml) was heated at 175° C. for six hours. After cooling, excess benzylamine was removed by high vacuum distillation and ethyl acetate added to the residue. After washing the organic phase with water and drying over magnesium sulfate, the solvent was removed in vacuo and the residue chromatographed on silica gel using mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine (110 mg, 61%) as a solid, m.p. 179-180° C.

Anal. Calc'd For C₂₁H₁₇ClN₄: C, 69.90; H, 4.75; N, 15.53. Found: C, 69.69; H, 4.81; N, 15.11.

EXAMPLE A-221

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (250 mg, 0.75 mmol) in phenethylamine (5 ml) was heated at 175° C. for six hours under a nitrogen atmosphere. The excess amine was distilled off under high vacuum and the residue was dissolved in ethyl acetate and washed with water. After drying over magnesium sulfate and removal of solvent, the residue was chromatographed on silica gel with mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine (230 mg, 81%) as a solid, m.p. 185-186° C.

Anal. Calc'd For C₂₂H₁₉ClN₄: C, 70.49; H, 5.11; N, 14.95. Found: C, 70.29; H, 5.15; N, 14.66.

EXAMPLE A-222

4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (300 mg, 0.9 mmol) in ethylamine (3.5 ml) and ethanol (5 ml) as heated at 150° C. in a sealed tube for 9 hours. The solvent was removed in vacuo and the residue chromatographed on silica gel with 70 ethyl acetate/30 toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine (125 mg, 46%) as a solid, m.p. 186-187° C.

Anal. Calc'd For C₁₆H₁₅ClN₄: C, 64.32; H, 7.06; N, 18.75. Found: C, 64.42; H, 7.01; N, 18.45.

The compounds of Examples A-223 through A-226 were synthesized in accordance with the chemistry described above (particularly in Scheme XVIII) by selection of the corresponding starting reagents:

EXAMPLE A-223

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide

Step 1:

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (prepared as set forth in Example A-208) (8.8 g, 0.037 mol) in methylene chloride was added m-chloroperoxybenzoic acid (mCPBA) in one portion at room temperature. After stirring for 16 hours, solvent was removed and the residue was treated with saturated sodium bicarbonate solution. The precipitate was filtered, air-dried to give 8.2 g of a product as a white solid (87%), mp: 207-209° C.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

To a solution of the product of step 1 (5.1 g, 0.02 mol) in 20 mL of DMF was added trimethylsilyl cyanide (2.5 g, 0.025 mol), followed by a solution of N,N-dimethylcarbamoyl chloride (2.7 g, 0.025 mol) in 5 mL of DMF at room temperature. After stirring overnight, the reaction mixture was basified by 200 mL of 10% potassium carbonate water solution. The aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was triturated with hexane and filtered to give 4.3 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (90%) as a pale yellow solid, mp: 238-239° C.

Step 3: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide:

To a solution of 4-(3-[4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile from step 2 (0.45 g, 0.0017 mol) in 10 mL of DMSO was added hydrogen peroxide (0.24 mL of 30% aqueous solution, 1.7 mmol) and potassium carbonate (0.04 g, 0.4 mmol) at 0° C. The mixture was stirred for 1 hour while allowing it to warm to room temperature. Water was added and the precipitate was collected by filtration and air-dried to give 0.32 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl-2-pyridinecarboxamide as a white solid (67% yield), mp: 230-231° C. Anal. Calc'd for C₁₅H₁₁FN₄O: C, 63.83; H, 3.93; N, 19.85. Found C, 63.42; H, 3.66; N, 19.58.

EXAMPLE A-224

Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide prepared as set forth in Example A-223 (2.9 g, 0.01 mol) in 50 mL of methanol was added N,N-dimethylformamide dimethyl acetal (3.67 g, 0.03 mol) dropwise. The reaction mixture was stirred at room temperature overnight and heated at reflux for 4 hours. After cooling, the precipitate was collected by filtration and air-dried to give 2.0 g of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate as a white solid (69% yield), mp: 239-241° C. Anal. Calc'd for C₁₆H₁₂FN₃O₂: C, 64.64; H, 4.07; N, 14.13. Found: C, 64.36; H, 4.10; N, 14.27.

EXAMPLE A-225

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide

A mixture of methyl 4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.45 g; 1.5 mmol) and 20 mL of methylamine (40% aqueous solution) was heated at 120° C. in a sealed tube for 16 hours. After cooling, water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to afford 0.4 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide as a white solid, mp: 88-89° C. Anal. Calc'd for C₁₆H₁₃FN₄O+0.4H₂O: C, 63.32; H, 4.58; N, 18.46. Found C, 63.10; H, 4.62; N, 18.35.

EXAMPLE A-226

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.90 g, 0.003 mol) in 10 mL of ethanol was added a solution of sodium hydroxide (0.24 g, 0.006 mol) in 5 mL of water. The reaction mixture was heated at reflux for 10 hours. After the removal of solvent, the residue was dissolved in water and acidified with citric acid solution to pH 5. Then the aqueous phase was extracted with ethyl acetate and the organic phase was dried over magnesium sulfate and concentrated. The crude was purified by treating with ether to give 0.62 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid as a white solid (73% yield), mp: 245° C.(dec). Anal Calc'd for C₁₅H₁₀FN₃O+0.2H₂O: C, 62.80; H, 3.65; N, 14.65. Found: C, 62.77; H, 3.42; N, 14.58.

Additional compounds of the present invention which were prepared according to one or more of above reaction schemes (particularly Schemes IX through XVIII) are disclosed in Table 3. The specific synthesis scheme or schemes as well as the mass spectroscopy and elemental analysis results for each compound also are disclosed in Table 3.

TABLE 3 Microanalysis General MS water EtOAc Example Procedure M + 1 C calc C found H calc H found N calc N found added added A-227 IX 240 69 69 4.3 4.6 17.2 16.8 0.25 A-228 IX 266 65.69 65.69 4.41 4.33 15.32 14.98 A-229 XI 254 70.6 70.6 4.8 4.5 16.5 16.3 0.1 A-230 IX 256 65.76 65.48 3.94 3.78 16.43 16.52 A-231 XI 280 64.18 63.95 4.39 4.31 13.86 13.90 A-232 XI 271 66.79 66.79 4.48 4.24 15.58 15.32 A-233 XI 284 66.9 66.8 5 5 14.6 14.9 0.2 A-234 XI 270 65.9 65.6 4.6 4.6 15.4 15.4 0.2 A-235 XI 264 77 76.7 6.5 6.5 15.8 15.7 0.1 A-236 IX 221 75.38 75.44 5.06 5.1 18.84 19 0.1 A-237 IX 290 61.52 61.67 3.58 3.51 14.35 14.32 A-238 XI 304 63.36 63.28 3.99 3.91 13.85 13.83 A-239 IX 258 65.37 65.39 3.53 3.52 16.33 16.31 A-240 IX 274 61.44 61.14 3.31 3.01 15.35 14.95 A-241 IX 300 56.02 55.99 3.36 3.26 14.00 14.01 A-242 XI 272 66.42 66.41 4.09 4.04 15.49 15.32 A-243 XI 314 57.34 57.22 3.85 3.68 13.37 13.27 A-244 IX 342 76.39 76.16 4.81 4.51 12.31 12.05 0.25 A-245 XII 341 64.89 64.65 6.36 6.17 15.93 15.82 0.6 A-246 XII 391 66.08 66.18 5.04 5.56 14.01 12.26 0.5 A-247 XII 362 64.46 64.16 4.65 4.34 18.79 18.65 0.6 A-249 XII 258 64.91 64.84 3.58 3.63 16.22 15.98 0.1 A-250 IX 348 48.44 48.07 2.9 2.82 12.1 12.01 A-251 XI 362 49.88 49.89 3.35 3.51 11.63 11.54 A-252 XI 304 63.36 63.34 3.99 3.96 13.85 13.81 A-253 XII 377 68.24 68.17 5 4.71 14.47 14.34 0.6 A-254 XII 363 66.31 66.12 4.77 4.31 14.73 14.6 1 A-215 XIV 265 67.3 67.4 3.5 3.4 20.9 20.7 0.2 A-255 XII 298 64.63 64.64 5.42 5.41 23.55 23.32 A-256 XI 272 66.42 66.58 4.09 4.26 15.49 14.78 A-257 IX 276 60.11 60.4 3.06 3.18 15.02 14.73 0.25 A-258 IX 254 A-259 XI 268 71.89 71.63 5.28 5.24 15.72 15.84 A-260 X 290 62.28 62.41 3.48 3.48 14.53 14.51 A-261 X, XV 311 69.26 69.2 6.2 6.25 17.95 17.89 0.1 A-262 XI 376 72.71 72.5 5.17 4.98 11.06 10.99 0.25 A-263 XII 428 70.81 70.59 6.28 6.45 15.88 15.08 0.75 A-264 XII 326 63.79 63.76 6.39 6.09 20.66 20.45 0.75 A-265 IX 400 66.18 66.77 4.1 4.23 16.78 15.83 1 A-266 XII 368 62.32 62.38 6.28 6.5 18.17 17.56 1 A-267 XI 302 62.66 62.85 4.47 4.34 13.7 13.53 0.4 A-268 XII 349 62.9 63.2 5.2 4.8 22.7 22.5 0.75 0.1 A-269 XI, XV 371 61.85 61.84 5.71 5.24 14.42 14.17 1 A-270 XI, XV 404 70.66 70.7 4.82 4.61 10.3 10.15 0.25 A-271 XI, XV 329 65.8 65.3 5.5 5.6 17.1 16.8 A-272 XI 406 69.95 70.13 5.35 5.28 10.14 9.89 0.5 A-273 XI 354 66.9 67.2 6.9 6.6 19.1 18.7 0.2 0.1 A-274 XI, XII, 434 63.6 63.1 6.3 5.8 14.4 14 2 0.2 XV A-275 XI, XV 433 70.44 70.74 6.18 6.3 12.64 12.05 0.6 A-276 XI, XII, 476 65.9 66.2 6.1 6.1 13.3 13.6 0.5 0.5 XV A-277 XII 338 61.11 63.02 6.48 6.39 18.75 16.61 A-278 XI, XV 357 64.2 63.8 6.5 6 15 14.8 1 A-279 XI, XII, 462 67.4 67.1 6.7 6.2 13.6 13.7 0.6 0.5 XV A-280 XII 299 61.27 61.47 5.37 5.11 17.86 17.21 0.9 A-281 XII 313 64.63 64.94 5.55 5.63 17.73 17.48 0.2 A-282 XII 313 64.63 64.81 5.55 5.43 17.73 17.38 0.3 A-283 XI, XII 407 67.2 67 5 5.2 13.6 13.2 0.25 A-284 XI, XV 339 70 70.3 6.9 6.9 16.3 16.2 0.25 A-285 XI, XII, 476 68.2 68.5 5.7 6.2 14.7 13.6 XV A-286 XVII 382 59.77 59.69 6.81 6.56 16.6 16.65 2.25 A-287 XVII 340 56.07 56.26 7.31 7.1 17.21 17.27 3.75 A-288 XVII 293 69.42 69.4 4.52 4.6 19.05 19.09 0.1 A-289 XI, XII 407 68 67.5 5 4.5 13.8 13.5 A-290 XI, XII 407 64 64.5 5.3 4.9 13 12.4 1.4 A-291 IX 290 74.7 74.9 4.2 4.2 14.5 14.5 A-292 XVII 326 61.22 61.46 4.77 4.53 16.8 16.97 0.4 A-293 XVII 313 55.75 55.98 4.85 4.02 16.25 16.37 1.8 A-294 XI 278 73.6 73.2 4.4 4.2 15.2 15 A-295 XI 278 67.9 67.7 4.9 4.3 14 13.7 1.3 A-296 IX 70.3 70.4 4.5 4.7 25.2 25.4 A-297 IX 57.9 57.7 3.1 2.9 14.5 14.5

EXAMPLE A-227

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-228

4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine EXAMPLE 229

4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-230

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-231

4-[3-(1,3-benzodioxol-5-y)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-232

4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-233

4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine EXAMPLE 234

4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine and 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-235

2-methyl-4-[1-methyl-3 (or 5)-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-236

4-(3-phenyl-1H-pyrazol-4-yl)pyridine EXAMPLE A-237

4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine EXAMPLE A-238

4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine EXAMPLE A-239

4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-240

4-[3-4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine EXAMPLE A-241

4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-242

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-243

4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-244

(E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethenyl)pyridine EXAMPLE A-245

(S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine EXAMPLE A-246

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxy-phenyl)methyl]-2-pyridinamine EXAMPLE A-247

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine EXAMPLE A-248

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-pyridinemethanamine

Anal Calc'd: C, 41.12; H, 3.58; N, 9.22. Found: C, 41.74; H, 5.05; N, 11.11.

EXAMPLE A-249

2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-250

4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-251

4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-252

4-[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine EXAMPLE A-253

N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-254

N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-255

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-methylhydrazino)pyridine EXAMPLE A-256

2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-257

4-[3-(3,4-difluorophenyl)-H-pyrazol-4-yl]-2-fluoro-pyridine EXAMPLE A-258

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine EXAMPLE A-259

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylpyridine EXAMPLE A-260

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine EXAMPLE A-261

3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine EXAMPLE A-262

2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine EXAMPLE A-263

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine EXAMPLE A-264

N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine EXAMPLE A-265

2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-266

N-[4-[3-(4-fluorophenyl)-1H -pyrazol-4-yl]2-pyridinyl]-4-morpholineethanamine EXAMPLE A-267

3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol EXAMPLE A-268

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine EXAMPLE A-269

4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine EXAMPLE A-270

(E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol EXAMPLE A-271

3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine EXAMPLE 272

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol EXAMPLE 273

4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine EXAMPLE A-274

4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[[4-fluorophenyl)methyl]-2-pyridinamine EXAMPLE A-275

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl) ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine EXAMPLE A-276

N-[(4-fluorophenyl)methyl]-4-[3(or 5)-(4-fluorophenyl)-1-[[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-277

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperadinyl-2-pyridinamine EXAMPLE A-278

N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanamine EXAMPLE A-279

4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine EXAMPLE A-280

2-[[4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol EXAMPLE A-281

2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethanol EXAMPLE A-282

3-[[4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-propanol EXAMPLE A-283

3 (or 5)-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol EXAMPLE A-284

N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine EXAMPLE A-285

N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-286

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine EXAMPLE A-287

N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine EXAMPLE A-288

5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine EXAMPLE A-289

3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol EXAMPLE A-290

5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol EXAMPLE A-291

4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline EXAMPLE A-292

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester EXAMPLE A 293

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine EXAMPLE A-294

4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-295

4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-296

4,4′-(1H-pyrazole-3,4-diyl)bis[pyridine] EXAMPLE A-297

4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine EXAMPLE A-298

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

The pyrimidine-substituted compounds of Examples A-299 through A-312 were synthesized in accordance with the chemistry described in Schemes I-XVIII by selection of the corresponding starting reagents:

EXAMPLE A-299

2-Chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

Step 1:

A mixture of 2,6-dichloro-4-methylpyrimidine (5.0 g, 0.031 mol), triethylamine (6.23 g, 0.062 mol) and catalytic amount of 5% Pd/C in 100 mL of THF was hydrogenated on a Parr apparatus under 40 psi at room temperature. After 0.5 hour, the catalyst was filtered and the filtrate was concentrated. The crude was purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 2.36 g of product as a pale yellow crystal (50% yield); mp: 47-49° C. Step 2: Preparation of 2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone

2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone

To a solution of lithium diisopropylamide (generated from BuLi (0.045 mol) and diisopropylamine (0.048 mol) in THF) at −78° C. was added a solution of the compound prepared in step 1 (5.5 g, 0.037 mol) in THF slowly over 30 minutes. After 1 hour, a solution of ethyl 4-fluorobenzoate (7.62 g, 0,045 mol) in THF was added and the reaction mixture was stirred overnight and allowed to warm up to room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 4.78 g of a yellow solid (51% yield), mp: 112-113° C. Step 3: Preparation of (E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one

(E)-2-(2-chloro-4-pyrimidiny)-3-dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one

A mixture of the compound prepared in step 2 (4.7 g, 0.17 mol) in 100 mL of dimethylformamide dimethyl acetal was stirred at room temperature overnight. Excess dimethylformamide dimethyl acetal was removed under vacuum to give 4.5 g of crude product as a thick brown oil, which was used without further purification.

Step 4: Preparation of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

A solution of the compound prepared in step 3 (4.4 g) and hydrazine hydrate (0.82 g, 0.014 mol) was stirred at room temperature for 6 hours. The yellow precipitate was collected by filtration and air-dried to give 1.85 g of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine as a yellow solid, mp: 204-205° C.; Anal. Calc'd for C₁₃H₈ClFN₄: C, 56.84; H, 2.94; N, 20.40; Cl, 12.91. Found: C, 56.43; H, 2.76; N, 20.02; Cl, 12.97.

EXAMPLE A-300

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone

A solution of the compound prepared in step 3 of Example A-299 (1.5 g) and hydrazine hydrate (5 mL) in ethanol was heated at reflux overnight. After the reaction mixture was cooled, the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by recrystallization from ethyl acetate and hexane to give 0.5 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone, as a pale yellow solid (38% yield), mp: 149-150° C.; Anal. Calc'd for C₁₃H₁₁FN₆: C, 57.77; H, 4.10; N, 31.10. Found: C, 57.70; H, 4.31; N, 30.73.

EXAMPLE A-301

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

Step 1: Preparation of

A solution of the compound prepared in step 2 of Example A-299 (3.0 g, 0.02 mol) and tertbutylbis(dimethylamino)methane (10.45 g, 0.06 mol) in 40 mL of DMF was stirred at 110° C. overnight. After the solvent was removed under vacuum, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by recrystallization from ethyl acetate and hexane to give 1.23 g of a yellow solid product (32% yield), mp: 76-77° C.; Anal. Calc'd for C₁₀H₁₆N₄: C, 62.47; H, 8.39; N, 29.14. Found: C, 62.19; H, 8.58; N, 29.02.

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

To a solution of the compound prepared in step 1 of the present Example (1.2 g, 0.0064 mol) and triethylamine (0.65 g, 0.0064 mol) in 10 mL of toluene was added 4-fluorobenzoyl chloride dropwise. The mixture was heated at reflux for 10 hours and the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude (1.6 g) was then dissolved in 50 mL of ethanol. The solution was treated with hydrazine hydrate (0.36 g, 0.006 mol) and the mixture was heated at reflux for 2 hours. After ethanol was removed, the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.6 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine, as a yellow solid (33% yield), mp: 155-156° C.; Anal. Calc'd for C₁₅H₁₄FN₅: C, 63.59; H, 4.98; N, 24.72. Found: C, 63.32; H. 4.92; N, 24.31.

EXAMPLE A-302

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

A suspension of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 (0.3 g, 0.0011 mol) in 10 mL of methylamine (40% water solution) was heated in a sealed tube at 100° C. overnight. The mixture was then cooled to room temperature and the precipitate was filtered, air-dried to give 0.2 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine, as a white solid (68% yield), mp: 217-218° C.; Anal Calc'd for C₁₄H₁₂FN₅: C, 62.45; H, 4.49; N, 26.01. Found: C, 62.58; H, 4.36; N, 25.90.

EXAMPLE A-303

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine

This compound was synthesize by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in benzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine, was obtained as a white solid in 95% yield; mp: 216-217° C.; Anal. Calc'd for C₂₀H₁₆FN₅: C, 69.55; H, 4.67; N, 20.28. Found: C, 69.73; H, 4.69; N, 19.90.

EXAMPLE A-304

N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

This compound was synthesized by stirring 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 with excess cyclopropylamine in methanol at 50° C. for 12 hours. The product, N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, was obtained as a white solid in 26% yield, mp: 203-204° C.; Anal. Calc'd for C₁₆H₁₄FN_(5: C,) 65.07; H, 4.78; N, 23.71. Found: C, 64.42; H, 4.82; N. 23.58.

EXAMPLE A-305

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine

This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in 4-methoxybenzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine, was obtained as a off-white solid in 80% yield, mp: 183-185° C.; Anal. Calc'd for C₂₁H₁₈FN₅O: C, 67.19; H, 4.83, N, 18.66. Found: C, 67.01; H, 5.11; N, 18.93.

EXAMPLE A-306

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

A solution of 4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine prepared in accordance with Example A-305 (0.35 g, 0.00093 mol) in 15 mL of trifluoroacetic acid was heated at reflux for 16 hours. Solvent was removed and the residue was partitioned between ethyl acetate and 1 N ammonia hydroxide. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate) to give 0.14 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, as a pale yellow solid (59% yield), mp: 273-274° C.; Anal. Calc'd for C₁₃H₁₀FN₅.0.25H₂O: C, 60.11; H, 4.07; N, 26.96. Found: C, 60.15; H, 3.82; N, 26.38.

EXAMPLE A-307

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide

To a mixture of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine prepared in accordance with Example A-303 (0.15 g, 0.00043 mol), DMAP (0.027 g, 0.00022 mol) and acetic anhydride (0.066 g, 0.00066 mol) in 10 mL of THF was added triethylamine (0.053 g, 0.00052 mol). The solution was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated NaHCO₃, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was triturated with ether to give 0.1 g of product, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide, as a white solid (60% yield), mp: 176-178° C.; Anal. Calc'd for C₂₂H₁₈FN₅: C, 68.21; H, 4.68; N, 18.08. Found: C, 67.67; H, 4.85; N, 17.79.

EXAMPLE A-308

Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine prepared in accordance with Example A-306 (0.26 g, 0.001 mol) in 5 mL of pyridine was added ethyl chloroformate dropwise. After the addition, the clear solution was stirred at room temperature for 6 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was trituated with ether to give 0.15 g of product, ethyl (4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate, as a white solid (46% yield), mp: 163-165° C.; Anal. Calc'd for C₁₆H₁₄FN₅O₂: C, 58.71; H, 4.31; N, 21.04. Found: C, 59.22; H, 4.51; N, 21.66.

EXAMPLE A-309

4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared by the same procedure as described for Example A-208 except that 1-methyl-3-(4′-pyrimidinylacetyl)benzene (prepared as set forth in Step 1 of Example A-19 from 4-methyl-pyrimidine and methyl 3-methylbenzoate) was used in place of 4-fluorobenzoyl-4-pyridinyl methane.

Anal. Calc'd for C₁₄H₁₂N₄ (236.27): C, 71.17; H, 5.12; N, 23.71. Found C, 70.67; H, 5.26; N, 23.53. m.p. (DSC): 151.67° C.

EXAMPLE A-310

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄Cl.0.25MH₂O: C, 59.78; H, 3.67; N, 21.45. Found: C, 59.89; H, 3.32; N, 21.56. m.p. (DSC): 218.17° C.

EXAMPLE A-311

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄F (240.24): C, 64.99; H, 3.78; N, 23.22. Found: C, 64.78; H, 3.75; N, 23.31. m.p. (DSC): 168.58° C.

EXAMPLE A-312

4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for C₁₃H₉N₄F (240.24): C, 64.99; H, 3.78; N, 23.32. Found: C, 64.94; H, 3.56; N, 23.44. m.p. (DSC): 191.47° C.

EXAMPLE A-313

The compound 1-[(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme VII:

Step 1: Preparation of 5-(4-fluorophenyl)-4-(4pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (5.8 g, 24.0909 mmol; prepared as set forth in Example A-4) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 mL) and tert-butanol (10 mL) was heated to reflux at 95 to 100° C. for 6 hours (or until all the potassium permanganate was consumed) and stirred at room temperature overnight. The mixture was diluted with water (150 mL) and filtered to remove manganese dioxide. The aqueous filtrate (pH>10) was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to a pH of about 6.5. A white precipitate was formed. This precipitate was collected by filtration, dried in air, and then dried in a vacuum oven overnight at 50° C. to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (2.7677 g, 40.6%). The remaining product (0.21 g, 3.1%) was isolated from the mother liquid by reverse phase chromotograhpy. The total isolated yield of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate was 43.7%. Anal. Calc'd for C₁₅H₁₀N₃FO₂.H₂O: C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH⁺): 284 (base peak). Step 2: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate

In a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate (0.9905 g, 3.5 mmol) from step 1 and 1-hydroxybenzotriazole hydrate (0.4824 g, 3.57 mmol) in dimethylformamide (20 mL) at 0° C. under N₂, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6983 g, 3.57 mmol) was added. The solution was stirred at 0° C. under N₂ for 1 hour, then was added 1-tert.-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) followed by N-methyl morpholine (0.40 mL, 3.6 mmol). The reaction was stirred from 0° C. to room temperature overnight. The reaction mixture was diluted with ethyl acetate and saturated NaHCO₃ solution, extracted. The organic layer was washed with water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure, and crude product was obtained (1.7595 g). The desired product 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)carbonyl]-1-piperazinecarboxylate (1.2375 g, 78.4%) was isolated by chromatography (silica gel, 10:90 isopropyl alcohol/toluene). Anal. Calc'd for C₂₄H₂₆N₅FO₃: C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH⁻): 452 (base peak).

Step 3: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine

To a suspension of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (0.451 g, 1.0 mL) in dry tetrahydrofuran (8 mL), 1.0N LiAlH₄ in tetrahydrofuran (2.5 mL, 2.5 mmol) was added dropwise at such a rate as to maintain reflux over 15 minutes. Upon the addition, the suspension became a clear light yellow solution, which was kept boiling for an additional 1.5 hours. Excess LiAlH₄ was decomposed by cautious addition of a solution of KOH (0.5611 g, 1.0 mmol) in water (3.5 mL). Upon hydrolysis, a white salt precipitated. After the addition was completed, the mixture was heated to reflux for 1 hour. The hot solution was filtered by suction through a buchner funnel. Any remaining product was extracted from the precipitate by refluxing with tetrahydrofuran (10 mL) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure to give a crude residue, which was then diluted with ethyl acetate and washed with water and brine. The organic layer was dried over MgSO₄. After filtration, the solvent was removed under reduced pressure, and a crude product was obtained. The desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine (0.1509 g, 50.1%) was obtained by chromatography (silica gel, 70:30:1 methanol/ethyl acetate/NH₄OH). Anal. Calc'd for C₂₀H₂₂N₅F.0.6H₂O: C, 66.32; H, 6.46; N, 19.33; Found: C, 66.31; H, 5.96; N, 18.83. MS (MH⁺): 352 (base peak).

EXAMPLE A-314

The compound 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was prepared in accordance with general synthetic Scheme VII:

Step 1: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monhydrate

A solution of 1,1-dimethylethyl 4-[[5-(4fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (0.6349 g; 1.4077 mmol; prepared as set forth in step 2 of Example A-313) in methylene chloride (3.5 mL) and TFA (1.1 mL, 14.077 mmol) was stirred at room temperature under N₂ for 2 hours. The solvents were removed under reduced pressure, and TFA was chased by methylene chloride and methanol. The resulting colorless oily residue was triturated with methanol. The resulting solid was collected by filtration and dried in a vacuum oven overnight to give the desired product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (0.7860 g, 96.4%). Anal. Calc'd for C₁₉H₁₈N₅OF.2TFA.H₂O: C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH⁺): 352 (base peak).

Step 2: Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine

By following the method of Example A-313, step 3 and substituting of 1-[(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate (prepared in step 1 of this Example) for 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate, the title product 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperazine was obtained. Anal. Calc'd for C₁₉H₂₀N₅F.0.75H₂O: C, 65.03, H, 6.18, N, 19.96. Found: C, 65.47, H, 5.83, N, 19.35. MS (MH⁺): 338 (base peak).

EXAMPLE A-315

The compound 4-[3-(4-fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme XX:

Step 1: Preparation of ethyl 1[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate

Ethyl 4-pyridyl acetate was converted to 2-(4-piperidinyl) ethyl acetate hydrochloride by hydrogenation (60 psi H₂) catalyzed by 5% Pt/C at 40° C. in ethanol and HCl solution. To a solution of 2-(4-piperidinyl)ethyl acetate hydrochloride (21.79 g, 0.105 mol) in tetrahydrofuran (500 mL) at 0° C., triethylamine (32.06 mL, 0.230 mL) was added followed by di-tert-butyldicarbonate (23.21 g, 0.105 mol). The reaction mixture was stirred under N₂ from 0° C. to room temperature overnight. After removing tetrahydrofuran, the reaction mixture was diluted with ethanol, washed with saturated NaHCO₃, 10% citric acid, water and brine, and dried over MgSO₄. After filtration, the solvent was removed under reduced pressure. The resulting oily product was dried under vacuum to give ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (27.37 g, 95.9%). The structure of this product was confirmed by NMR. Step 2: Preparation of 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate

To a solution of diisopropylamide (6.15 mL, 43.91 mmol) in dry tetrahydrofuran (40 mL) at 0° C. was added 2.5 M butyl lithium solution in hexane (16.22 mL, 40.53 mmol) dropwise over 10 minutes. After the addition, the lithium diisopropylamide solution was stirred at 0° C. for 20 minutes, then cooled to −78° C. 4-Picoline (3.98 mL, 40.53 mmol) was added to the above lithium diisopropylamide solution under N₂ dropwise over 10 minutes The resulting solution was stirred at −78° C. under N₂ for 1.5 hours, then transfered into a suspension of anhydrous cerium chloride (10.0 g, 40.53 mmol) in tetrahydrofuran (40 mL) at −78° C. under N₂. The mixture was stirred at −78° C. under N₂ for 2 hours, then a solution of ethyl 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidineacetate (from step 1 of this Example) (10.98 g, 40.53 mmol) in tetrahydrofuran (40 mL) was added slowly for 1 hour. The mixture was stirred under N₂ from −78° C. to room temperature overnight. The reaction was quenched with water, diluted with ethyl acetate, and washed with a pH 7 buffer. The organic layer was washed with water and brine. After filtration, the solvent was removed under reduced pressure to give a crude product mixture. The desired product 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate (3.19 g, 25%) was isolated by chromatography (silica gel, 50:50-75:25-100:0 ethyl acetate/hexane). Step 3: Preparation of 1,1-dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1piperidinecarboxylate

1,1-Dimethylethyl 4-[4-(4-fluorophenyl)-2-oxo-3-(4-pyridinyl)-3-butenyl]-1-piperidinecarboxylate was prepared by the same method as described for step 1 of Example A-1 by replacing 4-pyridylacetone and 3-fluoro-p-anisaldehyde with the ketone of step 2 of the present Example and 4-fluorobenzaldehyde, respectively. Step 4: Preparation of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate

1,1-Dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate was prepared by the same method as described for step 3 of Example A-2 by replacing 4-phenyl-3-(4-pyridyl)-3-butene-2-one with the α, β unsaturated ketone of step 3 of the present Example. Step 5: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate

To a solution of 1,1-dimethylethyl 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl) oxiranyl]-2-oxoethyl]-1-piperidinecarboxylate prepared in step 4 of this Example (3.45 g, 7.8409 mmol) in ethanol (15 mL), anhydrous hydrazine (0.50 mL, 15.6818 mmol) was added. The reaction was heated to reflux overnight. The reaction solution was cooled to room temperature and ethanol was removed under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, and dried over MgSO₄. After filtration the solvent was removed under reduced pressure. The crude residue was purified by chromatography (silica gel, 2:1-1:1-1:2 hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4,5-dihydro-4-hydroxy-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (1.9187 g, 53.9%). This intermediate (1.8611 g, 4.0993 mmol) was dissolved in dry methylene chloride (40 mL) and treated with Martin sulfurane dehydrating reagent (4.13 g, 6.1490 mmol). The reaction solution was stirred at room temperature under N₂ overnight, then diluted with ethyl acetate, washed with 1N sodium hydroxide solution, water and brine, dried over MgSO₄. After filtration the solvents were removed. The resulting crude pruduct mixture was purified by flash chromatoghaphy (silica gel, 2:1-1:1-1:2 Hexane/ethyl acetate) to give 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-1-piperidinecarboxylate (0.6964 g, 39%).

Step 6: Preparation of 4-[3-(4-fluorophenyl)-5-(4piperidinylmethyl)-1H-pyrazol-4-yl]pyridine

4-[3-(4-Fluorophenyl)-5-(4-piperidinylmethyl)-1H-pyrazol-4-yl]pyridine was prepared using the same method as described for Example A-314, step 1 by replacing 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine, monohydrate with the pyrazole of step 5 of the present Example. Anal. Calc'd for C₂₀H₂₁N₄F.2TFA.1.25H₂O: C, 49.11; H, 4.38; N, 9.54; Found: C, 48.74; H, 4.02; N, 9.57. MS (MH⁺): 337 (base peak).

EXAMPLE A-316

4-[3-(4-fluorophenyl)-5-[[(1-methyl-4-piperidinyl)methyl]-1H-pyrazol-4-yl]pyridine was prepared by the same method as described for step 3 of Example A-313 by replacing 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate with the pyrazole of step 5 of the present Example. Anal. Calc'd for C₂₁H₂₃N₄F.0.2H₂O: C, 71.24; H, 6.66; N, 15.82; Found: C, 71.04; H, 6.54; N, 15.56. MS (MH⁺): 351 (base peak).

EXAMPLE A-317

The compound 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate was prepared in accordance with general synthetic Scheme II:

2-(4-Pyridyl)-1-(4-fluorophenyl)ethanone hydrochloride (5.9 g, 0.023 moles) was dissolved in a methylene chloride/methanol solution (70/15) at room temperature and N-chlorosuccinimide (3.25 g, 0.024 moles) was added as a solid. The mixture was stirred at room temperature for 2.5 hours. N-methylpiperazinylthiosemicarbazide (4.1 g, 0.023 moles) was added as a solid and the mixture was stirred for 3 days at room temperature. The mixture was diluted with 100 mL of methylene chloride and washed with saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO₄) and solvent removed using a rotary evaporator. The residue was treated with ethyl acetate with stirring while cooling in an ice bath. The solid formed was filtered and recrystallized from ethyl acetate with a small amount of methanol to give 1.7 g (22%) of 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate. Anal. Calc'd. for C₁₉H₂₀FN₅.2H₂O: C, 61.11; H, 6.48; N, 18.75. Found: C, 60.59; H, 6.41; N, 18.44. M.p. (DSC) 262-264° C.; MH+=338.

EXAMPLE A-318

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate was prepared in accordance with general synthetic Scheme VII:

To a mixture of sodium hydride (30 mg, 1.5 mmol) in dimethylformamide (25 mL) stirred under a nitrogen atmosphere at room temperature was added 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonylpiperazinyl)pyrazole (500 mg, 1.1 mmol; prepared as set forth in Example A-169). After stirring for 1 hour, propargyl bromide (225 mg, 1.5 mmol, 80% solution in toluene) was added. After stirring for an additional 2 hour at room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried with MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed on silica gel using 70% ethyl acetate/hexane as the eluent to give 110 mg of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonyl-piperazinyl)pyrazole (24%), m.p. 204-205° C. Anal. Calc'd. for C₂₆H₂₈ClN₅O₂: C, 65.33; H, 5.90; N, 14.65. Found: C, 65.12; H, 5.81; N, 14.70.

A solution of HCl in methanol (5 mL) was generated by addition of acetyl chloride (200 mg) to methanol while cooling (5° C.). 3-(4-Chlorophenyl)-4-(4-pyridyl)-5-(4-N-tert.-butoxycarbonylpiperazinyl)pyrazole (100 mg, 0.2 mmol) prepared above was added and the reaction stirred in the cold for one hour. The reaction mixture was concentrated in vacuo and the residue azeotroped with toluene to give 100 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1-(2-propynyl)-1H-pyrazol-3-yl]piperazine, trihydrochloride monohydrate (90%), m.p.=231-233° C. (dec.). Anal. Calc'd. for C₂₁H₂₀N₅Cl.3HCl.H₂O: C, 49.92; H, 4.99; N, 13.86. Found: C, 49.71; H, 4.89; N, 13.61.

EXAMPLE A-319

The compound methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate was prepared in accordance with general synthetic Scheme II:

Methyl chloroformate (55 mg) was added to a solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl) pyrazole (200 mg, 0.54 mmol; prepared as set forth in Example A-169) and 4-dimethylaminopyridine (5 mg) in pyridine (10 mL). The mixture was stirred at room temperature for 3 hours. Additional methyl chloroformate (30 mg) was added and stirring was continued for 24 hours. The solvent was removed in vacuo. The residue was treated with water and extracted with ethyl acetate. After drying the organic layer (MgSO₄), the solvent was blown down to a volume of 10 mL and refrigerated. The resultant crystalline solid was filtered and air dried to give 103 mg (48%) of methyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate, monohydrate, mp 264-265° C. Anal. Calc'd. for C₂₀H₂₀ClN₅O₂.H₂O: C, 57.76; H, 5.33; N, 16.84. Found: C, 57.98; H, 4.89; N, 16.44.

EXAMPLE A-320

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate was prepared in accordance with general synthetic Scheme II:

A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), methanesulfonyl chloride (75 mg) and 4-dimethylaminopyridine (5 mg) in pyridine was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the residue was treated with water. The resultant crystalline solid was filtered, air dried and recrystallized from methanol and water to give 118 mg (37%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(methylsulfonyl)piperazine, monohydrate, m.p. 245-248° C. Anal. Calc'd. for C₁₉H₂₀ClN₅SO₂.H₂O: C, 52.35; H, 5.09; N, 16.07. Found: C, 52.18; H, 5.31; N, 16.00.

EXAMPLE A-321

The compounds 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate, and 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate, were prepared in accordance with general synthetic Scheme II:

A solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperzinyl)pyrazole (200 mg; 0.54 mmol; prepared as set forth in Example A-169), succinic anhydride (60 mg, 0.55 mmol) and 4-dimethylaminopyridine (5 mg) was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue treated with methanol and water (1:1). The resultant crystalline solid was filtered and air dried to give 170 mg (58%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate, m.p. 281-283° C. (dec.). Anal. Calc'd. for C₂₂H₂₂ClN₅O₃.2H₂O: C, 55.52; H, 5.51; N, 14.72. Found: C, 55.11; H, 5.20; N, 14.44.

A slurry of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, dihydrate (150 mg, 0.31 mmol) from above in methanol (10 mL) was treated with a solution of sodium hydroxide (12 mg, 0.31 mmol) in methanol (2 mL). The reaction was stirred at room temperature for 15 minutes until dissolution was completed. The solvent was removed in vacuo. The residue was treated with tetrahydrofuran and filtered and air dried to give 150 mg (97%) of 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-γ-oxo-1-piperazinebutanoic acid, monosodium salt dihydrate as a solid. Anal. Calc'd. for C₂₂H₂₁ClN₅O₃Na.2H₂O: C, 53.07; H, 5.06; N, 14.07. Found: C, 52.81; H, 5.11; N, 13.90.

EXAMPLE A-322

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine was prepared in accordance with general synthetic Scheme II:

To a solution of 3-(4-chlorophenyl)-4-(4-pyridyl)-5-(4-piperazinyl)pyrazole (1.95 g; 5.8 mmoles; prepared as set forth in Example A-169) and acetic acid (3.6 g, 60 mmol) containing 5A molecular sieves (6 g) was added [(1-ethoxycyclopropyl)oxy]trimethylsilane (6 g, 35 mmol). After stirring for 5 minutes, sodium cyanoborohydride (1.7 g, 26 mmol) was added and the mixture was refluxed under a nitrogen atmosphere for 6 hours. The reaction mixture was filtered hot and the filtrate concentrated in vacuo. Water (50 mL) was added and the solution made basic with 2N sodium hydroxide. The resultant gel was extracted with dichloroethane and the combined organic extracts dried (MgSO₄). Evaporation again yielded a gel which was treated with hot methanol. Upon cooling, the product crystallized to give 1.4 g (63%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-4-cyclopropylpiperazine, m.p. 264-265° C. Anal. Calc'd. for C₂₁H₂₂ClN₅.1.5H₂O: C, 61.99; H, 6.19; N, 17.21. Found: C, 62.05; H, 5.81; N, 16.81.

EXAMPLE A-323

The compound 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine was prepared in accordance with general synthetic Scheme V:

To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of dimethylformamide was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hour. Then 2-(trimethylsilyl)ethoxymethyl chloride (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by cautiously adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel using ethyl acetate/hexane (8:2) as the eluent to give 4.0 g of the major regioisomer as a clear oil.

To a solution of 4-fluorobenzoyl-4′-pyridyl methane (8.6 g, 0.04 mol, prepared as set forth in Step 1 of Example A-208) in 150 mL of ethanol was added p-methoxyphenylhydrazine hydrochloride (7.34 g, 0.042 mol), followed by triethylamine (4.05 g, 0.04 mol). The reaction mixture was refluxed for 16 hours. After the removal of solvent, the residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated and the crude residue was purified by recrystallization from ethyl acetate and hexane to give 8.45 g of the product hydrazone as a yellow solid. To a solution of sodium hexamethyldisilazide (9 mL of 1.0 M tetrahydrofuran solution, 0.009 mol) was added a solution of this hydrazone (1.35 g, 0.004 mol) in 10 mL of dry tetrahydrofuran at 0° C. After stirring for 30 minutes at this temperature, a solution of the regioisomer prepared above (1.1 g, 0.0042 mol) in 5 mL of dry tetrahydrofuran was added dropwise. The reaction mixture was stirred for 3 hours at room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by chromatography on silica gel using ethyl acetate as the eluent to give 0.74 g of the desired product as an orange solid (34%). Deprotection of the above solid by using tetrabutylammonium fluoride afforded 0.37 g of 4-[3-(4-fluorophenyl)-5-(1H-imidazol-4-yl)-1-(4-methoxyphenyl)-1H-pyrazol-4-yl]pyridine as a yellow solid (75%), mp: 124-126° C. Anal. Calc'd. for C₂₄H₁₈FN₅O.0.5H₂O: C, 68.56; H, 4.55; N, 16.66. Found: C, 68.44; H, 4.39; N, 16.00.

EXAMPLE A-324

The compound 4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:

A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.28 g; 0.001 mol; prepared as set forth in Example A-299) and 10 mL propargylamine was heated at reflux for 16 hour. Excess amine was removed in vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated and the residue purified by chromatography on silica gel using ethyl acetate/hexane (1:1) as the eluent to give 0.21 g of 4-[3-(4-fluorophenyl)-1H-pyazol-4-yl]-N-2-propynyl-2-pyrimidinamine as a pale yellow solid (68% yield), mp: 186-187° C. Anal. Calc'd. for C₁₆H₁₂FN₅: C, 65.52; H, 4.12; N, 23.88. Found: C, 64.99; H, 4.15; N, 23.91.

EXAMPLE A-325

The compound N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:

A mixture of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine (0.37 g; 0.0013 mol; prepared as set forth in Example A-299), 7 mL of 2-fluoroaniline and 2 drops of methanol was heated at 180° C. in a sealed tube for 16 hours. Excess amine was removed by vacuum distillation and the residue was treated with ethyl acetate to give 0.35 g of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine as a yellow solid (77%), mp: 239-240° C. Anal. Calc'd. for C₁₉ ₁₃F₂N₅: C, 65.33; H, 3.75; N, 20.05. Found: C, 64.95; H, 3.80; N, 19.77.

EXAMPLE A-326

The compound 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)-2-pyrimidinamine was prepared in accordance with general synthetic Scheme XII:

4-3-(4-Fluorophenyl)-1H-pyrazol-4-yl]]-N-(2-methoxyphenyl)-2-pyrimidinamine was synthesized in 41% yield using the same method described for the preparation of N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine in Example A-325 using 2-methoxyaniline in place of 2-fluoroaniline; mp: 265° C. (dec.). Anal. Calc'd. for C₂₀H₁₆FN₅O: C, 66.47; H, 4.46; N, 19.38. Found: C, 66.70; H, 4.53; N, 19.20.

EXAMPLE A-327

The compound 1-[5-(3-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was prepared in accordance with general synthetic Scheme II:

1-[5-(3-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine was synthesized in 12% yield as a pale yellow solid using the same method described for the preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine in Example A-170 using 2-(4-pyridyl)-1-(3-chlorophenyl)ethanone in place of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone; mp: 229-231° C. Anal. Calc'd. for C₁₉H₂₀ClN₅.0.4H₂O: C, 63.21; H, 5.81; N, 19.40. Found: C, 62.85; H, 5.57; N, 19.77.

Additional aminopyrazole compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents include the compounds disclosed in Table 3-1 below.

TABLE 3-1 Theoretical Found EXAMPLE FORMULA MW C H N C H N DSC (mp) A-328 C₁₈H₁₈ClN₅.⅛H₂O 342.08 63.20 5.30 20.47 63.04 5.36 20.33 199° C. A-329 C₂₃H₃₃ClN₆O₂ 533.08 65.34 6.24 15.77 64.98 6.11 15.58 (168- 171° C.) A-330 C₂₃H₂₅ClN₅O₂ 457.94 60.33 5.50 15.29 59.97 5.52 15.17 (253- 255° C.) A-331 C₂₂H₂₄ClN₅O₂ 425.92 62.04 5.68 16.44 61.64 5.94 16.29 (273- 275° C.) A-332 C₁₉H₂₃Cl₄N₅.H₂O 481.26 47.42 4.82 14.35 47.66 5.11 13.74 (217- 219° C.) A-333 C₂₁H₂₀ClN₅.2.5H₂O 422.92 59.64 4.77 16.56 59.67 4.88 15.96 (247° C.) (d) A-334 C₂₀H₂₂ClN₅.¼H₂O 372.39 64.51 5.96 18.81 64.79 5.97 18.95 242° C. A-335 C₂₄H₂₂ClN₅.¾H₂O 429.44 67.13 5.16 16.31 67.04 5.31 16.32 230° C. A-336 C₂₅H₂₄ClN₅O.¼H₂O 450.46 66.66 5.37 15.55 66.64 5.11 15.69 (270- 271° C.) A-337 C₂₂H₂₄FN₅O₂.H₂O 427.48 61.81 5.66 16.38 61.88 5.96 16.41 249° C. A-338 C₂₀H₂₂FN₅.½H₂O 360.44 66.65 6.15 19.43 66.74 6.59 19.37 241° C. A-339 C₁₉H₂₀FN₅.3HCl.½H₂O 455.79 50.07 5.09 15.30 49.87 5.47 15.30 (237- 239° C.)

EXAMPLE A-328

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine EXAMPLE A-329

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-[(phenylmethyl)amino]-4-pyridinyl-1H-pyrazol-3-yl]amino]propyl]carbamate EXAMPLE A-330

1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate EXAMPLE A-331

ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate EXAMPLE A-332

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-3H-pyrazol-3-yl]-4-piperidineamine, trihydrochloride, monohydrate EXAMPLE A-333

The compound 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine was prepared in accordance with general synthetic Scheme II. To a suspension of of 1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (92 mg, 0.27 mmole) in 2 mL of dimethylformamide was added 75 mg (0.54 mmole) of anhydrous potassium carbonate and then 60 microliters of 80% propargyl bromide solution in toluene (containing 64 mg, 0.54 mmole). The resulting mixture was stirred for 30 minutes and then partitioned betwen ethyl acetate and water. The aqueous layer was further extracted with ethyl acetate, and the combined organic extracts filtered through silica gel using 10% methanol-ethyl acetate as eluent to give, after evaporation of the appropriate fractions, 34 mg of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-propynyl)piperazine as a pale yellowish solid, m.p. 247° C. (decomp.). Anal. Calc'd. for C₂₁H₂₀ClN₅.2.5H₂O (MW 422.92): C, 59.64, H, 4.77, N, 16.56. Found: C, 59.67, H, 4.88, N, 15.96.

EXAMPLE A-334

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine EXAMPLE A-335

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-phenylpiperazine EXAMPLE A-336

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(2-methoxyphenyl)piperazine EXAMPLE A-337

Ethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate, monohydrate EXAMPLE A-338

N-[5-(4-fluorophenyl)-4-(pyridinyl)-1H-pyrazol-3-yl]-1-methyl-4-piperidinamine

EXAMPLE A-339

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride EXAMPLE A-340

The compound of Example A-170 was also synthesized in the following manner. 1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine (12.2 g, 36 mmol, prepared as set forth in Example A-169), 88% formic acid (20 mL), and formaldehyde (37% formalin solution; 44 g, 540 mmol) were combined and stirred at 60° C. for 16 hours under a nitrogen atmosphere. Excess solvent was removed on the rotary evaporator and the residue was dissolved in water (150 mL). The pH was adjusted to 8-9 by addition of solid sodium bicarbonate. The resulting precipitate was filtered and air dried. It was then treated with hot methanol (400 mL), filtered and blown down to a volume of 75 mL, cooled and filtered. After drying in a vacuum is oven at 80° C. overnight, there was obtained 8.75 g (68%) of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, m.p. 262-264° C. Anal. Calc'd. for C₁₉H₂₀N₅Cl: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.04; H, 5.68; N, 19.63.

The compounds of Examples A-341 through A-345 were synthesized, for example, in accordance with the chemistry described in Scheme XXI by selection of the corresponding starting reagents.

EXAMPLE A-341

The compound of Example A-170 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone

To a solution of 2-(4-pyridyl)-1-(4-chlorophenyl)ethanone (70.0 g, 0.3 mol) prepared in a similar manner as the compound of Step 1 of Example A-19, dibromomethane (200 mL) and carbon disulfide (25.9 g, 0.34 mol) in acetone (800 mL) was added potassium carbonate (83.0 g, 0.6 mol). The reaction mixture was stirred at room temperature for 24 hours. An additional two equivalents of potassium carbonate and one equivalent of carbon disulfide was added and the stirring was continued for another 24 hours. Solvent was removed and the residue was partitioned between dichloromethane and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was stirred with 1000 mL of a mixture of ethyl acetate and ether (1:9) to give 78.4 g of pure product, 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone, as a yellow solid (82%), mp: 177-179° C. Anal. Calc'd. for C₁₅H₁₀ClNOS₂: C, 56.33; H, 3.15; N, 4.38. Found: C, 55.80; H, 2.84; N, 4.59. Step 2: Preparation of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine

A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (78.3 g, 0.24 mol) and 1-methylpiperazine (75.0 g, 0.73 mol) in 800 mL of toluene was heated at reflux for 2 hours. Solvent and excess 1-methylpiperazine was removed under vacuum and the residue was triturated with a mixture was ethyl acetate and ether (1:3) to give 53.0 g of product, 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine, as yellow crystals (60%), mp: 149-151° C. Anal. Calc'd. for C₁₉H₂₀ClN₃OS: C, 61.03; H, 5.39; N, 11.24. Found: C, 60.74; H, 5.35; N, 11.14.

Step 3: Preparation of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

To a suspension of 1-[3-(4-chlorophenyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine (52.0 g, 0.14 mol) in 500 mL of dry tetrahydrofuran was added anhydrous hydrazine (8.9 g, 0.28 mol) dropwise. The reaction mixture was stirred at room temperature for 16 hours. The pale yellow precipitate was filtered and recrystallized from hot methanol to give 30.2 g of 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine as a white powder (60%), mp: 267-268° C. Anal. Calc'd. for C₁₉H₂₀ClN₅: C, 64.49; H, 5.70; N, 19.79. Found: C, 64.89; H, 5.55; N, 19.99.

EXAMPLE A-342

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine

A mixture of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 2,6-dimethylpiperazine (3.43 g, 0.03 mol) in 35 mL of toluene was heated at reflux for 12 hours. Toluene and excess 2,6-dimethylpiperazine were then removed under vacuum and the crude thiamide produced was used without purification. A solution of the crude thiamide and anhydrous hydrazine (0.65 g, 0.02 mol) in 40 mL of dry tetrahydrofuran was stirred at room temperature overnight. After the removal of tetrahydrofuran, the residue was stirred with a mixture of ethyl acetate and 5 ammonium hydroxide for one hour. The precipitate was filtered and air dried to give 1.6 g of 2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine as a white solid (43% overall yield), mp: 236-238° C. Anal. Calc'd. for C₂₀H₂₂ClN₅.0.25H₂O: C, 64.51; H, 6.09; N, 18.81; Cl, 9.52. Found; C, 64.28; H, 5.85; N, 18.70; Cl, 9.67.

EXAMPLE A-343

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-H-pyrazol-3-yl]-3-methylpiperazine

1-[5-(4-Chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine was prepared according to the same procedure set forth above in Example A-342 except that 2-methylpiperazine was used in place of 2,6-dimethylpiperazine (4% overall yield), mp: 235-237° C. Anal. Calc'd. for C₁₉H₂₀ClN₅.0.75H₂O: C, 62.12; H, 5.90; N, 19.06. Found: C, 62.23; H, 5.53; N, 18.80.

EXAMPLE A-344

The compound of Example A-317 was also synthesized in the following manner:

Step 1: Preparation of 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone

To a solution of 4-fluorobenzoyl-4′-pyridyl methane (70.0 g, 0.3 mol, prepared as set forth in Step 1 of Example A-208) and dibromomethane (125 mL) was added solid anhydrous potassium carbonate (55.0 g, 0.4 mol) portionwise over five minutes. Carbon disulfide (17 g, 0.22 mol) was added dropwise over 15 minutes at room temperature. After stirring for 16 hours under a nitrogen atmosphere, the reaction was incomplete. Additional carbon disulfide (15 g) was added and the reaction mixture was stirred for an additional 24 hours. The reaction mixture was filtered and the potassium carbonate was washed on the filter with methylene chloride. The filtered solid was dissolved in water and extracted with methylene chloride. The extract was combined with the filtrate and dried over magnesium sulfate. The drying agent was filtered and the filtrate concentrated in vacuo. The residue was treated with ethyl acetate/ether (1:1), filtered and air dried to give 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone (26 g, 86%) as a solid, m.p. 182-183° C.; Anal. Calc'd. for C₁₅H₁₀FNOS₂: C, 59.39; H, 3.32; N, 4.62. Found: C, 59.18; H, 3.41; N, 4.49.

Step 2: Preparation of 1-[5-(4-fluorophenyl)-4-[4pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate

A mixture of the 1-(4-pyridyl)-1-(methylenedithioketene)-2-(4-fluorophenyl)-ethanone (3 g, 0.01 mol) prepared in Step 1 and 1-methylpiperazine (3 g, 0.03 mol) in 30 mL of toluene was refluxed under a nitrogen atmosphere for three hours. The mixture was cooled and solvent was removed under vacuum. The residue was dissolved in dry tetrahydrofuran (30 mL) and anyhydrous hydrazine (640 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature for 16 hours and the resulting precipitate was filtered. The precipitate was warmed in methanol and a few drops of concentrated ammonium hydroxide were added. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product crystallized and was filtered to give 1.5 g (42%) of 1-[S-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine, dihydrate, mp: 238-240° C.; Anal. Calc'd. for C₁₉H₂₀FN₅.2H₂O: C, 61.11; H, 65.48; N, 18.75. Found: C, 60.79; H, 6.21; N, 18.98.

EXAMPLE A-345

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4-piperidinamine, dihydrate

Step 1: Preparation of 1-methyl-4-methylaminopiperidine

A mixture of 1-methyl-4-piperidone (20 g, 0.18 mol) in methanol:tetrahydrofuran (100 mL, 1:1) and methyl amine (2 M in tetrahydrofuran, 3 mole excess) was placed in a Parr shaker with 5% Pd/C and hydrogenated for two hours at 60 psi and 70° C. The catalyst was filtered and the filtrate concentrated on the rotary evaporator. The crude material was distilled at 44-45° C. at 0.3 mm Hg to give 20 g (87%) of 1-methyl-4-methylaminopiperidine. Anal. Calc'd for C₇H₁₆N₂: C, 65.57; H, 12.58; N, 21.85. Found: C, 65.49; H, 12.44; N: 21.49.

Step 2: Preparation of N-[5-(4-chlorophenyl)-4-(4pyridinyl)-1H-pyrazol-3-yl]-4-N,1-dimethyl-4piperidinamine, dihydrate

A solution of 1-(4-chlorophenyl)-2-(1,3-dithietan-2-ylidene)-2-(4-pyridinyl)ethanone (3.2 g, 0.01 mol; prepared as set forth in Step 1 of Example A-341) and 1-methyl-4-methylaminopiperidine (3.8 g, 0.03 mol) in 30 mL of toluene refluxed for six hours under nitrogen; The mixture was cooled and solvent was removed under vacuum. The residue was dissolved in dry tetrahydrofuran (30 mL) and anyhydrous hydrazine (650 mg, 0.02 mol) was added. The reaction mixture was stirred at room temperature under nitrogen for 16 hours. The resulting precipitate was filtered and warmed in methanol and a few drops of concentrated ammonium hydroxide. The mixture was filtered hot and the filtrate blown down to half the volume. As the filtrate cooled, a product separated and was filtered to give 395 of pure N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-N,l-dimethyl-4-piperidinamine, dihydrate, m.p. 260-261° C. Anal. Calc'd for C₂₁H₂₄ClN₅.2H₂O: C, 60.35; H, 6.75; N, 16.76. Found: C, 59.89; H, 6.56; N: 16.40.

Additional compounds of the present invention that were prepared according to one or more of above reaction schemes (particularly Schemes IX through XVIII) are disclosed in Table 3-2. The specific synthesis scheme or schemes as well as the mass spectroscopy and elemental analysis results for each compound also are disclosed in Table 3-2.

TABLE 3-2 Microanalysis MS C C H H N N Water EtOAc CHCl₃ Toluene HCI Example General M+ Found Found Calc Found Calc Found Added Added Added Added Added A-346 XII A-347 XII 329 59.33 59.59 5.65 5.47 15.55 15.41 0.8 0.2 A-348 XII 439 68.46 66.59 8.04 8.48 19.16 16.17 A-349 XII 397 61.85 61.99 7.79 7.52 17.45 17.39 1.3 0.7 A-350 XII 449 66.29 66.75 7.60 7.68 17.84 17.00 1.25 A-351 XII 352 68.36 57.51 6.31 7.31 19.93 17.17 A-352 XII 366 69.02 66.27 6.62 6.59 19.16 18.22 A-353 XII 430 69.26 71.50 7.40 6.91 18.36 14.87 A-354 XII 355 70.48 70.12 6.80 7.15 13.99 13.91 0.5 A-355 XII 341 66.73 67.09 6.29 6.77 16.04 15.78 0.1 A-356 XVII 410 63.42 63.61 6.00 6.06 16.81 16.63 0.4 A-357 XVII 392 54.37 53.93 5.91 6.32 13.78 14.68 0.4 A-358 XII 394 70.20 68.50 7.17 7.68 17.80 16.58 A-359 XVII 396 69.21 69.33 7.68 8.01 17.55 17.61 0.2 A-360 XVII 366 50.81 50.74 5.97 5.80 14.11 14.00 1.2 3 A-361 XII 389 71.12 68.67 5.45 5.64 14.42 12.90 A-362 XII 375 70.57 68.54 5.12 5.39 14.96 13.90 A-363 XII 389 71.12 68.86 5.45 5.58 14.42 13.09 A-364 XVII 368 68.31 68.39 7.15 7.49 18.97 18.93 0.1 A-365 XVII 338 48.72 48.57 5.47 5.45 14.95 14.79 1.2 3 A-366 XII 397 56.34 56.21 7.31 7.03 17.92 17.89 2 1 A-367 XVII 321 70.25 69.83 5.43 5.62 17.25 17.82 0.25 A-368 XII 313 64.66 64.28 5.73 5.62 16.76 16.93 0.25 A-369 XII 412 66.76 66.60 7.36 7.61 16.93 16.74 0.1 A-370 XII 313 64.66 64.36 5.73 5.59 16.76 16.82 0.25 A-371 XVII 63.78 63.63 6.37 6.09 17.71 17.24 1 A-372 XII 68.63 68.80 7.26 7.53 17.40 17.14 0.5 A-373 XVII 389 58.10 57.99 5.00 4.88 17.83 17.48 0.25 A-374 XII 354 67.97 67.23 6.84 6.81 19.81 19.38 A-375 XII 366 68.18 68.06 6.67 6.80 18.93 18.56 0.25 A-376 XII 375 70.57 68.19 5.12 6.06 14.96 13.13 A-377 XII 396 64.14 64.44 6.99 6.78 16.02 16.02 0.35 A-378 XVII 337 66.42 66.44 5.22 4.91 16.31 16.27 0.4 A-379 XVII 339 62.76 62.80 6.04 5.43 15.41 15.17 1.4 A-380 XVII 381 63.31 63.40 5.19 5.82 14.06 13.84 1 1 A-381 XVII 307 70.57 69.69 4.94 5.00 18.29 17.68 A-382 XVII A-383 XVII A-384 320 55.48 53.44 5.64 5.00 17.03 21.60 A-385 XI 280 52.65 52.51 5.98 5.17 10.83 11.12 1 A-386 XII 351 64.96 64.77 5.82 5.34 14.85 15.03 1 0.1 A-387 XII 353 65.29 65.62 6.32 6.14 14.64 14.47 0.7 0.2 A-388 394 54.93 55.34 6.21 6.79 13.93 14.01 3

EXAMPLE A-346

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-1-piperazinepropanamine(2E)-2-butenedioate (1:1) EXAMPLE A-347

3-[[4-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1,2-propanediol EXAMPLE A-348

N,N,N″-triethyl-N′-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-1,3-propanediamine EXAMPLE A-349

N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N′,N′-trimethyl-1,3-propanediamine EXAMPLE A-350

N-(2-[1,4′-bipiperidin]-1′-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-351

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)-2-pyridinamine EXAMPLE A-352

N-(1-ethyl-4-piperidinyl)-4-[3-[4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-353

N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl-1,2-ethanediamine EXAMPLE A-354

(2S)-2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-1-pentanol EXAMPLE A-355

2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl-1-butanol EXAMPLE A-356

ethyl 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-piperidinecarboxylate EXAMPLE A-357

4-[3-(4-fluorophenyl)-5-(4-(1-pyrrolidinyl)-1-piperidinyl]-1H-pyrazol-4-yl]pyridine, trihydrochloride EXAMPLE A-358

N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine EXAMPLE A-359

N1,N1-diethyl-N4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-pentanediamine EXAMPLE A-360

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-4-piperidinamine, trihydrochloride EXAMPLE A-361

(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol EXAMPLE A-362

(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol EXAMPLE A-363

(βS)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene propanol EXAMPLE A-364

N,N-diethyl-N′-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine EXAMPLE A-365

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine, trihydrochloride EXAMPLE A-366

N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-1,4-pentanediamine EXAMPLE A-367

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,3,6-hexahydropyridine EXAMPLE A-368

(2R)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol EXAMPLE A-369

N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-1,4-pentanediamine EXAMPLE A-370

(2S)-1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-2-propanol EXAMPLE A-371

ethyl 4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate EXAMPLE A-372

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[3-(2-methyl-1-piperidinyl)propyl]-2-pyridinamine EXAMPLE A-373

1-[5-(3,4-dichlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine EXAMPLE A-374

N,N-diethyl-N′-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,2-ethanediamine EXAMPLE A-375

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]-2-pyridinamine EXAMPLE A-376

(βR)-β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzene ethanol EXAMPLE A-377

N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1,4-pentanediamine EXAMPLE A-378

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinone EXAMPLE A-379

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinol EXAMPLE A-380

8-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,4-dioxa-8-azaspiro[4.5]decane EXAMPLE A-381

5-(4-fluorophenyl)-N-methyl-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine EXAMPLE A-382

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine EXAMPLE A-383

1-[5-(3,4-difluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine EXAMPLE A-384

1-methyl-4-[5-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine EXAMPLE A-385

4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-yl]pyridine, monohydrochloride EXAMPLE A-386

trans-4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanol EXAMPLE A-387

4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]cyclohexanone EXAMPLE A-388

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-diethyl-4-piperidinamine, trihydrochloride EXAMPLE A-389

1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl-4-methylpiperazine

Step 1. Preparation of 1-tolyl-2-(4-pyridyl)ethanone

Methyl 3-methylbenzoate (6.0 g, 40 mmol) tetrahydrofuran (50 mL), and 4-picoline (4.1 g, 44 mmol) were stirred at −78° C. under an atmosphere of nitrogen. Sodium (bis)trimethylsilylamide 1.0 M in tetrahydrofuran (88 mL, 88 mmol) was added dropwise. The mixture was allowed to warm to room temperature, stirred for 16 hours and then was poured into saturated aqueous sodium bicarbonate solution. The mixture was then extracted with ethyl acetate (3×50 mL). The combined organics were washed with brine (2×50 mL), dried over magnesium sulfate, and concentrated. The product was recrystallized from ethyl acetate/hexane to yield a light yellow solid (5.7 g, 67%), mp 118.0-119.0° C.; ¹H NMR (acetone-d6/300 MHz) 8.50 (m, 2H), 7.90 (m, 2H), 7.44 (m, 2H), 7.29 (m, 2H), 4.45 (s, 2H), 2.41 (s, 3H); ESHRMS =m/z 212.1067 (M+H, C₁₄H₁₃NO requires 212.1075); Anal. Calc'd for C₁₄H₁₃NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.54; H, 6.30; N, 6.56. Step 2. Preparation of 1-(3-tolyl)-2-(1.3-dithietan-2-ylidene)-2-(4-pridyl)ethanone

1-tolyl-2-(4-pyridyl)ethanone (4.22 g, 20 mmol), acetone (100 mL), potassium carbonate (8.3 g, 60 mmol), carbon disulfide 4.56 g, 60 mmol), and dibromomethane (10.43 g, 60 mmol) were stirred at room temperature for 16 hours. Water (100 mL) was added and the mixture was extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine (2×50 mL), dried over magnesium sulfate and concentrated. This crude material was purified by either flash column chromatography eluting with ethyl acetate:hexane or crystallization from ethyl acetate/hexane to yield a yellow solid (4.8 g, 80%), mp 178.6-179.2° C.; ¹H NMR (acetone-d6/300 MHz) 8.47 (m, 2H), 7.08 (m, 6H), 4.37 (s, 2H), 2.21 (s, 3H); ESHRMS m/z 300.0521 (M+H, C₁₆H₁₃NOS₂ requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.08; H, 4.25; N, 4.62. Step 3. Preparation of 1-[3-(3-tolyl)-3-oxo-2-(4-pyridinyl)-1-thiopropyl]-4-methylpiperazine

The dithietane compound from step 2 above (3.0 g, 10 mmol), N-methylpiperazine (5.0 g, 50 mmol), and toluene (50 mL) were refluxed using a Dean-Stark apparatus for one to three hours. The reaction was allowed to cool to room temperature and was concentrated to dryness under high vacuum. This thick, oily material was crystallized from ethyl acetate/hexane (2.9 g, 82%), mp 124.8-125.8° C.; ¹H NMR (acetone-d6/300 MHz) 8.57 (m, 2H), 7.75 (m, 2H), 7.54 (m, 2H), 7.37 (m, 2H) 6.54 (s, 1H), 4.27 (m, 2H), 4.19 (m, 1H), 3.83 (m, 1H), 2.47-2.28 (m, 6H), 2.22 (s, 3H), 2.17 (m, 1H); ESHRMS m/z 354.1669 (M+H, C₂₀H₂₃N₃OS requires 354.1640); Anal. Calc'd for C₂₀H₂₃N₃OS: C, 67.96; H, 6.56; N, 11.89. Found: C, 67.79; H, 6.66; N, 11.88.

Step 4. Preparation of 1-[5-(3-tolyl)-4-(4-pyridinyl)-1H-Pyrazol-3-yl-4-methylipierazine.

The thioamide compound from step 3 above (1.06 g, 3 mmol), tetrahydrofuran (50 mL), and hydrazine (15 mL, 15 mmol, 1.0 M) in tetrahydrofuran were stirred at room temperature for 16 hours. A white solid was collected by filtration. Purification when necessary was by trituration or recrystallization (0.98 g, 97%), mp 261.9-262.0° C.; ¹H NMR (DMSO-d6/300 MHz) 12.6 (brs, 1H), 8.42 (m, 2H), 7.2 (m, 4H), 7.12 (s, 1H), 7.0 (m, 1H), 2.86 (m, 4H), 2.34 (m, 4H) 2.25 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 334.2049 (M+H, C₂₀H₂₃N₅ requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 71.83; H, 7.06; N, 20.83.

Additional dithietanes and pyrazoles that were synthesized by selection of the corresponding starting reagents in accordance with the chemistry described in Scheme XXI and further illustrated in Example 389 above include compounds A-390 through A-426 disclosed below.

EXAMPLE A-390

mp 185.3-185.4° C.; ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.31 (m, 4H), 7.09 (m, 2H), 4.39 (s, 2H); ESHRMS m/z 319.9981 (M+H, C₁₅H₁₀ClNOS₂ requires 319.9971); Anal. Calc'd for C₁₅H₁₀ClNOS₂: C, 56.33; H, 3.15; N, 4.38. Found: C, 56.47; H, 3.13; N, 4.44.

EXAMPLE A-391

1-(4-chloro-3-methylphenyl)-2-1,3-dithietan-2-ylidene-2-pyridin-4-yl-ethanone

mp 164.0-165.0° C.; ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.25 (m, 2H), 7.0 (m, 3H), 4.38 (s, 2H), 2.24 (s, 3H); ESHRMS m/z 334.0130 (M+H, C₁₆H₁₂ClNOS₂ requires 334.0127); Anal. Calc'd for C₁₆H₁₂ClNOS₂: C, 57.56; H, 3.62; N, 4.20. Found: C, 57.68; H, 3.67; N, 4.17.

EXAMPLE A-392

mp 126.5-126.6° C.; ¹H NMR (acetone-d6/300 MHz) 8.40 (m, 2H), 7.17 (m, 2H), 7.0 (m, 4H), 4.39 (s, 2H), 2.85 (s, 3H); ESHRMS m/z 300.0483 (M+H, C₁₆H₁₃NOS₂ requires 300.0517); Anal. Calc'd for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.68. Found: C, 64.05; H, 4.27; N, 4.59.

EXAMPLE A-393

mp 159.6-159.7° C.; ¹H NMR (acetone-d6/300 MHz) 8.52 (m, 2H), 7.6 (m, 1H), 7.50 (s, 1H), 7.21 (m, 2H), 7.13 (m, 2H), 4.40 (s, 2H); ESHRMS m/z 363.9503 (M+H, C₁₅H₁₀BrNOS₂ requires 363.9465); Anal. Calc'd for C₁₅H₁₀BrNOS₂: C, 49.46; H, 2.77; N, 3.84. Found: C, 49.51; H, 2.68; N, 3.74.

EXAMPLE A-394

mp 198.8-198.9° C.; ¹H NMR (acetone-d6/300 MHz) 8.45 (m, 2H), 7.05 (m, 3H), 6.95 (m, 1H), 6.82 (m, 1H), 4.29 (s, 2H), 2.14 (s, 3H), 2.08 (s, 3H); ESHRMS m/z 314.0691 (M+H, C₁₇H₁₅NOS₂ requires 314.0673).

EXAMPLE A-395

mp 182.6-183.0° C. ¹H NMR (acetone-d6/300 MHz) 8.50 (m, 2H), 7.42 (d, 2H, J=8.5 Hz), 7.23 (d, 2H, J=8.5 Hz), 7.10 (m, 2H), 4.40 (s, 2H). ESHRMS m/z 370.0173 (M+H, C₁₆H₁₀F₃NO₂ requires 370.0183).

EXAMPLE A-396

mp 193.3-193.4° C. ¹H NMR (acetone-d6/300 MHz) 8.49 (m, 2H), 7.69 (d, 2H, J=8.2 Hz), 7.46 (d, 2H, J=8.2 Hz), 7.01 (m, 2H), 4.43 (s, 2H). ESHRMS m/z 311.0327 (M+H, Cl₁₆H₁₀N₂₀S₂ requires 311.0313).

EXAMPLE A-397

mp 191.5-192.5° C.; ¹H NMR (CDCl₃/300 MHz) 8.55 (dd, 2H, J=4.6, 1.6 Hz), 7.4 (m, 1H), 7.09-7.03 (m, 3H), 6.67 (d, 1H, J=8.7 Hz), 4.17 (s, 2H), 3.86 (s, 3H); ESHRMS m/z 350.0090 (M+H, C₁₆H₁₂ClNO₂S₂ requires 350.0076); Anal. Calc'd. for C₁₆H₁₂ClNO₂S₂: C, 54.93; H, 3.60; N, 4.00; Cl, 10.13; S, 18.33. Found: C, 54.74; H, 3.60; N, 3.89; Cl, 10.45; S, 18.32.

EXAMPLE A-398

mp 172.1-173.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.23-7.21 (m, 4H), 7.04 (dd, 2H, J=4.6, 1.6 Hz), 4.17 (s, 2H), 1.25 (s, 9H); ESHRMS m/z 342.1004 (M+H, C₁₉H₁₉NOS₂ requires 342.0986) Anal. Calc'd for C₁₉H₁₉NOS₂: C, 66.83; H, 5.61; N, 4.10; S, 18.78. Found: C, 66.97; H, 5.89; N, 4.02; S, 18.64.

EXAMPLE A-399

mp 203.0-204.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.52 (dd, 2H, J=4.4, 1.6 Hz), 7.29 (d, 1H, J=6.8 Hz), 7.28 (d, 1H, J=7.0 Hz), 7.05 (dd, 2H, J=4.4, 1.6 Hz), 6.70 (d, 1H, J=6.8 Hz), 6.69 (d, 1H, J=6.8 Hz), 4.17 (s, 2H), 3.79 (s, 3H); ESHRMS m/z 316.0475 (M+H, C₁₆H₁₃NO₂S₂ requires 316.0466); Anal. Calc'd. for C₁₆H₁₃NO₂S₂: C, 60.93; H, 4.15; N, 4.44; S, 20.33. Found: C, 60.46; H, 4.17; N, 4.37; S, 19.84.

EXAMPLE A-400

mp 209.1-215.1° C.; ¹H NMR (CDCl₃/300 MHz) 8.50 (dd, 2H, J=4.4, 1.6 Hz), 7.20 (d, 2H, J=8.0 Hz), 7.03-6.99 (m, 4H), 4.18 (s, 2H), 2.30 (s, 3H); ESHRMS m/z 300.0517 (M+H, C₁₆H₁₃NOS₂ requires 300.0517); Anal. Calc'd. for C₁₆H₁₃NOS₂: C, 64.18; H, 4.38; N, 4.69; S, 21.42. Found: C, 64.02; H, 4.62; N, 4.54; S, 21.24.

EXAMPLE A-401

mp 257.6-257.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.57 (d, 2H, J=8.5 Hz), 7.27-6.99 (m, 4H), 4.18 (s, 2H); ESHRMS m/z 411.9348 (M+H, C₁₅H₁₀NIOS₂ requires 411.9327); Anal. Calc'd. for C₁₅H₁₀NIOS₂: C, 43.81; H, 2.45; N, 3.41. Found: C, 43.71; H, 2.27; N, 3.41.

EXAMPLE A-402

mp 197.3-202.2° C.; ¹H NMR (CDCl₃/300 MHz) 8.53 (dd, 2H, J=4.4, 1.6 Hz), 7.26 (d, 2H, J=9.3 Hz), 7.09 (dd, 2H, J=4.4, 1.6 Hz), 6.43 (d, 2H, J=9.3 Hz), 4.14 (s, 2H), 2.97 (s, 6H); ESHRMS m/z 329.0789 (M+H, C₁₇H₁₆N₂OS₂ requires 329.0782); Anal. Calc'd. for C₁₇H₁₆N₂OS₂: C, 62.17; H, 4.91; N, 8.53; S, 19.53. Found; C, 61.93; H, 5.12; N, 8.46; S, 19.26.

EXAMPLE A-403

mp 176.6-176.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.51 (dd, 2H, J=4.4, 1.6 Hz), 7.29-7.22 (m, 4H), 7.03 (dd, 2H, J=4.4, 1.6 Hz), 6.64 (dd, 1H, J=17.5, 10.9 Hz), 5.76 (d, 1H, J=17.7 Hz), 5.31 (d, 1H, J=10.9 Hz), 4.19 (s, 2H); ESHRMS 312.0513 (M+H, C₁₇H₁₃NOS₂ requires 312.0517); Anal. Calc'd. for C₁₇H₁₃NOS₂: C, 65.56; H, 4.21; N, 4.50. Found: C, 65.75; H, 4.11; N, 4.46.

EXAMPLE A-404

mp 174.8-175.0° C.; ¹H NMR (CDCl₃/300 MHz) 8.50 (dd, 2H, J=4.4, 1.6 Hz), 7.23-7.20 (m, 4H), 7.03 (dd, 2H, J=4.6, 1.6 Hz), 4.17 (s, 2H), 2.59 (q, 2H, J=7.6 Hz), 1.17 (t, 3H, J=7.7 Hz); ESHRMS m/z 314.0677 (M+H, C₁₇H₁₅NOS₂ requires 314.0673); Anal. Calc'd. for C₁₇H₁₅NOS₂: C, 65.14; H, 4.82; N, 4.47. Found: C, 64.90; H, 4.62; N, 4.45.

EXAMPLE A-405

mp 167.1-167.5° C.; ¹H NMR (CDCl₃/300 MHz) 8.52 (dd, 1H, J=4.4, 1.6 Hz), 7.33 (d, 1H, J=8.3 Hz), 7.02-7.00 (m, 3H), 6.87-6.83 (m, 1H), 4.19 (s, 2H), 2.28 (s, 3H); ESHRMS m/z 379.9577 (M+H, C₁₆H₁₂BrNOS₂ requires 379.9622); Anal. Calc'd. for C₁₆H₁₂BrNOS₂: C, 50.80; H, 3.20; N, 3.70. Found: C, 50.69; H, 3.19; N, 3.71.

EXAMPLE A-406

mp 168.6-168.7° C.; ¹H NMR (CDCl₃/300 MHz) 8.54 (dd, 2H, J=4.6, 1.8 Hz), 7.68-7.62 (m 2H), 7.43-7.39 (m, 1H), 7.33-7.28 (m, 1H), 6.99 (dd, 2H, J=4.4, 1.6 Hz), 4.22 (s, 2H); ESHRMS m/z 311.0330 (M+H, C₁₆H₁₀N₂OS₂ requires 311.0313); Anal. Calc'd. for C₁₆H₁₀N₂OS₂: C, 61.91; H, 3.25; N, 9.02. Found: C, 61.45; H, 3.18; N, 8.91.

EXAMPLE A-407

1-[5-(3-methyl-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 236.7-239.3° C.; ¹H NMR (DMSO-d6/300 MHz) 12.6 (brs, 1H), 8.45 (m, 2H), 7.41 (m, 1H), 7.26 (m, 3H), 7.0 (m, 1H), 2.86 (m, 4H), 2.35 (m, 4H), 2.27 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 368.4653 (M+H, C₂₀H₂₂ClN₅ requires 368.1642).

EXAMPLE A-408

1-[5-(2-tolyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 244.0-244.2° C.; ¹H NMR (acetone-d6/300 MHz) 11.6 (brs, 1H), 8.35 (m, 2H), 7.35 (m, 2H), 7.25 (m, 4H), 3.05 (m, 4H), 2.47 (m, 4H), 2.25 (s, 3H), 2.00 (s, 3H); ESHRMS m/z 334.2018 (M+H, C₂₀H₂₃N₅ requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅: C, 72.04; H, 6.95; N, 21.00. Found: C, 72.03; H, 7.00; N, 20.85.

EXAMPLE A-409

1-[5-(3-bromophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 222.5-223.4° C.; ¹H NMR (acetone-d6/300 MHz) 11.8 (brs, 1H), 8.51 (m, 2H), 7.55 (m, 2H), 7.34 (m, 4H), 3.0 (m, 4H), 2.41 (m, 4H), 2.22 (s, 3H); ESHRMS m/z 398.0982 (M+H, C₁₉H₂₀BrN₅ requires 398.0980).

EXAMPLE A-410

1-[5-(3,4-dimethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 270.9-272.7° C.; ¹H NMR (DMSO-d6/300 MHz) 12.5 (brs, 1H), 8.41 (m, 2H), 7.24 (m, 2H), 7.26 (m, 3H), 7.10 (m, 2H), 6.92 (m, 1H), 2.86 (m, 4H), 2.38 (m, 4H), 2.21 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 348.2183 (M+H, C₂₁H₂₅N₅ requires 348.2188).

EXAMPLE A-411

1-[5-(4-trifluoromethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 221.0-221.2° C.; ¹H NMR (DMSO-d6/300 MHz) 12.7 (brs, 1H), 8.45 (m, 2H), 7.38 (s, 4H), 7.24 (m, 2H), 2.86 (m, 4H), 2.34 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 404.1698 (M+H, C₂₀H₂₀F₃N₅O requires 404.1698).

EXAMPLE A-412

1-[5-(4-cyanophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp>300° C.; ¹H NMR (DMSO-d6/300 MHz) 12.8 (brs, 1H), 8.47 (m, 2H), 7.83 (m, 2H), 7.42 (m, 2H), 2.88 (m, 4H), 2.39 (m, 4H), 2.20 (s, 3H); ESHRMS m/z 345.1848 (M+H, C₂₀H₂₀N₆ requires 345.1828).

EXAMPLE A-413

1-[5-(3-chloro-4-methoxyphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 272.7-276.4° C.; ¹H NMR (DMSO-d6/300 MHz) 8.44 (dd, 2H, J=4.6, 1.6 Hz), 7.32-7.13 (m, 5H), 3.84 (s, 3H), 2.90-2.85 (m, 4H), 2.38-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 384.1580 (M+H C₂₀H₂₂ClN₅O requires 384.1591).

EXAMPLE A-414

1-[5-(4-tert-butylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 243.6-244.3° C.; 1H NMR (DMSO-d6/300 MHz) 8.44 (dd, 2H, J=4.6, 1.6, Hz), 7.40 (d, 2H, J=8.3 Hz), 7.28-7.18 (m, 4H), 2.90-2.85 (m, 4H), 2.38-2.34 (m, 4H), 2.16 (s, 3H), 1.26 (s, 9H); ESHRMS m/z 376.2491 (M+H, C₂₃H₂₉N₅ requires 376.2561).

EXAMPLE A-415

1-(4-(4-methoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 259.0-260.2° C.; ¹H NMR (DMSO-d6/300 MHz) 8.53 (dd, 2H, J=4.4, 1.6 Hz), 7.24 (dd, 2H, J=4.4, 1.6 Hz), 7.18 (d, 2H, J=8.9 Hz), 6.94 (d, 2H, J=8.9 Hz), 3.75 (s, 3H), 2.90-2.85 (m, 4H), 2.39-2.35 (m, 4H), 2.16 (s, 3H); ESHRMS m/z 350.1991 (M+H, C₂₀H₂₃N₅O requires 350.1981); Anal. Calc'd. for C₂₀H₂₃N₅O+3.93% H₂O: C, 66.04; H, 6.81; N, 19.25. Found: C, 66.01; H, 6.62; N, 19.32.

EXAMPLE A-416

1-[5-(4-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 243.0-246.8° C.; ¹H NMR (DMSO-d6/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.24 (m, 6H), 2.91-2.86 (m, 4H), 2.40-2.35 (m, 4H), 2.29 (s, 3H), 2.16 (s, 3H); ESHRMS m/z 334.2041 (M+H, C₂₀H₂₃N₅ requires 334.2032); Anal. Calc'd for C₂₀H₂₃N₅+4.09% H₂O: C, 69.10; H, 7.13; N, 20.14. Found: C, 69.10; H, 7.08; N, 20.13.

EXAMPLE A-417

1-[5-(4-iodophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 265.2-265.8° C.; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.76-7.74 (m, 2H), 7.41-7.39 (m, 2H), 7.08-7.05 (m, 2H), 3.08-3.04 (m, 4H), 2.61-2.58 (m, 4H), 2.35 (s, 3H); ESHRMS m/z 446.0847 (M+H, C₁₉H₂₀IN₅ requires 446.0842); Anal. Calc'd. for C₁₉H₂₀IN₅+12.09% H₂O: C, 44.60; H, 5.39; N, 13.69. Found: C, 44.50; H, 4.56; N, 13.66.

EXAMPLE A-418

1-[5-(4-ethenylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp>300° C.; ¹H NMR (CD₃OD/300 MHz) 8.49 (dd, 2H, J=4.6, 1.6 Hz), 7.47-7.44 (m, 4H), 7.26 (d, 2H, J=8.4 Hz), 6.75 (dd, J=17.7, 11.1 Hz), 5.83 (d, 1H, J=17.5 Hz), 5.28 (d, 1H, J=11.1 Hz), 3.07-3.03 (m, 4H), 2.58-2.53 (m, 4H), 2.31 (s, 3H); ESHRMS m/z 346.2034 (M+H, C₂₁H₂₃N₅ requires 346.2032); Anal. Calc'd. for C₂₁H₂₃N₅+2.83% H₂O: C, 70.95; H, 6.84; N, 19.70. Found: C, 70.97; H, 6.49; N, 19.54.

EXAMPLE A-419

1-[5-(4-ethylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 221.6-222.6° C.; ¹H NMR (CD₃OD/300 MHz) 8.38 (dd, 2H, J=4.6, 1.6 Hz), 7.44-7.40 (m, 2H), 7.26-7.19 (m, 4H), 3.06-3.02 (m, 4H), 2.66 (q, 2H, J=7.5 Hz), 2.59-2.54 (m, 4H), 2.32 (s, 3H), 1.23 (t, 3H, J=7.5 Hz); ESHRMS m/z 348.2188 (M+H, C₂₁H₂₅N₅ requires 348.2188); Anal. Calc'd for C₂₁H₂₅N₅+2.59% H₂O: C, 70.71; H, 7.35; N, 19.63. Found: C, 70.76; H, 7.40; N, 19.46.

EXAMPLE A-420

1-[5-(4-bromo-3-methylphenyl)-4-(4-pyrdinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 294.7° C. decomp.; ¹H NMR (CD₃OD/300 MHz) 8.41 (dd, 2H, J=4.6, 1.6 Hz), 7.55 (d, 1H, J=8.2 Hz), 7.45-7.42 (m, 2H), 7.27-7.25 (m, 1H), 7.00-6.97 (m 2H), 3.08-3.03 (m, 4H), 2.59-2.54 (m, 4H), 2.35 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 412.1124 (M+H, C₂₀H₂₂BrN₅ requires 412.1137).

EXAMPLE A-421

1-[5-(4-dimethylaminophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp>300° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.37 (d, 2H, J=4.6 Hz), 7.44 (d, 2H, J=4.8 Hz), 7.12 (d, 2H, J=8.9 Hz), 6.73 (d, 2H, J=8.7 Hz), 3.04-3.02 (m, 4H), 2.96 (s, 6H), 2.54-2.49 (m, 4H), 2.31 (s, 3H); ESHRMS m/z 363.2266 (M+H, C₂₁H₂₆N₆ requires 363.22972).

EXAMPLE A-422

1-[5-(3-cyanophenyl)-4-(4-pyrdinyl)-1H-pyrazol-3-yl]4-methylpiperazine

mp 223.4-224.3° C.; ¹H NMR (CD₃OD/300 MHz) 8.44 (dd, 2H, J=4.6, 1.4 Hz), 7.75-7.69 (m, 2H), 7.56-7.54 (m, 2H), 7.40-7.38 (m, 2H), 3.05-3.03 (m, 4H), 2.54-2.49 (m, 4H), 2.53 (s, 3H); ESHRMS m/z 345.1840 (M+H, C₂₀H₂₀N₆ requires 345.1828).

EXAMPLE A-423

1-[5-(4-thiomethoxyphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp 275.6-281.9° C.; ¹H NMR (CD₃OD/300 MHz) 8.44-8.40 (m, 2H), 7.46-7.41 (m, 2H), 7.28-7.23 (m, 4H), 3.04-3.00 (m, 4H), 2.59-2.53 (m, 4H), 2.48 (s, 3H), 2.31 (s, 3H); ESHRMS m/z 366.1777 (M+H, C₂₀H₂₃N₅S requires 366.1752).

EXAMPLE A-424

1-[5-(3-trifluoromethylphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine

mp 212.6-213.7° C.; ¹H NMR (CD₃OD/300 MHz) 8.43 (d, 2H, J=4.8 Hz), 7.69-7.56 (m, 4H), 7.41 (s, 2H), 3.07-3.04 (m, 4H), 2.56-2.53 (m, 4H), 2.32 (s, 3H); ESHRMS m/z 388.1764 (M+H, C₂₀H₂₀F₃N₅ requires 388.1749).

EXAMPLE A-425

1-[5-(4-trifluoromethylphenyl)-4-(4-pyridinyl-1H-pyrazol-3-yl)-4-methylpiperazine

mp 240.5° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.43 (dd, 2H, J=4.6, 1.6 Hz), 7.70-7.67 (m, 2H), 7.51-7.48 (m, 2H), 7.42-7.38 (m 2H), 3.09-3.04 (m, 4H), 2.59-2.53 (m, 4H), 2.31 (s, 3H); ESHRMS m/z 388.1768 (M+H, C₂₀H₂₀F₃N₅ requires 388.1749).

EXAMPLE A-426

1-[5-(2-thienyl)-4-(4-pyridinyl-1H-pyrazol-3-yl]-4-methylpiperazine.

mp 199.7° C. (decomposed); ¹H NMR (CD₃OD/300 MHz) 8.44 (d, 2H, J=5.8 Hz), 7.47 (d, 2H, J=5.6 Hz), 7.13-7.07 (m, 3H), 3.04-3.00 (m, 4H), 2.53-2.49 (m, 4H), 2.30 (s, 3H); ESHRMS m/z 326.1454 (M+H, C₁₇H₁₉N₅S requires 326.1439).

EXAMPLE A-427

Step 1: Preparation of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propene-1-one

A solution of 4-chlorophenyl-2-(pyridin-4-yl)ethan-1-one (20.0 g, 86.4 mmol) and N,N-dimethylformamide dimethylacetal (57.6 mL, 0.43 mole) was heated at 100° C. for 3½ hours. The reaction mixture was concentrated in vacuo, and the residue crystallized from methyl butyl ether to give 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 93%). ¹H NMR (CDCl₃/300 MHz) δ 8.52 (d, 2H), 7.38 (d, 2H), 7.29 (d, 2H), 7.08 (d, 2H), 2.83 (s, 6H).

Step 2: Preparation of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole

A solution of 3-dimethylamino-1-(4-chlorophenyl)-2-(pyridin-4-yl)-2-propen-1-one (22.80 g, 79.7 mmol), hydroxylamine hydrochloride (18.01 g, 0.26 mole), and 150 mL ethanol was heated to reflux for 30 minutes. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The residue was dissolved in 1N hydrochloric acid and then treated with an aqueous saturated solution of sodium bicarbonate. The precipitates were collected by filtration, washed with water and ethanol, and dried to yield 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.50 g, 93%). m.p. 120.8-120.9° C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.53 (d, 2H), 8.46 (s, 1H), 7.51 (d, 2H), 7.41-7.34 (m, 4H). ESLRMS m/z 257 (M+H). ESHRMS m/z 257.0457 (M+H, C₁₄H₂N₂OCl requires 257.0482).

Step 3: Preparation of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile:

A solution of 5-(4-chlorophenyl)-4-(pyridin-4-yl)isoxazole (20.5 g, 79.9 mmol) and 150 mL of a 1N sodium hydroxide solution was stirred at 60° C. for 1 hour. The reaction mixture was cooled to room temperature and adjusted to pH 6 with concentrated hydrochloric acid. The precipitates were filtered, washed with water and ethanol, and dried to give 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (20.0 g, quantitative yield). m.p. 225.4-234.9° C. ¹H NMR (CDCl₃/CD₃OD/300 MHz) δ 8.12 (brs, 2H), 7.73-7.59 (m, 5H), 7.30 (d, 3H). ESLRMS m/z 257 (M+H). ESHRMS m/z 257.0481 (M+H, C₁₄H₉N₂₀Cl requires 257.0482).

Step 4: 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)pyrazole

A solution of 3-(4-chlorophenyl)-3-oxo-2-(pyridin-4-yl)propanenitrile (3.50 g, 13.6 mmol) in 40 mL acetonitrile and phosphorous trichloride (14.2 ml, 163 mmol) was stirred at 100° C. for 5 hours. The reaction mixture was concentrated in vacuo, and the residue taken up in toluene and concentrated again. The residue was then taken up in ethanol (150 mL) and treated with anhydrous hydrazine (1.71 mL, 54.4 mmol). The reaction mixture was heated to reflux for 3 hours, cooled, and concentrated in vacuo. The residue was triturated with a mixture of ethanol and dichloromethane (1:4), and filtered. The solid was washed with the ethanol/dichloromethane mixture, and dried to give 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (2.0 g, 54%): m.p.>300° C. ¹H NMR (DMSO/300 MHz) δ 8.40 (d, 2H), 7.40 (d, 2H), 7.29 (d, 2H), 7.11 (d, 2H), 5.05 (s, 2H). ESLRMS m/z 271 (M+H). ESHRMS m/z 271.0752 (M+H, C₁₄H₁₁N₄Cl requires 271.0750).

EXAMPLE A-428

A solution of 1,1′-carbonyldiimidazole (1.19 g, 7.38 mmol) and N-benzyliminodiacetic acid (0.824 g, 3.69 mmol) in dimethylformamide was heated at 75° C. for 30 minutes. To this mixture the 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.69 mmol) was added, and heating was continued at 75° C. overnight. The white solid was filtered, was washed with diethyl ether, methylene chloride, 5% methanol/methylene chloride, and ethanol, and was dried to give the desired imide as an off-white solid (0.9 g, 53%): m.p.>300° C. ¹H NMR (DMSO/300 MHz) δ 8.53 (m, 2H), 7.5 (d, 2H), 7.44-7.16 (m, 7H), 6.98 (m, 2H), 3.64 (m, 4H), 3.48 (m, 2H). ESLRMS m/z 458 (M+H). ESHRMS m/z 458.1380 (M+H, C₂₅H₂₀N₅O₂Cl requires 458.1384).

EXAMPLE A-429

Methyl 2-{[3-94-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate

A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (1.0 g, 3.7 mmol) in dimethylformamide (30 mL) was heated to 95° C. and methyl bromo acetate (0.34 mL, 3.7 mmol) was added dropwise. The resulting solution was stirred at 95° C. for 4 hours, cooled, and concentrated in vacuo to an orange viscous oil (1.79 g). A portion-of this product mixture (1.20 g) was crystallized from ethanol and diethyl ether to give methyl 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate as a bright yellow solid (805 mg): m.p. 195.4-196.8° C. ¹H NMR (CD₃OD/300 MHz) δ 8.49 (d, 2H), 7.68 (d, 2H), 7.44 (m, 4H), 5.37 (s, 2H), 3.84 (s, 3H). ESLRMS m/z 343 (M+H). ESHRMS m/z 343.0975 (M+H, C₁₇H₁₆N₄O₂Cl requires 343.0962).

EXAMPLE A-430

Lithium 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate

To a solution of methyl 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate (500 mg, 1.5 mmol) in 15 mL of methanol and 5 mL of water was added lithium hydroxide (189 mg, 4.5 mmol). The reaction mixture was stirred at room temperature for 5 hours. The solvent was removed in vacuo, and the residue taken up in ethanol. The precipitate was filtered and washed with methanol, and the filtrate was concentrated to give lithium 2-{[3-4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]amino}acetate as a yellow/orange solid (479 mg, 95%). mp>300° C. ¹H NMR (CD₃OD/300 MHz) δ 8.06 (d, 2H), 7.43 (d, 2H), 7.37 (m, 4H), 3.34 (s, 2H). ESLRMS m/z 329 (M+H), 335 (M+Li), 351 (M+Na). ESHMS m/z 329.0772 (M+H, C₁₆H₁₄N₄O₂Cl requires 329.0805).

EXAMPLE A-431

The above 4-chlorophenylketone was prepared according to the procedure used in Step 1 of Example C-1, infra, substituting methyl 4-chlorobenzoate for ethyl 4-fluorobenzoate. Yield; (74%), yellow solid, mp=95.5-97.3° C.; 1H-NMR (DMSO-d6/300 MHz) 8.57 (br d, 2H), 7.92 (d, 2H), 7.46 (d, 2H), 7.20 (d, 2H), 4.28 (s, 2H); ESLRMS m/z 232 (M+H).

EXAMPLE A-432

To the ketone (1.0 gm, 4.7 mmol) from Step 1 of Example C-1, infra, in anhydrous tetrahydrofuran (10 mL) was added 1M potassium t-butoxide in tetrahydroturan (10 mL, 10 mmol). The reaction mixture was stirred for 15 minutes at room temperature, then carbon disulfide (0.31 mL, 5.1 mmol) was added. After several minutes, methyl iodide (0.64 mL, 10.3 mmol) was added and the reaction allowed to stir for 4 hours. The reaction mixture was diluted with saturated sodium bicarbonate solution (25 mL) and extracted twice with ethyl acetate (35 mL). The combined ethyl acetate layers were washed with water (25 mL) and brine (25 mL). The organic solution was dried (MgSO₄), filtered and concentrated to an orange oil. The oil solidified on standing. Yield 1.4 gm (94%), mp 80.2-82.1° C.; ¹H-NMR (CDCl₃/300 MHz) 8.59 (d, 2H), 7.96 (m, 2H), 7.38 (m, 2H), 7.14 (m, 2H), 2.33 (s, 3H), 2.23 (s, 3H); Anal. Calc'd for C₁₆H₁₄FNOS₂: C, 60.16; H, 4.42; N, 4.39; S, 20.08. Found: C, 59.89; H, 4.09; N, 4.31; S, 20.14.

EXAMPLE A-433

The above compound was prepared in a manner analogous to Example A-432 starting with the product of Example A-431. Crude yield: 100%; mp 87.6-88.2° C.; ¹H NMR (CDCl₃/300 MHz) 8.60 (d, 2H), 7.87 (d, 2H), 7.44 (d, 2H), 7.37 (m, 2H), 2.33 (s, 3H), 2.22 (s, 3H); ESHRMS m/z 336.0297 (M+H, C₁₆H₁₅ClNOS₂ requires 336.0283); Anal. Calc'd for C₁₆H₁₄ClNOS₂: C, 57.22; H, 4.20; N, 4.17. Found: C, 57.44; H, 3.97; N, 4.04.

EXAMPLE A-434

To the compound of Example A-432 (1.4 gm, 4.4 mmol) in ethanol (15 mL) was added 1M hydrazine in acetic acid (5 mL, 5 mmol). The reaction was stirred at room temperature for 18 hours. No reaction had occurred, so additional hydrazine hydrate (1.08 mL, 22 mmol) was added and the reaction heated to reflux for 6 hours. The product began to precipitate from the reaction mixture. The reaction was cooled to room temperature and water was added to precipitate the product. The solid was collected by suction filtration and air dried. Yield: 675 mg (53%). The product was recrystallized from ethanol: 494 mg; mp 249.9-249.9° C.; ¹H-NMR (DMSO-d6/300 MHz) 13.51 (br s, 1H), 8.50 (d, 2H) 7.34 (m, 2H), 7.23 (m, 2H), 7.16 (m, 2H), 2.43 (s, 3H); ESHRMS m/z 286.0807 (M+H, C₁₅H₁₃FN₃S requires 286.0814); Anal. Calc'd for C₁₅H₁₂FN₃S: C, 63.14; H, 4.24; N, 14.73. Found: C, 63.01; H, 4.43; N, 14.81.

EXAMPLE A-435

The above compound was made in an analogous manner to Example A-434 starting with the compound of Example A-433. Yield: 750 mg (33%); mp 250.2-250.2° C.; ¹H NMR (DMSO-d6/300 MHz) 13.57 (br s, 1H), 8.51 (m, 2H), 7.45 (brs, 2H), 7.32 (m, 2H), 7.17 (m, 2H), 2.43 (m, 3H); ESHRMS m/z 302.0537 (M+H, C₁₅H₁₃ClN₃S requires 302.0518); Anal. Calc'd for C₁₅H₁₂ClN₃S: C, 59.70; H, 4.01;. N, 13.92. Found: C, 59.56; H, 3.96; N, 13.96.

EXAMPLE A-436

3-(4-fluorophenyl)-4-(methylsulfinyl)-4-pyridin-4-yl-1H-pyrazole

To the compound of Example A-434 (150 mg, 0.52 mmol) in ethanol (15 mL) was added ammonium persulfate (450 mg, 1.97 mmol). The reaction mixture was stirred at ambient temperature. After several hours an additional amount of ammonium persulfate (450 mg) was added. The reaction mixture was monitored by TLC (silica) using 5% methanol in dichloromethane as the eluting solvent. When the stating material had been consumed, the reaction mixture was quenched with saturated sodium bicarbonate (25 mL) and extracted with ethyl acetate (2×25 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). Filtration and concentration produced a white solid. The solid was triturated with diethyl ether, collected by suction filtration, and air dried. Yield 150 mg (96%), mp 262.9-262.9° C.; ¹H NMR (DMSO-d6/300 MHz) 14.22 (br s, 1H), 8.56 (d, 2H), 7.42-7.23 (br m, 6H), 2.94 (s, 3H); Anal. Calc'd for C₁₅H₁₂FN₃OS.0.25H₂O: C, 58.91; H, 4.12; N, 13.74; Found: C, 58.88; H, 4.17; N, 13.39.

EXAMPLE A-437

3-(4-fluorophenyl)-5-(methylsulfonyl)-4-pyridin-4-yl-1H-pyrazole

To the compound of Example A-434 (285 mg, 1 mmol) in ethanol (10 mL) was added potassium peroxymonosulfate (2.45 gm, 4 mmol) and water (5 mL). The reaction mixture was stirred at ambient temperature. After 6 hours the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2×30 mL). The ethyl acetate layers were combined, washed with brine (25 mL) and dried (MgSO₄). The ethyl acetate did not efficiently extract the product from the aqueous phase, so the aqueous layer was saturated with sodium chloride and extracted with acetonitrile (50 mL). The acetonitrile solution was dried (MgSO₄), filtered, and combined with the filtered ethyl acetate solution. The solvents were evaporated and the resulting solid was triturated with a small amount of acetonitrile, collected by suction filtration, and air dried. Yield: 203 mg (64%); mp 297.1->300° C.; ¹H NMR (DMSO-d6/300 MHz) 14.37 (brs, 1H), 8.54 (m, 2H), 7.29 (m, 6H), 3.26 (s, 3H); Anal. Calc'd for C₁₅H₁₂FN₃O₂S: C, 56.77; H, 3.81; N, 13.24. Found: C, 56.52; H, 4.03; N, 13.11.

EXAMPLE A-438

To the compound of Example A-432 (638 mg, 2 mmol) in toluene (6 mL) was added thiomorpholine (502 uL, 5 mmol). The reaction mixture was heated to between 80 and 110° C. After about three hours the bis-thiomorpholine substituted product began to precipitate from the reaction mixture. When the dithioketene acetal had been completely consumed, the reaction mixture was cooled to room temperature and the insoluble bis-thiomorpholine compound removed by filtration. To the toluene solution was added hydrazine hydrate (1 mL) and sufficient ethanol to create a homogeneous solution. The reaction mixture was then stirred at room temperature for 72 hours. The reaction mixture was diluted with ethyl acetate (50 mL) and extracted twice with water (25 mL) and once with brine (25 mL). The organic solution was dried (MgSO₄), filtered and concentrated to a reddish solid. The solid was triturated with acetonitrile, collected by suction filtration, and dried in-vacuo. The solid was then suspended in acetonitrile and heated to reflux. Ethyl acetate was then added until the solid almost completely dissolved. A small amount of ethanol was then added and the homogeneous yellow solution concentrated until a solid began to form. Allow to cool to room temperature. Collected a white solid by suction filtration. Yield: 63 mg, (7%); ¹H NMR (DMSO-d6/300 MHz) 12.65 (br s, 1H), 8.45 (d, 2H), 7.27 (m, 6H), 3.14 (m, 4H), 2.63 (m, 4H). ESLRMS m/z 341 (M+H); ESHRMS m/z 341.1241 (M+H, C₁₈H₁₈FN₆S requires 341.1236).

EXAMPLE A-439

The above compound was prepared in a similar manner to Example A-438 starting with the appropriate dithioketene acetal and N-methylpiperazine. A white solid was obtained, mp 270.2-270.7° C.; ¹H NMR (DMSO-d6/300 MHz) 12.7 (br s, 1H), 8.47 (m, 2H), 7.57 (m, 2H), 7.21 (m, 2H), 2.85 (m, 4H), 2.34 (m, 4H) 2.15 (s, 3H); ESHRMS 398.0993 (M+H, C₁₉H₂₁BrNS₅ requires 398.0980).

EXAMPLE A-440

To N-(2-hydroxyethyl)morpholine (363 uL, 3 mmol) in anhydrous tetrahydrofuran (7 mL), under nitrogen, was added 1M sodium hexamethyldisilamide (3 ml, 3 mmol) in tetrahydrofuran at ambient temperature. The reaction mixture was stirred for 15 minutes, then the dithietane prepared as set forth in Step 1 of Example A-341 (636 mg, 2 mmol) was added as a solid. The reaction mixture gradually became dark orange. After about 18 hours at ambient temperature, the reaction was quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL). The organic solutions were combined and washed with saturated NaCl solution (20 mL), then dried (MgSO₄), filtered, and concentrated to an orange oil. The oil was taken up in methanol (10 mL) and reconcentrated to remove any remaining ethyl acetate. The oil was then taken up in methanol (5 mL) and anhydrous hydrazine (69 uL) was added. The reaction mixture was allowed to stir at ambient temperature 18 hours, then quenched with saturated sodium bicarbonate solution (30 mL) and extracted twice with ethyl acetate (30 mL) The organic solutions were combined and washed with water (20 mL) and saturated NaCl solution (20 mL), then dried (MgSO₄), filtered, and concentrated to an orange semi-solid. The solid was triturated with acetonitrile (5 mL), collected by suction filtration, washed with acetonitrile and dried in-vacuo. Yield: off-white solid, 114 mg (14.8%); mp 198.9-199.9° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.21 (d, 2H), 4.33 (t, 2H), 3.54 (m, 4H), 2.70 (t, 2H), 2.44 (m 4H); ESHRMS m/z 385.1444 (M+H, C₂₀H₂₂ClN₄O₂ requires 385.1431).

EXAMPLE A-441

The above compound was prepared in an analogous manner to that of Example A-440 starting with 4-hydroxy-N-t-boc piperidine. Recrystallized from acetone/methanol. Yield: white solid 263 mg (29%); mp 230.1-231.8° C.; 1H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.42 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.20 (d, 2H), 4.88 (m, 1H), 3.52 (m, 2H), 3.30 (m, 2H), 1.93 (m, 2H), 1.65 (m, 2H), 1.39 (s, 9H); Anal. Calc'd for C₂₄H₂₇ClN₄O₃: C, 63.36; H, 5.98; N, 12.31; Found: C, 63.34; H, 5.97; N, 12.22.

EXAMPLE A-442

EXAMPLE A-441 (130 mg, 0.28 mmol) was treated with concentrated HCl (0.5 mL) in ethanol (5 mL) for two hours. The solvent was removed in-vacuo and the resulting residue dissolved in ethanol and reconcentrated twice. The resulting solid was triturated with acetonitrile to afford a white solid. Yield: 119 mg (91%) tri-hydrochloride salt; mp 220.6-222.1° C.; ¹H-NMR (DMSO-d6/300 MHz) 13.25 (br s, 1H), 9.10 (br s, 2H), 8.67 (d, 2H), 7.75 (d, 2H), 7.60 (d, 2H), 7.50 (d, 2H), 5.04 (m, 1H), 3.17 (br d, 4H), 2.21 (m, 2H), 2.03 (m, 2H); Anal. Calc'd for C₁₉H₁₉ClN₄O.3 HCl: C, 49.16; H, 4.78; N, 12.07. Found: C, 49.24; H, 4.72; N, 12.02.

EXAMPLE A-443

The above compound was prepared in a manner analogous to Example A-440 starting with (+/−)3-hydroxytetrahydrofuran. Recrystallized from ethanol. Yield: white crystalline solid, 57 mg (8%); mp>300° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.65 (br s, 1H), 8.42 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.18 (d, 2H), 5.28 (m, 1H), 3.86 (m, 2H), 3.82 (m, 1H), 3.75 (m, 1H), 2.26-2.01 (br m, 2H); Anal. Calc'd for C₁₈H₁₆ClN₃O₂: C, 63.25; H, 4.72; N, 12.29. Found: C, 63.12; H, 4.51; N, 12.31.

EXAMPLE A-444

The above compound was prepared in a manner analogous to Example A-440 starting with p-methoxybenzyl alcohol. Yield: off-white solid, 252 mg (21%); mp=229.1-229.2° C.; ¹H-NMR (acetone-d6/300 MHz) 11.62 (br s, 1H), 8.40 (br s, 2H), 7.76 (s, 2H), 7.39 (m, 4H), 7.30 (br s, 2H), 6.87 (d, 2H), 5.27 (s, 2H), 3.77 (s, 3H); Anal. Calc'd for C₂₂H₁₈ClN₃O₂. 0.25H₂O: C, 66.67; H, 4.70; N, 10.60. Found: C, 66.79; H, 4.95; N, 10.54.

EXAMPLE A-445

The above compound was prepared in a manner analogous to Example A-440 starting with N-tert-butoxycarbonyl-ethanolamine. Recrystallized from ethyl acetate/methanol. Yield: white solid, 75 mg (4%); mp>300° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.60 (br s, 1H), 8.38 (d, 2H), 7.53 (d, 2H), 7.38 (d, 2H), 7.22 (d, 2H), 7.02 (t, 1H), 4.20 (t, 2H), 3.34 (m, 2H), 1.36 (s, 9H); ESHRMS m/z 415.1551 (M+H, C₂₁H₂₄ClN₄O₃ requires 415.1537).

EXAMPLE A-446

The above compound was prepared in a manner analogous to Example A-440 starting with methanol. Yield: off-white solid, 119 mg (14%); mp=265.3-265.3° C.; ¹H-NMR (DMSO-d6/300 MHz) 12.61 (br s, 1H), 8.41 (d, 2H), 7.52 (d, 2H), 7.38 (d, 2H), 7.17 (d, 2H), 3.90 (s, 3H); ESHRMS m/z 286.0766 (M+H, C₁₅H₁₃ClN₃O requires 286.0747); Anal. Calc'd for C₁₅H₁₂ClN₃O.0.25H2O: C, 62.08; H, 4.34; N, 14.48. Found: C, 62.24; H, 4.11; N, 14.16.

EXAMPLE A-447

To the dithietane of Step 1 of Example A-341 (638 mg, 2 mmol) in toluene (15 mL) was added thiomorpholine (800 uL, 8 uL). The reaction mixture was heated to reflux for 6 hours, then cooled to room temperature and diluted with toluene (20 mL). The reaction mixture was then extracted twice with water (20 mL) and brine (20 mL). The organic solution was dried (MgSO₄), filtered, and concentrated to an oil. Hexane was added to the residue and heated to reflux, then decanted. The oil became semi-solid. The semi-solid was dissolved in tetrahydrofuran (10 mL) and potassium t-butoxide 1M in tetrahydrofuran (2 mL, 2 mmol) was added. This was followed by iodomethane (125 uL, 2 mmol). The reaction was stirred at room temperature for 1 hour, then quenched with water (20 mL). The reaction mixture was extracted with ethyl acetate (2×30 mL). The organic layers were pooled, washed with brine (20 mL) and dried (MgSO₄). Filtration and concentration produced an oil which was chased once with toluene to remove any ethyl acetate. The residue was dissolved in ethanol (10 mL) and hydrazine hydrate (97 uL, 2 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours then partitioned between ethyl acetate and saturated sodium bicarbonate solution (30 mL each). The layers were separated and the aqueous layer extracted again with ethyl acetate (30 mL). The combined organic layers were washed with brine (20 mL) and dried (MgSO₄). Filtration and concentration produced an orange residue which was triturated with acetonitrile to generate a tan solid. Yield: 295 mg (43%); mp>300° C.; ¹H NMR (DMSO-d6/300 MHz) 12.70 (br s, 1H), 8.47 (d, 2H), 7.46 (d, 2H), 7.26 (m, 4H), 3.13 (m, 4H), 2.62 (m, 4H); ESHRMS m/z 357.0942 (M+H, C₁₈H₁₈ClN₄S requires 357.0941); Anal. Calc'd for C₁₈H₁₇ClN₄S: C, 60.58; H, 4.80; N, 15.70. Found: C, 60.32; H, 4.96; N, 15.60.

EXAMPLE A-448

3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-oxy]-4-pyridin-4-yl-1H-pyrazole

The compound of Example A-441 (455 mg, 1.5 mmol) was combined with 98% formic acid (6 mL) and heated to 100° C. After three hours, 37% formaldehyde (1.22 mL, 15 mmol) was added and the reaction was heated for an additional five hours at 100° C. The reaction mixture was allowed to cool to room temperature and filtered. The solution was diluted with water (15 ml).and extracted once with ethyl acetate (30 mL). The aqueous solution was then basified with 2.5 N sodium hydroxide to pH 8. The cloudy mixture was then extracted twice with 1:1 tetrahydrofuran:ethyl acetate (30 mL). The organic layers were pooled and washed once with brine (25 mL), dried (MgSO₄), filtered and concentrated to an oil which solidified on standing. The solid was triturated with acetonitrile and collected by suction filtration. The solid was suspended in ethanol:water 2:1 (15 mL) and 1 mL of concentrated HCl was added. The solution was allowed to stir at room temperature for one hour, then filtered and concentrated. The residue was combined with ethanol (10 mL) and reconcentrated twice. The resulting solid was triturated with acetonitrile (10 mL) containing a small amount of ethanol (0.5 mL) to remove some colored impurities. The solid was collected by suction filtration, washed with acetonitrile and dried in-vacuo. Yield: 490 mg (88%); mp 255.9-256.8° C.; ¹H NMR (D₂O/DMSO-d6/NaOD/300 MHz) 7.93 (d, 2H), 7.09 (s, 4H), 7.00 (d, 2H), 4.42 (m, 1H), 2.26 (br m, 2H,) 2.12 (br m, 2H), 1.92 (s, 3H), 1.68 (br m, 2H), 1.57 (br m, 2H); ESLRMS m/z 369 (M+H).

EXAMPLE A-449

To the compound of Example C-1, infra, (4′-fluoro-1-(4-pyridyl)acetophenone, 14.0 g, 0.065 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium t-butoxide (1M in tetrahydrofuran, 150 mL). The mixture was stirred 30 minutes. Carbon disulfide (4.2 mL, 0.07 mol) in tetrahydrofuran (25 mL) was added dropwise and stirred 15 minutes. 2-Bromomethyl-1,3-dioxolane (25.0 g, 0.15 mol) in tetrahydrofuran (25 mL) was added dropwise and contents were refluxed 10 hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo leaving a red oil (29.3 g). Chromatography on-silica gel eluting with 25% ethyl acetate/hexanes gave the desired compound as a red oil, (5.5 g, 18% yield). ¹H NMR (CDCl³) 8.62-8.52 (m, 2H); 8.07-7.95 (m, 2H); 7.48-7.40 (m, 2H); 7.20-7.05 (m, 2H); 5.15-5.05 (m, 1H); 4.98-4.90 (m, 1H); 4.00-3.77 (m, 8H); 3.08 (d, J=6 Hz, 2H); 3.03 (d, J=6 Hz, 2H); ESHRMS m/z 464.0966 (M+H, C₂₂H₂₃FNO₅S₂ requires 464.1001); Anal. Calc'd for: C₂₂H₂₂FNO₅S₂ (0.1H₂O): C, 56.79; H, 4.81; N, 3.01. Found: C, 56.45; H, 4.71; N, 3.02.

EXAMPLE A-450

To the compound of Example C-1, infra, (4′-fluoro-1-(4-pyridyl)acetophenone, 7.0 g, 0.0325 mol) in anhydrous tetrahydrofuran (200 mL) was added dropwise potassium t-butoxide (1M in tetrahydrofuran, 75 mL). The mixture was stirred 30 minutes. Carbon disulfide (2.1 mL, 0.035 mol) in tetrahydrofuran (25 mL)was added dropwise and stirred 15 minutes. 4-Methoxybenzyl chloride (10.2 mL, 0.075 mol) in tetrahydrofuran (10 mL) was added dropwise and contents were stirred overnight. The contents were partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo leaving a red oil (19.1 g). Chromatography on silica gel eluting with 25% ethyl acetate/hexanes gave the desired as a white solid (11.8 g, 68% yield). Recrystallization from ethyl acetate/hexanes gave the desired as colorless crystals: mp 118.5-120.6° C.; ¹H NMR (CDCl₃) 8.43 (d, J=7 Hz, 2H); 7.62-7.52 (m, 2H); 7.20-6.72 (m, 12H); 3.98 (d, J=6 Hz, 4H); 3.83 (s, 3H); 3.81 (s, 3H); ESHRMS m/z 532.1408 (M+H, C₃₀H₂₇FNO₃S₂ requires 532.1416); Anal. Calc'd for: C₃₀H₂₆FNO₃S₂ (0.5 H₂₀): C, 66.65; H, 5.03; N, 2.59. Found: C, 66.34; H, 4.96; N, 2.55.

EXAMPLE A-451

The compound of Example A-449 (4.0 g, 9.2 mmol) and hydrazine monohydrate (2.2 mL, 46 mmol) were refluxed in ethanol (100 mL) for three hours. The mixture was is allowed to cool and stand overnight. A yellow precipitate was filtered to give the desired product as a yellow solid, (1.34 g, 41% yield); mp 202.1-205.4° C.; ¹H NMR (DMSO-d6) 13.5 (br s, 1H); 8.55-8.45 (m, 2H); 7.40-7.12 (m, 6H); 5.01 (s, 1H); 3.92-3.70 (m, 4H); 3.13 (s, 2H); ESHRMS m/z 358.1025 (M+H, C₁₈H₁₇FN₃O₂S requires 358.1025); Anal. Calc'd for: C₁₈H₁₆FN₃O₂S: C, 60.49; H, 4.51; N, 11.76. Found: C, 60.26; H, 4.55 N, 11.87.

EXAMPLE A-452

The above compound was prepared similarly to the compound of Example A-451 starting with the compound prepared in Example A-450. The desired product was obtained as a white solid (2.15 g, 49% yield) mp 214.7-215.8° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.70 (d, 2H); 7.60 (d, 2H); 7.42-7.38 (m, 2H); 7.30-7.20 (m, 2H); 6.70 (d, 2H); 4.10 (s, 2H); 3.68 (s, 3H); ESHRMS m/z 392.1225 (M+H, C₂₁H₁₉FN₃OS requires 392.1232); Anal. Calc'd for: C₂₂H₁₈FN₃OS: C, 67.50; H, 4.63; N, 10.73. Found: C, 67.46; H, 4.67 N, 10.77.

EXAMPLE A-453

The compound prepared in step 1 of Example A-341 (50 g, 0.156 mol) and anhydrous hydrazine (25 mL, 0.8 mol) were refluxed in ethanol (500 mL) for five hours. The mixture was allowed to cool and the precipitate filtered to afford the desired product as a yellow-orange solid (21.8 g). The filtrate was diluted with water (200 mL) and a second crop was obtained as a yellow-orange solid (18.0 g). The pH of the filtrate was adjusted to pH 8 with 3N HCl and the precipitated solid filtered to give more desired as a yellow-orange solid (2.0 g). The product was obtained in 93% yield. mp 266.3-268.9° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 12.20 (br s, 1H); 8.32 (s, 4H); 7.50-7.30 (m, 4H); ESHRMS m/z 288.0358 (M+H, C₁₄H₁₁ClN₃S requires 288.0362); Anal. Calc'd for: C₁₄H₁₀ClN₃S (0.4H₂O): C, 57.01; H, 3.69; N, 14.25. Found: C, 56.95; H, 3.50 N, 14.14.

EXAMPLE A-454

The above compound was prepared similarly to the compound of Example A-453. mp 261.3-263.9° C.; ¹H NMR (DMSO-d6) 11.55 (br s, 1H); 8.25-8.13 (m, 2H); 7.61-7.50 (m, 2H); 7.36-7.20 (m, 2H); 7.19-7.05 (m, 2H); ESHRMS m/z 272.0691 (M+H, C₁₄H₁₁FN₃S requires 272.0657); Anal. Calc'd for: C₁₄H₁₀FN₃S (0.25H₂O): C, 60.97; H, 3.84; N, 15.24. Found: C, 61.05; H, 3.64 N, 15.12.

EXAMPLE A-455

To the compound prepared in Example A-453 (100 mg, 0.35 mmol) in methanol (2 mL) was added 0.5 M sodium methoxide (0.7 mL, 0.35 mmol). The mixture was stirred for 15 minutes and filtered to remove some small particles. The filtrate was concentrated in vacuo, dissolved in water and concentrated in vacuo leaving the desired product as a white solid. ¹H NMR (DMSO-d6) 11.60 (br s, 1H); 8.20 (d, 2H); 7.60-7.50 (m, 2H); 7.40-7.20 (m, 4H); Anal. Calc'd for: C₁₄H₉ClN₃NaS (2.5H₂O): C, 47.40; H, 3.98; N, 11.84. Found: C, 47.39; H, 3.33; N, 11.50.

EXAMPLE A-456

[3-(4-chlorophenyl)-4-pyridin-4-yl-1H-pyrazole-5-yl]thio]-acetonitrile

To the compound prepared in Example A-453 (584 mg, 2.0 mmol) and bromoacetonitrile (140 ul, 2.0 mmol) in dimethylformamide (5 mL) was added anhydrous potassium carbonate (276 mg, 2.0 mmol). The contents were stirred overnight, then partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo leaving a tan solid. The solid was triturated with methanol and filtered to give the desired as a off-white solid (369 mg, 56% yield). mp 230.0-230.5° C.; ¹H NMR (DMSO-d6) 13.90 (br s, 1H); 8.58 (d, 2H); 7.60-7.13 (m, 6H); 4.10 (s, 2H); ESHRMS m/z 327.0482 (M+H, C₁₆H₁₂ClN₄S requires 327.0471); Anal. Calc'd for: C₁₆H₁₁C₁₁N₄S (0.3H₂O): C, 57.85, H, 3.52; N, 16.87. Found C, 57.88; H, 3.31; N, 16.77.

EXAMPLE A-457

The above compound was prepared similarly to the compound of Example A-456 except that when the contents were partitioned between ethyl acetate and water, an insoluble solid was filtered to give the desired product as a white solid (2.16 g). A second crop (1.68 g) of desired product gave a total yield of 61%. mp 192.8-195.2° C.; ¹H NMR (DMSO-d6+approximately 10% TFA) 9.80 (d, 2H); 7.80 (d, 2H); 7.52-7.34 (m, 4H); 3.92 (s, 2H); 3.57 (s, 3H); ESHRMS m/z 360.05735 (M+H, C₁₇H₁₄ClN₃O₂S requires 360.05732); Anal. Calc'd for: C₁₇H₁₄ClN₃O₂S (0.25H₂O): C, 56.05, H, 4.01; N, 11.53. Found C, 56.10; H, 3.72; N, 11.51.

EXAMPLE A-458

The compound prepared in Example A-453 (1.2 g, 4.2 mmol), potassium carbonate (630 mg, 4.6 mmol), N-tert-butoxycarbonyl-4-bromo piperidine (1.2 g, 4.5 mmol) were heated in dimethylformamide (15 mL) at 105° C. for three hours. Contents were allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo. The residue was triturated with ethyl acetate and filtered to give the desired as a white solid (1.2 g, 61% yield). mp 220.9-221.0° C.; ¹H NMR (DMSO-d6) 13.70 (br, 1H); 8.60-8.50 (m, 2H); 7.58-7.10 (m, 6H); 3.80-3.60 (m, 2H); 3.40-3.20 (m, 1H); 3.00-2.63 (m, 2H); 2.00-1.53 (m, 2H); 1.50-1.05 (m, 2H); 1.40 (s, 9H); ESHRMS m/z 471.1605 (M+H, C₂₄H₂₈ClN₄OS requires 471.1622); Anal. Calc'd for: C₂₄H₂₇ClN₄OS (0.5H₂O): C, 60.05; H, 5.88; N, 11.67. Found: C, 60.04; H, 5.57; N, 11.31.

EXAMPLE A-459

3-(4-chlorophenyl)-5-[(piperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

The compound prepared in Example A-458 (5.0 g, 11 mmol), and TFA (30 mL) were mixed in methylene chloride (50 mL) and stirred overnight. The mixture was concentrated in vacuo leaving a pale yellow oil which was dissolved in water. The pH was adjusted with 2.5 N sodium hydroxide to pH 9, precipitating a white solid which was filtered to give the desired product as a white solid (3.7 g, 93% yield). mp 211.1-211.2° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 8.55 (d, 2H); 8.40 (br, 1H); 7.50-7.15 (m, 6H); 3.50-3.00 (m, 3H); 3.00-2.80 (m, 2H); 2.05-1.80 (m, 2H); 1.65-1.42 (m, 2H); ESHRMS m/z 371.1103 (M+H, C₁₉H₂₀ClN₄S requires 371.1097); Anal. Calc'd for: C₁₉H₁₉ClN₄S (H₂O): C, 58.68; H, 5.44; N, 14.41. Found: C, 58.86; H, 5.28; N, 14.25.

EXAMPLE A-460

To 1-(2-chloroethyl)pyrrolidine hydrochloride (306 mg, 1.8 mmol) in methanol (10 mL) was added 0.5 M sodium methoxide (7.0 mL, 3.6 mmol). The mixture was stirred 10 minutes and the compound of Example A-453 (500 mg, 1.8 mmol) added. The contents were refluxed one hour, allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo leaving a light amber solid. The solid was recrystallized from methanol (15 mL) to give the desired product as a white solid (213 mg, 33% yield). mp 189.9-190.1° C; ¹H NMR (DMSO-d6) 13.65 (br, 1H); 8.52 (d, 2H); 7.42 (d, 2H); 7.38-7.10 (m, 4H); 3.10-2.93 (m, 2H); 2.63-2.51 (m, 2H); 2.38 (br s, 4H); 1.70-1.52 (m, 4H); ESHRMS m/z 385.1262 (M+H, C₂₀H₂₂ClN₄S requires 385.1254); Anal. Calc'd for: C₂₀H₂₁ClN₄S: C, 62.41, H, 5.50; N, 14.56. Found C, 62.22; H, 5.62; N, 14.48.

EXAMPLE A-461

Method A: The compound prepared in Example A-457 (1.3 g, 3.6 mmol) in methanol (10 mL), 2.5N sodium hydroxide (4 mL) and water (10 mL) were stirred overnight. The mixture was concentrated in vacuo to remove the methanol and the aqueous solution left was made acidic to pH 6 with 3N HCl, precipitating a solid. The solid was extracted into ethyl acetate, dried over MgSO₄ and concentrated in vacuo leaving light tan crystals (205 mg). Brine was added to the aqueous layer precipitating more solid. The solid did not extract into ethyl acetate, but was filtered to give more desired product as a light tan powder (529 mg). Total yield was 61% yield. ¹H NMR (DMSO-d6+10% TFA) 8.80 (d, 2H); 7.83 (d, 2H); 7.55-7.35 (m, 4H); 3.87 (s, 2H).

Method B: The compound prepared in Example A-457 (3.8 g, 11 mmol) and 3N HCl (30 mL) were refluxed for three hours. The mixture was allowed to cool and concentrated in vacuo. The residue was mixed with CH₃CN (50 mL). Upon standing overnight, pale yellow crystals grew and were filtered to give the desired product as the HCl salt (2.9 g, 69% yield). ¹H NMR (DMSO-d6) 8.79 (d, 2H); 7.75 (d, 2H); 7.51-7.38 (m, 4H); 3.88 (s, 2H); ESHRMS m/z 346.0435 (M+H, C₁₇H₁₆ClN₄OS requires 346.0417); Anal. Calc'd for: C₁₆H₁₂ClN₃O₂S (HCl, 0.5H₂O): C, 49.12; H, 3.61; N, 10.74. Found: C, 49.36; H, 3.48; N, 10.72.

EXAMPLE A-462

The compound prepared in Example A-457 (400 mg, 11 mmol) and a 2M solution of methyl amine in tetrahydrofuran (25 mL) were refluxed for three hours. The mixture was stirred overnight at room temperature before filtering to give the desired as a light amber solid (335 mg, 85% yield). mp 284.0-288.4° C.; ¹H NMR (DMSO-d6) 13.58 (br, 1H); 8.60-8.45 (m, 2H); 7.98 (br s, 1H); 7.55-7.12 (m, 6H); 3.60 (s, 2H); 2.46 (s, 3H); ESHRMS m/z 359.0733 (M+H, C₁₇H₁₆ClNI₄OS requires 359.0745); Anal. Calc'd for: C₁₇H₁₅ClN₄OS: C, 56.90; H, 4.21; N, 15.61. Found: C, 56.74; H, 4.11; N, 15.17.

EXAMPLE A-463

The compound prepared in Example A-457 (415 mg, 12 mmol) and N,N-dimethylaminopropylamine were refluxed in methanol (25 mL) for three hours. The mixture was stirred overnight at room temperature before concentrating in vacuo leaving a solid. The solid was triturated with ethyl acetate and filtered to give the desired as a white solid (256 mg, 50 t yield). mp 168.8-169.5° C.; ¹H NMR (DMSO-d6) 13.80 (br, 1H); 8.55-8.50 (m 2H); 8.02 (t, 1H); 7.50-7.40 (m, 6H); 3.61 (s, 2H); 3.30-2.98 (m, 2H); 2.14-2.10 (m, 2H); 2.04 (s, 6H); 1.50-1.40 (m, 2H); ESHRMS m/z 430.1472 (M+H, C₂₁H₂₅ClNI₂₅OS requires 430.1468); Anal. Calc'd for: C₂₁H₂₄ClN₅OS (0.5 H₂O): C, 57.46; H, 5.74; N, 15.95. Found: C, 57.71; H, 5.56; N, 16.12.

EXAMPLE A-464

To the compound prepared in Example A-458 (1.0 g, 2.1 mmol) in methylene chloride (25 mL) was added meta-chloroperbenzoic acid (425 mg, 2.1 mmol). The mixture was stirred 15 minutes and chromatographed on silica gel (20 g) eluting with ethyl acetate. The desired product precipitated out of the ethyl acetate elutant upon standing and was filtered to give the desired product as a white solid (958 mg, 93% yield). mp 215.8-215.9° C.; ¹H NMR (DMSO-d6) 14.34 (br s, 1H); 8.57-8.54 (m, 2H); 7.51-7.25 (m, 6H); 4.00-3.82 (m, 2H); 3.60-3.40 (m, 1H); 2.85-2.70 (m, 2H); 2.10-1.95 (m, 1H); 1.56-1.10 (m, 3H); 1.36 (s, 9H); ESHRMS m/z 487.1580 (M+H, C₁₇H₁₆ClN₄OS requires 487.1571); Anal. Calc'd for: C₂₄H₂₇ClNI₂₄O₃S: C, 59.19; H, 5.59; N, 11.50. Found: C, 59.00; H, 5.76; N, 11.46.

EXAMPLE A-465

To the compound prepared in Example A-458 (320 mg, 0.68 mmol) in ethanol (5 mL) was added an aqueous solution of potassium peroxymonosulfate (420 mg, 0.68 mmol). The mixture was stirred two hours and extracted into ethyl acetate which was dried over MgSO₄ and concentrated in vacuo leaving a white solid. The solid was triturated with methanol and filtered to give the desired as a white solid (90 mg, 26% yield). mp 228.0-230.8° C.; ¹H NMR (DMSO-d6) 8.61 (d, 2H); 7.48 (d, 2H); 7.31-7.20 (m, 4H); 4.05-3.90 (m, 2H); 3.54-3.35 (m, 1H); 2.85-2.60 (m, 2H); 1.92-1.80 (m, 2H); 1.48-1.25 (m, 2H); 1.32 (m, 9H); ESHRMS m/z 503.1541 (M+H, C₂₄H₂₇ClN₄O₄S requires 503.1520); Anal. Calc'd for: C₂₄H₂₇ClN₄O₄S (H₂O): C, 56.30; H, 5.51; N, 10.94. Found: C, 56.41; H, 5.78; N, 10.54.

EXAMPLE A-466

The above compound was prepared similarly to the compound of Example A-464. After chromatography the solid obtained was recrystallized from CH₃CN to give the desired product as white crystals (64 mg, 33% yield). mp 189.5-189.5° C.; ¹H NMR (DMSO-d6) 14.28 (br s, 1H); 8.50 (d, 2H); 7.40-7.20 (m, 4H); 7.20-7.05 (m, 4H); 6.85 (d, 2H); 4.41 (s, 2H); 3.70 (s, 3H); ESHMS m/z 408.1168 (M+H, C₂₂H₁₉FN₃O₂S requires 408.1182); Anal. Calc'd for: C₂₂H₁₈FN₃O₂S: C, 64.85; H, 4.45; N, 10.31. Found; C, 64.44; H, 4.34; N, 10.70.

EXAMPLE A-467

To the compound prepared in Example A-466 (1.2 g, 2.5 mmol) in methylene chloride (50 mL) was added meta-chloroperbenzoic acid (1.0 g, 5.0 mmol). The mixture was stirred 1.5 hours and filtered a white solid (620 mg) which was inorganic salts. The filtrate was chromatographed on silica gel (20 g) eluting with ethyl acetate to give the desired product as a white solid (98 mg, 9% yield). mp 241.9-242.0° C.; ¹H NMR (DMSO-d6) 8.48-8.40 (m, 2H); 7.33-6.80 (m, 10H); 4.55 (s, 2H); 3.72 (s, 3H); ESHRMS m/z 424.1143 (M+H, C₂₄H₂₇ClN₄O₄S requires 424.1131); Anal. Calc'd for: C₂₂H₁₈FN₃O₃S: C, 62.40; H, 4.28; N, 9.92. Found: C, 62.14; H, 4.42; N, 9.68.

EXAMPLE A-468

3-(4-chlorophenyl)-5-[(1-methylpiperidin-4-yl)-thio]-4-pyridin-4-yl-1H-pyrazole

The compound prepared in Example A-458 (5.0 g, 0.01 mol) and formic acid (96%, 7 mL) were heated at 100° C. for one hour. The mixture was allowed to cool to about 50° C. and formaldehyde (37%, 13 mL) was added. The contents were heated at 80° C. for two hours. The contents were allowed to cool, diluted with water (200 mL) and made basic to pH 11 with 2.5N sodium hydroxide, precipitating a white solid. The solid was filtered and recrystallized from methanol to give the desired as a white solid (174 mg. 33% yield). mp 227.7-227.7° C.; ¹H NMR (DMSO-d6) 13.70 (br s, 1H); 8.56-8.48 (m, 2H); 7.50-7.15 (m, 6H); 3.10-2.92 (m, 1H); 2.63-2.50 (m, 2H); 2.05 (s, 3H); 1.95-1.65 (m, 4H); 1.50-1.30 (m, 2H); ESHRMS m/z 385.1233 (M+H, C₂₀H₂₂ClN₄S requires 385.1254); Anal. Calc'd for: C₂₀H₂₁H₃ClN₄S: C, 62.41; H, 5.50; N, 14.56. Found: C, 62.40; H, 5.80; N, 14.61.

EXAMPLE A-469

3-(4-chlorophenyl)-5-[(2-methoxyethyl)-thio]-4-pyridin-4-yl-1H-pyrazole

The above compound was prepared similarly to the compound of Example A-456 using bromoethyl methyl ether except contents were heated at 70° C. for one hour before partitioning between ethyl acetate and water. The crude product was recrystallized from methanol/ethyl acetate to give the desired product as a white solid (210 mg, 35% yield). mp 189.2-190.2° C.; ¹H NMR .(DMSO-d6) 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 3.60-2.85 (m, 7H); ESHRMS m/z 346.0799) M+H, C₁₇H₁₇ClN₃OS requires 346.0781); Anal. Calc'd for: C₁₇H₁₆ClN₃OS (H₂O): C, 58.73; H, 4.70; N, 12.09. Found: C, 58.67; H, 4.86; N, 12.03.

EXAMPLE A-470

The above compound was prepared similarly to the compound of Example A-456 using 2-chloromethylbenzimidazole except contents were heated at 70° C. for one hour before partitioning between ethyl acetate and water. An insoluble solid was filtered from the two layers and triturated with methanol to give the desired product as a light amber solid (292 mg, 40% yield). mp 257.7-257.7° C.; ¹H NMR (DMSO-d6) 13.75 (br s, 1H); 12.30 (br s, 1H); 8.55-8.30 (m, 2H); 7.65-6.90 (m, 10H); 4.40 (br s, 2H); ESHRMS m/z 418.0895 (M+H, C₂₂H₁₇ClN₅S requires 418.0893); Anal. Calc'd for: C₂₂H₁₆ClN₅S (0.75H₂O): C, 61.25; H, 4.09; N, 16.23. Found: C, 61.27; H, 3.90; N, 15.92.

EXAMPLE A-471

The above compound was prepared similarly to the Ad compound of Example A-456 using DL-alpha-bromo-beta-(5-imidazolyl)propionic acid except the mixture was heated at 70° C. for one hour. The mixture contained an insoluble solid which was diluted with water and the pH was adjusted with 3N HCl to pH 7. The mixture was filtered and triturated with methanol to give the desired product as a white solid (1.5 g, 81% yield). mp 163.0-165.SOC; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.92 (d, 1H); 8.83-8.75 (m, 2H); 7.80+(d, 2H); 7.55-7.30 (m, 5H); 4.20-4.05 (m, 1H); 3.25-3.00 (m, 2H). ESHRMS m/z 426.0799 (M+H, C₂₀H₁₇ClN₅O₂S requires 426.0791); Anal. Calc'd for: C₂₀H₁₆ClN₅O₂S (1.8H₂O): C, 52.41 H, 4.31; N, 15.28. Found: C, 52.68; H, 4.58; N, 15.37.

EXAMPLE A-472

To the compound prepared in Example A-453 (264 mg, 0.9 mmol) and alpha-methylenebutyrolactone (0.08 mL, 0.9 mmol) in ethanol was added a drop of triethylamine. The mixture was stirred overnight. The resulting solid was filtered and triturated with methanol to give the desired product as a pale yellow solid (181 mg, 51% yield). mp 224.2-225.90C; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.53-7.33 (m, 4H); 4.30-4.05 (m, 2H); 3.50-3.40 (m, 1H); 3.15-2.90 (m, 2H); 2.32-2.20 (m, 1H) 2.10-1.90 (m, 1H); ESHRMS m/z 386.0760 (M+H, C₁₉H₁₇ClN₃O₂S requires 386.0730); Anal. Calc'd for: C₁₉H₁₆ClN₃O₂S: C, 59.14 H, 4.18; N, 10.89. Found: C, 58.97; H, 4.21; N, 10.96.

EXAMPLE A-473

The above compound was prepared similarly to the compound of Example A-456 using 2-bromomethyl-1,3-dioxolane except the mixture was heated at 80° C. for two hours. The mixture was diluted with water and filtered to give a white solid (502 mg). The solid was recrystallized from ethanol to give the desired product as off-white crystals (280 mg, 43% yield). mp 197.0-198.2° C.; ¹H NMR (DMSO-d6) 13.60 (br s, 1H); 8.60-8.45 (m, 2H); 7.60-7.10 (m, 6H); 5.15-4.85 (m, 1H); 3.95-3.62 (m, 4H); 3.40-2.95 (m, 2H); ESHRMS m/z 374.0741 (M+H, C₁₈H₁₇ClN₃O₂S requires 374.0730); Anal. Calc'd for: C₁₈H₁₆ClN₃O₂S: C, 57.83 H, 4.31; N, 11.24. Found: C, 57.69; H, 4.41; N, 11.15.

EXAMPLE A-474

The above compound was prepared similarly to the compound of Example A-456 using 2-(2-bromoethoxy)tetrahydro-2H-pyran except that the mixture was heated at 80° C. for four hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄ and concentrated in vacuo leaving a solid (737 mg). The solid was recrystallized from ethanol to give the desired product as pale yellow crystals (281 mg, 39% yield). mp 163.2-163.5° C.; ¹H NMR (DMSO-d6) 13.80-13.70 (m, 1H), 8.60-8.42 (br s, 1H); 7.60-7.10 (m, 6H); 4.60-4.30 (m, 1H); 3.90-2.90 (m, 6H); 1.70-1.20 (m, 6H); ESHRMS m/z 416.1200 (M+H, C₂₁H₂₃ClN₃O₂S requires 416.1198); Anal. Calc'd for: C₂₁H₂₂ClN₃O₂S: C, 60.64 H, 5.33; N, 10.10. Found: C, 60.49; H, 5.71; N, 9.96.

EXAMPLE A-475

The above compound was prepared similarly to the compound of Example A-456 using 4-bromobutyronitrile except the mixture was heated at 55° C. for one hour. The mixture was diluted with water (75 mL) and filtered to give a white solid (567 mg). The solid was recrystallized from methanol to give the desired product as white crystals (333 mg, 54% yield). mp 216.7-216.9° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.80-8.75 (m, 2H); 7.83-7.75 (m, 2H); 7.50-7.35 (m, 4H); 3.10-3.00 (m, 2H); 2.60-2.45 (m, 2H); 1.95-1.80 (m, 2H); ESHRMS m/z 355.0818 (M+H, C₁₈H₁₆ClN₄S requires 355.0784); Anal. Calc'd for: C₁₈H₁₅ClN₄S (0.5H₂O): C, 59.42 H, 4.43; N, 15.40. Found: C, 59.64; H, 4.11; N, 15.44.

EXAMPLE A-476

The compound prepared in Example A-461 (416 mg, 1.1 mmol), morpholine (4 mL), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (481 mg, 1.5 mmol) and dimethylformamide (10 mL) were stirred overnight. The mixture was diluted with water (75 mL) and the resulting solid was filtered (363 mg). The solid was recrystallized from ethanol to give the desired product as a white solid (219 mg, 48% yield). mp 215.4-215.5° C.; ¹H NMR (DMSO-d6) 13.70-13.60 (m, 1H); 8.60-8.50 (m, 2H); 7.50-7.10 (m, 6H); 3.93-3.86 (m, 2H); 3.60-3.20 (m, 8H); ESHRMS m/z 415.0995 (M+H, C₂₀H₂₀ClN₄O₂S requires 415.1001); Anal. Calc'd for: C₂₀H₁₉ClN₄O₂S: C, 57.90 H, 4.62; N, 13.50. Found: C, 57.87; H, 4.86; N, 13.53.

EXAMPLE A-477

The above compound was prepared similarly to the compound of Example A-456 using 2-bromopropionitrile except the mixture was heated at 70° C. for one hour. The mixture was diluted with water (75 mL) and filtered to give an off-white solid (662 mg). The solid was recrystallized from methanol to give the desired product as a white solid (220 mg, 37% yield). mp 211.1-212.8° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.87-8.80 (m, 2H); 7.90-7.80 (m, 2H); 7.55-7.45 (m, 6H); 4.42 (q, 1H); 1.50 (d, 3H); ESHRMS m/z 341.0628 (M+H, C₁₈H₁₆ClN₄S requires 341.0628); Anal. Calc'd for: C₁₇H₁₃ClN₄S: C, 59.91 H, 3.84; N, 16.44. Found; C, 59.64; H, 4.01; N, 16.18.

EXAMPLE A-478

The above compound was prepared similarly to the compound of Example A-456 using propargyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (577 mg). The solid was triturated with methanol to give the desired product as a white solid (388 mg, 68% yield). mp 212.7-213.2° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.80 (d, J=6.8 Hz, 2H); 7.82 (d, J=6.8 Hz, 2H); 7.50-7.35 (m, 4H); 3.81 (d, J=2.6 Hz, 2H); 3.05 (t, J=2.6 Hz, 1H); ESHRMS m/z 326.0533 (M+H, C₁₇H₁₃ClN₃S requires 326.0519); Anal. Calc'd for: C₁₇H₁₂ClN₃S (0.2H₂O): C, 61.98 H, 3.79; N, 12.76. Found: C, 61.89; H, 3.45; N, 12.67.

EXAMPLE A-479

The above compound was prepared similarly to the compound of Example A-456 using allyl bromide. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was recrystallized from methanol to give the desired product as a pale yellow solid (187 mg, 33% yield). mp 207.3-208.1° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.50-7.30 (m, 4H); 5.90-5.70 (m, 1H); 5.10-4.95 (m, 2H); 3.62 (d, 2H); ESHRMS m/z 328.0693 (M+H, C₁₇H₁₅ClN₃S requires 328.0675); Anal. Calc'd for: C₁₅H₁₄ClN₃S (0.1H₂O): C, 61.94 H, 4.34; N, 12.75. Found: C, 61.83; H, 4.21; N, 12.76.

EXAMPLE A-480

The above compound was prepared similarly to the compound of Example A-456 using 2-bromoethylamine except two equivalents of potassium carbonate were used. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (509 mg). The solid was recrystallized from methanol to give the desired product as a pale yellow solid (262 mg, 45% yield). mp 186.8-187.8° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.85-8.75 (m, 2H); 8.90 (br s, 2H); 8.85-8.75 (m, 2H); 7.55-7.35 (m, 4H); 3.30-3.00 (m, 4H), ESHRMS m/z 331.0779 (M+H, C₁₆H₁₆ClN₄S requires 331.0784); Anal. Calc'd for: C₁₆H₁₅ClN₄S (0.5H₂O): C, 56.55; H, 4.75; N, 16.49. Found: C, 56.28; H, 4.38; N, 16.20.

EXAMPLE A-481

The above compound was prepared similarly to the compound of Example A-456 using 3-(2-bromoethyl)indole. The mixture was diluted with water (75 mL) and filtered to give a pale yellow solid (752 mg). The solid was triturated with methanol to give the desired product as a white solid (682 mg, 91% yield). mp 211.9-213.2° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 10.80 (s, 1H); 8.72 (d, 2H); 7.71 (d, 2H); 7.55-7.35 (m, 5H); 7.29 (d, 1H); 7.12-6.88 (m, 3H); 3.40-3.30 (m, 2H); 3.05-2.95 (m, 2H); ESHRMS m/z 431.1095 (M+H, C₂₄H₂OClN₄S requires 431.1097); Anal. Calc'd for: C₂₄H₁₉ClN₄S (0.15H₂O): C, 66.47; H, 4.49; N, 12.92. Found: C, 66.44; H, 4.51; N, 12.84.

EXAMPLE A-482

The compound of Example A-464 (464 mg, 0.95 mmol) and TFA (8 mL) were mixed in methylene chloride (10 mL) and stirred overnight. The mixture was concentrated in vacuo and the residue was partitioned between ether and water. The aqueous layer was made basic to pH 10 with 2.5N sodium hydroxide and extracted with ethyl acetate (2×100 mL). Upon standing overnight, a solid precipitated from the aqueous layer and was filtered to give the desired product as a white solid (183 mg, 50% yield). mp 189.1-190.8° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.85 (d, 2H); 8.80-8.60 (m 1H); 8.45-8.25 (m, 1H); 7.90 (d, 2H); 7.55-7.30 (m, 4H); 3.65-3.20 (m 3H); 3.10-2.80 (m, 2H); 2.20-2.00 (m, 1H); 1.90-1.50 (m, 3H); ESHRMS m/z 387.1032 (M+H, C₁₉H₂₀ClN₄OS requires 387.1046); Anal. Calc'd for: C₁₉H₂₀ClN₄OS (2H₂O): C, 53.96; H, 5.48; N, 13.25. Found: C, 53.75; H, 4.99; N, 13.21.

EXAMPLE A-483

The above compound was prepared similarly to the compound of Example A-456 using 3-bromopropionitrile. The mixture was diluted with water (75 mL) and extracted into ethyl acetate, which was dried over MgSO₄ and concentrated in vacuo leaving an orange waxy solid (523 mg). The solid was dissolved in CH₃CN and filtered through a pad of silica gel and eluted with ethyl acetate to give a white solid. The solid was triturated with ethyl acetate and filtered to give the desired product as a white solid (76 mg, 13% yield). mp 205.7-206.5° C.; ¹H NMR (DMSO-d6+approx. 10% TFA) 8.80 (d, 2H); 7.80 (d, 2H); 7.55-7.35 (m, 4H); 3.30-3.20 (m, 2H); 2.90-2.80 (m, 2H); ESHRMS m/z 341.0639 (M+H, C₁₉H₂₀ClN₄OS requires 341.0628); Anal. Calc'd for: C₁₇H₁₃ClN₄S (0.25H₂O): C, 59.13; H, 3.94; N, 16.22. Found: C, 59.03; H, 3.93; N, 15.90.

EXAMPLE A-484

A solution of 5-amino-3-(4-chlorophenyl)-4-(pyridin-4-yl)-pyrazole (200 mg, 0.74 mmol) and toluene sulfonyl chloride (564 mg, 2.94 mmol, prepared as set forth in Example A-427) in pyridine (5 mL) was stirred at 100° C. for two days. The mixture was concentrated in vacuo to a brown residue. The residue was chromatographed on a silica gel column eluting with 10% methanol/dichloromethane. The fractions containing the desired product were combined and concentrated to a yellow solid which was washed with diethyl ether and filtered to afford 78 mg (25%) of the desired sulfonamide as a white solid. m.p. 284.3-284.4° C. ¹H NMR (DMSO/300 MHz) δ 13.33 (brs, 0.8H), 9.94 (brs, 0.75H), 8.48 (brs, 1.75H), 8.22 (brs, 0.3H), 7.63 (d, 1.7H), 7.47 (d, 1.85H), 7.24 (m, 6.45H), 7.02 (brs, 0.25H), 6.81 (brs, 0.20H). ESLRMS m/z 425 (M+H). ESHRMS m/z 425.0848 (M+H, C₂₁H₁₈N₄ClS requires 425.0839).

EXAMPLE A-485

1-[cyclohexyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine

mp>300° C. (decomposed). ¹H NMR (CD₃OD/300 MHz) 8.50 (d, 2H, J=6.0 Hz), 7.51 (d, 2H, J=5.8 Hz), 2.99-2.93 (m, 4H), 2.52-2.48 (m, 4H), 3.04-3.02 (m, 4H), 2.96 (s, 3H), 2.54-2.49 (m, 1H), 2.31-2.26 (m, 4H), 1.84-1.33 (m, 10H). FABLRMS m/z 326 (M+H).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:

4-[3-(4-chlorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

1-[5-(4-bromophenyl)-4-(4-pyridinyl)-1H-pyrazol-4-yl]pyrimidine

1-[1-(4-pyridinyl)-5-[4-(trifluoromethyl)pheny]-1H-pyrazol-3-yl]piperazine

4-[5-(1-piperazinyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]benzonitrile

1-[5-(1-ethynylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine

5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

3-(4-fluorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

3-(4-chlorophenyl)-5-(1-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

4-[2-aminoethyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo-[1,5-a]pyrimidin-6-ol

4-[2-aminoethyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-6-ol

3-(4-chlorophenyl)-4-(4-pyrimidinyl-1H-pyrazole-1-ethanol

5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-3-ethanamine

5-(4-chlorophenyl)-4-(4-pyrimidinyl]-1H-pyrazole-3-ethanamine

4-[3-(4-fluorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine

4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinylpropanamide

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]propanamide

6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-purine

6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-1H-purine

N-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide

N-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)propanamide

1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine;

1-[2-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine

1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]piperazine

1-[2-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]ethyl]-4-methylpiperazine

1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methylpiperazine

1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-methylpiperazine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanol

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazineethanamine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3,5-dimethylpiperazine

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2,6-trimethylpiperazine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-methylpiperazine

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-dimethylpiperazine

5-(4-chlorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

5-(4-chlorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine

5-(4-fluorophenyl)-4-(4-pyridinyl)-N-3-pyrrolidinyl-1H-pyrazol-3-amine

5-(4-fluorophenyl)-N-(1-methyl-3-pyrrolidinyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-pyrrolidinamine

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-3-pyrrolidinamine

5-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine

5-(4-fluorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-(4-pyridinyl)-1H-pyrazol-3-amine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-3-piperidinamine

N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-3-piperidinamine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1methyl-2-piperazinemethanamine

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanol

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinemethanamine

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanol

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinemethanamine

4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

1-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl]-4-piperidinol

1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]methyl-4-piperidinol

4-[3-(4-chlorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

4-[3-(4-fluorophenyl)-5-(4-methyl-1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid

ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-1-methyl-2-piperazinecarboxylic acid

ethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxamide

4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylic acid

ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxylate

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-piperazinecarboxamide

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylic acid

ethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-methyl-2-piperazinecarboxylate

4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-yl]-1-methyl-2-piperazinecarboxamide

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-ethyl-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(phenylmethyl)-4-piperidinamine

1-acetyl-N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-H-pyrazol-3-yl]-1-(2-propynyl)-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-cyclopropyl-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methoxyacetyl)-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-(methylethyl)-4-piperidinamine

N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-propyl-4-piperidinamine

ethyl 4-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]-1-piperidinecarboxylate

Additional compounds of specific interest include the compounds of Tables 3-3, 3-4, 3-5 and 3-6:

TABLE 3-3

R² R⁵ R¹² 4-piperidinyl methyl m- or p-fluoro 4-piperidinyl ethyl m- or p-fluoro 4-piperidinyl amino m- or p-fluoro 4-piperidinyl methylamino m- or p-fluoro 4-piperidinyl dimethylamino m- or p-fluoro 4-piperidinyl ethylamino m- or p-fluoro 4-piperidinyl diethylamino m- or p-fluoro 4-piperidinyl propylamino m- or p-fluoro 4-piperidinyl dipropylamino m- or p-fluoro 4-piperidinyl hydroxyethylamino m- or p-fluoro 4-piperidinyl 1-hydroxy-1,1-dimethylethyl m- or p-fluoro 4-piperidinyl methoxyethylamino m- or p-fluoro 4-piperidinyl methyl m- or p-chloro 4-piperidinyl ethyl m- or p-chloro 4-piperidinyl amino m- or p-chloro 4-piperidinyl methylamino m- or p-chloro 4-piperidinyl dimethylamino m- or p-chloro 4-piperidinyl ethylamino m- or p-chloro 4-piperidinyl diethylamino m- or p-chloro 4-piperidinyl propylamino m- or p-chloro 4-piperidinyl dipropylamino m- or p-chloro 4-piperidinyl hydroxyethylamino m- or p-chloro 4-piperidinyl 1-hydroxy-1,1-dimethylethyl m- or p-chloro 4-piperidinyl methoxyethylamino m- or p-chloro 4-piperidinyl methyl m- or p-methyl 4-piperidinyl ethyl m- or p-methyl 4-piperidinyl amino m- or p-methyl 4-piperidinyl methylamino m- or p-methyl 4-piperidinyl dimethylamino m- or p-methyl 4-piperidinyl ethylamino m- or p-methyl 4-piperidinyl diethylamino m- or p-methyl 4-piperidinyl propylamino m- or p-methyl 4-piperidinyl dipropylamino m- or p-methyl 4-piperidinyl hydroxyethylamino m- or p-methyl 4-piperidinyl 1-hydroxy-1,1-dimethylethyl m- or p-methyl 4-piperidinyl methoxyethylamino m- or p-methyl 4-piperazinyl methyl m- or p-fluoro 4-piperazinyl ethyl m- or p-fluoro 4-piperazinyl amino m- or p-fluoro 4-piperazinyl methylamino m- or p-fluoro 4-piperazinyl dimethylamino m- or p-fluoro 4-piperazinyl ethylamino m- or p-fluoro 4-piperazinyl diethylamino m- or p-fluoro 4-piperazinyl propylamino m- or p-fluoro 4-piperazinyl dipropylamino m- or p-fluoro 4-piperazinyl hydroxyethylamino m- or p-fluoro 4-piperazinyl 1-hydroxy-1,1-dimethylethyl m- or p-fluoro 4-piperazinyl methoxyethylamino m- or p-fluoro 4-piperazinyl methyl m- or p-chloro 4-piperazinyl ethyl m- or p-chloro 4-piperazinyl amino m- or p-chloro 4-piperazinyl methylamino m- or p-chloro 4-piperazinyl dimethylamino m- or p-chloro 4-piperazinyl ethylamino m- or p-chloro 4-piperazinyl diethylamino m- or p-chloro 4-piperazinyl propylamino m- or p-chloro 4-piperazinyl dipropylamino m- or p-chloro 4-piperazinyl hydroxyethylamino m- or p-chloro 4-piperazinyl 1-hydroxy-1,1-dimethylethyl m- or p-chloro 4-piperazinyl methoxyethylamino m- or p-chloro 4-piperazinyl methyl m- or p-methyl 4-piperazinyl ethyl m- or p-methyl 4-piperazinyl amino m- or p-methyl 4-piperazinyl methylamino m- or p-methyl 4-piperazinyl dimethylamino m- or p-methyl 4-piperazinyl ethylamino m- or p-methyl 4-piperazinyl diethylamino m- or p-methyl 4-piperazinyl propylamino m- or p-methyl 4-piperazinyl dipropylamino m- or p-methyl 4-piperazinyl hydroxyethylamino m- or p-methyl 4-piperazinyl 1-hydroxy-1,1-dimethylethyl m- or p-methyl 4-piperazinyl methoxyethylamino m- or p-methyl aminocyclohexyl methyl m- or p-fluoro aminocyclohexyl ethyl m- or p-fluoro aminocyclohexyl amino m- or p-fluoro aminocyclohexyl methylamino m- or p-fluoro aminocyclohexyl dimethylamino m- or p-fluoro aminocyclohexyl ethylamino m- or p-fluoro aminocyclohexyl diethylamino m- or p-fluoro aminocyclohexyl propylamino m- or p-fluoro aminocyclohexyl dipropylamino m- or p-fluoro aminocyclohexyl hydroxyethylamino m- or p-fluoro aminocyclohexyl 1-hydroxy-1,1-dimethylethyl m- or p-fluoro aminocyclohexyl methoxyethylamino m- or p-fluoro aminocyclohexyl methyl m- or p-chloro aminocyclohexyl ethyl m- or p-chloro aminocyclohexyl amino m- or p-chloro aminocyclohexyl methylamino m- or p-chloro aminocyclohexyl dimethylamino m- or p-chloro aminocyclohexyl ethylamino m- or p-chloro aminocyclohexyl diethylamino m- or p-chloro aminocyclohexyl propylamino m- or p-chloro aminocyclohexyl dipropylamino m- or p-chloro aminocyclohexyl hydroxyethylamino m- or p-chloro aminocyclohexyl 1-hydroxy-1,1-dimethylethyl m- or p-chloro aminocyclohexyl methoxyethylamino m- or p-chloro aminocyclohexyl methyl m- or p-methyl aminocyclohexyl ethyl m- or p-methyl aminocyclohexyl amino m- or p-methyl aminocyclohexyl methylamino m- or p-methyl aminocyclohexyl dimethylamino m- or p-methyl aminocyclohexyl ethylamino m- or p-methyl aminocyclohexyl diethylamino m- or p-methyl aminocyclohexyl propylamino m- or p-methyl aminocyclohexyl dipropylamino m- or p-methyl aminocyclohexyl hydroxyethylamino m- or p-methyl aminocyclohexyl 1-hydroxy-1,1-dimethylethyl m- or p-methyl aminocyclohexyl methoxyethylamino m- or p-methyl

Still other compounds of specific interest include those compounds of Table 3-3 modified as follows:

(1) The 4-piperidinyl moiety is replaced with a 1-, 2- or 3-piperidinyl moiety; and/or

(2) The 4-piperidinyl, 3-piperidinyl, 2-piperidinyl or piperazinyl ring is substituted at a nitrogen ring atom with methyl, ethyl, isopropyl, cyclopropyl, propargyl, benzyl, hydroxyethyl, methoxyethyl, or methoxyacetyl; and/or

(3) The 1-piperidinyl ring is substituted at a carbon ring atom with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, cyclopropylamino, propargylamino, benzylamino, hydroxyethylamino, methoxyethylamino, or methoxyacetylamino; and/or

(4) The amino group of the aminocyclohexyl is replaced with methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, methoxyethylamino, or methoxyacetylamino; and/or

(5) A linking group selected from the group consisting of methylene, —S—, —O—, and —NH— separates the piperidinyl, piperazinyl or cyclohexyl moiety from the pyrazole nucleus.

TABLE 3-4

R⁴ R³ R²⁰⁰ R²⁰¹ 4-pyridyl 4-methylphenyl H O 4-pyridyl 4-methylphenyl CH₃ O 4-pyrimidyl 4-methylphenyl H O 4-pyrimidyl 4-methylphenyl CH₃ O 4-pyridyl 4-methylphenyl H S 4-pyridyl 4-methylphenyl CH₃ S 4-pyrimidyl 4-methylphenyl H S 4-pyrimidyl 4-methylphenyl CH₃ S 4-pyridyl 3-methylphenyl H O 4-pyridyl 3-methylphenyl CH₃ O 4-pyrimidyl 3-methylphenyl H O 4-pyrimidyl 3-methylphenyl CH₃ O 4-pyridyl 3-methylphenyl H S 4-pyridyl 3-methylphenyl CH₃ S 4-pyrimidyl 3-methylphenyl H S 4-pyrimidyl 3-methylphenyl CH₃ S

TABLE 3-5

R⁴ n X 4-chlorophenyl 1 S 4-chlorophenyl 2 SO 4-chlorophenyl 2 SO₂ 4-chlorophenyl 2 CH₂ 4-chlorophenyl 2 CHCH₃ 4-chlorophenyl 2 CHOH 4-chlorophenyl 1 CH₂ 4-chlorobenzyl 2 NCH₃ 2-chlorophenyl 2 NCH₃ 3,4-methylenedioxyphenyl 2 NCH₃ cyclohexyl 2 NCH₃ 2-thienyl 2 NCH₃ 5-chloro-2-thienyl 2 NCH₃ 4-propynylphenyl 2 NCH₃ 4-methylsulfoxylphenyl 2 NCH₃ 4-methylsulfonylphenyl 2 NCH₃ 2-(1-methyl-5-chloro)indolyl 2 NCH₃

TABLE 3-6

R⁴ R³ R⁴⁰⁰ p-Cl phenyl 4-pyridyl —SO₂CH₃ p-Cl phenyl 4-pyridyl —CH₂CN p-Cl phenyl 4-pyridyl

p-Cl phenyl

H

BIOLOGICAL EVALUATION p38 Kinase Assay

Cloning of Human p38a:

The coding region of the human p38a cDNA was obtained by PCR-amplification from RNA isolated from the human monocyte cell line THP.1. First strand cDNA was synthesized from total RNA as follows: 2 μg of RNA was annealed to 100 ng of random hexamer primers in a 10 μl reaction by heating to 70° C. for 10 minutes followed by 2 minutes on ice. cDNA was then synthesized by adding 1 μl of RNAs in (Promega, Madison Wis.), 2 μl of 50 mM dNTP's, 4 μl of 5×buffer, 2 μl of 100 mM DTT and 1 μl (200 U) of Superscript II™ AMV reverse transcriptase. Random primer, dNTP's and Superscript™ reagents were all purchased from Life-Technologies, Gaithersburg, Mass. The reaction was incubated at 42° C. for 1 hour. Amplification of p38 cDNA was performed by aliquoting 5 μl of the reverse transcriptase reaction into a 100 μl PCR reaction containing the following: 80 μl dH₂O, 2 μl 50 mM DNTP's, 1 μl each of forward and reverse primers (50 pmol/μl), 10 μl of 10×buffer and 1 μl Expand™ polymerase (Boehringer Mannheim). The PCR primers incorporated BamHI sites onto the 5′ and 3′ end of the amplified fragment, and were purchased from Genosys. The sequences of the forward and reverse primers were 5′-GATCGAGGATTCATGTCTCAGGAGAGGCCCA-3′ and 5′ GATCGAGGATTCTCAGGACTCCATCTCTTC-3′ respectively. The PCR amplification was carried out in a DNA Thermal Cycler (Perkin Elmer) by repeating 30 cycles of 94° C. for 1 minute, 60° C. for 1 minute and 68° C. for 2 minutes. After amplification, excess primers and unincorporated dNTP's were removed from the amplified fragment with a Wizard™ PCR prep (Promega) and digested with BamHI (New England Biolabs). The BamHI digested fragment was ligated into BamHI digested PGEX 2T plasmid DNA (PharmaciaBiotech) using T-4 DNA ligase (New England Biolabs) as described by T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd ed. (1989). The ligation reaction was transformed into chemically competent E. coli DH10B cells purchased from Life-Technologies following the manufacturer's instructions. Plasmid DNA was isolated from the resulting bacterial colonies using a Promega Wizard™ miniprep kit. Plasmids containing the appropriate BamHI fragment were sequenced in a DNA Thermal Cycler (Perkin Elmer) with Prism™ (Applied Biosystems Inc.). cDNA clones were identified that coded for both human p38a isoforms (Lee et al. Nature 372, 739). One of the clones which contained the cDNA for p38a-2 (CSBP-2) inserted in the cloning site of pGEX 2T, 3′ of the GST coding region was designated pMON 35802. The sequence obtained for this clone is an exact match of the cDNA clone reported by Lee et al. This expression plasmid allows for the production of a GST-p38a fusion protein.

Expression of Human p38a:

GST/p38a fusion protein was expressed from the plasmid pMON 35802 in E. coli, stain DH10B (Life Technologies, Gibco-BRL). Overnight cultures were grown in-Luria Broth (LB) containing 100 mg/ml ampicillin. The next day, 500 ml of fresh LB was inoculated with 10 ml of overnight culture, and grown in a 2 liter flask at 37° C. with constant shaking until the culture reached an absorbance of 0.8 at 600 nm. Expression of the fusion protein was induced by addition of isopropyl b-D-thiogalactosidse (IPTG) to a final concentration of 0.05 mM. The cultures were shaken for three hours at room temperature, and the cells were harvested by centrifugation. The cell pellets were stored frozen until protein purification.

Purification of p38 Kinase-α:

All chemicals were from Sigma Chemical Co. unless noted. Twenty grams of E. coli cell pellet collected from five 1 L shake flask fermentations was resuspended in a volume of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.3) up to 200 ml. The cell suspension was adjusted to 5 mM DTT with 2 M DTT and then split equally into five 50 ml Falcon conical tubes. The cells were sonnicated (Ultrasonics model W375) with a 1 cm probe for 3×1 minutes (pulsed) on ice. Lysed cell material was removed by centrifugation (12,000×g, 15 minutes) and the clarified supernatant applied to glutathione-sepharose resin (Pharmacia).

Glutathione-sepharose Affinity Chromatography:

Twelve ml of a 50% glutathione sepharose-PBS suspension was added to 200 ml clarified supernatant and incubated batchwise for 30 minutes at room temperature. The resin was collected by centrifugation (600×g, 5 min) and washed with 2×150 ml PBS/1% Triton X-100, followed by 4×40 ml PBS. To cleave the p38 kinase from the GST-p38 fusion protein, the glutathione-sepharose resin was resuspended in 6 ml PBS containing 250 units thrombin protease (Pharmacia, specific activity>7500 units/mg) and mixed gently for 4 hours at room temperature. The glutathione-sepharose resin was removed by centrifugation (600×g, 5 min) and washed 2×6 ml with PBS. The PBS wash fractions and digest supernatant containing p38 kinase protein were pooled and adjusted to 0.3 mM PMSF.

Mono O Anion Exchange Chromatography:

The thrombin-cleaved p38 kinase was further purified by FPLC-anion exchange chromatography. Thrombin-cleaved sample was diluted 2-fold with Buffer A (25 mM HEPES, pH 7.5, 25 mM beta-glycerophosphate, 2 mM DTT, 5% glycerol) and injected onto a Mono Q HR 10/10 (Pharmacia) anion exchange column equilibrated with Buffer A. The column was eluted with a 160 ml 0.1 M-0.6 M NaCl/Buffer A gradient (2 ml/minute flowrate). The p38 kinase peak eluting at 200 mM NaCl was collected and concentrated to 3-4 ml with a Filtron 10 concentrator (Filtron Corp.).

Sephacryl S100 Gel Filtration Chromatography:

The concentrated Mono Q-p38 kinase purified sample was purified by gel filtration chromatography (Pharmacia HiPrep 26/60 Sephacryl S100 column equilibrated with Buffer B (50 mM HEPES, pH 7.5, 50 mM NaCl, 2 EM DTT, 5% glycerol)). Protein was eluted from the column with Buffer B at a 0.5 ml/minute flowrate and protein was detected by absorbance at 280 nm. Fractions containing p38 kinase (detected by SDS-polyacrylamide gel electrophoresis) were pooled and frozen at −80° C. Typical purified protein yields from 5 L E. coli shake flasks fermentations were 35 mg p38 kinase.

In Vitro Assay

The ability of compounds to inhibit human p38 kinase alpha was evaluated using two in vitro assay methods. In the first method, activated human p38 kinase alpha phosphorylates a biotinylated substrate, PHAS-I (phosphorylated heat and acid stable protein-insulin inducible), in the presence of gamma ³²P-ATP (³²P-ATP). PHAS-I was biotinylated prior to the assay and provides a means of capturing the substrate which is phosphorylated during the assay. p38 Kinase was activated by MKK6. Compounds were tested in 10 fold serial dilutions over the range of 100 μM to 0.001 μM using 1% DMSO. Each concentration of inhibitor was tested in triplicate.

All reactions were carried out in 96 well polypropylene plates. Each reaction well contained 25 mM HEPES pH 7.5, 10 mM magnesium acetate and 50 μM unlabeled ATP. Activation of p38 was required to achieve sufficient signal in the assay. Biotinylated PHAS-I was used at 1-2 μg per 50 μl reaction volume, with a final concentration of 1.5 μM. Activated human p38 kinase alpha was used at 1 μg per 50 μl reaction volume representing a final concentration of 0.3 μM. Gamma ³²P-ATP was used to follow the phosphorylation of PHAS-I. ³²P-ATP has a specific activity of 3000 Ci/mmol and was used at 1.2 μCi per 50 μl reaction volume. The reaction proceeded either for one hour or overnight at 30° C.

Following incubation, 20 μl of reaction mixture was transferred to a high capacity streptavidin coated filter plate (SAM-streptavidin-matrix, Promega) prewetted with phosphate buffered saline. The transferred reaction mix was allowed to contact the streptavidin membrane of the Promega plate for 1-2 minutes. Following capture of biotinylated PHAS-I with ³²P incorporated, each well was washed to remove unincorporated ³²P-ATP three times with 2M NaCl, three washes of 2M NaCl with 1% phosphoric, three washes of distilled water and finally a single wash of 95% ethanol. Filter plates were air dried and 20 μl of scintillant was added. The plates were sealed and counted. Results are shown in Table 4.

A second assay format was also employed that is based on p38 kinase alpha induced phosphorylation of EGFRP (epidermal growth factor receptor peptide, a 21 mer) in the presence of ³³P-ATP. Compounds were tested in 10 fold serial dilutions over the range of 100 μM to 0.001 μM in 10% DMSO. Each concentration of inhibitor was tested in triplicate. Compounds were evaluated in 50 μl reaction volumes in the presence of 25 mM Hepes pH 7.5, 10 mM magnesium acetate, 4% glycerol, 0.4% bovine serum albumin, 0.4 mM DTT, 50 μM unlabeled ATP, 25 μg EGFRP (200 μM), and 0.05 μCi gamma ³³P-ATP. Reactions were initiated by addition of 0.09 μg of activated, purified human GST-p38 kinase alpha. Activation was carried out using GST-MKK6 (5:1,p38:MKK6) for one hour at 30° C. in the presence of 50 μM ATP. Following incubation for 60 minutes at room temperature, the reaction was stopped by addition of 150 μl of AG 1X8 resin in 900 mM sodium formate buffer, pH 3.0 (1 volume resin to 2 volumes buffer). The mixture was mixed three times with pipetting and the resin was allowed to settle. A total of 50 μl of clarified solution head volume was transferred from the reaction wells to Microlite-2 plates. 150 μl of Microscint 40 was then added to each well of the Microlite plate, and the plate was sealed, mixed, and counted.

TABLE 4 p38 kinase Example IC50 (μM) 1 4.6 2 1.5 8 <0.1 16 3.8 23 1.5 25 2.6 26 0.7 28 0.3 33 2.5 34 8.0 36 12.1 38 0.8 39 1.1 40 1.3 42 0.3 43 <0.1 44 <0.1 45 <0.1 46 <0.1 47 3.2 48 1.8 50 2.3 51 <0.1 52 0.1 53 0.9 54 0.7 55 6.4 143 <0.1

TNF Cell Assays

Method of Isolation of Human Peripheral Blood Mononuclear Cells:

Human whole blood was collected in Vacutainer tubes containing EDTA as an anticoagulant. A blood sample (7 ml) was carefully layered over 5 ml PMN Cell Isolation Medium (Robbins Scientific) in a 15 ml round bottom centrifuge tube. The sample was centrifuged at 450-500×g for 30-35 minutes in a swing out rotor at room temperature. After centrifugation, the top band of cells were removed and washed 3 times with PBS w/o calcium or magnesium. The cells were centrifuged at 400×g for 10 minutes at room temperature. The cells were resuspended in Macrophage Serum Free Medium (Gibco BRL) at a concentration of 2 million cells/ml.

LPS Stimulation of Human PBMs:

PBM cells (0.1 ml, 2 million/ml) were co-incubated with 0.1 ml compound (10-0.41 μM, final concentration) for 1 hour in flat bottom 96 well microtiter plates. Compounds were dissolved in DMSO initially and diluted in TCM for a final concentration of 0.1% DMSO. LPS (Calbiochem, 20 ng/ml, final concentration) was then added at a volume of 0.010 ml. Cultures were incubated overnight at 37° C. Supernatants were then removed and tested by ELISA for TNF-a and IL1-b. Viability was analyzed using MTS. After 0.1 ml supernatant was collected, 0.020 ml MTS was added to remaining 0.1 ml cells. The cells were incubated at 37° C. for 2-4 hours, then the O.D. was measured at 490-650 nM.

Maintenance and Differentiation of the U937 Human Histiocytic Lymphoma Cell Line:

U937 cells (ATCC) were propagated in RPMI 1640 containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine (Gibco). Fifty million cells in 100 ml media were induced to terminal monocytic differentiation by 24 hour incubation with 20 ng/ml phorbol 12-myristate 13-acetate (Sigma). The cells were washed by centrifugation (200×g for 5 min) and resuspended in 100 ml fresh medium. After 24-48 hours, the cells were harvested, centrifuged, and resuspended in culture medium at 2 million cells/ml.

LPS Stimulation of TNF Production by U937 Cells:

U937 cells (0.1 ml, 2 million/ml) were incubated with 0.1 ml compound (0.004-50 μM, final concentration) for 1 hour in 96 well microtiter plates. Compounds were prepared as 10 mM stock solutions in DMSO and diluted in culture medium to yield a final DMSO concentration of 0.1% in the cell assay. LPS (E coli, 100 ng/ml final concentration) was then added at a volume of 0.02 ml. After 4 hour incubation at 37° C., the amount of TNF-α released in the culture medium was quantitated by ELISA. Inhibitory potency is expressed as IC50 (μM). Results of these TNF Cell Assays are shown in Table 5.

TNF Inhibition: Human Whole Blood Assay

Human peripheral blood is obtained in heparinized tubes. A 190 μL aliquot of blood is placed in each well of a 96 well u-bottom plate. A compound or control vehicle (phosphate buffered saline with dimethylsulfoxide and ethanol) is added to the blood in 10 μL aliquots for serial dilutions providing final concentrations of 25, 5, 1 and 0.25 μM. The final dimethylsulfoxide and ethanol concentrations are 0.1% and 1.5%, respectively. After one hour of incubation at 37° C., 10 mL of lipopolysaccharide (Salmonella typhosa, Sigma) in phosphate buffered saline is added resulting in a final concentration of 10 mg/mL. After four to five hours of incubation at 37° C., the supernatants are harvested and assayed at 1:10 or 1:20 dilutions for human TNF using ELISA.

TABLE 5 Human PBM Assay U937 Cell Assay Example IC50 (μM) IC50 ((μM) 1 0.5 2 1.6 0.578 4 0.1 0.222 5 0.274 7 0.2 0.201 8 <0.1 9 0.4 10 0.7 1.687 12 8.5 13 4.8 14 1.2 17 1.1 19 0.3 0.484 20 1.089 21 0.077 22 3.2 24 8.2 26 <0.1 0.029 27 2.7 28 0.1 29 2.2 30 2.6 31 0.8 1.053 32 2.696 33 0.4 34 0.5 35 0.7 36 1.4 37 1.5 0.099 38 0.2 0.208 39 0.7 0.244 40 0.4 41 1.0 42 0.7 43 <0.1 0.243 44 0.4 0.477 45 <0.1 0.04 46 0.329 47 2.359 48 2.2 0.522 49 6.8 50 0.9 51 0.074 54 0.2 0.13 55 <0.1 0.228 143 0.301

Rat Assay

The efficacy of the novel compounds in blocking the production of TNF also was evaluated using a model based on rats challenged with LPS. Male Harlen Lewis rats [Sprague Dawley Co.] were used in this model. Each rat weighed approximately 300 g and was fasted overnight prior to testing. Compound administration was typically by oral gavage (although intraperitoneal, subcutaneous and intravenous administration were also used in a few instances) 1 to 24 hours prior to the LPS challenge. Rats were administered 30 μg/kg LPS [salmonella typhosa, Sigma Co.] intravenously via the tail vein. Blood was collected via heart puncture 1 hour after the LPS challenge. Serum samples were stored at −20° C. until quantitative analysis of TNF-α by Enzyme Linked-Immuno-Sorbent Assay (“ELISA”) [Biosource]. Additional details of the assay are set forth in Perretti, M., et al., Br. J. Pharmacol. (1993), 110, 868-874, which is incorporated by reference in this application.

Mouse Assay

Mouse Model of LPS-induced TNF Alpha Production:

TNF alpha was induced in 10-12 week old BALB/c female mice by tail vein injection with 100 ng lipopolysaccharide (from S. Typhosa) in 0.2 ml saline. One hour later mice were bled from the retroorbital sinus and TNF concentrations in serum from clotted blood were quantified by ELISA. Typically, peak levels of serum TNF ranged from 2-6 ng/ml one hour after LPS injection.

The compounds tested were administered to fasted mice by oral gavage as a suspension in 0.2 ml of 0.5% methylcellulose and 0.025% Tween 20 in water at 1 hour or 6 hours prior to LPS injection. The 1 hour protocol allowed evaluation of compound potency at Cmax plasma levels whereas the 6 hour protocol allowed estimation of compound duration of action. Efficacy was determined at each time point as percent inhibition of serum TNF levels relative to LPS injected mice that received vehicle only.

Additional results obtained using the above-described assays are set forth in Table 6 below. p38 assay and U937 cell assay results are expressed as IC₅₀ (μm). Mouse-LPS assay results are expressed as percent inhibition.

TABLE 6 Ex- mLPS mLPS mLPS ample p38¹ p38² U937 8 h 6 h dose 1 h, 30 mpk A-212 0.49 0.74 0.0967 20 10 93 A-208 0.104 0.049 0.1896 98 30 97 A-227 0.06 96 A-228 0.76 0.339 0.4173 32 30 92 A-229 1.4 0.4622 76 91 A-230 0.42 0.178 96 A-231 0.174 0.3225 86 30 94 A-232 0.048 96 A-233 0.044 53 A-234 0.103 A-235 0.104 56 A-236 0.237 94 A-237 0.093 0.087 60 A-238 0.177 0.4016 A-239 0.034 51 30 87 A-240 0.961 78 30 85 A-241 0.338 79 30 87 A-242 0.047 95 30 87 A-243 0.729 82 A-244 0.099 A-245 <.001 0.0337 65 A-246 0.403 0.592 0.4952 A-247 <0.01 0.166 A-249 0.432 73 30 86 A-250 2.873 A-251 0.637 32 87 A-252 0.774 1.197 48 30 75 A-253 <.001 0.0044 61 A-254 0.081 0.1411 A-215 2.34 0.2976 38 30 80 A-256 0.813 0.4562 A-257 1.081 <.01 0.5167 A-213 0.22 57 A-258 0.48 1.2083 68 A-259 0.17 0.7574 62 A-210 0.16 0.1983 85 30 93 A-260 0.23 1.2821 47 30 79 A-214 0.06 1.4006 70 A-261 0.008 0.2542 48 30 92 A-216 0.018 1.8287 27 30 91 A-262 <0.1 0.3267 45 A-263 <0.01 <0.1 0.5434 49 A-264 0.2594 61 A-265 <0.1 0.6016 32 A-266 0.5393 0 A-267 0.43 2.6681 80 A-268 <0.01 0.0074 11 A-217 0.697 0.3486 9 A-269 >10 uM 51 A-270 0.015 0.3466 53 A-271 0.216 4.2144 68 A-272 0.073 0.583 −8 A-273 6.98 >10 43 A-274 <0.1 0.92 21 30 A-275 10.142 >10 A-276 0.176 0.45 −24 30 A-277 0.026 33 30 A-278 0.285 2.3 62 30 A-279 0.005 0.7 64 30 A-280 0.134 15 30 A-281 0.053 22 30 A-218 0.044 18 30 A-282 0.045 0.0973 30 30 A-283 <0.1 0.7998 −20 30 A-284 0.98 0.5088 −1 A-285 <0.1 0.1795 11 30 A-286 0.057 0.09 29 30 A-287 0.041 0.27 −24 30 A-288 0.017 0.3 40 30 A-289 <0.1 0.14 44 30 A-290 6.0191 4 30 A-291 0.388 1.1309 36 30 A-292 1.15 >10 A-293 0.73 A-294 0.015 0.5 61 30 A-295 7.66 >10 94 30 A-296 26 A-297 0.52 0.17 89 30 ¹p38α in vitro assay results based on PHAS-I assay procedure ²p38α in vitro assay results based on EGFRP assay procedure Induction and Assessment of Collagen-induced Arthritis in Mice:

Arthritis was induced in mice according to the procedure set forth in J. M. Stuart, Collagen Autoimmune Arthritis, Annual Rev. Immunol. 2:199 (1984), which is incorporated herein by reference. Specifically, arthritis was induced in 8-12 week old DBA/1 male mice by injection of 50 μg of chick type II collagen (CII) (provided by Dr. Marie Griffiths, Univ. of Utah, Salt Lake City, Utah) in complete Freund's adjuvant (Sigma) on day 0 at the base of the tail. Injection volume was 100 μl. Animals were boosted on day 21 with 50 μg of CII in incomplete Freund's adjuvant (100 μl volume). Animals were evaluated several times each week for signs of arthritis. Any animal with paw redness or swelling was counted as arthritic. Scoring of arthritic paws was conducted in accordance with the procedure set forth in Wooley et al., Genetic Control of Type II Collagen Induced Arthritis in Mice: Factors Influencing Disease Suspectibility and Evidence for Multiple MHC Associated Gene Control., Trans. Proc., 15:180 (1983). Scoring of severity was carried out using a score of 1-3 for each paw (maximal score of 12/mouse). Animals displaying any redness or swelling of digits or the paw were scored as 1. Gross swelling of the whole paw or deformity was scored as 2. Ankylosis of joints was scored as 3. Animals were evaluated for 8 weeks. 8-10 animals per group were used.

Preparation and Administration of Compounds:

The compounds tested on mice having collagen-induced arthritis were prepared as a suspension in 0.5% methylcelluose (Sigma, St. Louis, Mo.), 0.025% Tween 20 (Sigma). The compound suspensions were administered by oral gavage in a volume of 0.1 ml b.i.d. Administration began on day 20 post collagen injection and continued daily until final evaluation on day 56. Scoring of arthritic paws was conducted as set forth above. Assay results are set forth in Table 7.

TABLE 7 Compound % Inhibition of Arthritis A-210 58.5 @ 15 mpk A-172  49.3 @ 100 mpk A-189 51.6 @ 30 mpk A-208 97.5 @ 60 mpk A-208 75.0 @ 60 mpk

Additional results for selected compounds obtained using the above-described assays are set forth in Tables 8, 9 and 10 below:

TABLE 8 Rat LPS TNF Assay % Inhibition- p38α Kinase Inhibition Human Whole Assay (Dose in Blood Assay IC₅₀ in μM Example mg/kg) (μM) (% DMSO) A-313, Step 1 1.34 (1) A-313, Step 3 96.0 (20.0) 0.12 0.036 (1) 0.37 (10) A-314, Step 1 0.85 (1) 0.37 (10) A-314, Step 2 0 (1.0) 0.47 0.032 (10) 53.0 (5.0) 85.0 (20.0) A-315 1.75 0.049 (10) A-317 58.0 (3.0) 0.45 0.07 (10) 10.0 (3.0) 0.11 (10) 69.0 (10.0) A-318 54.0 (3.0) 0.167 0.29 (1) 0.58 (10) 0.37 (10) 0.6 (10) A-319 62.0 (3.0) >25.0 6.06 (1) 0.13 (10) A-320 1.0 (3.0) 0.27 (1) 0.05 (10) 0.15 (10) A-321 >25.0 0.77 (1) (dihydrate) A-321 14.0 (3.0) (monosodium salt dihydrate) A-322 51.5 (3.0) 4.2 0.15 (10) 0.25 (10) A-323 40.0 (30.0) 0.39 (10) 54.0 (30.0) A-324 44.0 (3.0) 0.08 (10) A-325 25.0 (3.0) 0.057 0.021 (1) 11.0 (30.0) <0.1 (10) A-326 0 (10.0) >25.0 0.97 (10) A-327 83.0 (20.0) 0.18 0.15 (10) A-328 0.012 (1) A-331 13.0 (20.0) >100 (1) 0.64 (10) A-332 33.0 (1.0) 0.45 0.04 (1) 26.0 (3.0) 0.04 (10) 25.0 (5.0) 0.015 (10) −85.0 (10.0) <0.1 (10) A-333 69.0 (5.0) 0.585 0.052 (10) A-334 95.0 (20.0) 0.22 0.07 (10) 57.0 (5.0) 36.0 (1.0) A-335 >25.0 89.9 (10) A-336 1.16 (10) A-337 >25.0 1.35 (10) A-338 0.059 0.018 (10) A-339 0.056 0.052 (10) A-342 98.0 (20.0) 0.31 0.012 (10) A-343 96.0 (20.0) 0.016 (10)

TABLE 9 Rat LPS TNF Assay % Inhibition- p38α Kinase Inhibition Human Whole Assay (Dose in Blood Assay IC₅₀ in μM Example mg/kg) (μM) (10% DMSO) A-350 65 (20) A-351 0 (20) 0.49 0.27 A-352 36 (20) 9.8 0.13 A-353 49 (20) 5.3 0.037 A-354 0 (20) 25 0.22 A-355 0 (20) 0.095 0.05 A-356 73 (20) 5.3 <0.01 A-357 74 (20) 0.25 0.12 A-358 71 (20) 4 0.23 A-359 70 (20) 1 0.3 A-360 95 (20) 0.5 0.06 14 (5) 0 (1) A-361 9 (20) 1 A-362 0 (20) 5.5 0.69 A-363 6 (20) 25 1.5 A-364 79 (20) 0.255 0.49 A-365 95 (20) 0.057 0.032 50 (5) 12 (1) A-366 92 (20) 0.29 0.041 DR: 6 (1) 0.06 45 (5) 0.04 97 (20) A-368 88 (20) 0.66 0.042 DR: 28 (1) 41 (5) 97 (20) A-369 94 (20) 0.84 0.019 52 (5) 0.011 0.0027 A-370 90 (20) 1.92 0.16 46 (5) A-371 52 (20) 25 7.9 A-372 56 (20) 21 0.53 A-374 88 (20) 0.31 0.38 0 (5) 3 (1) A-375 43 (20) 28% 2.3 A-376 24 (20) 1 0.032 A-377 84 (20) 0.67 0.004 DR: 32 (1) 0.0019 67 (5) 96 (20) A-378 73 (10) 49% 6.2 A-379 61 (10) 44% 0.19 A-380 85 (30) 32% 0.85 62 (10) 33 (3) A-385 0.18 1.25 A-386 91 (20) 0.16 0.016 A-387 83 (20) 0.11 0.005 A-388 97 (20) 0.34 0.21 67 (5)

TABLE 10 Rat LPS Assay % TNF p38α Kinase Inhibition Inhibition- Assay IC₅₀ (Dose in Human Whole (μM) mg/kg @ 4.0 Blood Assay (10% DMSO; @ Example hours) (μM) 1.0 hour) A-389, Step 4 55.0 (5.0) 0.16 94.0 (20.0) A-389, Step 1 1.72 A-390 >25.0 15.1 A-391 53.0 (20.0) >25.0 4.83 A-392 29.7 A-393 2.32 A-394 9.11 A-395 >100 A-397 30.0 A-398 >25.0 45.6 A-399 22.9 A-400 >25.0 4.77 A-401 21.2 A-402 28.9 A-403 >25.0 4.89 A-404 >25.0 4.13 A-405 >25.0 4.85 A-406 >25.0 7.24 A-407 21.0 (5.0) 3.86 0.18 82.0 (20.0) A-408 20.0 (5.0) 11.7 5.59 49.0 (20.0) A-409 41.0 (5.0) 5.27 0.21 89.0 (20.0) A-410 11.0 (5.0) 0.21 0 (20.0) A-411 40.0 (5.0) 3.37 0 (20.0) A-412 0 (5.0) 2.15 0 (20.0) A-413 45.0 (5.0) 6.51 0.91 85.0 (20.0) A-414 3.0 (5.0) 11.2 9.51 14.0 (20.0) A-415 17.0 (5.0) 0.51 84.0 (84.0) A-416 5.07 0.041 A-417 40.0 (5.0) 12.0 0.19 70.0 (20.0) A-418 0.12 A-419 24.0 (5.0) 1.31 58.0 (10.0) A-420 47.0 (5.0) 0.32 91.0 (20.0) A-427 56.0 (5.0) 24.1 0.19 77.0 (20.0) A-428 0.68 0.4 A-429 56.3 A-430 >100 A-434 5.84 A-435 10.0 (1.0) >25.0 0.35 0 (5.0) 14.0 (20.0) A-436 4.61 2.81 A-437 >25.0 7.76 A-438 49.0 (20.0) >25.0 0.56 A-439 58.0 (5.0) 5.63 0.15 93.0 (20.0) A-440 A-441 14.0 (5.0) >25.0 1.21 62.0 (20.0) A-442 51.0 (1.0) 0.16 0.022 56.0 (5.0) 92.0 (20.0) A-443 4.89 0.47 A-444 6.99 A-445 >25.0 1.08 A-446 3.38 0.9 A-447 >25.0 0.77 A-448 73.0 (5.0) 0.12 0.084 97.0 (20.0) A-449 59.0 A-450 >100 A-451 15.0 0.078 A-452 0.24 2.87 A-454 8.41 A-453 10.2 A-455 12.9 A-456 36.0 (1.0) 0.98 0.12 48.0 (5.0) 53.0 (20.0) A-457 >25.0 0.4 A-458 >25.0 8.7 A-459 0 (1.0) 0.26 0.027 54.0 (5.0) 80.0 (20.0) A-459 (salt) 0.28 0.1 A-460 8.91 1.84 A-461 30.6 A-462 >25.0 1.66 A-463 >25.0 1.66 A-464 >100 A-465 >100 A-466 20.1 A-467 21.4 A-468 46.0 (1.0) 0.3 50.0 (5.0) 94.0 (20.0) A-469 51.0 (5.0) 7.17 0.095 68.0 (20.0) A-470 10.4 A-471 4.92 A-472 >25.0 0.39 A-473 58.0 (20.0) 0.56 0.17 A-474 59.0 (20.0) 1.47 0.11 A-475 5.11 0.28 A-476 35.0 (20.0) 0.97 1.01 A-477 0.34 A-478 0.49 0.18 A-479 2.97 0.072 A-480 0.16 0.11 A-481 >25.0 0.2 A-482 15.0 (20.0) 0.69 1.62 A-483 0.51 0.3

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this invention in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly (IV), intraperitoneally, subcutaneously, intramuscularly (IM) or topically. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, hard or soft capsule, lozenges, dispensable powders, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection (IV, IM, subcutaneous or jet) as a composition wherein, for example, saline, dextrose, or water may be used as a suitable carrier. The pH of the composition may be adjusted, if necessary, with suitable acid, base, or buffer. Suitable bulking, dispersing, wetting or suspending agents, including mannitol and PEG 400, may also be included in the composition. A suitable parenteral composition can also include a compound formulated as a sterile solid substance, including lyophilized powder, in injection vials. Aqueous solution can be added to dissolve the compound prior to injection. The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the inflammation or inflammation related disorder, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 1000 mg, preferably in the range of about 7.0 to 350 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably between about 0.5 to 30 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day. For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The anti-inflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

All patent documents listed herein are incorporated by reference.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Description of parallel array synthesis methodology utilized to prepare compounds of Examples B-i, B-ii, and B-iii.

Scheme B-1 (FIG. 1) describes the parallel array reaction blocks that were utilized to prepare compounds of Examples B-0001 through B-1574, and by analogy could also be used to prepare compounds of Examples B-1575 through B-2269. Parallel reactions were performed in multi-chamber reaction blocks. A typical reaction block is capable of performing 48 parallel reactions, wherein a unique compound is optionally prepared in each reaction vessel B1. Each reaction vessel B1 is made of either polypropylene or pyrex glass and contains a frit B2 toward the base of the vessel. Each reaction vessel is connected to the reaction block valve assembly plate B3 via leur-lock attachment or through a threaded connection. Each vessel valve B4 is either opened or closed by controlling the leur-lock position or by the opening or closing of levers B5 within a valve assembly plate row. Optionally, solutions can be either drained or maintained above the vessel flits by leaving the valves in the opened position and controlling the back pressure beneath the valve assembly plate by control of inert gas flow through the inert gas inlet valve B6. The parallel reactions that are performed in these reaction blocks are allowed to progress by incubation in a jacketed, temperature controlled shaking station.

Temperature control of the reaction chambers is effected by passing a heat-transfer liquid through jacketed aluminum plates that make contact with the reaction block mantle B7. Mixing is effected at the shaking station by either vertical orbital shaking of the up-right reaction block or by lateral shaking of the reaction block tilted on its side.

Functionalized resins are optionally added to each reaction vessel B1 during the course of reaction or at the conclusion of the reaction. These functionalized resins enable the rapid purification of each reaction vessel product. Vacuum filtration of the reaction block apparatus by opening of the vacuum valve B8 allows purified products to be separated from resin-sequestered non-product species. Valve B8 is located on the bottom reaction block chamber B10 which houses the quadrant collection vial racks B11. The desired products are obtained as filtrates in unique collection vials B9. Removal of solvent from these collection vials affords desired products.

Scheme B-2 illustrates the various utilizations of functionalized resins to purify reaction vessel products B22 prior to filtration from the fritted vessels B1 into collection vials B9. Said functionalized resins perform as 1) resin-bound reagents B12, which give rise to resin-bound reagent byproducts B13; 2) sequestrants B14 or B15 of excess solution-phase reactants B16 or B17, respectively. Solution-phase reactants B16 and B17 contain inherent reactive functionality -rf₁ and -rf₂ which enable their chemoselective sequestration by the complementary reactive functionality -Crf₁ and -Crf₂ attached to resins B14 and B15; 3) sequestrants B18 of solution-phase byproducts B19. Byproduct B19 contains molecular recognition functionality -mr₂ which enables its chemoselective sequestration by the complementary functionality -Cmr₂ attached to resin B18; 4) reaction-quenching resins B20 which give rise to quenched resins B21. Resin B20 contains functionality -Q which mediates reaction quenching (for instance, proton transfer) of product B22 to form a desired isolable form of product B22. Upon performing reaction quench, the resin B20 is converted to resin B21 wherein -q represents the spent functionality on resin B21; 5) sequestrants B23 of chemically-tagged reagents B24 and their corresponding reagent byproducts B25. The soluble reagent B24 contains a bifunctional chemical group, -tag, which is inert to the reaction conditions but is used to enable the post-reaction sequestration of B24 by the complementary functionality -Ctag attached to resin B23. Additionally, the soluble reagent byproduct B25, formed during the course of reaction, contains the same chemical function -tag that also enables its sequestration by resin B23. Additionally, some reactants B16, particularly sterically-hindered reactants and/or electron deficient nucleophiles, contain poorly sequestrable functionality (rf1 in this case is a poorly sequestable functionality). These poorly sequestable reactants B16 can be transformed in situ to more robustly sequestrable species B27 through their reaction with sequestration-enabling-reagents B26. B26 contain highly reactive, complementary functionality Crf₁ which reacts with B16 to form B27 in situ. The bifunctional molecular recognition functionality, mr, contained within B26 is also present on the in situ derivatized B27. Both B26 and B27 are sequestered by the complementary molecular recognition functionality attached to resin B28; By analogy, some reactions contain poorly sequestable byproducts B19, wherein the molecular recognition functionality mr₂ in this case is not able to mediate the direct sequestration of B19 by the complementary functionality attached to resin B18. Similar use of the bifunctional sequestration-enabling-reagent B29 transforms B19 into the more readily sequestrable species B30. The imparted molecular recognition functionality, mr, present in B30 is readily sequestered by the complementary functionality, Cmr, attached to resin B31. In some reactions, multiple sequestration resins are utilized simultaneously to perform reaction purifications. Even resins containing incompatible (mutually reactive) functional groups can be used simultaneously because these resins scavenge complementary functionalized solution phase reactants, reagents, or byproducts from solution phase faster than resin cross-neutralization. Similarly, resins containing mutually reactive or neutralizing reaction-quenching functionality are able to quench solution phase reactants, products, or byproducts faster than resin cross-neutralization.

Scheme B3 (FIG. 2) describes the modular robotics laboratory environment that was utilized to prepare compounds of Examples B-0001 through B-1574. Chemicals that are utilized in the robotics laboratory are weighed and then dissolved or suspended into solvents at Station #1 (Automated Chemistry Prep Station). Thus, solutions or suspensions of known molarity are prepared for use at the other robotics workstations. Station #1 also optionally bar-code labels each chemical solution so that its identity can be read by bar-code scanning at this and other robotics workstations.

Reactions are initiated at the modular Stations #2 and #2 DUP. Station #2DUP is defined as a duplicate of Station #2 and is used to increase capacity within the robotics laboratory. A reaction block is mounted at Station #2 or #2 DUP. Also, racks containing reactants, reagents, solvents, and resin slurries are also mounted at Station #2 or 12 DUP. Under the control of a chemical informatics mapping file, reactions are initiated by the transfer of reactant solutions, reagent solutions, solvents, and/or resin slurries into each mounted reaction block vessel. The transfer of known volumes of solutions, suspensions, or solvents is mediated by syringes which control a one-up septum piercing/argon purging cannula, a wide-bore resin slurry-despensing cannula, or by a six-up cannula which can simultaneously deliver volumes to a row of six reaction vessels. The reaction block and/or chemical solution racks may be optionally cooled below room temperature during the chemical solution transfer operations. After the transfer of chemical solutions and solvents has been performed by Station #2 or #2DUP, incubation of the reaction block may occur while the reaction block is mounted at the robot station. Preferably, however, the reaction block is removed after all volume transfers are complete and the reaction block is brought to ambient temperature. The reaction block is transferred off-line to either a vertical- or lateral shaking Incubator Station #5.

The Automated weighing/archival Station #3 performs the functions of weighing empty collection vials (to obtain tare weights of collection vials) and also performs the functions of weighing collection vials containing filtered, purified products (to obtain gross weights of collection vials). After product-containing collection vials have been weighed (gross weight determinations) at workstation #3, the collection vial products are optionally redissolved into an organic solvent at workstation #3. Transfer of solvents is accomplished with syringes which control a mounted one-up septum-piercing/argon purging cannula. Each product-containing collection vial is prepared as a solution of known molarity as directed and recorded by the chemical informatics system. These product solutions may be subsequently mounted at Station #2 or #2DUP for subsequent reaction steps or taken to Station #7 or #7DUP for analytical processing.

Rapid solvent evaporation of product-containing collection vials is accomplished by mounting the collection racks at Savant Automated Solvent Evaporation Stations #4, #4 DUP, or #4 TRIP, wherein #4DUP and #4TRIP are defined as a duplicate and a triplicate of Station #4 to increase the capacity for solvent removal within the robotics laboratory. Commercially available solvent removal stations were purchased from the Savant Company (model #SC210A speedvac unit equipped with model #RVT4104 vapor trap and model #VN100 vapornet cryopump).

Stations #7 and #7DUP perform analytical processing functions. Station #7DUP is defined as a duplicate of Station #7 to increase capacity within the robotics laboratory. Product-containing collection racks are mounted at either of these stations. Each product-containing collection vial is then prepared as a solution of known molarity as directed and recorded by the chemical informatics mapping file. Optionally, this dissolution function is performed by prior processing of the collection vial rack at Station #3 as described above. Station #7 or #7DUP, under the control of the chemical informatics mapping file, transfers aliquots of each product vial into unique and identifable microtiter plate wells that are utilized to perform analytical determinations.

One such microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at the Automated HPLC/Mass Spectrometer Station #8 or #8DUP. Station #8DUP is a duplicate of Station #8 to increase the analytical capacity of the robotics laboratory. Stations #8 and #8DUP are commercially available benchtop LC/Mass spec units purchased from Hewlett Packard (model HP1100 HPLC connected to HP1100 MSD (G1946A) mass spectrometer; this unit is also equipped with a model #G1322A solvent degasser, model #G1312A binary pump, a model #G1316A column heater, and a model #G1315A diode array detector. The HP unit has been interfaced with a commercially available autosampler rack (Gilson Company #215 autosampler). Station #8 or #8DUP is utilized for the determination of product purity and identity by performing high performance liquid chromatography (HPLC) and companion atmospheric pressure chemi-ionization (APCI) or electrospray mass spectrometry for molecular weight determination.

Another microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at a commercially available flow-probe Varian NMR spectrometer Station #10 (Varian Instruments flow probe NMR, 300 MHz, interfaced with a commercially available Gilson 215 autosampler). Proton, ¹³-Carbon, and/or ¹⁹-Fluorine NMR spectra are determined at this Station #10.

Other microtiter plates are optionally mounted at Station #7 or #7DUP for the purpose of preparing product-containing plates for biological assays. Aliquots of product-containing collection vials are transferred to these biological assay microliter plates under the control of the chemical informatics mapping file. Identity and amount of each transferred product is recorded by the chemical informatics system for retrieval by biologists who perform the biological assaying of products.

The Fourier Transfrom InfraRed (FT-IR) Spectrometer Station #11 is utilized to analyze resins for the identity of organic functional groups chemically attached to these resins. The resins, as mentioned above, contain chemical functionality utilized as reagents, chemoselective sequestrants, or reaction quenching media for the workup and purification of the crude product mixtures contained within reaction block vessels. The robotics laboratory utilizes a commercially available FT-IR spectrometer purchased from Nicolet Instruments (model #MagnaIR 560 interfaced with an InspectIR microscope for resin mounting and positioning).

Scheme B-3

The lines interconnecting the modular Stations denote the transfer of chemical racks, reaction blocks, and/or collection vial racks from one modular Station to another.

The ChemLib IT system is a composite of software running on the client's desktop and software running on a remote server.

The ChemLib IT system is a client/server software application developed to support and document the data handling flow in the robotics laboratory described above. This IT system integrates the chemist with the robotics synthesis laboratory and manages the data generated by this processes.

The software running on the server warehouses all the electronic data for the robotics chemistry unit. This server, a Silicon Graphics IRIX station v6.2, runs the database software, Oracle 7v7.3.3.5.0, that warehouses the data. Connection from the client's desktop to the server is provided by Oracle's TCP/IP Adapter v2.2.2.1.0 and SQL*Net v2.2.2.1.0A. SQL*Net is Oracle's network interface that allows applications running on the client's desktop to access data in Oracles' database.

The client's desktop is Microsoft Windows 95. The ChemLib IT system client software is composed of Omnis 7v3.5 and Microsoft Visual C++ v5.0. This composition on the client side is what is herein referred to as ChemLib. ChemLib communicates with the server for its data via Oracle's PL/SQL v2.3-3.4.0. These PL/SQL calls within ChemLib creates a network socket connection to oracle's SQL*Net driver and the TCP/IP Adapter thereby allowing access to the data on the server.

A “library” is defined as a composite number of wells, where each well defines a single compound. ChemLib defines a library in a module called the Electronic Spreadsheet. The Electronic Spreadsheet is then a composite of n-number of wells containing the components that are required to synthesize the compound that exist in each these well(s).

The chemist begins by populating the Electronic Spreadsheet with those components required for the compound synthesis. The identity and the availability of these components are defined in the Building Block Catalog module of ChemLib. The Building Block Catalog is a catalog of a listing of all reagents, solvents, peripherals available in the robotics laboratory. Upon selecting the components for each compound we also declare the quantity of each component to be utilized. The quantity of each component can be identified by its molarity and volumetric amounts (ul) or by it's solid state form (mg). Therefore a well in the Electronic Spreadsheet defines a compound that is identified by its components and the quantity of each of these components.

The assembly or the synthesis of these components for each compound in the Electronic Spreadsheet is defined in the WS Sequence module of ChemLib. The Define WS Sequence module identifies the synthesis steps to be performed at the robotics workstations and any activities to be performed manually or off-line from the robotics workstation. With this module we identify which components from the Electronic Spreadsheet and the activity that should be performed with this component in the robotics laboratory. In the Define WS Sequence module the chemist chooses from a list of activities to be performed in the robotics laboratory and assembles them in the order in which they are to occur. The ChemLib system takes these set of activities identified, and with the component data in the Electronic Spreadsheet assembles and reformats these instructions into terminology for the robotics workstation use. This robotics terminology is stored in a ‘sequence’ file on a common server that is accessible by the robotics workstation.

The robotics workstation performs the synthesis in a reaction block apparatus as described. Each well in the Electronic Spreadsheet is tracked and mapped to a unique location in the reaction block apparatus on the robotics workstation. The compound or product synthesized at the robotics workstation in the reaction block is then captured into collection vials.

The collection vials are first tarred then grossed on the robotics workstation after collecting their products from the reaction block. These weights (tare and gross) are recorded into the ChemLib system with the Tare/Gross Session module. The Tare/Gross Session module then calculates the product or compound yields and its final mass.

Preparation of the compound for analytical analysis and screening is defined by the Analytical WS Setup module in ChemLib. The Analytical WS Setup module identifies the dilution factor for each well in the Electronic Spreadsheet, based on the compound's product yield and the desired molar concentration. This identifies the quantity, in uL, to be transferred at the robotics workstation, to a specific location on the MTP (microtiter plate) to be sent for analysis and/or biological assaying. The mass spectrometric and HPLC results for each well are recorded and scored into the ChemLib system.

The Dilute/Archive WS module further identifies each compound by mapping the compound's well from the Electronic Spreadsheet to a specific MX block location for long term storage and archival as part of the registration process.

All communications between ChemLib and the robotics workstations are by ASCII files. These files are placed on a server by the ChemLib system that is accessible by the robotics workstations. Reports generated by the robotics workstations are also placed on the server where the ChemLib system can read these files to record the data generated. Each robotics workstation consists of robotics hardware by Bohdan Automation, Inc. Mundelein, Ill., and a PC currently running Microsoft Windows for Workgroup v3.11 and Ethernet software. The robotics workstation PC is logged into the network for one-way communication that allows the workstation to access the server for file access only.

General Scheme B4

Scaffold C-i with a primary amine functionality contained within the R⁴ substituent is reacted in spatially addressed, parallel array reaction block vessels with excess of electrophiles R^(J)-Q wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^(J)-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-i with R^(J)-Q is effected in the presence of a tertiary amine base at room temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent. As illustrated in Scheme B-4 the products of the general formulae B-i are isolated in purified form by addition of a carbonyl-functionalized resin B32 which covalently sequesters any unreacted primary amine scaffold C-i as resin-bound adduct B35, and also by the addition of a primary amine-functionalized resin B33 which covalently sequesters any remaining electrophile R^(J)-Q from each reaction mixture as resin-bound adduct B34. Resin B33 also sequesters the HQ byproduct from the reaction mixture by proton transfer from solution-phase Base-HQ. Incubation at room temperature, filtration, rinsing of the resin cake, and concentration of the filtrates affords purified products B-i filtered away from resin-bound adducts B32, B33, B34, B35, and B36.

Scheme B-5 specifically illustrates the derivatization of the primary amine-containing scaffold C1 to afford the desired products B-i in a parallel array synthesis format. In a parallel array synthesis reaction block, individual reaction products are prepared in each of multiple reaction block vessels in a spatially addressed format. A solution of the desired primary amine-containing scaffold C1 (limiting amount,) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0 fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added the electrophiles: either a 2.0 fold stoichiometric excess when R^(J)-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^(J)-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^(J)-Q is an isocyanate. Excess electrophiles and N-methylmorpholine were used to effect more rapid and/or more complete conversion of scaffold C1 to products B-0001-B-0048 compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-3 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 and the aldehyde-functionalized resin B32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^(J)-Q and any unreacted scaffold amine C1 are removed from the reaction medium as insoluble adducts B34 and B37 respectively. In addition the N-methylmorpholine hydrochloride salt formed during the course of the reaction is also neutralized to its free base form by proton transfer reaction to the amine-functionalized resin B33. Simple filtration of the insoluble resin-adducts B32, B33, B34, B36, and B37, rinsing of the resin cake with dichloroethane, and evaporation of the filtrates affords the desired products B-i in purified form.

Scheme B-6 illustrates a general synthetic method involving the parallel array reaction of a scaffold C-ii containing a secondary amine functionality within the definition of the R⁴ substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-ii, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^(L)-Q into each vessel, wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^(L)-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-ii with R^(L)-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotics solvent and/or a halogenated solvent. After solution-phase reactions have progressed to afford crude product mixtures in each vessel, the products.

B-ii are isolated in purified form by the addition of the isocyanate-functionalized resin B38 which covalently sequesters remaining secondary amine scaffold C-ii as resin-bound adduct B39, and also by the addition of the primary amine-functionalized resin B33 which covalently sequesters remaining electrophile R^(L)-Q from each reaction vessel as resin-bound adducts B40. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, either simultaneously or sequentially, followed by filtration, rinsing, and concentration of the filtrates affords purified products B-ii filtered away from resin-adducts B33, B36, B38, B39, and B40.

Scheme B-7 illustrates the conversion of the secondary-amine containing scaffold C-2 to the desired products B-ii. In a parallel array synthesis reaction block, individual reaction products are prepared in each of 48 multiple reaction block vessels. A solution of the scaffold C-2 (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile R^(L)-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R^(L)-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^(L)-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^(L)-Q is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 and the isocyanate-functionalized resin B32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R^(L)-Q and unreacted scaffold amine C-2 are removed from the reaction medium as insoluble adducts B40 and B39, respectively. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, followed by filtration and rinsing with solvent mixtures of DMF and/or DCE, affords purified product solutions in collection vials filtered away from resin-adducts B33, B36, B38, B39, and B40. Concentration of filtrates affords purified products B-ii.

Scheme B-8 illustrates another general synthetic method involving the parallel array reaction of a scaffold C-ii containing a secondary amine functionality within the definition of the R⁴ substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-ii, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^(L)-Q into each vessel. Reaction of scaffold C-ii with R^(L)-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent.

Excess electrophiles and N-methylmorpholine are used to effect more rapid and/or more complete conversion of scaffold C-ii to products B-ii compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-8 h. Each reaction vessel is then charged with the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-ii, converting C-ii to the in situ-derivatized compound B42. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^(L)-Q, HQ, B41, and B42 as the resin-bound adducts B40, B36, B44, and B43, respectively. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin-adducts B33, B36, B40, B43 and B44 and subsequent rinsing of the vessel resin-bed with DMF and/or DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.

Scheme B-9 illustrates the method of Scheme B-8 using scaffold C-2. A solution of the scaffold C-2 (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile R^(L)-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R^(L)-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R^(L)-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R^(L)-Q is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. After solution-phase reactions have progressed to afford crude product mixtures, each reaction vessel is then charged with a dichloroethane solution of the sequestration-enabling reagent phenylsulfonylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-2, converting C-2 to the in situ-derivatized compound B45. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^(L)-Q, HQ, B41, and B45 as the resin-bound adducts B40, B36, B44, and B46, respectively. The resin-charged reaction block is shaken vertically for 20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin-adducts B33, B36, B40, B44, and B46 and subsequent rinsing of the vessel resin-bed with DCE affords filtrates containing the purified products B-ii. Concentration of the filtrates affords the purified products B-ii.

Another general method for the parallel array reaction block synthesis is illustrated in Scheme B-10 for the derivatization of the carboxylic acid-containing scaffold C-iii. Scaffold C-iii with a free carboxylic acid functionality is reacted in spatially addressed, parallel array reaction block vessels with excesses of optionally different primary or secondary amines B47 in the presence of the polymer-bound carbodiimide reagent B48 and a tertiary amine base in a mixture of a polar aprotic solvent and/or a halogenated solvent. After filtration of each crude vessel product misture away from resins B48 and B49, each reaction mixture is purified by treatment with the sequestration-enabling-reagent B50 (tetra-fluorophthalic anhydride). The reagent B50 reacts with remaining excess amine B47 to afford the in situ-derivatized intermediates B51 which contain carboxylic acid molecular recognition functionality. Subsequent incubation of each reaction mixture with a 15-20-fold stoichiometric excess of the primary amine-functonalized resin B33 sequesters B51, B50, and any remaining acid scaffold C-iii as resin-bound adducts B52, B53, and B54, respectively. Filtration of solution-phase products B-iii away from these resin-bound adducts and rinsing of the resin beds with a polar aprotic solvent and/or halogenated solvent affords filtrates containing purified products B-iii. Concentration of the filtrates affords purified B-iii.

Scheme B-11 illustrates the conversion of the acid containing scaffold C-49 to the desired amide products B-iii in a parallel synthesis format. A limiting amount of the scaffold C-49 is added as a solution in dimethylformamide to each reaction vessel containing the polymer bound carbodiimide reagent B48 (5 fold stoichiometric excess). A solution of pyridine (4 fold stoichiometric excess) in dichloromethane is added to this slurry, followed by addition of an excess amount of a dimethylformamide solution of a unique amine B47 (1.5 fold stoichiometric excess) to each vessel. The parallel reaction block is then agitated vertically on an orbital shaker for 16-18 h at ambient temperature and filtered to separate the solution phase product mixture away from resin-bound reagent B48 and resin-bound reagent byproduct B49. The resulting solutions (filtrates) containing a mixture of the desired amide products B-iii, excess amines B47 and any unreacted acid containing scaffold C-49, are treated with tetrafluorophthalic anhydride B50. B50 converts the excess amines B47 in each filtrate vessel to its respective sequestrable half acid form B51. After two h incubation time, an excess of the amine-functionalized resin B33 and dichloromethane solvent are added to each reaction vessel. The amine-containing resin B33 converts B51, any remaining B50, and any remaining C-49 to their resin-bound adducts E52, B53, and B55, respectively. The resin-charged reaction block is shaken vertically for 16 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin-adducts B33, B52, B53, and B55 and subsequent rinsing of the vessel resin-bed with dimethylformamide affords filtrates containing the purified products B-iii. Concentration of the filtrates affords the purified products B-iii.

Although Schemes B-1 through B-11 describe the use of parallel array chemical library technology to prepare compounds of general formulae B-i, B-ii, and B-iii, it is noted that one with ordinary skill in the art of classical synthetic organic chemistry would be able to prepare B-i, B-ii, and B-iii by conventional means (one compound prepared at a time in conventional glassware and purified by conventional means such as chromatography and/or crystallization).

A general synthesis of pyridylpyrazole scaffolds C-i, C-ii, and C-iii is depicted in Scheme C-1.

Step A: Picoline is treated with a base chosen from but not limited to n-butyllithium (n-BuLi), lithium di-iso-propylamide (LDA), lithium hexamethyldisilazide (LiHMDS), potassium t-butoxide (tBuOK), or sodium hydride (NaH) in an organic solvent such as tetrahydrofuran (THF), diethyl ether, t-butyl methyl ether, t-BuOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of ester B56. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B57 is isolated as a crude solid which can be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone B57 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, diethyl ether, t-butyl methyl ether, or t-BuOH from −78° C. to 50° C. for a period of time from ranging from 10 minutes to 3 hours. An appropriately substituted activated ester or acid halide derived from R⁴—CO₂H is then added as a solution in THF, ether, or dioxane to the monoketone anion of B57 while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to three hours. The resulting pyridyl diketone intermediate B58 is utilized without purification in Step C.

Step C: The solution containing the pyridyl diketone B58 is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate was then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole C-i or C-ii is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D In some cases the pyridyl pyrazole C-i or C-ii is alkylated with Q-C(R^(A))—(CH₂)_(n)CO₂alkyl wherein Q is halogen. C-i or C-ii is treated with a base chosen from NaH, NaOEt, KOtBu, or NEt₃ in an organic solvent such as THF, methylene chloride, dioxane, or DMF at temperatures between −20° C. and 150° C. and reaction times between 30 minutes and 12 hours. The resulting alkylated pyridyl pyrazole ester is then hydrolyzed to the acid by treament with NaOH or LiOH in aqueous/alcohol solvent mixtures or in THF/water solvent mixtures. Alternatively, the ester function is removed by treatment with an organic or inorganic acid if the alkyl residue is t-butyl. Acidification, followed by extraction with an organic solvent affords C-iii which may be purified by chromatography or crystallography. In some cases, regioisomeric alkylated products C-iv are also formed. The desired C-iii can be separated away from C-iv by chromatographic purification or by fractional crystallization.

A synthesis of pyridylpyrazole scaffold C-1 is depicted in Scheme C-2.

Step A:

Picoline is added to a solution of LiHMDS in THF at room temperature over a time period ranging from 30 minutes to 1 hour. The resulting solution is stirred for an additional 30 minutes to 1 hour at room temperature. This solution is then added to neat ethyl p-fluorobenzoate B60 at room temperature over 1-2 h. The mixture is then allowed to stir at room temperature for 16-24 h. Equal portions of water and ethyl acetate are then added to the reaction and the mixture is partitioned in an extraction funnel. The organic layer is dried, filtered, and evaporated to give an oily solid. Hexanes are then added and the solid is filtered and washed with cold hexanes leaving the pyridyl monoketone B61 for use in Step B.

Step B:

The pyridyl monoketone B61 is added as a solution in THF to a flask maintained at room temperature which contains t-BuOK in a THF/t-BuOH cosolvent. A yellow precipitate forms and stirring at room temperature is continued for 1-3 h. After this time, N-Cbz-protected glycine N-hydroxysuccinimide B62 is added dropwise at room temperature as a solution in THF over 1-3 h. This solution, containing crude diketone B63, is used directly in Step C.

Step C:

The solution from step C is treated with water and the pH is adjusted to between 6 and 7 with acetic acid. Hydrazine hydrate is then added dropwise to the mixture as a solution in water over 30 minutes to 1 h at room temperature. Water and ethyl acetate are then added to the flask and the mixture is then partitioned in a separatory funnel. The organic layer is dried, filtered, and evaported to give a crude oil which is purified by silica gel chromatography, giving rise to purified C-1Cbz.

Step: D

The Cbz protecting group contained in compound C-1Cbz is cleaved using hydrogen gas underpressure and Pd—C in methanol solvent. The resulting amine C-1 is obtained by filtration and concentration.

A number of pyridyl pyrazole scaffolds of type C-v are prepared as shown in Scheme C-3.

Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOR, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of an appropriately activated ester analog of a carboxylic acid CbzNR^(H)—(CH₂)_(n)CR^(F)(R^(G))—CO₂H or BocNR^(H)—(CH₂)_(n)CR^(F)(R^(G))—CO₂H, preferably but not limited to the N-hydroxysuccinimide B64. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B65 is isolated as a crude solid which can be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone B65 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The anion sometimes precipitates as a yellow solid. An appropriately substituted activated ester such as the N-hydroxysuccinimide B66 is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from ranging from 5 minutes to 3 hours. The resulting pyridyl diketone intermediate B67 is utilized without further purification in Step C.

Step C: The solution containing the pyridyl diketone B67 is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole C-vBoc or C-vCbz is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D

The carbamate protecting groups from C-vBoc or C-vCbz are removed to afford the scaffolds C-v containing either a free primary amine (R^(H) is hydrogen) or a free secondary amine (R^(H) not equal to hydrogen). The Boc protecting carbamate groups are cleaved utilizing 1:1 trifluoroacetic acid (TFA)/methylene chloride at room temperature for several hours. The CBZ carbamate protecting groups are cleaved using hydrogen gas under pressure and Pd—C in an alcoholic solvent. The resulting amines C-v are then optionally crystallized or purified by chromatography.

The synthesis of scaffolds C-vi is accomplished as shown in Scheme C-4.

Step A:

A Boc protected pyridylpyrazole B68 is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine B69 is used in step B without further purification.

Step B:

The pyridylpyrazole imine B69 is dissolved in THF and stirred under nitrogen at temperatures ranging from −78 to −20° C. A base such as LDA, n-BuLi, or LiHMS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two-five equivalents of an alklyating agent R^(F)-Q are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give C-vi.

The synthesis of maleimide-containing scaffolds C-vii is accomplished as shown in Scheme C-5.

The maleimide pyrazole scaffolds C-vii are synthesized as depicted in scheme C-5. Condensation reaction of a primary amine H₂N—R with a maleic anhydride B70 that is substituted at position 3 with either a bromo, chloro, or triflate group generates compound B71. The formed maleimide derivative B71 then reacts with an acetophenone derivative B72 in the presence of a Pd(0) catalyst and base to afford compound B73. The methylene position of B73 is then acylated with an acid anhydride B74 or an activated acid ester B75, forming the di-ketone derivative B76. The di-ketone B76 condenses with hydrazine to afford the desired maleimide pyrazole scaffold C-vii.

Scheme C-6 illustrates the synthesis of the maleimide pyrazole scaffold C-63 wherein R⁴ is hydrogen. The synthesis starts with the condensation reaction of bromomaleic anhydride B77 with 2,4-dimethoxybenzylamine in acetic acid and acetic anhydride, giving rise to intermediate B76. The maleimide B78 is then treated with 4′-fluoroacetophenone in the presence of catalytic amount Pd₂(dba)₃ and sodium t-butoxide to form the fluoroacetophenone substituted maleimide B79. The B79 is treated with tert-butoxybis(dimethylamino)methane to yield the a-ketoenamine B80. The a-ketoenamine B80 is condensed with hydrazine to form the maleimide pyrazole skeleton B81. The 2,4-dimethoxybenzyl group protecting group is optionally removed with ceric ammonium nitrate (CAN) to give compound C-63.

Scheme C-7 illustrates the synthesis of maleimide-containing scaffolds C-64 and C-65. These scaffolds C-49 and C-50 are synthesized according to the general methods illustrated in Scheme C-5 and exemplified with the utilization of N-hydroxysuccinimides B82 and B83 to afford the maleimide-containing pyrazoles B86 and B87, respectively. Optional removal of the 2,4-dimethoxylbenzyl groups with CAN and subsequent removal of the Boc-protecting groups with trifluoroacetic acid (TFA) affords the scaffolds C-64 and C-65.

The various functionalized resins and sequestration-enabling-reagents utilized to prepare and purify parallel reaction mixtures are more fully described below, including their commercial source or literature reference to their preparation.

B32

4-benzyloxybenzaldehyde functionalized polystyrene. Novabiochem cat. #01-64-0182 B33

Prepared as reported in D. L. Flynn et al, J. American Chemical Society (1997) 119, 4874-4881. B38

Methylisocyanate functionalized polystyrene. Novabiochem cat. #01-64-0169 B48

Polymer bound EDC, prepared as reported by M. C. Desai et al, Tetrahedron Letters (1993) 34, 7685. B41

Benzenesulfonylisocyanate, purchased from Aldrich Chemical Company. Cat #23,229-7 B50

Tetra-fluorophthalic anhydride, purchased from Aldrich Chemical Company. Cat #33,901-6

Experimental procedure for the parallel synthesis of a series of amides, carbamates, ureas and sulfonamides B-0001 through B-0048 from scaffold C-1.

EXAMPLES B-0001 THROUGH B-0048

To each reaction vessel (polypropylene syringe tubes fitted with a porous frit, closed at the bottom) of a parallel reaction apparatus was added 200 uL of dimethylformamide. A stock solution of the scaffold amine C-1 in dimethylformamide (0.1 M, 500 uL) was added to each reaction vessel followed by the addition of a stock solution of N-methylmorpholine in dimethylformamide (1.0 M, 200 uL). A stock solution of each of the electrophiles was then added to the appropriate reaction vessels: a) 500 uL of a 0-2 M solution of the acid chlorides in dichloroethane or b) 500 uL of a 0.2 M solution of the chloroformates in dichloroethane or c) 313 uL of a 0.2 M solution of the isocyanates in dichloroethane or d) 375 uL of a 0.2 M solution of the sulfonyl chlorides in dichloroethane. The parallel reaction apparatus was then orbitally shaken (Labline Benchtop orbital shaker) at 200 RPM at ambient temperature (23-30° C.) for a period of 2-3 h. under a gentle flow of nitrogen. At this time each reaction vessel was treated with approximately 250 mg of polyamine resin B33 (4.0 meq N/g resin) and approximately 100 mg of polyaldehyde resin B32 (2.9 mmol/g resin). Each reaction vessel was diluted with 1 mL dimethylformamide and 1 mL dichloroethane and the orbital shaking was continued at 200 RPM for a period of 14-20 h at ambient temperature. Each reaction vessel was then opened and the desired solution phase products separated from the insoluble quenched byproducts by filtration and collected in individual conical vials. Each vessel was rinsed twice with dichloroethane (1 mL) and the rinsings were also collected. The solutions obtained were then evaporated to dryness in a Savant apparatus (an ultracentrifuge equipped with high vacuum, scalable temperature settings and a solvent trap to condense the volatile solvent vapors). The resulting amide, carbamate, urea and sulfonamide products were then weighed and characterized. The yields and analytical data for the products obtained using this method are shown below.

Observed Calcd. Mass Spec Example # R² R^(J) % Yield Mass Spec (M + H) B-0001

85 397 398 B-0002

94 412 413 B-0003

91 340 341 B-0004

79 368 369 B-0005

92 498 499 B-0006

92 416 417 B-0007

86 450 451 B-0008

86 448 449 B-0009

83 368 369 B-0010

86 338 339 B-0011

92 402 403 B-0012

74 442 443 B-0013

91 446 447 B-0014

84 352 353 B-0015

94 380 381 B-0016

89 440 441 B-0017

83 498 499 B-0018

24 439 440 B-0019

69 474 475 B-0020

90 440 441 B-0021

85 386 387 B-0022

35 417 418 B-0023

94 397 398 B-0024

87 417 418 B-0025

 5 354 — B-0026

87 426 427 B-0027

89 350 351 B-0028

92 456 457 B-0029

89 428 429 B-0030

37 498 499 B-0031

18 407 408 B-0032

86 462 463 B-0033

 3 352 — B-0034

92 446 447 B-0035

28 569 570 B-0036

93 416 417 B-0037

91 422 423 B-0038

84 390 393 B-0039

87 402 403 B-0040

92 416 417 B-0041

75 444 445 B-0042

54 390 391 B-0043

80 396 397 B-0044

81 310 311 B-0045

91 408 409 B-0046

25 464 465 B-0047

88 430 431 B-0048

95 414 415

By analogy to the procedure identified above for the preparation of Examples B0001-30048, the following examples B-0049 through B-1573 were prepared.

Observed Calcd. Mass Spec Example# R² R^(J) % Yield Mass Spec (M + H)

B-0049

85 414 415 B-0050

9 458 459 B-0051

91 426 427 B-0052

79 407 408 B-0053

92 407 408 B-0054

92 363 364 B-0055

86 505 506 B-0056

86 487 488 B-0057

83 394 395 B-0058

86 462 463 B-0059

92 466 467 B-0060

74 456 457 B-0061

35 458 459 B-0062

94 458 459 B-0063

87 372 373 B-0064

5 394 395 B-0065

87 420 395 B-0066

89 350 351 B-0067

92 386 387 B-0068

89 432 433 B-0069

37 390 391 B-0070

18 432 433 B-0071

86 440 441 B-0072

3 432 433 B-0073

92 450 451 B-0074

28 390 391 B-0075

93 402 403 B-0076

91 400 401 B-0077

84 382 383 B-0078

87 396 397 B-0079

92 364 365 B-0080

75 447 448 B-0081

54 370 371 B-0082

80 430 431 B-0083

81 382 383 B-0084

91 464 465 B-0085

25 462 463 B-0086

88 432 433 B-0087

95 416 417 B-0088

438 439 B-0089

336 337 B-0090

444 445 B-0091

368 369 B-0092

506 507 B-0093

436 437 B-0094

461 462 B-0095

408 409 B-0096

410 411 B-0097

14 486 487 B-0098

8 465 — B-0099

75 464 465 B-0100

72 388 389 B-0101

23 408 409 B-0102

37 487 488 B-0103

11 492 493 B-0104

59 426 427 B-0105

79 360 361 B-0106

56 374 375 B-0107

33 346 347 B-0108

12 466 467 B-0109

65 450 451 B-0110

55 458 459 B-0111

41 458 459 B-0112

19 467 468 B-0113

78 453 454 B-0114

14 453 454 B-0115

33 453 B-0116

11 459 487 B-0117

77 438 439 B-0118

52 422 423 B-0119

82 434 435 B-0120

49 422 423 B-0121

64 414 415 B-0122

87 501 502 B-0123

100 450 451 B-0124

87 456 457 B-0125

45 472 473 B-0126

100 476 477 B-0127

100 433 434 B-0128

100 482 — B-0129

96 480 481 B-0130

93 468 469 B-0131

90 468 469 B-0132

78 436 437 B-0133

76 426 427 B-0134

87 444 445 B-0135

67 476 477 B-0136

100 570 — B-0137

35 480 481 B-0138

60 500 — B-0139

73 585 586 B-0140

62 434 459 B-0141

100 483 484 B-0142

90 444 445 B-0143

61 492 493 B-0144

49 448 449 B-0145

48 433 434 B-0146

32 415 416 B-0147

67 471 472 B-0148

79 465 — B-0149

65 353 354 B-0150

53 465 466 B-0151

68 401 402 B-0152

39 383 — B-0153

96 427 428 B-0154

44 459 460 B-0155

74 479 480 B-0156

44 459 460 B-0157

72 415 416 B-0158

96 445 446 B-0159

97 411 412 B-0160

49 417 418 B-0161

93 459 460 B-0162

91 405 406 B-0163

94 455 456 B-0164

84 455 456 B-0165

52 411 412 B-0166

72 417 418 B-0167

66 447 448 B-0168

27 415 416 B-0169

91 415 416 B-0170

8 351 352 B-0171

10 437 438 B-0172

62 471 472 B-0173

40 455 456 B-0174

92 405 406 B-0175

96 387 388 B-0176

25 415 416 B-0177

100 397 398 B-0178

34 429 430 B-0179

72 429 430 B-0180

91 463 464 B-0181

100 463 464 B-0182

50 447 448 B-0183

22 455 456 B-0184

63 465 466 B-0185

65 471 472 B-0186

42 429 430 B-0187

62 481 482 B-0188

98 439 440 B-0189

21 453 454 B-0190

57 417 418 B-0191

24 477 478 B-0192

35 455 456 B-0193

42 378 379 B-0194

65 365 366 B-0195

93 587 588 B-0196

82 365 366 B-0197

100 587 588 B-0198

86 373 374 B-0199

81 373 374 B-0200

78 373 374 B-0201

95 352 353 B-0202

100 416 417 B-0203

69 354 355 B-0204

93 340 341 B-0205

94 354 355 B-0206

79 424 425 B-0207

82 326 327 B-0208

88 378 379 B-0209

83 362 363 B-0210

100 364 365 B-0211

60 325 326 B-0212

79 339 340 B-0213

71 353 354 B-0214

77 311 312 B-0215

24 353 354 B-0216

339 340 B-0217

381 382 B-0218

365 366 B-0219

401 402 B-0220

415 416 B-0221

367 368 B-0222

96 486 487 B-0223

100 465 466 B-0224

75 486 509a B-0225

100 442 443 B-0226

88 482 483 B-0227

73 482 483 B-0228

37 452 — B-0229

100 476 477 B-0230

94 476 477 B-0231

100 460 461 B-0232

90 440 441 B-0233

99 476 477 B-0234

100 486 487, 489 B-0235

89 486 487, 489 B-0236

100 476 477 B-0237

100 476 477 B-0238

92 438 — B-0239

100 442 443 B-0240

100 442 443 B-0241

100 476 477 B-0242

100 460 461 B-0243

87 456 457 B-0244

100 436 437 B-0245

100 422 423 B-0246

100 452 453 B-0247

100 476 477 B-0248

73 468 — B-0249

100 516 517, 519 B-0250

72 458 — B-0251

100 427 428 B-0252

100 450 451 B-0253

100 472 473 B-0254

100 433 434 B-0255

84 547 548 B-0256

100 484 507a B-0257

85 534 535 B-0258

100 491 492 B-0259

100 554 555 B-0260

91 500 501 B-0261

100 486 487 B-0262

100 481 482 B-0263

100 554 555 B-0264

75 375 376 B-0265

71 459 460 B-0266

100 412 413 B-0267

100 386 387 B-0268

89 406 407 B-0269

84 386 387 B-0270

92 440 441 B-0271

98 428 429 B-0272

57 498 499 B-0273

100 440 441 B-0274

94 397 398 B-0275

90 422 423 B-0276

100 408 409 B-0277

88 408 409 B-0278

100 426 427 B-0279

54 440 441 B-0280

79 414 415 B-0281

82 458 459 B-0282

89 426 427 B-0283

90 458 459 B-0284

100 458 459 B-0285

94 458 459 B-0286

100 458 459 B-0287

96 458 459 B-0288

100 458 459 B-0289

96 406 407 B-0290

96 386 387 B-0291

95 440 441 B-0292

94 390 391 B-0293

100 408 409 B-0294

100 440 441 B-0295

91 408 409 B-0296

96 426 427 B-0297

88 390 391 B-0298

95 408 409 B-0299

90 408 409 B-0300

95 406 407 B-0301

99 450 451, 453 B-0302

94 440 441 B-303

100 378 379 B-0304

100 391 392 B-0305

70 326 327 B-0306

59 340 341 B-0307

59 354 355 B-0308

60 368 369 B-0309

61 352 353 B-0310

61 366 367 B-0311

65 356 357 B-0312

75 342 343 B-0313

68 356 357 B-0314

31 370 371 B-0315

61 384 385 B-0316

75 368 369 B-0317

62 366 367 B-0318

52 388 389 B-0319

53 424 425 B-0320

50 424 425 B-0321

54 442 443 B-0322

64 474 475 B-0323

58 474 475 B-0324

60 422 423 B-0325

64 422 423 B-0326

58 422 423 B-0327

63 378 379 B-0328

68 389 390 B-0329

63 362 363 B-0330

48 376 377 B-0331

66 424 425 B-0332

61 442 443 B-0333

60 458 459 B-0334

55 502 503 B-0335

60 454 455 B-0336

100 500 501 B-0337

65 458 — B-0338

69 502 503 B-0339

69 454 — B-0340

77 492 493 B-0341

64 458 459 B-0342

41 438 — B-0343

63 430 431 B-0344

96 464 465 B-0345

62 507 508 B-0346

56 497 498 B-0347

61 341 342 B-0348

3 367 — B-0349

57 403 404 B-0350

57 481 482 B-0351

31 355 356 B-0352

51 397 398

B-0353

71 382 383 B-0354

35 512 513 B-0355

37 352 353 B-0356

57 404 405 B-0357

88 366 367 B-0358

88 410 411 B-0359

100 324 325 B-0360

56 364 365 B-0361

70 350 351 B-0362

100 464 465 B-0363

73 512 513 B-0364

88 377 378 B-0365

70 396 397 B-0366

100 354 355 B-0367

71 416 417 B-0368

86 454 455 B-0369

40 440 441 B-0370

94 364 365 B-0371

88 460 461 B-0372

69 430 431 B-0373

100 430 431 B-0374

75 400 401 B-0375

74 386 387 B-0376

53 378 379 B-0377

71 387 388 B-0378

69 387 388 B-0379

66 387 388 B-0380

85 416 417 B-0381

93 430 431 B-0382

84 382 383 B-0383

74 583 584 B-0384

63 438 439 B-0385

83 440 441 B-0386

99 422 423 B-0387

47 388 389 B-0388

100 448 449 B-0389

71 436 437 B-0390

100 458 459 B-0391

45 414 415 B-0392

100 440 441 B-0393

75 388 389 B-0394

92 402 403 B-0395

87 374 375 B-0396

86 360 361 B-0397

81 452 453 B-0398

88 428 429 B-0399

99 436 437 B-0400

82 482 483 B-0401

94 367 368 B-0402

73 325 326 B-0403

91 415 416 B-0404

41 379 380 B-0405

88 395 396 B-0406

100 419 420 B-0407

52 353 354 B-0408

83 339 340 B-0409

74 415 416 B-0410

100 419 420 B-0411

94 429 430 B-0412

91 365 366 B-0413

79 367 368 B-0414

85 429 430 B-0415

82 401 402 B-0416

93 429 430 B-0417

97 429 430 B-0418

100 419 420 B-0419

100 431 432 B-0420

36 381 382 B-0421

96 353 354 B-0422

100 461 462 B-0423

100 406 407 B-0424

76 366 367 B-0425

21 368 369 B-0426

100 354 355 B-0427

100 379 380 B-0428

100 379 380 B-0429

86 368 369 B-0430

51 500 501 B-0431

76 479 480 B-0432

90 500 501 B-0433

96 456 457 B-0434

75 496 497 B-0435

52 496 497 B-0436

73 506 B-0437

19 466 B-0438

100 490 491 B-0439

67 464 465 B-0440

96 472 473 B-0441

87 472 473 B-0442

72 481 482 B-0443

66 473 474 B-0444

80 515 516 B-0445

94 490 491 B-0446

84 464 465 B-0447

89 470 471 B-0448

100 490 491 B-0449

100 474 475 B-0450

100 447 448 B-0451

100 454 455 B-0452

95 496 497 B-0453

100 490 491 B-0454

100 500 501 B-0455

96 500 501 B-0456

89 494 495 B-0457

93 482 483 B-0458

100 490 491 B-0459

100 490 491 B-0460

93 450 451 B-0461

84 452 453 B-0462

96 456 457 B-0463

66 456 457 B-0464

69 490 491 B-0465

86 490 491 B-0466

78 474 475 B-0467

78 470 471 B-0468

91 450 451 B-0469

85 436 437 B-0470

99 466 467 B-0471

100 490 491 B-0472

37 482 483 B-0473

92 462 463 B-0474

99 530 532 B-0475

55 472 473 B-0476

89 441 442 B-0477

79 464 465 B-0478

92 486 487 B-0479

97 447 448 B-0480

75 561 562 B-0481

74 498 499 B-0482

57 548 549 B-0483

83 505 506 B-0484

100 568 569 B-0485

100 495 496 B-0486

100 426 427 B-0487

32 389 390 B-0488

100 568 569 B-0489

91 500 501 B-0490

40 473 474 B-0491

73 514 515 B-0492

89 400 401 B-0493

100 420 421 B-0494

100 400 401 B-0495

100 454 455 B-0496

100 442 443 B-0497

50 512 513 B-0498

100 454 455 B-0499

98 411 412 B-0500

100 436 437 B-0501

100 422 423 B-0502

100 422 423 B-0503

92 440 441 B-0504

67 454 455 B-0505

68 428 429 B-0506

98 472 473 B-0507

82 440 441 B-0508

99 472 473 B-0509

100 472 473 B-0510

96 472 473 B-0511

100 472 473 B-0512

100 472 473 B-0513

100 472 473 B-0514

100 420 421 B-0515

100 400 401 B-0516

100 454 455 B-0517

100 404 405 B-0518

99 422 423 B-0519

100 454 455 B-0520

98 422 423 B-0521

99 440 441 B-0522

88 404 405 B-0523

100 422 423 B-0524

100 422 423 B-0525

100 420 421 B-0526

100 464 465 B-0527

100 454 455 B-0528

100 392 393 B-0529

94 405 406

B-0530

67 382 383 B-0531

66 512 513 B-0532

37 352 353 B-0533

56 404 405 B-0534

100 366 367 B-0535

100 410 411 B-0536

41 324 325 B-0537

100 364 365 B-0538

29 350 351 B-0539

70 464 465 B-0540

50 512 513 B-0541

61 377 378 B-0542

61 396 397 B-0543

59 354 355 B-0544

45 416 417 B-0545

100 454 455 B-0546

44 440 441 B-0547

64 364 365 B-0548

89 460 461 B-0549

100 430 431 B-0550

100 430 431 B-0551

81 400 401 B-0552

38 386 387 B-0553

31 378 379 B-0554

100 387 388 B-0555

66 387 388 B-0556

32 387 388 B-0557

70 416 417 B-0558

57 430 431 B-0559

74 382 383 B-0560

36 583 584 B-0561

51 438 439 B-0562

88 440 441 B-0563

68 422 423 B-0564

47 388 389 B-0565

100 448 449 B-0566

76 436 437 B-0567

99 458 459 B-0568

45 414 415 B-0569

88 440 441 B-0570

61 388 389 B-0571

58 402 403 B-0572

75 374 375 B-0573

72 360 361 B-0574

97 452 453 B-0575

71 428 429 B-0576

88 436 437 B-0577

72 482 483 B-0578

89 367 368 B-0579

100 325 326 B-0580

75 415 416 B-0581

44 379 380 B-0582

75 395 396 B-0583

80 419 420 B-0584

57 353 354 B-0585

83 339 340 B-0586

71 415 416 B-0587

100 419 420 B-0588

94 429 430 B-0589

78 365 366 B-0590

82 367 368 B-0591

72 429 430 B-0592

82 401 402 B-0593

88 429 430 B-0594

100 429 430 B-0595

99 419 420 B-0596

93 431 432 B-0597

40 381 382 B-0598

93 353 354 B-0599

100 461 462 B-0600

98 406 407 B-0601

66 366 367 B-0602

25 368 369 B-0603

90 354 355 B-0604

86 379 380 B-0605

87 379 380 B-0606

72 368 369 B-0607

34 500 501 B-0608

100 479 480 B-0609

82 500 501 B-0610

100 456 457 B-0611

76 496 497 B-0612

69 496 497 B-0613

61 506 B-0614

18 466 B-0615

100 490 491 B-0616

77 464 465 B-0617

93 472 473 B-0618

84 472 473 B-0619

71 481 482 B-0620

89 473 474 B-0621

68 515 516 B-0622

70 490 491 B-0623

92 464 465 B-0624

98 470 471 B-0625

96 490 491 B-0626

100 474 475 B-0627

100 447 448 B-0628

64 454 455 B-0629

100 496 497 B-0630

85 490 491 B-0631

75 500 501 B-0632

83 500 501 B-0633

58 494 495 B-0634

63 482 483 B-0635

95 490 491 B-0636

100 490 491 B-0637

91 450 451 B-0638

96 436 437 B-0639

100 456 457 B-0640

100 456 457 B-0641

88 490 491 B-0642

99 490 491 B-0643

92 474 475 B-0644

100 470 471 B-0645

92 450 451 B-0646

100 436 437 B-0647

90 466 467 B-0648

94 490 491 B-0649

57 482 B-0650

82 462 463 B-0651

100 530 531 B-0652

53 472 B-0653

84 441 442 B-0654

92 464 465 B-0655

100 486 487 B-0656

98 447 448 B-0657

85 561 562 B-0658

92 498 499 B-0659

46 548 549 B-0660

80 505 506 B-0661

100 568 569 B-0662

98 495 496 B-0663

74 426 427 B-0664

30 389 390 B-0665

100 568 569 B-0666

93 500 501 B-0667

54 473 474 B-0668

66 514 515 B-0669

65 400 401 B-0670

45 420 421 B-0671

43 400 401 B-0672

45 454 455 B-0673

41 442 443 B-0674

16 512 513 B-0675

39 454 455 B-0676

34 411 412 B-0677

46 436 437 B-0678

37 422 423 B-0679

34 422 423 B-0680

60 440 441 B-0681

31 454 455 B-0682

37 428 429 B-0683

46 472 473 B-0684

50 440 441 B-0685

44 472 473 B-0686

66 472 473 B-0687

57 472 473 B-0688

52 472 473 B-0689

42 472 473 B-0690

34 472 473 B-0691

52 420 421 B-0692

41 400 401 B-0693

56 454 455 B-0694

38 404 405 B-0695

43 422 423 B-0696

57 454 455 B-0697

51 422 423 B-0698

59 440 441 B-0699

46 404 405 B-0700

47 422 423 B-0701

46 422 423 B-0702

43 420 421 B-0703

57 464 465 B-0704

44 454 455 B-0705

33 392 393 B-0706

35 405 406

B-0707

76 516 517 B-0708

61 498 499 B-0709

37 464 465 B-0710

76 524 525 B-0711

75 512 513 B-0712

91 534 535 B-0713

42 490 491 B-0714

87 516 517 B-0715

60 464 465 B-0716

59 478 479 B-0717

61 450 451 B-0718

65 436 437 B-0719

84 528 529 B-0720

69 504 505 B-0721

63 512 513 B-0722

88 558 559 B-0723

68 443 444 B-0724

75 401 402 B-0725

83 491 492 B-0726

24 455 456 B-0727

67 471 472 B-0728

89 495 496 B-0729

38 429 430 B-0730

76 415 416 B-0731

60 491 492 B-0732

86 495 496 B-0733

81 505 506 B-0734

87 441 442 B-0735

83 443 444 B-0736

91 505 506 B-0737

9 477 — B-0738

87 505 506 B-0739

82 505 506 B-0740

85 495 496 B-0741

68 507 508 B-0742

14 457 — B-0743

77 429 430 B-0744

86 537 538 B-0745

82 482 483 B-0746

74 442 443 B-0747

83 444 445 B-0748

94 430 431 B-0749

100 455 456 B-0750

100 455 456 B-0751

48 444 445

B-0752

84 516 517 B-0753

67 498 499 B-0754

31 464 465 B-0755

85 524 525 B-0756

77 512 513 B-0757

57 534 535 B-0758

36 490 491 B-0759

79 516 517 B-0760

53 464 465 B-0761

50 478 479 B-0762

60 450 451 B-0763

75 436 437 B-0764

43 528 529 B-0765

75 504 505 B-0766

67 512 513 B-0767

43 558 559 B-0768

78 443 444 B-0769

76 401 402 B-0770

57 491 492 B-0771

14 455 456 B-0772

72 471 472 B-0773

100 495 496 B-0774

41 429 430 B-0775

91 415 416 B-0776

64 491 492 B-0777

90 495 496 B-0778

19 505 506 B-0779

79 441 442 B-0780

40 443 444 B-0781

93 505 506 B-0782

57 477 478 B-0783

99 505 506 B-0784

100 505 506 B-0785

92 495 496 B-0786

91 507 508 B-0787

15 457 458 B-0788

48 429 430 B-0789

91 537 538 B-0790

93 482 483 B-0791

76 442 443 B-0792

96 444 445 B-0793

54 430 431 B-0794

100 455 456 B-0795

100 455 456 B-0796

94 444 445 B-0797

90 458 459 B-0798

90 588 589 B-0799

82 428 429 B-0800

92 480 481 B-0801

82 442 443 B-0802

95 486 487 B-0803

89 400 401 B-0804

87 440 441 B-0805

100 426 427 B-0806

99 540 541 B-0807

96 588 589 B-0808

82 453 454 B-0809

92 472 473 B-0810

98 430 431 B-0811

88 492 493 B-0812

81 530 531 B-0813

98 516 517 B-0814

100 440 441 B-0815

100 536 537 B-0816

99 506 507 B-0817

98 506 507 B-0818

86 476 477 B-0819

90 462 463 B-0820

91 454 455 B-0821

69 463 464 B-0822

79 463 464 B-0823

79 463 464 B-0824

82 492 493 B-0825

100 506 507 B-0826

97 458 459 B-0827

100 659 660 B-0828

97 514 515 B-0829

63 458 459 B-0830

70 588 589 B-0831

100 428 429 B-0832

81 480 481 B-0833

73 442 443 B-0834

79 486 487 B-0835

5 400 401 B-0836

28 440 441 B-0837

81 426 427 B-0838

84 540 541 B-0839

80 588 589 B-0840

71 453 454 B-0841

55 472 473 B-0842

71 430 431 B-0843

68 492 493 B-0844

61 530 531 B-0845

84 516 517 B-0846

87 440 441 B-0847

86 536 537 B-0848

79 506 507 B-0849

81 506 507 B-0850

69 476 477 B-0851

83 462 463 B-0852

77 454 455 B-0853

87 463 464 B-0854

73 463 464 B-0855

92 463 464 B-0856

75 492 493 B-0857

86 506 507 B-0858

84 458 459 B-0859

80 659 660 B-0860

94 514 515

B-0861

84 583 584 B-0862

96 475 476 B-0863

69 423 424 B-0864

86 437 438 B-0865

62 395 — B-0866

81 421 422 B-0867

100 535 536 B-0868

89 583 584 B-0869

100 448 449 B-0870

100 425 426 B-0871

100 487 488 B-0872

78 501 502 B-0873

78 471 472 B-0874

92 475 476 B-0875

37 458 459 B-0876

69 507 508 B-0877

70 445 446 B-0878

91 431 432 B-0879

92 511 512 B-0880

89 410 411 B-0881

84 490 491 B-0882

85 500 501 B-0883

85 424 425 B-0884

86 532 533

B-0885

51 583 — B-0886

97 475 — B-0887

29 423 424 B-0888

82 437 438 B-0889

93 395 396 B-0890

91 421 422 B-0891

43 535 536 B-0892

62 583 584 B-0893

95 448 449 B-0894

100 425 426 B-0895

76 487 488 B-0896

62 501 502 B-0897

80 471 472 B-0898

79 475 476 B-0899

70 458 459 B-0900

62 507 508 B-0901

43 445 446 B-0902

93 431 432 B-0903

100 511 512 B-0904

95 410 411 B-0905

89 490 491 B-0906

69 500 501 B-0907

28 424 425 B-0908

64 532 533

B-0909

83 542 543 B-0910

80 434 435 B-0911

91 382 383 B-0912

100 396 397 B-0913

94 354 355 B-0914

95 380 381 B-0915

98 494 495 B-0916

84 542 543 B-0917

79 407 408 B-0918

89 384 385 B-0919

91 446 447 B-0920

99 460 461 B-0921

84 430 431 B-0922

81 434 435 B-0923

76 417 418 B-0924

70 466 467 B-0925

64 404 405 B-0926

47 390 391 B-0927

89 470 471 B-0928

53 369 370 B-0929

100 449 450 B-0930

14 459 460 B-0931

41 383 384 B-0932

94 491 492

B-0933

48 447 448 B-0934

44 429 430 B-0935

33 485 486 B-0936

30 479 — B-0937

68 367 368 B-0938

72 479 480 B-0939

76 415 416 B-0940

36 397 398 B-0941

41 441 442 B-0942

27 473 474 B-0943

55 493 494 B-0944

53 473 474 B-0945

82 429 430 B-0946

100 459 460 B-0947

60 425 426 B-0948

100 431 432 B-0949

98 473 474 B-0950

64 419 420 B-0951

100 469 470 B-0952

61 469 470 B-0953

67 425 426 B-0954

62 431 432 B-0955

39 461 462 B-0956

66 429 430 B-0957

93 429 430 B-0958

86 365 366 B-0959

73 451 452 B-0960

98 485 486 B-0961

100 469 470 B-0962

100 419 420 B-0963

83 401 402 B-0964

38 429 430 B-0965

90 411 412 B-0966

76 443 444 B-0967

100 443 444 B-0968

100 477 478 B-0969

77 477 478 B-0970

38 461 462 B-0971

95 469 470 B-0972

98 479 480 B-0973

96 485 486 B-0974

74 443 444 B-0975

100 495 496 B-0976

70 453 454 B-0977

100 467 468 B-0978

91 431 432 B-0979

54 491 492 B-0980

65 469 470 B-0981

78 382 383 B-0982

82 512 513 B-0983

94 352 353 B-0984

81 404 405 B-0985

84 366 367 B-0986

80 410 411 B-0987

85 324 325 B-0988

91 364 365 B-0989

88 350 351 B-0990

68 464 465 B-0991

86 512 513 B-0992

79 377 378 B-0993

81 396 397 B-0994

100 354 355 B-0995

75 416 417 B-0996

65 454 455 B-0997

64 440 441 B-0998

81 364 365 B-0999

79 460 461 B-1000

84 430 431 B-1001

78 430 431 B-1002

85 400 401 B-1003

83 386 387 B-1004

87 378 379 B-1005

57 387 388 B-1006

80 387 388 B-1007

64 387 388 B-1008

64 416 417 B-1009

81 430 431 B-1010

81 382 383 B-1011

66 583 584 B-1012

69 438 439 B-1013

53 440 441 B-1014

61 422 423 B-1015

47 388 389 B-1016

74 448 449 B-1017

63 436 437 B-1018

82 458 459 B-1019

41 414 415 B-1020

100 440 441 B-1021

100 388 389 B-1022

74 402 403 B-1023

76 374 375 B-1024

73 360 361 B-1025

100 452 453 B-1026

95 428 429 B-1027

98 436 437 B-1028

100 482 483 B-1029

98 367 368 B-1030

88 325 326 B-1031

97 415 416 B-1032

64 379 380 B-1033

83 395 396 B-1034

67 419 420 B-1035

73 353 354 B-1036

79 339 340 B-1037

78 415 416 B-1038

100 419 420 B-1039

95 429 430 B-1040

91 365 366 B-1041

88 367 368 B-1042

78 429 430 B-1043

79 401 402 B-1044

93 429 430 B-1045

100 429 430 B-1046

94 419 420 B-1047

100 431 432 B-1048

58 381 382 B-1049

97 353 354 B-1050

100 461 462 B-1051

88 406 407 B-1052

82 366 367 B-1053

21 368 B-1054

98 354 355 B-1055

100 379 380 B-1056

85 379 380 B-1057

30 368 369 B-1058

35 500 501 B-1059

77 479 480 B-1060

37 500 501 B-1061

86 456 457 B-1062

58 496 497 B-1063

59 496 497 B-1064

58 506 — B-1065

24 466 — B-1066

100 490 491 B-1067

74 464 465 B-1068

79 472 473 B-1069

97 472 473 B-1070

54 481 482 B-1071

67 473 474 B-1072

35 515 516 B-1073

100 490 491 B-1074

100 464 465 B-1075

100 470 471 B-1076

93 490 491 B-1077

100 474 475 B-1078

80 447 448 B-1079

85 454 455 B-1080

100 496 497 B-1081

100 490 491 B-1082

100 500 501 B-1083

93 500 501 B-1084

81 494 495 B-1085

93 482 483 B-1086

92 490 491 B-1087

100 490 491 B-1088

97 450 451 B-1089

100 436 437 B-1090

100 456 457 B-1091

100 456 457 B-1092

96 490 491 B-1093

100 490 491 B-1094

100 474 475 B-1095

81 470 471 B-1096

77 450 451 B-1097

100 436 437 B-1098

93 466 467 B-1099

100 490 491 B-1100

47 482 — B-1101

64 462 463 B-1102

98 530 531 B-1103

65 472 — B-1104

88 441 442 B-1105

100 464 465 B-1106

91 486 487 B-1107

96 447 448 B-1108

55 561 562 B-1109

100 498 499 B-1110

73 548 549 B-1111

94 505 506 B-1112

100 568 569 B-1113

100 495 496 B-1114

73 426 427 B-1115

30 389 390 B-1116

100 568 569 B-1117

83 500 501 B-1118

55 473 — B-1119

70 514 515 B-1120

84 400 401 B-1121

86 420 421 B-1122

90 400 401 B-1123

100 454 455 B-1124

91 442 443 B-1125

50 512 513 B-1126

85 454 455 B-1127

93 411 412 B-1128

87 436 437 B-1129

78 422 423 B-1130

96 422 423 B-1131

84 440 441 B-1132

77 454 455 B-1133

62 428 429 B-1134

91 472 473 B-1135

85 440 441 B-1136

82 472 473 B-1137

95 472 473 B-1138

100 472 473 B-1139

100 472 473 B-1140

92 472 473 B-1141

100 472 473 B-1142

88 420 421 B-1143

90 400 401 B-1144

87 454 455 B-1145

93 404 405 B-1146

90 422 423 B-1147

100 454 455 B-1148

87 422 423 B-1149

87 440 441 B-1150

90 404 405 B-1151

82 422 423 B-1152

85 422 423 B-1153

90 420 421 B-1154

78 464 465 B-1155

79 454 455 B-1156

95 392 393 B-1157

81 405 406

B-1158

54 396 397 B-1159

42 526 527 B-1160

27 366 367 B-1161

58 418 419 B-1162

62 380 381 B-1163

58 424 425 B-1164

67 338 339 B-1165

66 378 379 B-1166

65 364 365 B-1167

64 478 479 B-1168

76 526 527 B-1169

70 391 392 B-1170

76 410 411 B-1171

82 368 369 B-1172

73 430 431 B-1173

74 468 469 B-1174

83 454 455 B-1175

76 378 379 B-1176

96 474 475 B-1177

94 444 445 B-1178

90 444 445 B-1179

57 414 415 B-1180

75 400 401 B-1181

66 392 393 B-1182

74 401 402 B-1183

62 401 402 B-1184

51 401 402 B-1185

90 430 431 B-1186

86 444 445 B-1187

74 396 397 B-1188

76 597 598 B-1189

60 452 453 B-1190

44 454 455 B-1191

47 436 437 B-1192

50 402 403 B-1193

62 462 463 B-1194

49 450 451 B-1195

61 472 473 B-1196

52 428 429 B-1197

54 454 455 B-1198

44 402 403 B-1199

67 416 417 B-1200

45 388 389 B-1201

52 374 375 B-1202

100 466 467 B-1203

91 442 443 B-1204

100 450 451 B-1205

83 496 497 B-1206

97 381 382 B-1207

100 339 340 B-1208

90 429 430 B-1209

69 393 394 B-1210

35 409 410 B-1211

100 433 434 B-1212

83 367 368 B-1213

78 353 354 B-1214

68 429 430 B-1215

65 433 434 B-1216

91 443 444 B-1217

99 379 380 B-1218

92 381 382 B-1219

74 443 444 B-1220

67 415 416 B-1221

14 443 444 B-1222

19 443 444 B-1223

71 433 434 B-1224

100 445 446 B-1225

75 395 396 B-1226

58 367 368 B-1227

98 475 476 B-1228

71 420 421 B-1229

85 380 381 B-1230

10 382 — B-1231

66 368 369 B-1232

100 393 394 B-1233

96 393 394 B-1234

66 382 383 B-1235

50 514 515 B-1236

100 493 494 B-1237

91 514 515 B-1238

100 470 471 B-1239

71 510 511 B-1240

27 510 511 B-1241

73 520 B-1242

26 480 481 B-1243

100 504 B-1244

52 478 479 B-1245

100 486 487 B-1246

56 486 487 B-1247

43 495 496 B-1248

61 487 488 B-1249

32 529 530 B-1250

56 504 505 B-1251

58 478 479 B-1252

98 484 485 B-1253

59 504 505 B-1254

100 488 489 B-1255

96 461 B-1256

79 468 469 B-1257

63 510 511 B-1258

100 504 505 B-1259

95 514 515 B-1260

92 514 515 B-1261

98 508 509 B-1262

97 496 497 B-1263

100 504 505 B-1264

100 504 505 B-1265

100 464 465 B-1266

79 466 451 B-1267

100 470 471 B-1268

87 470 471 B-1269

100 504 505 B-1270

100 504 505 B-1271

56 488 489 B-1272

98 484 485 B-1273

90 464 465 B-1274

87 450 451 B-1275

94 480 481 B-1276

100 504 505 B-1277

60 496 511 B-1278

68 476 477 B-1279

100 544 545 B-1280

68 486 — B-1281

98 455 456 B-1282

100 478 479 B-1283

58 500 501 B-1284

58 461 462 B-1285

65 575 576 B-1286

87 512 513 B-1287

79 562 563 B-1288

100 519 520 B-1289

77 582 583 B-1290

100 509 510 B-1291

91 440 441 B-1292

35 403 404 B-1293

73 582 583 B-1294

49 514 515 B-1295

48 487 — B-1296

76 528 529 B-1297

62 447 448 B-1298

66 452 453 B-1299

65 479 431 B-1300

71 444 445 B-1301

100 472 473 B-1302

75 410 411 B-1303

74 424 425 B-1304

11 430 431 B-1305

2 424 — B-1306

30 433 434 B-1307

100 522 523 B-1308

100 508 509 B-1309

100 448 449 B-1310

26 430 431 B-1311

45 397 398 B-1312

14 507 508 B-1313

67 450 451 B-1314

69 444 445 B-1315

57 450 451 B-1316

75 393 394 B-1317

100 461 462 B-1318

31 450 451 B-1319

23 464 465 B-1320

59 512 513 B-1321

63 414 415 B-1322

45 434 435 B-1323

53 414 415 B-1324

32 468 469 B-1325

45 456 457 B-1326

50 526 527 B-1327

55 468 469 B-1328

29 425 426 B-1329

67 450 451 B-1330

59 436 437 B-1331

45 436 437 B-1332

81 454 455 B-1333

23 468 469 B-1334

53 442 443 B-1335

81 486 487 B-1336

69 454 455 B-1337

67 486 487 B-1338

39 486 487 B-1339

61 486 487 B-1340

49 486 487 B-1341

55 486 487 B-1342

51 486 487 B-1343

72 434 435 B-1344

52 414 415 B-1345

43 468 469 B-1346

40 418 419 B-1347

67 436 437 B-1348

39 468 469 B-1349

68 436 437 B-1350

73 454 455 B-1351

54 418 419 B-1352

77 436 437 B-1353

66 436 437 B-1354

58 434 435 B-1355

77 478 479 B-1356

50 468 469 B-1357

36 406 407 B-1358

39 419 420

B-1359

95 552 553 B-1360

77 444 445 B-1361

100 392 393 B-1362

85 406 407 B-1363

100 364 365 B-1364

99 390 391 B-1365

92 504 505 B-1366

100 552 553 B-1367

100 417 418 B-1368

86 394 395 B-1369

100 456 457 B-1370

100 470 471 B-1371

77 440 441 B-1372

100 444 445 B-1373

42 427 428 B-1374

60 476 477 B-1375

94 414 415 B-1376

87 400 401 B-1377

100 480 481 B-1378

95 379 380 B-1379

93 459 460 B-1380

89 469 470 B-1381

84 393 394 B-1382

85 501 502 B-1383

46 416 417 B-1384

56 432 433 B-1385

59 426 427 B-1386

50 427 428 B-1387

12 427 428 B-1388

66 504 505 B-1389

48 460 461 B-1390

44 494 495 B-1391

50 456 457 B-1392

47 451 452 B-1393

44 444 445 B-1394

52 460 461 B-1395

77 440 441 B-1396

58 451 452 B-1397

64 460 461 B-1398

65 504 505 B-1399

50 494 495 B-1400

74 440 441 B-1401

76 462 463 B-1402

65 462 463 B-1403

64 445 446 B-1404

70 512 513 B-1405

57 512 513 B-1406

73 512 513 B-1407

80 512 513 B-1408

2 512 513 B-1409

62 512 513 B-1410

42 512 513 B-1411

19 462 463 B-1412

74 462 463 B-1413

75 494 495 B-1414

68 462 463 B-1415

48 462 463 B-1416

48 494 495 B-1417

57 494 495 B-1418

49 494 495 B-1419

39 494 495 B-1420

72 378 379 B-1421

74 406 407 B-1422

68 394 395 B-1423

57 408 409 B-1424

77 422 423 B-1425

26 408 409 B-1426

41 406 407 B-1427

37 404 405 B-1428

60 456 457 B-1429

2 418 419 B-1430

61 442 443 B-1431

64 428 429 B-1432

71 429 430 B-1433

74 462 463 B-1434

88 466 467 B-1435

75 481 482 B-1436

71 504 505 B-1437

63 468 469 B-1438

78 502 503 B-1439

70 545 546 B-1440

62 535 536 B-1441

82 608 B-1442

79 555 556 B-1443

28 513 514 B-1444

75 522 523 B-1445

74 526 527 B-1446

70 570 571 B-1447

73 506 507 B-1448

76 530 531 B-1449

82 530 531 B-1450

83 530 531 B-1451

74 530 531 B-1452

76 530 531 B-1453

73 530 531 B-1454

81 498 499 B-1455

83 498 499 B-1456

78 498 499 B-1457

74 496 497 B-1458

82 540 541 B-1459

80 476 477 B-1460

78 530 531 B-1461

82 487 488 B-1462

71 540 541 B-1463

78 546 547 B-1464

83 480 481 B-1465

84 496 497 B-1466

80 540 541 B-1467

79 476 477 B-1468

79 530 531 B-1469

75 487 488 B-1470

80 480 481 B-1471

74 496 497 B-1472

75 540 541 B-1473

77 476 477 B-1474

81 530 531 B-1475

70 487 488 B-1476

54 540 541 B-1477

79 546 547 B-1478

87 394 395 B-1479

41 504 505 B-1480

87 451 452 B-1481

18 416 417 B-1482

77 427 428 B-1483

74 406 407 B-1484

82 422 423 B-1485

85 460 461 B-1486

64 406 407 B-1487

71 392 393 B-1488

82 427 428 B-1489

87 444 445 B-1490

81 462 463 B-1491

87 462 463 B-1492

69 364 365 B-1493

53 417 418 B-1494

17 426 427 B-1495

79 460 461 B-1496

80 444 445 B-1497

82 460 461 B-1498

72 378 379 B-1499

70 432 433 B-1500

68 390 391 B-1501

63 394 395 B-1502

78 408 409 B-1503

55 404 405 B-1504

39 418 419 B-1505

69 540 541 B-1506

69 462 463 B-1507

70 496 497 B-1508

65 480 481 B-1509

56 414 415 B-1510

62 400 401 B-1511

30 468 469 B-1512

50 476 477 B-1513

44 540 541 B-1514

42 530 531 B-1515

68 496 497 B-1516

27 429 430 B-1517

92 466 467 B-1518

33 379 380 B-1519

50 393 394 B-1520

82 435 436 B-1521

86 509 510 B-1522

12 405 406 B-1523

59 459 460 B-1524

81 459 460 B-1525

57 419 420 B-1526

73 410 411 B-1527

66 520 521 B-1528

91 467 468 B-1529

73 432 433 B-1530

91 443 444 B-1531

74 422 423 B-1532

68 438 439 B-1533

84 476 477 B-1534

72 422 423 B-1535

78 408 409 B-1536

77 443 444 B-1537

86 460 461 B-1538

74 478 479 B-1539

85 478 479 B-1540

71 380 381 B-1541

71 433 434 B-1542

89 442 443 B-1543

82 476 477 B-1544

76 460 461 B-1545

77 476 477 B-1546

76 394 395 B-1547

58 448 449 B-1548

83 406 407 B-1549

67 410 411 B-1550

37 424 425 B-1551

55 420 421 B-1552

23 434 435 B-1553

83 556 557 B-1554

84 478 479 B-1555

93 512 513 B-1556

83 496 497 B-1557

62 430 431 B-1558

45 416 417 B-1559

67 484 485 B-1560

16 492 493 B-1561

84 556 557 B-1562

74 546 547 B-1563

72 512 513 B-1564

57 445 446 B-1565

64 482 483 B-1566

71 395 396 B-1567

54 409 410 B-1568

76 451 452 B-1569

70 525 526 B-1570

79 421 422 B-1571

60 475 476 B-1572

77 475 476 B-1573

65 435 436

Observed Calcd. Mass Spec Example # R² R^(L) % Yield Mass Spec (M + H) B-1525

57 419 420 B-1526

73 410 411 B-1527

66 520 521 B-1528

91 467 468 B-1529

73 432 433 B-1530

91 443 444 B-1531

74 422 423 B-1532

68 438 439 B-1533

84 476 477 B-1534

72 422 423 B-1535

78 408 409 B-1536

77 443 444 B-1537

86 460 461 B-1538

74 478 479 B-1539

85 478 479 B-1540

71 380 381 B-1541

71 433 434 B-1542

89 442 443 B-1543

82 476 477 B-1544

76 460 461 B-1545

77 476 477 B-1546

76 394 395 B-1547

58 448 449 B-1548

83 406 407 B-1549

67 410 411 B-1550

37 424 425 B-1551

55 420 421 B-1552

23 434 435 B-1553

83 556 557 B-1554

84 478 479 B-1555

93 512 513 B-1556

83 496 497 B-1557

62 430 431 B-1558

45 416 417 B-1559

67 484 485 B-1560

16 492 493 B-1561

84 556 557 B-1562

74 546 547 B-1563

72 512 513 B-1564

57 445 446 B-1565

64 482 483 B-1566

71 395 396 B-1567

54 409 410 B-1568

76 451 452 B-1569

70 525 526 B-1570

79 421 422 B-1571

60 475 476 B-1572

77 475 476 B-1573

65 435 436

Proton NMR data for selected members from Examples B-0001 through B-1573 are shown in the following table.

Plate ID 1 H NMR(solvent), d ppm B-0120 (DMF-d7) d 8.53(bd, J=4.99Hz, 2H), 7.44-7.24(m, 11H), 4.41(s, 2H), 4.31(br, 2H) B-0224 (DMF-d7) d 8.56(bd, J=4.98Hz, 2H), 7.78-7.69(m, 4H), 7.39-7.19(m, 6H), 4.23(br, 2H) B-0235 (DMF-d7) d 8.47(br, 2H), 7.91-7.75(m, 3H), 7.57-7.53(m, 1H), 7.38-7.34(m, 2H), 7.21-7.13(m, 4H), 4.20(br, 2H) B-0244 (CDCl3/CD3OD) d 8.38(d, J=5.38Hz, 1H), 7.62-7.32(m, 9H), 7.04-6.95(m, 4H), 6.86-6.80(m, 2H), 4.52(q, J=6.96Hz, 1H), 1.40(d, J=6.88Hz, 3H) B-0256 (DMF-d7) d 8.45(bd, J=2.85, 2H), 7.87(br s, 4H), 7.76-7.75 (m, 2H), 7.53- 7.33(m, 5H), 7.18-7.13(br, 4H) B-0426 (DMF-d7), 1.32(br, 3H), 1.67(br, 3H), 4.17(br, 2H), 5.12(br, 1H), 7.50(m, 6H), 8.77(m. 2H), 13.54(br, 1H). B-0438 (DMSO), 1.14(t, J=6.9Hz, 3H), 4.54(m, 1H), 6.99(br, 2H), 7.21(br, 4H), 7.45(s, 1H), 7.61(q, J=8.7Hz, 2H), 8.52(d, J=5.2Hz, 2H). B-0466 (DMF-d7), 1.61(brd, J=30.6Hz, 3H), 4.61 (br, 1H), 7.25(m, 6H), 7.65(m, 3H), 8.59(br, 2H), 13.34(brd, J=34.8Hz, 1H). B-0473 (CD3OD), 1.53(d, J=7.2Hz, 3H), 4.59(q, J=7.2Hz, 1H), 6.88(d, J=4Hz, 1H), 7.09(m, 3H), 7.15(dd, J=4.4, 1.6Hz, 2H), 7.26(m, 2H), 8.46(d, J=6.0Hz, 2 H). B-0477 (DMF), 1.80(br, 3H), 2.35(s, 1H), 4.98(br, 1H), 7.38(m, 6H), 7.85(m, 2H), 8.45(br, 1H), 8.75(d, J=6.0Hz, 2H). B-0479 (Methanol-d4), 1.57(d, J=5.6Hz, 3H), 4.74(br, 1H), 7.23(m, 4H), 7.60(m, 2H), 7.81(m, 4H), 8.67(br, 2H). B-0487 (DMF), 1.78(s, 3H), 2.76(br, 6H), 4.85(br, 1H), 7.42(br, 2H), 7.54(br, 2H), 7.66(br, 3H), 8.82(s, 2H). B-0566 (CD3OD), 1.38(d, J=7.2Hz, 3H), 4.15(br, 2H), 4.50(br, 1H), 7.04(br, 2H), 7.18(br, 2H), 7.30(m, 7H), 8.45(m, 2H). B-0569 (CD3OD), 1.56(br, 3H), 4.66(q, J=6.7Hz, 1H), 7.17(m, 8H), 7.56(m. 2H), 8.47(s, 2H). B-0574 (Methanol-d4), 1.49(br, 3H), 3.86(br, 3H), 4.60(br, 1H), 6.92(br, 2H), 7.19(br, 2H), 7.31(br, 2H), 7.76(m, 4H), 8.60(br, 2H). B-0639 (DMF-d7), 1.58(brd, J=30.0Hz, 3H), 4.62(br, 1H), 7.25(m, 6H), 7.60(m, 4H), 8.59(br, 2H), 13.30(brd, J=12.3Hz). B-0643 7.18(m, 2H), 7.32(dd, J=6.0, 4.4Hz, 1H), 7.70(dd, J=9.0, 5.8Hz, 1H), 8.43(dd, J=4.8, 3.2Hz, 2H). B-0650 (CD3OD), 1.58(br, 3H), 4.62(q, J=6.6Hz, 1H), 6.93(br, 1H), 7.17(m, 5H), 7.31(br, 2H), 8.51(br, 2H). B-0656 (CDCl3/CD3OD) d 8.48 (d, J=5.30Hz, 2H), 7.72-7.59(m, 4H), 7.14-7.10(m, 2H), 7.03-6.97(m, 4H), 4.60(q, J=7.57Hz, 1H), 1.43(d, J=7.26Hz, 3H) B-0663 (CD3OD), 1.52(d, J=6.8Hz, 3H), 3.75(s, 3H), 7.21(m, 2H), 7.42(m, 2H), 7.57(s, 1H), 7.76(s, 1H), 7.98(br, 2H), 8.76(br, 2H). B-1165 Hz, 2H), 3.06(m, 1H), 3.43(q, J=6.1Hz, 2H), 7.02(m, 2H), 7.14(m, 2H), 7.41(m, 2H), 8.59(d, J=5.6Hz, 2H). B-1169 = 1.6Hz, 1H), 7.04(t, J=8.6Hz, 2H), 7.14(m, 2H), 7.36(m, 2H), 8.39(d, J=1.8Hz, 1H), 8.60(m, 2H). B-1171 6.83(br, 1H), 7.02(t, J=8.7Hz, 2H), 7.15(d, J=5.6Hz, 2H), 7.40(m, 2H), 8.59(d, J=5.0Hz, 2H). B-1179 (CDCl3), 1.94(br, 2H), 2.53(s, 3H), 2.85(t, J=6.2Hz, 2H), 3.65(br, 2H), 6.15(br, 1H), 7.04(m, 3H), 7.22(m, 3H), 7.41(br, 4H), 8.60(br, 2H). B-1183 (CDCl3), 2.00(br, 2H), 2.85(br, 2H), 3.64(br, 2H), 7.03(br, 3H), 7.17(br, 2H), 7.36(br, 2H), 7.66(br, 2H), 8.60(br, 2H), 8.77(br, 2H). B-1194 (DMSO), 1.76(br, 2H), 2.66(br, 2H), 2.91(br, 2H), 4.30(s, 2H), 7.18(br, 5H), 7.35(m, 6H), 8.54(d, J=5.8Hz, 2H). B-1200 (DMSO), 1.17(br, 3H), 1.76(br, 2H), 2.71(br, 2H), 2.97(br, 4H), 7.18(br, 4H), 7.36(br, 2H), 8.54(br, 2H). B-1206 (DMSO), 1.03(s, 6H), 1.68(br, 2H), 2.63(br, 2H), 3.00(br, 2H), 3.65(br, 1H), 5.69(m, 2H), 7.16(br, 4H), 7.35(br, 2H), 8.54(br, 2H). B-1216 (DMSO), 1.75(m, 2H), 2.14(s, 6H), 2.66(br, 2H), 3.10(br, 2H), 7.04(br, 3H), 7.18(br, 4H), 7.35(m, 2H), 7.47(br, 1H), 8.54(d, J=4.8Hz, 2 H). B-1226 (DMF), 1.25(br, 3H), 2.01(br, 2H), 3.35(br, 4H), 6.20(s, 1H), 6.30(s, 1H), 7.42(br, 4H), 7.65(br, 2H), 8.77(s, 2H). B-1360 (DMSO-d6), 1.80(br, 4H), 2.82(br, 1H), 2.94(br, 1H), 3.10(br, 1H), 3.60(br, 1H), 4.54(br, 1H), 7.18(m, 4H), 7.30(m, 4H), 7.46(m, 2H), 8.54(br, 2H). B-1361 (DMSO-d6), 0.99(br, 6H), 1.73(br, 4H), 2.89(br, 2H), 3.03(m, 1H), 4.04(br, 2H), 4.44(m, 1H), 7.18(m, 4H), 7.30(m, 2H), 8.57(d, J=4.64Hz, 2H). B-1363 (DMSO-d6), 1.78(br, 4H), 2.01(s, 3H), 2.89(br, 1H), 3.05(br, 1H), 3.34(br, 1H), 3.85(br, 1H), 4.48(br, 1H), 7.12(br, 2H), 7.21(br, 2H), 7.30(br, 2H), 8.69(br, 2H), B-1364 (CDCl3), 0.78(dd, J=3.0, 2.9Hz, 2H), 1.00(s, 2H), 1.78(m, 1H), 1.86(b, 4H), 2.64(m, 1H), 2.99(m, 1H), 3.16(m, 1H), 4.33(br, 1H), 4.70(br, 1H), 6.99(m, 2H), 7.14(s, 2H), 7.29(m, 2H), 8.64(s, 2H). B-1368 (CDCl3), 1.89(s, 4H), 2.65(m, 1H), 2.96(m, 1H), 3.06(m, 1H), 3.43(s, 3H), 3.93(d, J=13.2Hz, 1H), 4.09(d, J=13.5Hz, 1H), 4.18(d, J=13.5Hz, 1H), 4.68(d, J=12.4Hz, 1H), 7.60(m, 2H), 7.12(s, 2H), 7.26(m, 2H), 8.63(s, 2H).

By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-1574 through B-2269 are prepared.

Examples B-1574 through B-1597 are prepared from Scaffold C-27 Example # R² R^(L) B-1574

B-1575

B-1576

B-1577

B-1578

B-1579

B-1580

B-1581

B-1582

B-1583

B-1584

B-1585

B-1586

B-1587

B-1588

B-1589

B-1590

B-1591

B-1592

B-1593

B-1594

B-1595

B-1596

B-1597

Examples B-1598 through B-1621 are prepared from Scaffold C-28 Example # R² R^(L) B-1598

B-1599

B-1600

B-1601

B-1602

B-1603

B-1604

B-1605

B-1606

B-1607

B-1608

B-1609

B-1610

B-1611

B-1612

B-1613

B-1614

B-1615

B-1616

B-1617

B-1618

B-1619

B-1620

B-1621

Examples B-1622 through B-1645 are prepared from Scaffold C-38 Example # R² R^(L) B-1622

B-1623

B-1624

B-1625

B-1626

B-1627

B-1628

B-1629

B-1630

B-1631

B-1632

B-1633

B-1634

B-1635

B-1636

B-1637

B-1638

B-1639

B-1640

B-1641

B-1642

B-1643

B-1644

B-1645

Examples B-1646 through B-1669 are prepared from Scaffold C-39 Example # R² R^(L) B-1646

B-1647

B-1648

B-1649

B-1650

B-1651

B-1652

B-1653

B-1654

B-1655

B-1656

B-1657

B-1658

B-1659

B-1660

B-1661

B-1662

B-1663

B-1664

B-1665

B-1666

B-1667

B-1668

B-1669

Examples B-1670 through B-1693 are prepared from Scaffold C-65 Example # R² R^(L) B-1670

B-1671

B-1672

B-1673

B-1674

B-1675

B-1676

B-1677

B-1678

B-1679

B-1680

B-1681

B-1682

B-1683

B-1684

B-1685

B-1686

B-1687

B-1688

B-1689

B-1690

B-1691

B-1692

B-1693

Examples B-1694 through B-1717 are prepared from Scaffold C-66 Example # R² R^(L) B-1694

B-1695

B-1696

B-1697

B-1698

B-1699

B-1700

B-1701

B-1702

B-1703

B-1704

B-1705

B-1706

B-1707

B-1708

B-1709

B-1710

B-1711

B-1712

B-1713

B-1714

B-1715

B-1716

B-1717

Examples B-1718 through B-1741 are prepared from Scaffold C-69 Example # R² R^(L) B-1718

B-1719

B-1720

B-1721

B-1722

B-1723

B-1724

B-1725

B-1726

B-1727

B-1728

B-1729

B-1730

B-1731

B-1732

B-1733

B-1734

B-1735

B-1736

B-1737

B-1738

B-1739

B-1740

B-1741

Examples B-1742 through B-1765 are prepared from Scaffold C-70 Example # R² R^(L) B-1742

B-1743

B-1744

B-1745

B-1746

B-1747

B-1748

B-1749

B-1750

B-1751

B-1752

B-1753

B-1754

B-1755

B-1756

B-1757

B-1758

B-1759

B-1760

B-1761

B-1762

B-1763

B-1764

B-1765

Examples B-1766 through B-1789 are prepared from Scaffold C-71 Example # R² R^(L) B-1766

B-1767

B-1768

B-1769

B-1770

B-1771

B-1772

B-1773

B-1774

B-1775

B-1776

B-1777

B-1778

B-1779

B-1780

B-1781

B-1782

B-1783

B-1784

B-1785

B-1786

B-1787

B-1788

B-1789

Examples B-1790 through B-1813 are prepared from Scaffold C-72 Example # R² R^(L) B-1790

B-1791

B-1792

B-1793

B-1794

B-1795

B-1796

B-1797

B-1798

B-1799

B-1800

B-1801

B-1802

B-1803

B-1804

B-1805

B-1806

B-1807

B-1808

B-1809

B-1810

B-1811

B-1812

B-1813

Examples B-1814 through B-1837 are prepared from Scaffold C-73 Example # R² R^(L) B-1814

B-1815

B-1816

B-1817

B-1818

B-1819

B-1820

B-1821

B-1822

B-1823

B-1824

B-1825

B-1826

B-1827

B-1828

B-1829

B-1830

B-1831

B-1832

B-1833

B-1834

B-1835

B-1836

B-1837

Examples B-1838 through B-1861 are prepared from Scaffold C-33 Example # R² R^(L) B-1838

B-1839

B-1840

B-1841

B-1842

B-1843

B-1844

B-1845

B-1846

B-1847

B-1848

B-1849

B-1850

B-1851

B-1852

B-1853

B-1854

B-1855

B-1856

B-1857

B-1858

B-1859

B-1860

B-1861

Examples B-1862 through B-1885 are prepared from Scaffold C-45 Example # R² R^(L) B-1862

B-1863

B-1864

B-1865

B-1866

B-1867

B-1868

B-1869

B-1870

B-1871

B-1872

B-1873

B-1874

B-1875

B-1876

B-1877

B-1878

B-1879

B-1880

B-1881

B-1882

B-1883

B-1884

B-1885

Examples B-1886 through B-1909 are prepared from Scaffold C-42 Example # R² R^(L) B-1886

B-1887

B-1888

B-1889

B-1890

B-1891

B-1892

B-1893

B-1894

B-1895

B-1896

B-1897

B-1898

B-1899

B-1900

B-1901

B-1902

B-1903

B-1904

B-1905

B-1906

B-1907

B-1908

B-1909

Examples B-1910 through B-1933 are prepared from Scaffold C-44 Example # R² R^(L) B-1910

B-1911

B-1912

B-1913

B-1914

B-1915

B-1916

B-1917

B-1918

B-1919

B-1920

B-1921

B-1922

B-1923

B-1924

B-1925

B-1926

B-1927

B-1928

B-1929

B-1930

B-1931

B-1932

B-1933

Examples B-1934 through B-1957 are prepared from Scaffold C-41 Example # R² R^(L) B-1934

B-1935

B-1936

B-1937

B-1938

B-1939

B-1940

B-1941

B-1942

B-1943

B-1944

B-1945

B-1946

B-1947

B-1948

B-1949

B-1950

B-1951

B-1952

B-1953

B-1954

B-1955

B-1956

B-1957

Examples B-1958 through B-1981 are prepared from Scaffold C-43 Example # R² R^(L) B-1958

B-1959

B-1960

B-1961

B-1962

B-1963

B-1964

B-1965

B-1966

B-1967

B-1968

B-1969

B-1970

B-1971

B-1972

B-1973

B-1974

B-1975

B-1976

B-1977

B-1978

B-1979

B-1980

B-1981

Examples B-1982 through B-2005 are prepared from Scaffold C-30 Example # R² R^(L) B-1982

B-1983

B-1984

B-1985

B-1986

B-1987

B-1988

B-1989

B-1990

B-1991

B-1992

B-1993

B-1994

B-1995

B-1996

B-1997

B-1998

B-1999

B-2000

B-2001

B-2002

B-2003

B-2004

B-2005

Examples B-2006 through B-2029 are prepared from Scaffold C-60 Example # R² R^(J) B-2006

B-2007

B-2008

B-2009

B-2010

B-2011

B-2012

B-2013

B-2014

B-2015

B-2016

B-2017

B-2018

B-2019

B-2020

B-2021

B-2022

B-2023

B-2024

B-2025

B-2026

B-2027

B-2028

B-2029

Examples B-2030 through B-2053 are prepared from Scaffold C-36 Example # R² R^(J) B-2030

B-2031

B-2032

B-2033

B-2034

B-2035

B-2036

B-2037

B-2038

B-2039

B-2040

B-2041

B-2042

B-2043

B-2044

B-2045

B-2046

B-2047

B-2048

B-2049

B-2050

B-2051

B-2052

B-2053

Examples B-2054 through B-2077 are prepared from Scaffold C-34 Example # R² R^(J) B-2054

B-2055

B-2056

B-2057

B-2058

B-2059

B-2060

B-2061

B-2062

B-2063

B-2064

B-2065

B-2066

B-2067

B-2068

B-2069

B-2070

B-2071

B-2072

B-2073

B-2074

B-2075

B-2076

B-2077

Examples B-2078 through B-2101 are prepared from Scaffold C-57 Example # R² R^(J) B-2078

B-2079

B-2080

B-2081

B-2082

B-2083

B-2084

B-2085

B-2086

B-2087

B-2088

B-2089

B-2090

B-2091

B-2092

B-2093

B-2094

B-2095

B-2096

B-2097

B-2098

B-2099

B-2100

B-2101

Examples B-2102 through B-2125 are prepared from Scaffold C-52 Example # R² R^(J) B-2102

B-2103

B-2104

B-2105

B-2106

B-2107

B-2108

B-2109

B-2110

B-2111

B-2112

B-2113

B-2114

B-2115

B-2116

B-2117

B-2118

B-2119

B-2120

B-2121

B-2122

B-2123

B-2124

B-2125

Examples B-2126 through B-2149 are prepared from Scaffold C-56 Example # R² R^(J) B-2126

B-2127

B-2128

B-2129

B-2130

B-2131

B-2132

B-2133

B-2134

B-2135

B-2136

B-2137

B-2138

B-2139

B-2140

B-2141

B-2142

B-2143

B-2144

B-2145

B-2146

B-2147

B-2148

B-2149

Examples B-2150 through B-2173 are prepared from Scaffold C-32 Example # R² R^(J) B-2150

B-2151

B-2152

B-2153

B-2154

B-2155

B-2156

B-2157

B-2158

B-2159

B-2160

B-2161

B-2162

B-2163

B-2164

B-2165

B-2166

B-2167

B-2168

B-2169

B-2170

B-2171

B-2172

B-2173

Examples 2174 through B-2197 are prepared from Scaffold C-64 Example # R² R^(J) B-2174

B-2175

B-2176

B-2177

B-2178

B-2179

B-2180

B-2181

B-2182

B-2183

B-2184

B-2185

B-2186

B-2187

B-2188

B-2189

B-2190

B-2191

B-2192

B-2193

B-2194

B-2195

B-2196

B-2197

Examples B-2198 through B-2221 are prepared from Scaffold C-22 Example # R² R^(J) B-2198

B-2199

B-2200

B-2201

B-2202

B-2203

B-2204

B-2205

B-2206

B-2207

B-2208

B-2209

B-2210

B-2211

B-2212

B-2213

B-2214

B-2215

B-2216

B-2217

B-2218

B-2219

B-2220

B-2221

Examples B-2222 through B-2245 are prepared from Scaffold C-29 Example # R² R^(J) B-2222

B-2223

B-2224

B-2225

B-2226

B-2227

B-2228

B-2229

B-2230

B-2231

B-2232

B-2233

B-2234

B-2235

B-2236

B-2237

B-2238

B-2239

B-2240

B-2241

B-2242

B-2243

B-2244

B-2245

Examples B-2246 through B-2269 are prepared from Scaffold C-35 Example # R² R^(J) B-2246

B-2247

B-2248

B-2249

B-2250

B-2251

B-2252

B-2253

B-2254

B-2255

B-2256

B-2257

B-2258

B-2259

B-2260

B-2261

B-2262

B-2263

B-2264

B-2265

B-2266

B-2267

B-2268

B-2269

EXAMPLES B-2270 THROUGH B-2317

In a parallel array reaction block containing 48 fritted vessels, each reaction vessel was charged with 250 mg of polymer bound carbodiimide B48 (1.0 mmol/g resin) and a solution of the acid-containing scaffold C-49 in dimethylformamide (0.1 M, 500 uL). To each slurry was added a solution of pyridine in dichloromethane (0.2 M, 1000 uL) followed by a solution of a unique amine B47 (0.2 M, 375 uL) in dimethylformamide. The reaction mixtures were agitated on a Labline benchtop orbital shaker at 250 RPM for 16-20 h at ambient temperature. The reaction mixtures were filtered into conical vials and the polymer was washed with 1.5 mL of dimethylformamide and 2.0 mL of dichloromethane. The filtrates were evaporated to dryness in a Savant apparatus and dimethylformamide (350 uL) was added to each conical vial to dissolve the residue. A solution of tetrafluorophthalic anhydride (1.0 M, 150 uL) in dimethylformamide was added to the reconstituted conical vials and the mixture incubated for 2 hours at ambient temperature. Polyamine polymer B33 (4.0 meq N/g resin, 250 mg) and 1.0 mL dichloromethane was then added to the reaction mixture in each conical vial. After agitating the reaction mixtures for 16 h at 250 RPM on an orbital shaker at ambient temperature, the mixtures were filtered through a polypropylene syringe tube fitted with a porous frit. The polymers were washed twice with dimethylformamide (1.0 mL each) and the filtrates and washings collected in conical vials. The filtrates were evaporated to dryness and weighed to afford the desired amide products B-2270 through B-2317 as oils or solids. The analytical data and yields for the products prepared in this manner are listed below.

R²

Yield Calcd. Mass Spec. Observed Mass Spec M + H B-2270

12 352 353 B-2271

39 432 433 B-2272

26 400 — B-2273

14 396 397 B-2274

30 434 435 B-2275

43 443 — B-2276

35 364 365 B-2277

33 490 — B-2278

53 460 461 B-2279

10 420 — B-2280

7 435 436 B-2281

18 401 402 B-2282

22 390 413^(a) ^(a)M + Na B-2283

10 394 417^(a) ^(a)M + Na B-2284

7 423 — B-2285

23 450 — B-2286

4 506 — B-2287

5 437 438 B-2288

8 435 436 B-2289

4 450 451 B-2290

9 456 457 B-2291

9 415 416 B-2292

5 368 369 B-2293

5 366 367 B-2294

5 381 382 B-2295

16 410 411 B-2296

4 483 — B-2297

7 490 — B-2298

4 537 — B-2299

4 507 508 B-2300

7 442 — B-2301

20 396 397 B-2302

30 459 — B-2303

6 482 B-2304

5 395 396 B-2305

10 460 — B-2306

11 466 467 B-2307

5 421 422 B-2308

26 470 — B-2309

24 424 425 B-2310

9 348 — B-2311

21 338 339 B-2312

28 398 399 B-2313

6 410 — B-2314

15 363 364 B-2315

11 444 — B-2316

11 418 — B-2317

36 428 —

By analogy to the procedure identified above for the preparation of Examples B-2270 through B-2317, the following examples B-2318 through B-2461 were prepared.

R²

Yield Calcd. Mass Spec. Observed Mass Spec M + H B-2318

23 426 427 B-2319

23 394 — B-2320

50 490 491 B-2321

49 426 427 B-2322

40 366 367 B-2323

68 410 411 B-2324

57 456 457 B-2325

41 382 383 B-2326

71 440 441 B-2327

36 464 465 B-2328

32 467 468 B-2329

34 465 466 B-2330

26 364 365 B-2331

38 464 465 B-2332

33 483 484 B-2333

36 378 379 B-2334

44 428 429 B-2335

27 406 407 B-2336

41 428 429 B-2337

27 423 424 B-2338

33 469 470 B-2339

52 518 519 B-2340

64 442 443 B-2341

41 350 351 B-2342

34 414 415 B-2343

29 424 425 B-2344

33 492 493 B-2345

30 420 421 B-2346

35 474 475 B-2347

34 392 393 B-2348

51 458 459 B-2349

73 517 518 B-2350

22 448 449 B-2351

64 486 487 B-2352

41 482 483 B-2353

57 438 439 B-2354

63 484 485 B-2355

28 536 537 B-2356

29 408 409 B-2357

41 436 437 B-2358

41 451 452 B-2359

57 502 503 B-2360

46 496 497 B-2361

13 476 477 B-2362

46 493 494 B-2363

57 396 397 B-2364

61 438 439 B-2365

72 424 425 B-2366

34 380 381 B-2367

52 480 481 B-2368

35 407 407 B-2369

31 435 436 B-2370

33 414 415 B-2371

28 366 367 B-2372

37 422 423 B-2373

50 432 433 B-2374

29 382 383 B-2375

35 395 396 B-2376

36 428 429 B-2377

68 438 439 B-2378

55 446 447 B-2379

33 364 365 B-2380

51 421 422 B-2381

52 429 430 B-2382

48 407 408 B-2383

53 382 383 B-2384

38 447 448 B-2385

59 498 450 B-2386

45 429 430 B-2387

74 558 — B-2388

53 475 — B-2389

33 493 494 B-2390

53 487 488 B-2391

30 435 436 B-2392

57 464 465 B-2393

50 418 419 B-2394

65 488 489 B-2395

59 437 438 B-2396

34 534 535 B-2397

32 516 517 B-2398

81 533 534 B-2399

55 502 — B-2400

34 381 382 B-2401

32 378 379 B-2402

71 519 520 B-2403

68 527 528 B-2404

62 447 448 B-2405

71 536 537 B-2406

47 394 395 B-2407

65 508 509 B-2408

34 495 496 B-2409

47 448 449 B-2410

73 542 543 B-2411

81 489 490 B-2412

54 409 410 B-2413

37 493 494 B-2414

14 473 474 B-2415

19 421 422 B-2416

13 386 387 B-2417

29 414 415 B-2418

6 420 421 B-2419

10 454 — B-2420

5 442 443 B-2421

28 454 455 B-2422

47 420 421 B-2423

53 400 401 B-2424

15 400 401 B-2425

18 522 523 B-2426

38 464 465 B-2427

26 468 469 B-2428

22 432 433 B-2429

41 404 405 B-2430

15 476 477 B-2431

6 446 447 B-2432

37 404 405 B-2433

8 428 429 B-2434

13 476 477 B-2435

23 442 443 B-2436

5 486 487 B-2437

4 492 493 B-2438

58 422 423 B-2439

12 454 455 B-2440

8 521 522 B-2441

6 443 444 B-2442

37 514 515 B-2443

15 518 — B-2444

52 520 — B-2445

33 517 518 B-2446

70 500 501 B-2447

56 488 489 B-2448

51 522 523 B-2449

19 512 513 B-2450

16 538 539 B-2451

71 511 512 B-2452

71 500 501 B-2453

61 470 — B-2454

15 472 473 B-2455

39 520 — B-2456

51 533 534 B-2457

55 540 — B-2458

22 488 489 B-2459

8 486 487 B-2460

13 534 535 B-2461

13 542 —

EXAMPLE C-1 5-AMINOMETHYL-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone. 4-picoline (40 g, 0.43 mol) was added to a LiHMDS solution (0.45 mol, 450 mL of a 1.0 M solution in THF) over 30 minutes at room temperature (a slight exotherm was observed) The resulting solution was stirred for 1 h. This solution was added to ethyl 4-fluorobenzoate (75.8 g, 0.45 mol, neat) over 1 h. The mixture was stirred overnight (16 h). Water (200 mL) was added and the mixture was extracted with EtOAc (2×200 mL). The organic layer was washed with brine (1×200 mL) and dried over Na₂SO₄. The organic layer was filtered and the solvent was removed to leave oily solid. Hexane was added to the oil and the resulting solid was filtered and washed with hexane (cold). A yellow solid was isolated (50 g, 54%): ¹H NMR (CDCl₃) δ 8.58 (d, J=5.7 Hz, 2H), 8.02 (dd, J=5.5, 8.0, 2H), 7.12-7.21 (m, 4H), 4.23 (s. 2H); ¹⁹F NMR (CDCl₃) δ −104.38 (m); LC/MS, t_(r)=2.14 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=216; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 216.0825. Found: 216.0830 (Δ mmu=0.5).

N-benzyloxycarbonyl-5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole. A 3 L round bottom flask fitted with a mechanical stirrer, N₂ inlet and an addition funnel was charged with 557 mL (0.56 mol) of 1 M t-BuOK in THF and 53 mL (0.56 mol) of t-BuOH. The ketone, 1 (60 g, 0.28 mol) was dissolved in 600 mL of THF and added to the stirred mixture at room temperature. A yellow precipitate formed and the mixture was stirred for 1 h. N-benzyloxycarbonyl-glycinyl N-hydroxysuccinimide (128.6 g, 0.42 mol) was dissolved in 600 mL of THF and added dropwise at r.t. over 1 h. The mixture was stirred for another 5 minutes and 150 mL of water was added the pH was adjusted to 6.7 with 70 mL of AcOH. Hydrazine monohydrate (41 mL in 100 mL of water) was added via an addition funnel. The mixture was stirred for 1 h and was diluted with 500 mL of water and 500 mL of ethyl acetate. The biphasic mixture was transferred to a sep funnel and the layers were separated. The aqueous layer was extracted with EtOAc (3×300 mL). The organic layer was dried (Na₂SO₄), filtered and evaporated to leave 157 g of a crude reddish oil.

The oil was suspended in CH₂Cl₂ and filtered to remove any insoluble material (DCU, hydrazone of the monoketone). The solution was split into two portions and each portion was chromatographed (Biotage 75 L, 3% EtOH/CH₂Cl₂ then 6% EtOH/CH₂Cl₂). The appropriate fractions were concentrated (some contamination from the monoketone and the hydrazone) from each portion to leave a yellow solid. The solid was suspended in ethyl acetate and heated to boiling for 10 minutes. The solution was allowed to cool to R.T. overnight. The precipitate was filtered to give 30 g of a white solid (27% yield of 2): ¹H NMR (DMF-d₇) δ 13.36 (s, 1H), 8.57 (d, J=5.8 Hz, 2H), 7.16-7.52 (m, 11H), 5.11 (s, 2H), 4.48 (d, J=5.4 Hz, 2H); ¹⁹F NMR (DMF-d₇) δ −114.9 (m), −116.8 (m) (split fluorine signal is due to the pyrazole tautomers); LC/MS. t_(r)=3.52 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=403; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 403.1570. Found: 403.1581 (Δ mmu=1.1).

5-aminomethyl-4-(4-pyridyl]-3-[4-fluorophenyl)pyrazole. To a 1 L Parr bottle was added 7 g (17.4 mmol) of 2 and 180 mL of MeOH and 90 mL of THF to give a clear solution. The bottle was purged with nitrogen and 1.5 g of 10% Pd/C (wet Degussa type E101) was added. The Parr bottle was pressured to 40 psi (H₂) and was agitated. Hydrogen uptake was 5 psi after 5 h. The bottle was repressured to 42 psi and was agitated overnight. The bottle was purged with N₂ and was filtered through Celite. The Celite was washed with MeOH (3×50 mL) and the filtrate was concentrated to give 4.5 g of an off-white solid (94%). ¹H NMR (DMSO-d₆) δ 8.52 (d, J=4.63 Hz, 2H), 7.36 (dd, J=5.64, 8.1 Hz, 2H), 7.16-7.30 (m, 4H), 3.79 (s, 2H); ¹⁹F NMR (DMSO-d₆) δ −114.56 (m); LC/MS, t_(r)=1.21 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50° C.), M+H=269 m/z; High Resolution MS Calcd for C₁₅H₁₄N₄F (M+H): 269.1202. Found: 269.1229 (Δ mmu=2.7).

The following pyridylpyrazoles (C-2 through C-21, Table C-1) were prepared according to the experimental procedure described above for example C-1.

TABLE C-1 MW, M + H Example No. Structure Calculated Found ⁺H NMR (solvent), ppm C-2

323.1672 323.1670 (DMF-d₇): 8.77(t, J=4.4Hz, 2H), 7.60(m, 2H), 7.44(t, J=4.4Hz, 2H), 7.35(m, 2H), 3.22(bd, 2H), 3.01(septet, J=5.3Hz, 1H), 2.74(m, 2H), 1.95(m, 4H) C-3

282.127 (M) 282.1245 (M, EI) (DMF-d₇): 8.77(br s, 2H), 7.64-7.62(m, 2H), 7.50(br s, 2H), 7.38-7.34(m, 2H), 4.40-4.37(m, 1H), 1.56(br s, 3H) C-4

282.127 (M) 282.1147 (M, EI) (DMF-d₇): 8.77(br s, 2H), 7.64-7.62(m, 2H), 7.50(br s, 2H), 7.38-7.35(m, 2H), 4.40-4.37(m, 1H), 1.57(br s, 3H) C-5

323.1672 323.1687 (DMSO-d₆): 8.56(br, 2H), 7.32(m, 2H), 7.18(m, 4H), 2.91(m, 2H), 2.71(m, 2H) 1.88(m, 1H), 1.65(m, 2H), 1.40(m, 2H) C-6

359 359 (DMSO-d₆): 8.46(d, J=4.6Hz, 2H), 7.32-7.13(m, 7H), 6.98-6.96(m, 4H), 4.06(t, J=7.0Hz, 1H), 2.98-2.95(m, 2H) C-7

359 359 (DMSO-d₆): 8.46(d, J=5.4Hz, 2H), 7.32-7.28(m, 2H), 7.20-7.12(m, 5H), 6.98-6.96(m, 4H), 4.06(t, J=7.0Hz, 1H), 2.98-2.94(m, 2H) C-8

313.1465 313.1492 (DMSO-d₆): 13.83(bs, 1H), 8.61(d, J=5.7Hz, 2H), 8.33(bs, 1H), 7.33(m, 6H), 4.44(m, 1H), 3.63(m, 2H), 3.27(s, 3H) C-9

313.1465 313.1457 (DMSO-d₆): 8.55(dd, J=1.5, 4.4Hz, 2H), 7.37-7.32(m, 2H), 7.26(dd, J=1.6, 4.4Hz, 2H), 7.22-7.16(m, 2H), 4.06(t, J=6.5Hz, 1H), 3.49(d, J=6.6Hz, 2H), 3.20(s, 3H) C-10

354 354 (DMSO-d₆): 13.03(bs, 1H), 8.50(dd, J=1.6, 2.7Hz, 2H), 7.58(bq, J=4.3Hz, 1H), 7.3(m, 2H), 7.12-7.21(m, 4H), 3.77(t, J=6.3Hz, 1H), 2.45(d, J=4.5Hz, 3H), 1.97(t, J=7.4Hz, 2H), 1.85(dt, J=7.3, 7.1Hz, 2H) C-11

354 354 (DMSO-d₆): 13.03(bs, 1H), 8.50(dd, J=1.6, 2.7Hz, 2H), 7.58(bq, J=4.3Hz, 1H), 7.3(m, 2H), 7.12-7.21(m, 4H), 3.77(t, J=6.3Hz, 1H), 2.45(d, J=4.5Hz, 3H), 1.97(t, J=7.4Hz, 2H), 1.85(dt, J=7.3, 7.1Hz, 2H) C-12

283.1359 283.1363 (DMSO-d₆): 8.53(d, J=5.0Hz, 2H), 7.37-7.32(m, 2H), 7.21-7.17(m, 4H), 2.83(d, J=6.0Hz, 2H), 2.77(d, J=6.0Hz, 2H) C-13

297.1515 297.1515 (DMSO-d₆): 8.53(d, J=5.4Hz, 2H), 7.34(dd, J=5.8, 8.2Hz, 2H), 7.18(dd, J=5.8, 9.8Hz, 4H), 2.68(t, J=7.3Hz, 2H), 2.52(m, 2H), 1.64(m, 2H) C-14

284.0829 284.0806 (CD₃OD): 8.74(br, 2H), 7.77(br, 2H), 7.45-7.58(m, 3H), 7.30-7.40(m, 1H), 4.43(s, 2H) C-15

285 285 (DMSO-d₆): 8.53(br, 2H), 7.56(br, 2H), 7.26(m, 4H), 3.75(br, 2H) C-16

329, 331 329, 331 (DMSO-d₆): 8.53(d, J=4.4Hz, 2H), 7.42(d, J=7.9Hz, 2H), 7.34(d, J=8.5Hz, 2H), 7.24(d, J=4.6Hz, 2H), 3.76(bs, 2H) C-17

339 339 (DMSO-d₆): 8.53(t, J=4.3Hz, 2H), 7.33(m, 3H), 7.19(t, J=4.6Hz, 2H), 7.14(d, J=7.3Hz, 1H), 3.23(m, 2H), 2.88, (m, 3H), 1.92, (m, 3H), 1.70(m, 1H) C-18

339 339 (DMSO-d₆): 8.57(d, J=4.6Hz, 2H), 7.41(d, J=8.3Hz, 2H), 7.29(d, J=8.5Hz, 2H), 7.20(d, J=4.8Hz, 2H), 3.18(bd, 2H), 2.88(m, 1H), 2.76(m, 2H), 1.82(br, 4H) C-19

383, 385 383, 385 (DMSO-d₆): 8.56(br, 2H), 7.52(br, 2H), 7.14-7.29(m, 4H), 2.99(br, 2H), 2.71(br, 1H), 2.51(br, 2H), 1.68(br, 4H)

The following pyridylpyrazoles (C-22 through C-40, Table C-2) are prepared utilizing the general schemes C-1 and C-2 and the experimental procedure described for example C-1 above.

TABLE C-2 Cmpd. No. Structure C-22

C-23

C-24

C-25

C-26

C-27

C-28

C-29

C-30

C-31

C-32

C-33

C-34

C-35

C-36

C-37

C-38

C-39

C-40

C-41

C-42

C-43

C-44

C-45

C-46

C-47

C-48

EXAMPLE C-49

Step A

The pyrazole (2.60 g, 10.3 mmol) from example C-4 was suspended in 52 mL of dichloroethane and 52 mL of 2.5 M NaOH. Tetrabutylammonium hydroxide (0.5 mL of a 1 M aqueous solution) was added to the stirred mixture. To this mixture was added t-butyl bromoacetate (2.10 g, 10.8 mmol). The reaction mixture was stirred at room temperature for 4 h. The mixture was poured onto 200 mL of CH₂Cl₂ and 200 mL of H₂O. The phases were separated and the organic phase was washed with water (1×100 mL) and brine (1×100 mL). The organic layer was dried over Na₂SO₄ and was filtered. The solvent was removed to leave an off-white solid. This solid was triturated with hexane and the resulting solid isolated by filtration. The solid was washed with hexane to leave 3.4 g of a white solid (90%).

Step B

The alkylated pyrazole (3.7 g. 10.1 mmol) from Step A was treated with 57 mL of 4 N HCL in dioxane. The solution was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was dissolved in THF. The solution was treated with propylene oxide (10.3 mmol) and was stirred for 1 h at room temperature. The solvent was removed to leave an oil. The residual solvent was chased with several portions of EtOH. The resulting solid was triturated with Et₂O and the title compound Example C-49 was isolated by filtration to afford 3.0 g of an off-white solid (95%). Mass spec: M+H cald: 312; found 312. ¹H NMR (DMSO-d6): 8.81 (d, J=6.4 Hz, 2H), 7.73 (d, 5.8 Hz, 2H), 7.40 (m, 2H), 7.23 (t, J=8.5 Hz, 1H), 5.16 (s, 2H), 2.40 (s, 3H).

EXAMPLE C-50

According to the procedure described above in Example C-49, Example C-50 was also prepared starting from 4-[3-(4-fluorophenyl)-1H-pyrazole-4-ylpyridine. Mass spec: M+H cald: 298; found 298. ¹H NMR (DMSO-d6): 8.75 (d, J=6.4 Hz, 2H), 8.68 (s, 1H), 7.78 (d, J=6.6 Hz, 2H), 7.52 (dd, J=5.4, 8.5 Hz, 2H), 7.31 (t, J=8.9 Hz, 2H), 5.16 (s, 2H).

EXAMPLE C-51

Starting with the N-Boc-piperidinyl analog of Example C-2, Example C-51 is also prepared according to the methods described in Scheme C-1.

EXAMPLE C-52

Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. The picoline solution is then added to a solution of N-Cbz-(L)-phenylalaninyl N-hydroxysuccinimide. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from −20° C. to 120° C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone is isolated as a crude solid which could be purified by crystallization and/or chromatography.

Step B: A solution of the pyridyl monoketone in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from −78° C. to 50° C. for a period of time from 10 minutes to 3 hours. Formyl acetic anhydride is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between −50° C. and 50° C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to several hours. The resulting pyridyl diketone intermediate is utilized without purification in Step C.

Step C: The solution containing the pyridyl diketone is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between −20° C. and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between −20° C. and 40° C. for a period of 30 minutes to several hours. The mixture is then poured into water and extracted with an organic solvent. The N-Cbz-protected pyridyl pyrazole is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D

The CBZ protecting group is cleaved using hydrogen gas under pressure and Pd—C in an alcohol solvent, affording scaffold C-52 after filtration and concentration.

The following compounds C-53 through C-59 in Table C-3 are prepared according to the general procedure described above for the preparation of C-52.

TABLE C-3 Example No. Structure C-53

C-54

C-55

C-56

C-57

C-58

C-59

EXAMPLE C-60

Step A:

A Boc protected pyridylpyrazole is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine is used in step B without further purification.

Step B:

The pyridylpyrazole imine is dissolved in THF and stirred under nitrogen at temperatures ranging from −78 to −20° C. A base such as LDA, n-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two equivalents of a methyl iodide are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give purified C-60. Step B

EXAMPLE C-61

Example C-61 is prepared according to the method described in example C-60, substituting 1,4-dibromoethane for methyl iodide.

EXAMPLE C-62

Example C-62 is prepared according to the method described in example C-60, substituting 1,3-dibromoethane for methyl iodide.

EXAMPLE C-63

The synthesis of compound C-63 starts with the condensation reaction of bromomaleic anhydride B77 with 2,4-dimethoxybenzylamine in acetic acid and acetic anhydride. The maleimide B78 is then treated with 4′-fluoroacetophenone in the presence of catalytic amount Pd₂(dba)₃ and sodium t-butoxide to form the fluoroacetophenone substituted maleimide B79. B79 is then treated with tert-butoxybis(dimethylamino)methane to yield the a-ketoenamine B80. The a-ketoenamine B80 is condensed with hydrazine to form the N-protected maleimide pyrazole B81. The 2,4-dimethoxybenzyl group is cleaved with ceric ammonium nitrate (CAN) to give the title compound C-63.

EXAMPLE C-64

Using the method described in Schemes C-6 and C-7, Example 64 is prepared.

EXAMPLE C-65

Using the method described in Schemes C-6 and C-7, Example 65 is prepared.

EXAMPLE C-66

Using the method described in Schemes C-6 and C-7, Example C-66 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.

EXAMPLE C-67

Using the method described in Schemes C-6 and C-7, Example C-67 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78, and substituting N-Boc-glycyl N-hydroxysuccinimide for B82.

EXAMPLE C-68

Using the method described in Schemes C-6 and C-7, Example C-68 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.

EXAMPLE C-69

Using the method described in Schemes C-6 and C-7, Example 69 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-70

Using the method described in Schemes C-6 and C-7, Example 70 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-71

Using the method described in Schemes C-6 and C-7, Example 71 is prepared, substituting N-methyl-3-bromomaleimide for B78.

EXAMPLE C-72

Using the method described in Schemes C-6 and C-7, Example 72 is prepared, substituting N-methyl-3-bromomaleimide for B78, and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

EXAMPLE C-73

Using the method described in Schemes C-6 and C-7. Example 73 is prepared, substituting N-methyl-3-bromomaleimide for B78 and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

General Synthetic Procedures

Scheme C-8 illustrates a general method that can be used for the introduction of various groups on an unsubstituted nitrogen atom that is present as part of pyrazole (Cviii) with appropriately substituted aldehydes (R₃₀₂CHO) or ketones (R₃₀₂COR₃₀₃) in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride affords the desired products (Cix). Typical conditions for the reductive alkylation include the use of an alcoholic solvent at temperatures ranging from 20° C. to 80° C. In Scheme C-8, R₃₀₂ and R₃₀₃ are selected from but not limited to alkyl, benzyl, substituted benzyl, arylalkyl, heteroarylalkyl.

Scheme C-9 illustrates another method for introduction of substituents on the unsubstituted nitrogen atom present as part of the C-3 position of the pyrazole (Cviii). Treatment of the pyrazole (Cviii) with a suitable alkylating agent (R₃₀₄X) such as an alkyl chloride, alkyl bromide, alkyl iodide or with an alkyl methanesulfonate or alkyl p-toluenesulfonate in the presence of a suitable base affords the desired alkylated pyrazoles (Cx). Examples of suitable bases include diisopropylethylamine, triethylamine, N-methylmorpholine, potassium carbonate and potassium bicarbonate.

Typical conditions for the alkylation include reaction with the suitable base in a polar aprotic solvent such as acetonitrile, dimethylformamide, dimethylacetamide or dimethyl sulfoxide at temperatures ranging from 20° C. to 150° C. Typical R₃₀₄ substituents are selected from but are not limited to alkyl, substituted benzyl, heteroaromatic, substituted heteroalkyl and substituted heteroarylalkyl groups.

Compounds containing acyl, sulfonyl or ureidyl groups at the nitrogen atom can be prepared as shown in Scheme C-10. Treatment of the pyrazole Cviii with a suitable acylating agent in the presence of a base such as N-methylmorpholine, triethylamine, diisopropylethylamine or dimethylamino pyridine in an organic solvent such as dichloromethane, dichloroethane or dimethylformamide at temperatures ranging from 20° C. to 120° C. affords the desired acylated pyrazoles (Cxi). Suitable acylating agents include acid halides, activated esters of acids such as the N-hydroxysuccinimde esters, p-nitrophenyl esters, pentafluorophenyl esters, sulfonyl halides, isocyanates, and isothiocyanates.

A general synthesis of 2-substituted pyrimidinylpyrazole compounds of type Cxv is shown in Scheme C-1.

Step A:

4-Methyl-2-methylmercaptopyrimidine is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH in an organic solvent such as THF, ether, t-BuOH, dioxane from −78° C. to 50° C. for a period of time from 30 minutes to 5 hours. The resulting 4-methyl anion is then added to a solution of an appropriate ester B88. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from 0° C. to 100° C. The reaction mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent-the desired monoketone B89 is isolated as a crude solid which can be recrystallized or purified by chromatography.

Step B:

Monoketone B89 is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH, K₂CO₃ or Cs₂O₃ in an organic solvent such as THF, ether, t-BuOH, dioxane, toluene or DMF from −78° C. to 50° C. for a period of time from 30 minutes to 5 hours. A solution of an appropriately activated ester of a carboxylic acid CbzNR^(H)—(CH₂)_(n)CR^(F)(R^(G))—COOH or BocNR^(H)—(CH₂)_(n)CR^(F)(R^(G))—COOH, preferably but not limited to the N-hydroxysuccinimide ester B90 is then added to the monoketone anion while maintaining the temperature between 0° C. to 100° C. The reaction is allowed to stir at the specified temperature for a period of time ranging from 30 minutes to 48 hours. The resulting pyrimidine diketone intermediate B91 is utilized without further purification in Step C.

Step C:

The solution or suspension containing the diketone intermediate 391 is quenched with water and the pH adjusted to between 4 and 8 using an acid chosen from AcOH, H₂SO₄, HCl or HNO₃ while maintaining the temperature between 0° C. to 40° C. Hydrazine or hydrazine monohydrate is then added to the mixture while maintaining the temperature between 0° C. to 40° C. The mixture is stirred for a period of 30 minutes to 16 hours maintaining the temperature between 20° C. to 50° C., poured into water and extracted with an organic solvent. The pyrimidinyl pyrazole CxiiBoc or CxiiCbz is obtained as crude solid which is purified by chromatography or crystallization.

Step D:

The 2-methylmercapto group in the pyrimidinyl pyrazole (CxiiBoc or CxiiCbz) is oxidized to the 2-methylsulfone (where n=2) or the 2-methylsulfoxide (where n=1) using either Oxone or m-chloroperbenzoic acid as an oxidizing agent in a suitable solvent at temperatures ranging from 25° C. to 100° C. Solvents of choice for the oxidation include dichloromethane, acetonitrile, tetrahydrofuran or hydroalcoholic mixtures. The 2-methylsulfone (n=2) or the 2-methylsulfoxide (n=1) (CxiiiBoc or cxiiiCbz) is purified by crystallization or chromatography.

Step E:

The 2-methylsulfone/2-methylsulfoxide group in CxiiiBoc or CxiiiCBz is conveniently displaced with various amines or alkoxides at temperatures ranging from 20° C. to 200° C. in solvents that include but are not limited to dimethylformamide, acetonitrile, tetrahydrofuran and dioxane. The alkoxides can be generated from their alcohols by treatment with a base selected from but not limited to sodium hydride, lithium hexamethyldisilazide, potassium tertiary-butoxide in solvents such as tetrahydrofuran, dimethylformamide and dioxane at temperatures ranging from 0° C. to 100° C. The resulting 2-amino or 2-oxo derivatives (CxivBoc or CxivCbz) are purified by either chromatography or crystallization.

Step F:

The carbamate protecting groups from CxivBoc or CxivCbz are removed to afford the desired compounds Cxv containing either a free primary amine (R^(H) is hydrogen) or a free secondary amine (R^(H) is not equal to hydrogen). The Boc protecting groups are cleaved utilizing either trifluoroacetic acid in methylene chloride or hydrochloric acid in dioxane at room temperature for several hours. The Cbz protecting groups are cleaved using hydrogen gas at atmospheric or higher pressures and a catalyst (palladium on charcoal) in an alcoholic solvent. The resulting amines Cxv are then crystallized or purified by chromatography.

The following examples contain detailed descriptions of the methods of preparation of compounds that form part of the invention. These descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

EXAMPLE C-74 5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹H NMR (d₆-DMSO) δ 8.57 (d, J=4.83 Hz, 2H), 7.41 (d, J=8.26 Hz, 2H), 7.29 (d, J=8.26 Hz, 2H), 7.20 (d, J=4.63 Hz, 2H), 3.18 (bd, J=12.08 Hz, 2H), 2.88 (m, 1H), 2.76 (m, 2H), 1.82 (bs, 4H). MS (M+H): 339 (base peak).

EXAMPLE C-75 5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) (25 g, 61 mmol) in 140 mL of formic acid (96%) was added 50 g of formaldehyde (37%). The solution was stirred at 75° C. for 48 h and was cooled to room temperature. The excess formic acid was removed under reduced pressure and the residue was dissolved in 100 mL of water. The solution was added to concentrated NH₄OH/H₂O and the mixture was extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine (1×250 mL) and was dried over Na₂SO₄. The solution was filtered and concentrated to leave a white solid. The solid was triturated with ether and was filtered to afford the title compound: MS (M+H): 353 (base peak).

EXAMPLE C-76 5-(N-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) (1 g, 2.4 mmol) in 24 mL of CH₂Cl₂ was added 4-dimethylamino pyridine (0.88 g, 7.2 mmol) and acetyl chloride (0.21 g, 2.6 mmol). The solution was stirred for 3 h and the solvent was removed under reduced pressure. The residue was treated with saturated NH₄OH (20 mL) and the suspension was extracted with ethyl acetate (3×30 mL). The combined extracts were washed with brine (1×50 mL), dried over MgSO₄, filtered and concentrated to leave a solid. The solid was triturated with ether and was filtered to leave the title compound: MS (M+H): 381 (base peak).

EXAMPLE C-77 5-(N-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting methoxy acetyl chloride for acetyl chloride the title compound was prepared: ¹H NMR (DMSO-d₆) δ 8.75 (d, J=6.72 Hz, 2H), 7.70 (d, J=6.72 Hz, 2H), 7.38 (d, J=8.60 Hz, 2H), 7.29 (dd, J=6.72, 1.88 Hz, 2H), 4.40 (d, J=11.8 Hz, 1H), 4.05 (m, 2H), 3.70 (d, J=12.70 Hz, 1H), 3.25 (s, 3H), 3.0 (m, 2H), 2.55 (m, 1H), 1.7 (m, 4H). MS (M+H); 411 (base peak).

EXAMPLE C-78 5-(N-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting methylsulfonyl chloride (2.0 equivalents) for acetyl chloride the title compound was prepared: ¹H NMR (DMSO-d₆) δ 8.70 (d, J=6.72 Hz, 2H), 7.72 (d, J=6.72 Hz, 2H), 7.38 (d, J=7.66 Hz. 2H), 7.30 (dd, J=6.72, 1.88 Hz, 2H), 3.58 (bd, J=11.8 Hz, 2H), 2.87 (m, 1H), 2.82 (s, 3H), 2.72 (m, 2H), 1.85 (m, 4H). MS (M+H): 417 (base peak).

EXAMPLE C-79 5-[N-METHOXYETHYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) (500 mg, 1.2 mmol) in 12 mL of DMF was added Hunig's base (790 mg, 6.1 mmol) and 2-bromoethyl methyl ether (850 mg, 6.1 mmol). The solution was stirred at room temperature for 5 days. The solution was poured onto 2.5 N NaOH and was extracted with ethyl acetate (3×100 mL). The combined extracts were washed with water (3×100 mL) and brine (1×100 mL). The organic phase was dried over Na₂SO₄ and was filtered. The solvent was removed under reduced pressure to leave a solid. The solid was triturated and filtered to leave the title compound: ¹H NMR (CDCl₃) δ 8.63 (d, J=4.23 Hz, 2H), 7.28 (m, 4H), 7.14 (d, J=4.43 Hz, 2H), 3.57 (t, J=5.24 Hz, 2H), 3.38 (s, 3H), 3.14 (bd, J=10.1 Hz, 2H), 2.79 (m, 1H), 2.68 (t, J=5.04, 2H), 2.08 (m, 4H), 1.92 (m, 2H). MS (M+H): 397 (base peak).

EXAMPLE C-80 5-(N-ALLYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of example C-79 and substituting allyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 379 (base peak).

EXAMPLE C-81 5-(N-PROPARGYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of example C-79 and substituting propargyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 377 (base peak).

EXAMPLE C-82 5-[N-(2-METHYLTHIAZOLYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) in 12 mL of MeOH was added trimethyl orthoformate (2.6 g, 24.4 mmol) and 2-thiazolecarboxaldehyde (1.4 g, 12.2 mmol). The suspension was stirred at room temperature for 2 h. To this mixture was added NaCNBH₃ (1.5 g, 24.4 mmol) and the resulting suspension was stirred at room temperature for 7 days. The mixture was poured onto 2.5 N NaOH and was extracted with ethyl acetate (2×100 mL). The combined extracts were washed with brine (1×100 mL), dried over Na₂SO₄, filtered and concentrated to leave a solid. This solid was triturated with ether and filtered to afford the title compound: MS (M+H): 436 (base peak).

EXAMPLE C-83 5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 373 (base peak).

EXAMPLE C-84 5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl]pyrazole hydrochloride (Example C-83) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

EXAMPLE C-85 5-[N-(2-PROPYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl]pyrazole (Example C-83) (300 mg, 0.7 mmol) in 50 mL of acetone was added 1 mL of AcOH and NaBH(OAc)₃ (15 g, 70.8 mmol). The mixture was warmed to reflux and was stirred for 5 days. The reaction mixture was poured onto 100 mL of 2.5 N NaOH and was extracted with ethyl acetate (2×100 mL). The extracts were combined and washed with brine (1×100 mL). The organic phase was dried over Na₂SO₄, filtered, and concentrated to afford the title compound: MS (M+H): 415 (base peak).

EXAMPLE C-86 5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 373 (base peak) the pyrazole C-3 substituent (Cviii). Treatment of the

EXAMPLE C-87 5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl]pyrazole hydrochloride (Example C-86) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

EXAMPLE C-88 5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 339 (base peak).

EXAMPLE C-89 5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(3-chlorophenyl)pyrazole hydrochloride (Example C-88) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 353 (base peak).

EXAMPLE C-90 5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 323 (base peak).

EXAMPLE C-91 5-(N-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole hydrochloride (Example C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

EXAMPLE C-92 5-cis-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: ¹H NMR (d₆-DMSO) δ 8.56 (d, J=6.04 Hz, 2H), 7.39 (d, J=8.66 Hz, 2H), 7.31 (d, J=8.46 Hz, 2H), 7.17 (d, J=5.84 Hz, 2H), 3.05 (m, 1H), 2.62 (m, 1H), 1.99 (m, 2H), 1.53 (m, 6H). MS (M+H): 353 (base peak).

EXAMPLE C-93 5-cis-(4-N,N-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

EXAMPLE C-94 5-[cis-4-N-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a slurry of 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) (1.0 g, 2.8 mmol, 1.0 eq) in methylene chloride (28 mL) was added acetone (0.5 mL), acetic acid (0.5 mL) and solid sodium triacetoxyborohydride. The slurry was stirred for 5 h and the volatiles were removed. The residue was partitioned between 2.5 M NaOH (25 mL) and ethyl acetate (25 mL) and the aqueous layer was extracted with ethyl acetate (3×25 mL). The combined organic layer was washed with brine (50 mL), dried over MgSO₄ and evaporated. The residue was triturated with ether to yield the title compound as a white powder: ¹H NMR (d₆-DMSO) δ 8.56 (d, J=5.84 Hz, 2H), 7.40 (d, J=8.26 Hz, 2H), 7.30 (d, J=8.66 Hz, 2H), 7.18 (d, J=5.64 Hz, 2H), 2.95 (m, 2H), 2.72 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H), 1.55 (m, 4H), 1.07 (d, J=5.64 Hz, 6H). MS (M+H): 395 (base peak).

EXAMPLE C-95 5-cis-[4-N-(ACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 39S (base peak).

EXAMPLE C-96 5-cis-[4-N-(METHOXYACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 425 (base peak).

EXAMPLE C-97 5-cis-[4-N-(METHYLSULFONYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 431 (base peak).

EXAMPLE C-98 5-cis-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 337 (base peak).

EXAMPLE C-99 5-(cis-4-N,N-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-98) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-100 5-cis-[4-N-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-94 and substituting cis-5-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-98) for 5-(cis-4-n-(2-propyl)aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-92) the title compound was prepared: MS (M+H): 379 (base peak).

EXAMPLE C-101 5-cis-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

EXAMPLE C-102 5-cis-(4-N,N-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl]pyrazole (Example C-101) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

EXAMPLE C-103 5-cis-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

EXAMPLE C-104 5-cis-(4-N,N-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL]PYRAZOLE

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-(trifluoromethyl)phenyl)pyrazole (Example C-103) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

EXAMPLE C-105 5-cis-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-cis-4-aminocyclohexanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 353 (base peak).

EXAMPLE C-106 5-cis-(4-N,N-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-cis-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl)pyrazole hydrochloride (Example C-105) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

EXAMPLE C-107 5-(N-ACETIMIDO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-2) (0.11 g, 0.35 mmol) in 2 mL EtOH was added ethyl acetamidate hydrochloride (0.065 g, 0.53 mmol) and the mixture was refluxed for 30 minutes. The solution was left at 5-10° C. for 16 h and filtered to obtain the title compound as a white solid: MS (M+H): 364 (base peak).

EXAMPLE C-108 5-(N-CARBOXAMIDINO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (C-2) (1.5 g, 4.7mmol) in 47 mL of DMF was added Hunig's base (0.60 g, 4.7 mmol) and pyrazole carboxamide hydrochloride (0.68 g, 4.7 mmol). The slurry was allowed to stir at room temperature for 4 days. The reaction mixture was poured onto 300 mL of ether. The resulting precipitate was filtered to leave the title compound as the hydrochloride salt: MS (M+H): 365 (base peak).

EXAMPLE C-109 5-(N-CYCLOPROPANOYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting cyclopropanoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 407 (base peak).

EXAMPLE C-110 5-[N-(2-FLUORO)BENZOYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 2-fluorobenzoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 461 (base peak).

EXAMPLE C-111 5-(N-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 401 (base peak).

EXAMPLE C-112 5-(N-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

EXAMPLE C-113 5-(N-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole Example (C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole Example (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-114 5-[2-(1,1-DIMETHYL)AMINOETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting N-t-butoxycarbonyl-2-amino-2,2-dimethylpropanoyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 327 (base peak).

EXAMPLE C-115 5-(METHOXYMETHYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2-methoxyacetyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 300 (base peak).

EXAMPLE C-116 5-(4-AMINOBENZYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-4-aminophenyl acetyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 361 (base peak).

EXAMPLE C-117 5-[4-(N,N-DIMETHYL)AMINOBENZYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 389 (base peak).

EXAMPLE C-118 5-[4-(N-ACETYL)AMINOBENZYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example c-116) for 5-[4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 403 (base peak).

EXAMPLE C-119 5-(N-METHYLAMINOETHYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole. To a suspension of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-1) (8.04 g, 30 mmol) in 120 mL dichloromethane was added p-nitrophenylformate (6.01 g, 36 mmol) as a solid. The suspension was stirred for 24 h at room temperature and the solvents removed under reduced pressure. The residue was triturated with ether and filtered to obtain the desired 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole derivative as a white solid: MS (M+H): 297 (base peak).

5-(N-methylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole. To a suspension of 5-(N-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (8.74 g, 29.5 mmol) in 90 mL anhydrous tetrahydrofuran was added a 1.0 M solution of borane in tetrahydrofuran (90 mL, 90 mmol) and the mixture was stirred at room temperature for 24 h. 1 N aqueous hydrochloric acid (100 mL) was then added to this mixture and the solution was refluxed for 5 hours and cooled to room temperature. The solution was extracted with ether (2×250 mL) and the pH of the aqueous layer adjusted to 9 by addition of concentrated ammonium hydroxide. The aqueous layers (pH ˜9) were then extracted with ethyl acetate (4×150 mL). The organic extracts were dried over sodium sulfate, filtered and evaporated to dryness under reduced pressure. The residue was triturated with acetonitrile and filtered to obtain the title compound as a white solid: MS (M+H): 283 (base peak).

EXAMPLE C-120 5-[N-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

5-(N-t-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole. To a solution of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-1) (0.27 g₁ 1 mmol) in anhydrous dimethylformamide (4 mL) was added N-tert-butoxycarbonyl aminoisobutyric acid N-hydroxysuccinimide ester (0.33 g, 1.1 mmol) and the mixture stirred at 40° C. for 24 h. The resulting solution was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and washed with a saturated solution of sodium bicarbonate (2×20 mL) and brine (20 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure to dryness to afford 5-(N-t-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole as a white solid.

5-(N-(2-amino-2,2-dimethylacetyl)aminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole. To a solution of the above compound in acetonitrile (2 mL) was added 1 mL of a 4.0 M solution of hydrochloric acid in dioxane. The reaction mixture was stirred at room temperature for 6 hours. The suspension was evaporated to dryness under reduced pressure. The resulting residue was stirred in acetonitrile (5 mL), filtered and dried in a vacuum dessicator to afford the title compound as a hydrochloride salt: MS (M+H): 354 (base peak).

EXAMPLE C-121 5-[N-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-120 and substituting 5-aminomethyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (Example C-15) for 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-1) the title compound was prepared: MS (M+H): 370 (base peak).

EXAMPLE C-122 5-[4-N-(2-DIMETHYTAMINOACETYL)PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

To a solution of N,N-dimethylglycine hydrochloride (0.28 g, 2 mmol) in dimethylformamide (4 mL) was added hydroxybenzotriazole (0.27 g, 2 mmol), N,N-diisopropylethyl amine (0.7 mL, 4 mmol) and polymer supported ethyl carbodimide (Example B-49) (1 g, 2.39 mol). To this solution after 30 minutes at room temperature was added 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74), 0.41 g, 1 mmol). The suspension was agitated on a labtop orbital shaker for 24 h. The suspension was filtered, washed with dimethylformamide (2×5 mL) and the filtrates evaporated under high pressure. The residue was dissolved in dichloromethane (30 mL), washed with a saturated solution of sodium bicarbonate (50 mL) and brine (50 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under high vacuum to afford the title compound as a white solid: MS (M+H): 424 (base peak).

EXAMPLE C-123 (S)-5-(2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting (S)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

EXAMPLE C-124 (S)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting (S)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-123) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

EXAMPLE C-125 (R)-5-(2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

EXAMPLE C-126 (R)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting (R)-5-(2-pyrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

EXAMPLE C-127 (R)-5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 323 (base peak).

EXAMPLE C-128 (R)-5-(N-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting (R)-5-(3-piperidyl)-4-(4-pyridyl)-3-(4fluorophenyl)pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

EXAMPLE C-129 2,2-DIMETHYL-4-[4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLYL]BUTYRIC ACID

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2,2-dimethyl glutaric anhydride for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 370 (base peak).

EXAMPLE C-130 4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLYL]BUTYRIC ACID

By following the method of Example C-1 and substituting glutaric anhydride for N-benzyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 326 (base peak).

EXAMPLE C-131 4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLYL]BUTYRAMIDE

Methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyrate. To a solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyric acid (Example C-130) (40 g, 123 mmol) in 650 mL of MeOH was added 20 mL of concentrated H₂SO₄. The solution was stirred overnight at room temperature. The solution was concentrated and diluted with 200 mL of water. The solution was cooled with an ice/water bath and to the solution was added 150 mL of saturated NaHCO₃. The solution was neutralized further with 50% NaOH to pH 7. The resulting slurry was extracted with CH₂Cl₂ (3×250 mL). The combined extracts were washed with water (1×300 mL) and saturated NaHCO₃ (1×500 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated to afford methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyrate: MS (M+H): 340 (base peak).

4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyramide. A solution of methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyrate (39 g, 120 mmol) in 600 mL of MeOH was saturated with NH₃. The solution was periodically treated with additional NH₃ over a 24 h period. The solution was degassed with a stream of nitrogen and the solution was concentrated to leave a yellow solid. The solid was slurried in ether and filtered to leave the title compound: MS (M+H): 325 (base peak).

EXAMPLE C-132 5-[4-(1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

A stirred suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyric acid (Example C-130) (2 g, 6.15 mmol) in 100 ml of anhydrous ether was cooled to 0° C. under nitrogen. Lithium aluminum hydride (467 mg, 12.3 mmol) was added to this suspension slowly. After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched slowly with 1N KHSO₄ (80 ml). The mixture was transferred to a separatory funnel and the aqueous layer was removed. The aqueous layer was then made basic with K₂CO₃ (pH 8). The aqueous solution was extracted with ethyl acetate (2×100 mL). The combined ethyl acetate extracts were washed with water (1×100 mL), dried over MgSO₄, filtered and concentrated to give the title compound: MS (M+H): 312 (base peak).

EXAMPLE C-133 5-[4-(1,1-DIMETHYL-1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

A solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyric acid (Example C-130) (200 mg, 0.615 mmol) in 50 ml of MeOH was treated with 10 ml of 4 N HCl/dioxane. The reaction mixture was stirred for 5 hours and evaporated to dryness. To this residue was added 15 ml of 1N methyl magnesium bromide in butyl ether and 5 ml of anhydrous THF. The reaction was heated to reflux under nitrogen for 64 h.

The reaction was quenched with 20 ml of saturated ammonium chloride. This mixture was transferred to a separatory funnel and was extracted with 100 ml ethyl acetate (2×100 mL). The combined ethyl acetate extracts were washed with water (1×100 mL), dried over MgSO₄, filtered and concentrated to afford a crude oil. The crude oil was subjected to column chromatography by using 3.5% MeOH/CH₂Cl₂ followed by 6% MeOH/CH₂Cl₂ to give the title compound: MS (M+H): 340 (base peak).

EXAMPLE C-134 5-(4-(1-AMINO)BUTYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

To a suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl)butyramide (Example C-131) (2 g, 6.2 mmol) in 100 ml of anhydrous ether was added lithium aluminum hydride (467 mg, 12.3 mmol). After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched with 20 mL of ethyl acetate and was poured onto 100 mL of 2.5 N NaOH. The mixture was extracted with ethyl acetate (3×50 mL). The combined extracts were washed with brine (1×100 mL), dried over Na₂SO₄, filtered and concentrated to afford the title compound: MS (M+H): 311 (base peak).

EXAMPLE C-135 4-(4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLYL)PROPIONIC ACID

By following the method of Example C-1 and substituting succinic anhydride for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide the title compound was prepared: MS (M+H): 312 (base peak).

EXAMPLE C-136 5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate, N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benyloxycarbonyl-glycinyl N-hydroxysuccinimide and 4-methylpyrimidine for 4-picoline the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹H NMR (CDCl₃) δ 9.2 (s, 1H), 8.48 (d, J=5.19 Hz, 1H), 7.31 (m, 4H), 6.94 (d, J=4.79 Hz, 1H), (3.69 (m, 3H), 3.12 (m, 2H), 2.3 (m, 3H), 1.24 (m, 2H). MS (M+H): 340 (base peak).

EXAMPLE C-137 5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIMIDYL)-3-(4-CHLOROPHENYL)PYRAZOLE

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole (Example C-136) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole hydrochloride (Example C-74) the title compound was prepared: ¹H NMR (CDCl₃) δ 9.2 (d, J=1.2 Hz, 1H), 8.48 (d, J=5.59 Hz, 1H), 7.31 (m, 4H), 6.95 (dd, J=1.2, 5.6 Hz, 1H), 3.39 (m, 1H), 3.03 (d, J=11.6 Hz, 2H), 2.38 (s, 3H), 2.06 (m, 4H), 1.24 (m, 2H). MS (M+H): 354 (base peak).

EXAMPLE C-138 5-(N-ACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

EXAMPLE C-139 5-(N-METHOXYACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)PYRAZOLE

By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl)pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole (C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:

EXAMPLE C-140 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-141 5-(4-piperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-142 5-(4-N-methylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-4-(chlorophenyl)pyrazole

EXAMPLE C-143 5-(4-N-tbutoxycarbonylpiperidinyl)-4-[4-(2-methalnesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-144 5-(4-piperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-145 5-(4-N-methylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-146 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-147 5-(4-piperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-148 5-(4-N-methylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-149 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-150 5-(4-piperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-151 5-(4-N-methylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-152 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-153 5-(4-piperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-154 5-(4-N-methylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-155 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-156 5-(4-piperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-157 5-(4-N-methylpiperidinyl)-4-[4-(2-(2-methoxyethyamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-158 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-159 5-(4-piperidinyl)-4-(4-12-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-160 5-(4-N-methylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-161 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-162 5-(4-piperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-163 5-(4-N-methylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-164 5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-165 5-(4-piperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-166 5-(4-N-methylpiperidinyl)-4-[4-(2-(2-N,N-dimethylamino)ethoxy)pyridinyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE C-167 5-(N-acetylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-168 5-(N-benzylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-169 5-(N-phenylacethydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-170 5-[N-methyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-171 5-[N-isopropyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-172 5-[N-benzyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-173 5-[N-methyl-4-(4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-174 5-[N-methyl-4-(4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-175 5-[N-methyl-4-(4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-176 5-[N-methyl-4-(2,5-tetramethyl-4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-177 5-[N-methyl-4-(2,5-tetramethyl-4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-178 5-[N-methyl-4-(2,5-tetramethyl-4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-179 5-[4-(3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-180 5-[4-(N-methyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-181 5-[4-(N-isopropyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-182 5-[4-(1-benzyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-183 5-[4-(N-acetyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-184 5-[4-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-185 5-[4-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-186 5-[4-(N-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-187 5-[4-(N-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-188 5-[4-(N-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-189 5-[5-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-190 5-[5-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-191 5-[5-(N-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-192 5-[5-(N-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-193 5-[5-(N-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-194 5-(N-acethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-195 5-(N-benzhydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-196 5-(N-phenacethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-197 5-(2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-198 5-(N-methyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-199 5-(N-isopropyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-200 5-(N-benzyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-201 5-(N-acetyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-202 5-[trans-4-(N-t-butoxycarbonylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-203 5-(trans-4-aminomethylcyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-204 5-[trans-4-(N-isopropylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-205 5-trans-4-(N,N-dimethylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-206 5-[trans-4-(N-acetylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-207 5-trans-4-(N-t-butoxycarbonylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-208 5-(trans-4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-209 5-[trans-4-(N,N-dimethylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-210 5-[trans-4-(N-isopropylamino)cyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-211 5-[trans-4-(N-acetylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-212 5-[cis-4-(N-t-butoxycarbonyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-213 5-(cis-4-methylaminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-214 5-[cis-4-(N,N-dimethyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-215 5-[cis-4-(N-isopropyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-216 5-[cis-4-(N-acetyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-217 5-[3-(1,1-dimethyl-1-(N-t-butoxycarbonylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-218 5-[3-(1,1-dimethyl-1-amino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-219 5-[3-(1,1-dimethyl-1-(N,N-dimethylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-220 5-[3-(1,1-dimethyl-1-(N-isopropylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-221 5-[3-(1,1-diethyl-1-(N-acetylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-222 5-[4-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-223 5-[4-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-224 5-[4-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-225 5-[3-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-226 5-[3-(1-1-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-227 5-[3-(1-N-benzcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-228 5-[3-(N-t-butoxycarbonyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-229 5-(3-aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-230 5-[3-(N,N-dimethylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-231 5-[3-(N-isopropylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-232 5-[3-(N-benzylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-233 5-[3-(N-acetylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-234 5-[4-(2-amino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-235 5-[4-(2-N,N-dimethylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-236 5-[4-(2-N-isopropylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-237 5-[4-(2-N-benzylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-238 5-[4-(2-N-acetylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-239 5-[4-(2-amino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-240 5-[4-(2-N,N-dimethylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-241 5-[4-(2-N-isopropylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-242 5-[4-(2-N-benzylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-243 5-[4-(2-acetylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-244 5-[4-(2-amino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-245 5-[4-(2-N,N-dimethylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-246 5-[4-(2-N-isopropylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-247 5-[4-(2-N-benzylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE C-248 5-[4-(2-N-acetylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

Biological data from compounds of Examples B-0001 through B-1573 and of Examples B-2270 through B-2462 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

-   -   “P38 alpha kinase IC₅₀, uM or % inhib @ conc. (UM)”

In vitro whole cell assay for measuring the ability of the compounds to inhibit TNF production in human U937 cells stimulated with LPS are shown in the column identified as:

-   -   “U937 Cell IC₅₀, uM or % inhib @ conc., (uM)”

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNP release in the mouse is shown in the column identified as:

-   -   “Mouse LPS Model, % TNF inhib @ dose @ predose time”         wherein in the dose is milligram per kilogram (mpk) administered         by oral gavage and the predose time indicates the number of         hours before LPS challenge when the compound is administered.

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

-   -   “Rat LPS Model, % TNF inhib dose @ predose time”         wherein in the dose is milligram per kilogram (mpk) administered         by oral gavage and the predose time indicates the number of         hours before LPS challenge when the compound is administered.

P38 alpha kinase U937 Cell Mouse LPS Model % Rat LPS Model % IC50, uM or % IC50, uM or % TNF inhib @ inhib @ Example # inhib @ conc. (uM) inhib @ conc. (uM) dose @ predose time dose @ predose time B-0001 53.0% @ 1.0 uM 40.0% @ 1.0 uM B-0002 71.0% @ 1.0 uM 28.0% @ 10.0 uM B-0003 70.0% @ 1.0 uM 76.0% 10.0 uM B-0004 80.0% @ 1.0 uM 4.61 uM B-0005 95.0% @ 1.0 uM 2.97 uM B-0006 82.0% @ 1.0 uM 80% @ 10.0 uM B-0007 74.0% @ 1.0 uM 85.0% @ 10.0 uM B-0008 42.0% @ 1.0 uM 65.0% @ 10.0 uM B-0009 0.04 uM 0.72 uM B-0010 0.52 uM 0.65 uM B-0011 0.03 uM 4.47 uM B-0012 30.0% @ 1.0 uM 44.0% @ 1.0 uM B-0013 70.0% @ 1.0 uM 84.0% @ 10.0 uM B-0014 79.0% @ 1.0 uM 80.0% @ 10.0 uM B-0015 82.0% @ 1.0 uM 80.0% @ 10.0 uM B-0016 94.0% @ 1.0 uM 3.98 uM B-0017 56.0% @ 1.0 uM 79.0% @ 10.0 uM B-0018 60.0% @ 1.0 uM 59.0% @ 10.0 uM B-0019 84.0% @ 1.0 uM 100.0% @ 10.0 uM B-0020 73.0% @ 1.0 uM 81.0% @ 10.0 uM B-0021 68.0% @ 1.0 uM 76.0% @ 10.0 uM B-0022 69.0% @ 1.0 uM 44.0 @ 1.0 uM B-0023 90.0% @ 1.0 uM 77.0% @ 10.0 uM B-0024 94.0% @ 1.0 uM 52.0% @ 1.0 uM B-0025 89.0% @ 1.0 uM 79.0% @ 10.0 uM B-0026 96.0% @ 1.0 uM 3.27 uM B-0027 94.0% @ 1.0 uM 11.0 uM B-0028 69.0% @ 1.0 uM 45.0% @ 10.0 uM B-0029 91.0% @ 1.0 uM 58.0% @ 10.0 uM B-0030 92.0% @ 1.0 uM 75.0% @ 10.0 uM B-0031 94.0% @ 1.0 uM 100.0% @ 10.0 uM B-0032 94.0% @ 1.0 uM 78.0% @ 10.0 uM B-0033 97.0% @ 1.0 uM 10.0 uM B-0034 95.0% @ 1.0 uM 10.0 uM B-0035 94.0% @ 1.0 uM 10.0 uM B-0036 92.0% @ 1.0 uM 8.24 uM B-0037 91.0% @ 1.0 uM 86.0% @ 10.0 uM B-0038 71.0% @ 1.0 uM 84.0% @ 10.0 uM B-0039 89.0% @ 1.0 uM 72.0% @ 10.0 uM B-0040 93.0% @ 1.0 uM 2.3 uM B-0041 65.0% @ 1.0 uM 6 6.0% @ 10.0 uM B-0042 94.0% @ 1.0 uM 2.76 uM B-0043 0.22 uM 0.54 uM B-0044 0.14 uM 0.19 uM B-0045 94.0% @ 1.0 uM 1.01 uM B-0046 96.0% @ 1.0 uM 54.0% @ 1.0 uM B-0047 94.0% @ 1.0 uM 74.0% @ 10.0 uM B-0048 94.0% @ 1.0 uM 76.0% @ 10.0 uM B-0049 88% @ 1.0 uM 33.0% @ 1.0 uM B-0050 73% @ 1.0 uM 34.0% @ 1.0 uM B-0051 3.3 uM 2.15 uM 47% @ 100 mpk @ −6 h 79% @ 3 mpk @ −4 h B-0052 92% @ 1.0 uM 15.0% @ 1.0 uM B-0053 95% @ 1.0 uM 34.0% @ 1.0 uM B-0054 90% @ 1.0 uM 30.0% @ 1.0 uM B-0055 93% @ 1.0 uM >1.0 uM B-0056 96% @ 1.0 uM 21.0% @ 1.0 uM B-0057 96% @ 1.0 uM 29.0% @ 1.0 uM B-0058 79% @ 1.0 uM 18.0% @ 1.0 uM B-0059 83% @ 1.0 uM 35.0% @ 1.0 uM B-0060 73% @ 1.0 uM 22.0% @ 1.0 uM B-0061 62% @ 1.0 uM 27.0% @ 1.0 uM B-0062 94% @ 1.0 uM 36.0% @ 1.0 uM B-0063 96% @ 1.0 uM 40.0% @ 1.0 uM B-0064 90% @ 1.0 uM 4.0% @ 1.0 uM B-0065 83% @ 1.0 uM 21.0% @ 1.0 uM B-0066 94% @ 1.0 uM 28.0% @ 1.0 uM B-0067 91% @ 1.0 uM 1.0% @ 1.0 uM B-0068 72% @ 1.0 uM 22.0% @ 1.0 uM B-0069 96% @ 1.0 uM 37.0% @ 1.0 uM B-0070 92% @ 1.0 uM 30.0% @ 1.0 uM B-0071 86% @ 1.0 uM 31.0% @ 1.0 uM B-0072 77% @ 1.0 uM 32.0% @ 1.0 uM B-0073 91% @ 1.0 uM 24.0% @ 1.0 uM B-0074 92% @ 1.0 uM 42.0% @ 1.0 uM B-0075 91% @ 1.0 uM 35.0% @ 1.0 uM B-0076 58% @ 1.0 uM 21.0% @ 1.0 uM B-0077 0.8 uM 10.0 uM B-0078 80% @ 1.0 uM 20.0% @ 1.0 uM B-0079 93% @ 1.0 uM 13.0% @ 1.0 uM B-0080 73% @ 1.0 uM 73.0% @ 1.0 uM B-0081 92% @ 1.0 uM 13.0% @ 1.0 uM B-0082 47% @ 1.0 uM 27.0% @ 1.0 uM B-0083 0.22 uM 6.51 uM B-0084 56% @ 1.0 uM 30.0% @ 1.0 uM B-0085 83% @ 1.0 uM 21.0% @ 1.0 uM B-0086 91% @ 1.0 uM 37.0% @ 1.0 uM B-0087 0.55 uM 2.26 uM 38% @ 30 mpk @ −6 h B-0088 96% @ 1.0 uM 9.0% @ 1.0 uM B-0089 0.04 uM 3.33 uM B-0090 98% @ 1.0 uM 52.0% @ 1.0 uM B-0091 96% @ 1.0 uM 40.0% @ 1.0 uM B-0092 97% @ 1.0 uM 34.0% @ 1.0 uM B-0093 3.18 uM 1.25 uM 30% @ 30 mpk @ −6 h B-0094 96% @ 1.0 uM 52.0% @ 1.0 uM B-0095 98% @ 1.0 uM 38.0% @ 1.0 uM B-0096 91% @ 1.0 uM 22.0% @ 1.0 uM B-0097 72.0% @ 10.0 uM 38.0% @ 1.0 uM B-0098 66.0% @ 10.0 uM 12.0% @ 1.0 uM B-0099 43.0% @ 1.0 uM >1.0 uM B-0100 75.0% @ 1.0 uM 5.0 uM B-0101 71.0% @ 1.0 uM 2.11 uM B-0102 81.0% @ 1.0 uM 15.0% @ 1.0 uM B-0103 71.0% @ 1.0 uM 6.0% @ 1.0 uM B-0104 56.0% @ 1.0 uM 2.78 uM B-0105 78.0% @ 1.0 uM 5.0 uM B-0106 62.0% @ 1.0 uM 5.0 uM B-0107 0.27 uM 5.0 uM B-0108 61.0% @ 1.0 uM 4.85 uM B-0109 45.0% @ 1.0 uM 19.0% @ 1.0 uM B-0110 66.0% @ 1.0 uM 13.0% @ 1.0 uM B-0111 57.0% @ 1.0 uM >1.0 uM B-0112 97.0% @ 1.0 uM 1.12 uM B-0113 75.0% @ 1.0 uM 43.0% @ 1.0 uM B-0114 45.0% @ 1.0 uM 3.92 uM B-0115 47.0% @ 1.0 uM 2.0% @ 1.0 uM B-0116 73.0% @ 1.0 uM 35.0% @ 1.0 uM B-0117 0.46 uM 1.78 uM 30% @ 30 mpk @ −6 h B-0118 1.18 uM 1.29 uM B-0119 89.0% @ 10.0 uM 2.78 uM B-0120 0.008 uM 0.21 uM 77% @ 100 mpk @ −6 h 70% @ 3 mpk @ −4 h B-0121 79.0% @ 1.0 uM 1.22 uM B-0122 79.0% @ 10.0 uM 2.0% @ 1.0 uM B-0123 59.0% @ 1.0 uM >1.0 uM B-0124 73.0% @ 1.0 uM 15.0% @ 1.0 uM B-0125 70.0% @ 10.0 uM 17.0% @ 1.0 uM B-0126 66.0% @ 1.0 uM 1.57 uM B-0127 82.0% @ 1.0 uM 0.96 uM B-0128 78.0% @ 1.0 uM 1.81 uM B-0129 51.0% @ 1.0 uM 31.0% @ 1.0 uM B-0130 69.0% @ 1.0 uM 58.0% @ 1.0 uM B-0131 43.0% @ 1.0 uM 46.0% @ 1.0 uM B-0132 76.0% @ 1.0 uM 8.0% @ 1.0 uM B-0133 51.0% @ 1.0 uM 42.0% @ 1.0 uM B-0134 60.0% @ 1.0 uM 2.17 uM B-0135 78.0% @ 1.0 uM 58.0% @ 1.0 uM B-0136 77.0% @ 1.0 uM 44.0% @ 1.0 uM B-0137 41.0% @ 1.0 uM 37.0% @ 1.0 uM B-0138 50.0% @ 1.0 uM 32.0% @ 1.0 uM B-0139 54.0% @ 10.0 uM 17.0% @ 1.0 uM B-0140 67% @ 10.0 uM 9.0% @ 1.0 uM B-0141 78.0% @ 1.0 uM 10.0% @ 1.0 uM B-0142 86.0% @ 1.0 uM 12.0% @ 1.0 uM B-0143 42.0% @ 1.0 uM 3.63 uM B-0144 86.0% @ 1.0 uM 43.0% @ 1.0 uM B-0145 54.0% @ 10.0 uM 12.0% @ 1.0 uM B-0146 77.0% @ 10.0 uM 28.0% @ 1.0 uM B-0147 44.0% @ 1.0 uM 22.0% @ 1.0 uM B-0148 51.0% @ 1.0 uM >1.0 uM B-0149 1.15 uM 10.0 uM B-0150 27.0% @ 10.0 uM 35.0% @ 1.0 uM B-0151 43.0% @ 1.0 uM 30.0% @ 1.0 uM B-0152 51.0% @ 1.0 uM 24.0% @ 1.0 uM B-0153 57.0% @ 1.0 uM 21.0% @ 1.0 uM B-0154 65.0% @ 10.0 uM 14.0% @ 1.0 uM B-0155 40.0% @ 10.0 uM 26.0% @ 1.0 uM B-0156 42.0% @ 10.0 uM 13.0% @ 1.0 uM B-0157 48.0% @ 10.0 uM 9.0% @ 1.0 uM B-0158 58.0% @ 10.0 uM 39.0% @ 1.0 uM B-0159 54.0% @ 10.0 uM 5.0% @ 1.0 uM B-0160 59.0% @ 10.0 uM 26.0% @ 1.0 uM B-0161 72.0% @ 10.0 uM 13.0% @ 1.0 uM B-0162 23% @ 1.0 uM 2.05 uM B-0163 20.0% @ 10.0 uM 10.0% @ 1.0 uM B-0164 37.0% @ 10.0 uM 20.0% @ 1.0 uM B-0165 70.0% @ 10.0 uM 19.0% @ 1.0 uM B-0166 45.0% @ 10.0 uM 37.0% @ 1.0 uM B-0167 40.0% @ 1.0 uM 37.0% @ 1.0 uM B-0168 44% @ 1.0 uM 2.36 uM B-0169 43.0% @ 1.0 uM 21.0% @ 1.0 uM B-0170 43.0% @ 1.0 uM 30.0% @ 1.0 uM B-0171 61.0% @ 10.0 uM 21.0% @ 1.0 uM B-0172 16.0% @ 10.0 uM 11.0% @ 1.0 uM B-0173 33.0% @ 10.0 uM 48.0% @ 1.0 uM B-0174 54.0% @ 10.0 uM 43.0% @ 1.0 uM B-0175 41.0% @ 10.0 uM 31.0% @ 1.0 uM B-0176 50.0% @ 1.0 uM 30.0% @ 1.0 uM B-0177 70.0% @ 10.0 uM 27.0% @ 1.0 uM B-0178 12.0% @ 10.0 uM 35.0% @ 1.0 uM B-0179 27.0% @ 10.0 uM 37.0% @ 1.0 uM B-0180 34.0% @ 10.0 uM 23.0% @ 1.0 uM B-0181 5.0% @ 1.0 uM 2.0% @ 1.0 uM B-0182 39.0% @ 10.0 uM 40.0% @ 1.0 uM B-0183 12.0% @ 10.0 uM 34.0% @ 1.0 uM B-0184 66.0% @ 10.0 uM 17.0% @ 1.0 uM B-0185 65.0% @ 10.0 uM 25.0% @ 1.0 uM B-0186 40.0% @ 1.0 uM 25.0% @ 1.0 uM B-0187 4.0% @ 10.0 uM 14.0% @ 1.0 uM B-0188 70.0% @ 10.0 uM 35.0% @ 1.0 uM B-0189 42.0% @ 10.0 uM 9.0% @ 1.0 uM B-0190 59.0% @ 10.0 uM 31.0% @ 1.0 uM B-0191 40.0% @ 1.0 uM 29.0% @ 1.0 uM B-0192 12.0% @ 10.0 uM 47.0% @ 1.0 uM B-0193 0.54 uM 6% @ 1.0 uM B0194 1.31 uM 22% @ 1.0 uM B-0195 1.03 uM 55% @ 1.0 uM B-0196 2.24 uM >1.0 uM B-0197 2.0 uM 14% @ 1.0 uM B-0198 1.2 uM 2% @ 1.0 uM B-0199 1.34 uM 3% @ 1.0 uM B-0200 1.31 uM 16% @ 1.0 uM B-0201 0.29 uM 59% @ 1.0 uM B-0202 0.55 uM 2.26 uM B-0203 0.16 uM 65% @ 1.0 uM B-0204 0.21 uM 48% @ 1.0 uM B-0205 0.096 uM 54% @ 1.0 uM B-0206 5.76 uM 14% @ 1.0 uM B-0207 0.12 uM 52% @ 1.0 uM B-0208 0.067 uM >1.0 uM B-0209 0.29 uM 8% @ 1.0 uM B-0210 0.057 uM 67% @ 1.0 uM B-0211 0.25 uM 30% @ 1.0 uM B-0212 0.12 uM 28% @ 1.0 uM B-0213 0.31 uM 39% @ 1.0 uM B-0214 0.16 uM 50% @ 1.0 uM B-0215 0.11 uM 51% @ 1.0 uM B-0216 0.56 uM >1.0 uM B-0217 0.55 uM >1.0 uM B-0218 0.53 uM 18% @ 1.0 uM B-0219 0.91 uM 18% @ 1.0 uM B-0220 0.13 uM 40% @ 1.0 uM B-0221 2.4 uM >1.0 uM B-0222 0.4 uM 29.0% @ 1.0 uM B-0223 0.2 uM 1.0% @ 1.0 uM B-0224 <0.1 uM 93.0% @ 1.0 uM B-0225 0.047 uM 37.0% @ 1.0 uM B-0226 0.074 uM 20.0% @ 1.0 uM B-0227 0.045 uM 1.0% @ 1.0 uM B-0228 0.15 uM 44.0% @ 1.0 uM B-0229 <0.1 uM 61.0% @ 1.0 uM B-0230 0.041 uM 30.0% @ 1.0 uM B-0231 0.055 uM 40.0% 1.0 uM B-0232 0.048 uM 24.0% @ 1.0 uM B-0233 0.095 uM 43.0% @ 1.0 uM B-0234 0.11 uM 68.0% @ 1.0 uM B-0235 1.31 uM 90.0% @ 1.0 uM B-0236 0.077 uM 46.0% @ 1.0 uM B-0237 0.13 uM 60.0% @ 1.0 uM B-0238 0.47 uM 82.0% @ 1.0 uM B-0239 5.73 uM 84.0% @ 1.0 uM B-0240 0.2 uM 70.0% @ 1.0 uM B-0241 0.1 uM 45.0% @ 1.0 uM B-0242 <0.1 uM 78.0% @ 1.0 uM B-0243 0.039 uM 53.0% @ 1.0 uM B-0244 0.02 uM 57.0% @ 1.0 uM B-0245 0.13 uM 24.0% @ 1.0 uM B-0246 <0.1 uM >1.0 uM B-0247 0.082 uM 75.0% @ 1.0 uM B-0248 <0.1 uM 11.0% @ 1.0 uM B-0249 <0.1 uM 75.0% @ 1.0 uM B-0250 0.28 uM 36.0% @ 1.0 uM B-0251 0.31 uM 1.0% @ 1.0 uM B-0252 0.041 uM 54.0% @ 1.0 uM B-0253 0.061 uM 74.0% @ 1.0 uM B-0254 0.12 uM 59.0% @ 1.0 uM B-0255 0.32 uM 68.0% @ 1.0 uM B-0256 <0.1 uM 88.0% @ 1.0 uM B-0257 1.71 uM 11.0% @ 1.0 uM B-0258 0.37 uM 63.0% @ 1.0 uM B-0259 0.35 uM 58.0% @ 1.0 uM B-0260 0.56 uM 23.0% @ 1.0 uM B-0261 0.49 uM 23.0% @ 1.0 uM B-0262 0.41 uM 89.0% @ 1.0 uM B-0263 0.62 uM 64.0% @ 1.0 uM B-0264 0.14 uM 18.0% @ 1.0 uM B-0265 0.92 uM 24.0% @ 1.0 uM B-0266 0.25 uM 24.0% @ 1.0 uM B-0267 0.48 uM 11.0% @ 1.0 uM B-0268 3.39 uM 19.0% @ 1.0 uM B-0269 9.81 uM 19.0% @ 1.0 uM B-0270 5.79 uM 13.0% @ 1.0 uM B-0271 7.55 uM 12.0% @ 1.0 uM B-0272 1.81 uM 48.0% @ 1.0 uM B-0273 5.03 uM 13.0% @ 1.0 uM B-0274 2.68 uM 25.0% @ 1.0 uM B-0275 2.67 uM 33.0% @ 1.0 uM B-0276 1.25 uM 26.0% @ 1.0 uM B-0277 0.68 uM 34.0% @ 1.0 uM B-0278 1.26 uM 36.0% @ 1.0 uM B-0279 1.39 uM 33.0% @ 1.0 uM B-0280 0.86 uM 18.0% @ 1.0 uM B-0281 7.37 uM 24.0% @ 1.0 uM B-0282 0.75 uM 38.0% @ 1.0 uM B-0283 6.66 uM 29.0% @ 1.0 uM B-0284 0.083 uM 65.0% @ 1.0 uM B-0285 4.57 uM 29.0% @ 1.0 uM B-0286 0.33 uM 50.0% @ 1.0 uM B-0287 4.0 uM 22.0% @ 1.0 uM B-0288 4.46 uM 26.0% @ 1.0 uM B-0289 0.15 uM 55.0% @ 1.0 uM B-0290 0.66 uM 44.0% @ 1.0 uM B-0291 1.33 uM 20.0% @ 1.0 uM B-0292 0.22 uM 28.0% @ 1.0 uM B-0293 0.66 uM 53.0% @ 1.0 uM B-0294 0.68 uM 45.0% @ 1.0 uM B-0295 0.82 uM 45.0% @ 1.0 uM B-0296 8.03 uM 36.0% @ 1.0 uM B-0297 0.78 uM 30.0% @ 1.0 uM B-0298 0.58 uM 48.0% @ 1.0 uM B-0299 0.87 uM 54.0% @ 1.0 uM B-0300 0.78 uM 32.0% @ 1.0 uM B-0301 0.19 uM 50.0% @ 1.0 uM B-0302 4.02 uM 24.0% @ 1.0 uM B-0303 0.22 uM 10.0% @ 1.0 uM B-0304 0.55 uM 28.0% @ 1.0 uM B-0305 B-0306 B-0307 B-0308 B-0309 B-0310 B-0311 B-0312 B-0313 B-0314 B-0315 B-0316 B-0317 B-0318 B-0319 B-0320 B-0321 B-0322 B-0323 B-0324 B-0325 B-0326 B-0327 B-0328 B-0329 B-0330 B-0331 B-0332 B-0333 B-0334 B-0335 B-0336 B-0337 B-0338 B-0339 B-0340 B-0341 B-0342 B-0343 B-0344 B-0345 B-0346 B-0347 B-0348 B-0349 B-0350 B-0351 B-0352 B-0353 1.37 uM 55% @ 1.0 uM B-0354 1.0 uM 0.66 uM 51% @ 30 mpk @ −6 h 54% @ 3 mpk @ −4 h B-0355 0.75 uM 40.0% @ 1.0 uM B-0356 0.66 uM 24.0% @ 1.0 uM B-0357 1.46 uM 0.66 uM B-0358 0.37 uM 17.0% @ 1.0 uM B-0359 0.45 uM 47.0% @ 1.0 uM B-0360 1.6 uM 19.0% @ 1.0 uM B-0361 0.33 uM 46.0% @ 1.0 uM B-0362 0.52 uM 27.0% @ 1.0 uM B-0363 4.67 uM 25.0% @ 1.0 uM B-0364 1.44 uM 27.0% @ 1.0 uM B-0365 0.96 uM 27.0% @ 1.0 uM B-0366 0.7 uM 46.0% @ 1.0 uM B-0367 1.0 uM 23.0% @ 1.0 uM B-0368 1.0 uM 0.64 uM 37% @ 30 mpk @ −6 h B-0369 0.16 uM 57.0% @ 1.0 uM B-0370 0.65 uM 28.0% @ 1.0 uM B-0371 0.49 uM 28.0% @ 1.0 uM B-0372 0.35 uM 29.0% @ 1.0 uM B-0373 0.45 uM 18.0% @ 1.0 uM B-0374 1.38 uM 12.0% @ 1.0 uM B-0375 1.0 uM 19.0% @ 1.0 uM B-0376 2.99 uM 12.0% @ 1.0 uM B-0377 1.29 uM 36.0% @ 1.0 uM B-0378 1.1 uM 36.0% @ 1.0 uM B-0379 0.53 uM 24.0% @ 1.0 uM B-0380 1.41 uM 32.0% @ 1.0 uM B-0381 0.22 uM 47.0% @ 1.0 uM B-0382 0.41 uM 32.0% @ 1.0 uM B-0383 1.43 uM 10.0% @ 1.0 uM B-0384 4.02 uM 16.0% @ 1.0 uM B-0385 0.057 uM 0.9 uM 30% @ 30 mpk @ −6 h 0% @ 3 mpk @ −4 h B-0386 0.13 uM 54.0% @ 1.0 uM B-0387 0.41 uM 52.0% @ 1.0 uM B-0388 <0.1 uM 36.0% @ 1.0 uM B-0389 0.01 uM 0.05 uM 62% @ 3 mpk @ −4 h B-0390 0.089 uM 55.0% @ 1.0 uM B-0391 0.86 uM 18.0% @ 1.0 uM B-0392 0.13 uM 57.0% @ 1.0 uM B-0393 0.043 uM 66.0% @ 1.0 uM B-0394 0.13 uM 45.0% @ 1.0 uM B-0395 0.087 uM 48.0% @ 1.0 uM B-0396 0.097 uM 0.44 uM B-0397 0.17 uM 41.0% @ 1.0 uM B-0398 0.054 uM 66.0% @ 1.0 uM B-0399 0.14 uM 39.0% @ 1.0 uM B-0400 0.16 uM 25.0% @ 1.0 uM B-0401 0.46 uM 52.0% @ 1.0 uM B-0402 0.14 uM 1.51 uM B-0403 1.77 uM 2.42 uM B-0404 0.31 uM 48.0% @ 1.0 uM B-0405 0.79 uM 30.0% @ 1.0 uM B-0406 0.54 uM 35.0% @ 1.0 uM B-0407 0.76 uM 27.0% @ 1.0 uM B-0408 0.5 uM 50.0% @ 1.0 uM B-0409 0.53 uM 30.0% @ 1.0 uM B-0410 0.38 uM 44.0% @ 1.0 uM B-0411 0.62 uM 50.0% @ 1.0 uM B-0412 0.24 uM 48.0% @ 1.0 uM B-0413 0.18 uM 55.0% @ 1.0 uM B-0414 2.54 uM 25.0% @ 1.0 uM B-0415 0.42 uM 43.0% @ 1.0 uM B-0416 0.32 uM 34.0% @ 1.0 uM B-0417 0.91 uM 28.0% @ 1.0 uM B-0418 0.22 uM 27.0% @ 1.0 uM B-0419 0.85 uM 41.0% 2 1.0 uM B-0420 0.83 uM 49.0% @ 1.0 uM B-0421 0.46 uM 57.0% @ 1.0 uM B-0422 <0.1 uM 40.0% @ 1.0 uM B-0423 0.18 uM 33.0% @ 1.0 uM B-0424 0.083 uM 32.0% @ 1.0 uM B-0425 0.26 uM 54.0% @ 1.0 uM B-0426 0.055 uM 0.74 uM 41% @ 3 mpk @ −4 h B-0427 0.63 uM 39.0% @ 1.0 uM B-0428 0.99 uM 27.0% @ 1.0 uM B-0429 0.27 uM 45.0% @ 1.0 uM B-0430 0.29 uM 75.0% @ 1.0 uM B-0431 0.21 uM 64.0% @ 1.0 uM B-0432 <0.1 uM 89.0% @ 1.0 uM B-0433 <0.1 uM 92.0% @ 1.0 uM B-0434 0.12 uM 65.0% @ 1.0 uM B-0435 0.3 uM 61.0% @ 1.0 uM B-0436 1.11 uM 71.0% @ 1.0 uM B-0437 0.58 uM 59.0% @ 1.0 uM B-0438 <0.1 uM 91.0% @ 1.0 uM B-0439 2.12 uM 65.0% @ 1.0 uM B-0440 0.66 uM 63.0% @ 1.0 uM B-0441 0.8 uM 58.0% @ 1.0 uM B-0442 <0.1 uM 91.0% @ 1.0 uM B-0443 2.01 uM 71.0% @ 1.0 uM B-0444 1.01 uM 51.0% @ 1.0 uM B-0445 <0.1 uM 83.0% @ 1.0 uM B-0446 0.78 uM 80.0% @ 1.0 uM B-0447 0.19 uM 71.0% @ 1.0 uM B-0448 0.4 uM 79.0% @ 1.0 uM B-0449 0.83 uM 81.0% @ 1.0 uM B-0450 0.26 uM 81.0% @ 1.0 uM B-0451 0.071 uM 83.0% @ 1.0 uM 42% @ 30 mpk @ −5 h B-0452 0.7 uM 75.0% @ 1.0 uM B-0453 0.47 uM 75.0% @ 1.0 uM B-0454 0.11 uM 80.0% @ 1.0 uM B-0455 <0.1 uM 95.0% @ 1.0 uM 36% @ 3 mpk % −4 h B-0456 1.31 uM 67.0% @ 1.0 uM B-0457 0.089 uM 81.0% @ 1.0 uM B-0458 0.033 uM 70.0% @ 1.0 uM B-0459 0.099 uM 76.0% @ 1.0 uM B-0460 0.061 uM 92.0% @ 1.0 uM B-0461 0.025 uM 96.0% @ 1.0 uM B-0462 <0.1 uM 97.0% @ 1.0 uM B-0463 0.052 uM 95.0% @ 1.0 uM B-0464 <0.1 uM 91.0% @ 1.0 uM B-0465 0.084 uM 98.0% @ 1.0 uM B-0466 <0.1 uM 98.0% @ 1.0 uM 0% @ 3 mpk @ −4 h B-0467 <0.1 uM 77.0% @ 1.0 uM B-0468 0.031 uM 93.0% @ 1.0 uM B-0469 0.056 uM 92.0% @ 1.0 uM B-0470 0.063 uM 92.0% @ 1.0 uM B-0471 0.027 uM 97.0% @ 1.0 uM B-0472 0.19 uM 54.0% @ 1.0 uM B-0473 0.004 uM 95.0% @ 1.0 uM B-0474 0.024 uM 86.0% @ 1.0 uM B-0475 0.21 uM 74.0% @ 1.0 uM B-0476 0.56 uM 69.0% @ 1.0 uM B-0477 1.48 uM 96.0% @ 1.0 uM B-0478 0.034 uM 87.0% @ 1.0 uM B-0479 0.031 uM 90.0% @ 1.0 uM 15% @ 3 mpk @ −4 h B-0480 0.12 uM 88.0% @ 1.0 uM B-0481 0.014 uM 95.0% @ 1.0 uM 56% @ 3 mpk @ −4 h B-0482 0.97 uM 68.0% @ 1.0 uM B-0483 0.57 uM 68.0% @ 1.0 uM B-0484 0.28 uM 62.0% @ 1.0 uM B-0485 0.04 uM 95.0% @ 1.0 uM B-0486 0.24 uM 80.0% @ 1.0 uM B-0487 0.11 uM 89.0% @ 1.0 uM 54% @ 3 mpk @ −4 h B-0488 0.62 uM 88.0% @ 1.0 uM B-0489 0.3 uM 80.0% @ 1.0 uM B-0490 0.91 uM 74.0% @ 1.0 uM B-0491 0.43 uM 66.0% @ 1.0 uM B-0492 0.069 uM 42.0% @ 1.0 uM B-0493 0.3 uM 36.0% @ 1.0 uM B-0494 0.13 uM 30.0% @ 1.0 uM B-0495 0.12 uM 25.0% @ 1.0 uM B-0496 0.83 uM 16.0% @ 1.0 uM B-0497 0.44 uM 31.0% @ 1.0 uM B-0498 0.33 uM 11.0% @ 1.0 uM B-0499 0.39 uM 37.0% @ 1.0 uM B-0500 0.26 uM 41.0% @ 1.0 uM B-0501 0.049 uM 52.0% @ 1.0 uM B-0502 0.065 uM 48.0% @ 1.0 uM B-0503 0.16 uM 73.0% @ 1.0 uM B-0504 0.4 uM 43.0% @ 1.0 uM B-0505 0.28 uM 44.0% @ 1.0 uM B-0506 0.94 uM 43.0% @ 1.0 uM B-0507 0.18 uM 75.0% @ 1.0 uM B-0508 2.0 uM 48.0% @ 1.0 uM B-0509 0.1 uM 86.0% @ 1.0 uM B-0510 0.69 uM 61.0% @ 1.0 uM B-0511 0.007 uM 90.0% @ 1.0 uM B-0512 1.0 uM 53.0% @ 1.0 uM B-0513 0.72 uM 52.0% @ 1.0 uM B-0514 0.14 uM 87.0% @ 1.0 uM B-0515 0.42 uM 61.0% @ 1.0 uM B-0516 0.37 uM 84.0% @ 1.0 uM B-0517 0.094 uM 52.0% @ 1.0 uM B-0518 0.11 uM 64.0% @ 1.0 uM B-0519 0.043 uM 87.0% @ 1.0 uM B-0520 0.4 uM 67.0% @ 1.0 uM B-0521 1.37 uM 52.0% @ 1.0 uM B-0522 0.15 uM 75.0% @ 1.0 uM B-0523 0.19 uM 83.0% @ 1.0 uM B-0524 0.4 uM 77.0% @ 1.0 uM B-0525 0.16 uM 76.0% @ 1.0 uM B-0526 0.031 uM 87.0% @ 1.0 uM B-0527 1.09 uM 63.0% @ 1.0 uM B-0528 0.14 uM 70.0% @ 1.0 uM B-0529 0.11 uM 73.0% @ 1.0 uM B-0530 5.53 uM 45.0% @ 1.0 uM B-0531 0.5 uM 48.0% @ 1.0 uM B-0532 0.45 uM 1.01 uM 41% @ 30 mpk @ −6 h B-0533 1.23 uM 47.0% @ 1.0 uM B-0534 0.41 uM 54.0% @ 1.0 uM B-0535 0.44 uM 0.87 uM B-0536 0.46 uM 0.15 uM B-0537 3.44 uM 51.0% @ 1.0 uM B-0538 1.13 uM 45.0% @ 1.0 uM B-0539 2.84 uM 21.0% @ 1.0 uM B-0540 3.62 uM 54.0% @ 1.0 uM B-0541 3.24 uM 28.0% @ 1.0 uM B-0542 1.55 uM 50.0% @ 1.0 uM B-0543 1.56 uM 43.0% @ 1.0 uM B-0544 1.12 uM 27.0% @ 1.0 uM B-0545 1.06 uM 41.0% @ 1.0 uM B-0546 1.04 uM 18.0% @ 1.0 uM B-0547 1.24 uM 21.0% @ 1.0 uM B-0548 1.77 uM 28.0% @ 1.0 uM B-0549 2.22 uM 22.0% @ 1.0 uM B-0550 2.41 uM 14.0% @ 1.0 uM B-0551 1.08 uM 56.0% @ 1.0 uM B-0552 0.13 uM 46.0% @ 1.0 uM B-0553 1.44 uM 47.0% @ 1.0 uM B-0554 2.58 uM 20.0% @ 1.0 uM B-0555 1.87 uM 34.0% @ 1.0 uM B-0556 0.49 uM 39.0% @ 1.0 uM B-0557 1.37 uM 32.0% @ 1.0 uM B-0558 0.85 uM 33.0% @ 1.0 uM B-0559 0.53 uM 49.0% @ 1.0 uM B-0560 2.57 uM 31.0% @ 1.0 uM B-0561 2.07 uM 40.0% @ 1.0 uM B-0562 0.22 uM 0.3 uM 5% @ 3 mpk @ −4 h B-0563 0.18 uM 0.13 uM B-0564 0.82 uM 58% @ 1.0 uM B-0565 0.23 uM 0.59 uM B-0566 <0.1 uM 0.17 uM 0% @ 3 mpk @ −4 h B-0567 0.14 uM 0.28 uM B-0568 1.22 uM 46.0% @ 1.0 uM B-0569 0.15 uM 0.26 uM B-0570 0.27 uM 46.0% @ 1.0 uM B-0571 0.38 uM 44.0% @ 1.0 uM B-0572 0.27 uM 41.0% @ 1.0 uM B-0573 0.36 uM 1.7 uM B-0574 0.13 uM 0.66 uM 37% @ 3 mpk @ −4 h B-0575 0.032 uM 0.17 uM B-0576 0.068 uM 0.39 uM 65% @ 3 mpk @ −4 h B-0577 0.091 uM 66.0% @ 1.0 uM B-0578 1.88 uM 47.0% @ 1.0 uM B-0579 0.11 uM 79.0% @ 1.0 uM B-0580 2.23 uM 0.84 uM B-0581 0.26 uM 2.17 uM B-0582 1.03 uM 37.0% @ 1.0 uM B-0583 3.93 uM 26.0% @ 1.0 uM B-0584 0.66 uM 54.0% @ 1.0 uM B-0585 0.83 uM 79.0% @ 1.0 uM 50% @ 30 mpk @ −6 h B-0586 0.81 uM 51.0% @ 1.0 uM B-0587 6.84 uM 38% @ 1.0 uM B-0588 12.8 uM 42% @ 1.0 uM B-0589 1.71 uM 42% @ 1.0 uM B-0590 1.57 uM 38.0 uM B-0591 3.59 uM 29.0% @ 1.0 uM B-0592 1.62 uM 45.0% @ 1.0 uM B-0593 1.22 uM 36.0% @ 1.0 uM B-0594 — 41.0% @ 1.0 uM B-0595 2.42 uM 22.0% @ 1.0 uM B-0596 20.0 uM 41.0% @ 1.0 uM B-0597 1.68 uM 63.0% @ 1.0 uM B-0598 2.12 uM 50.0% @ 1.0 uM B-0599 4.16 uM 21.0% @ 1.0 uM B-0600 0.002 uM 28.0% @ 1.0 uM B-0601 0.089 uM 1.31 uM 43% @ 3 mpk % −4 h B-0602 0.97 uM 61.0% @ 1.0 uM B-0603 0.09 uM 51.0% @ 1.0 uM B-0604 0.3 uM 20.0% @ 1.0 uM B-0605 0.18 uM 47.0% @ 1.0 uM B-0606 0.17 uM 53.0% @ 1.0 uM B-0607 2.79 uM 70.0% @ 1.0 uM B-0608 0.059 uM 73.0% @ 1.0 uM B-0609 <0.1 uM 87.0% @ 1.0 uM B-0610 <0.1 uM 88.0% @ 1.0 uM B-0611 0.65 uM 60.0% @ 1.0 uM B-0612 0.16 uM 60.0% @ 1.0 uM B-0613 0.17 uM 76.0% @ 1.0 uM B-0614 0.76 uM 70.0% @ 1.0 uM 0% @ 3 mpk @ −4 h B-0615 0.08 uM 83.0% @ 1.0 uM B-0616 0.38 uM 87.0% @ 1.0 uM B-0617 0.045 uM 92.0% @ 1.0 uM B-0618 0.37 uM 80.0% @ 1.0 uM B-0619 <0.1 uM 88.0% @ 1.0 uM B-0620 1.59 uM 58.0% @ 1.0 uM B-0621 0.36 uM 68.0% @ 1.0 uM B-0622 0.076 uM 78.0% @ 1.0 uM B-0623 0.12 uM 76.0% @ 1.0 uM B-0624 0.085 uM 54.0% @ 1.0 uM B-0625 0.023 uM 88.0% @ 1.0 uM B-0626 <0.1 uM 85.0% @ 1.0 uM B-0627 0.25 uM 69.0% @ 1.0 uM B-0628 0.023 uM 72.0% @ 1.0 uM B-0629 0.2 uM 79.0% @ 1.0 uM B-0630 0.06 uM 77.0% @ 1.0 uM B-0631 0.065 uM 81.0% @ 1.0 uM B-0632 <0.1 uM 79.0% @ 1.0 uM B-0633 0.6 uM 80.0% @ 1.0 uM B-0634 0.6 uM 40.0% @ 1.0 uM B-0635 0.15 uM 55.0% @ 1.0 uM B-0636 <0.1 uM 86.0% @ 1.0 uM B-0637 0.11 uM 92.0% @ 1.0 uM B-0638 0.25 uM 89.0% @ 1.0 uM B-0639 0.051 uM 93.0% @ 1.0 uM 50% @ 3 mpk @ −4 h B-0640 0.36 uM 94.0% @ 1.0 uM B-0641 0.58 uM 65.0% @ 1.0 uM B-0642 0.49 uM 90.0% @ 1.0 uM B-0643 0.069 uM 85.0% @ 1.0 uM 0% @ 3 mpk @ −4 h B-0644 0.058 uM 89.0% @ 1.0 uM B-0645 0.58 uM 80.0% @ 1.0 uM B-0646 0.26 uM 94.0% @ 1.0 uM B-0647 1.61 uM 76.0% @ 1.0 uM B-0648 <0.1 uM 83.0% @ 1.0 uM B-0649 0.83 uM 39.0% @ 1.0 uM B-0650 0.006 uM 95.0% @ 1.0 uM 8% @ 3 mpk @ −4 h B-0651 1.78 uM 81.0% @ 1.0 uM B-0652 0.19 uM 83.0% @ 1.0 uM B-0653 2.01 uM 74.0% @ 1.0 uM B-0654 5.97 uM 78.0% @ 1.0 uM B-0655 1.25 uM 76.0% @ 1.0 uM B-0656 0.007 uM 95.0% @ 1.0 uM 28% @ 3 mpk @ −4 h B-0657 0.17 uM 83.0% @ 1.0 uM B-0658 1.14 uM 91.0% @ 1.0 uM B-0659 2.64 uM 87.0% @ 1.0 uM B-0660 0.088 uM 92.0% @ 1.0 uM B-0661 <0.1 uM 90.0% @ 1.0 uM B-0662 <0.1 uM 95.0% @ 1.0 uM B-0663 0.88 uM 74.0% @ 1.0 uM B-0664 0.39 uM 80.0% @ 1.0 uM B-0665 0.47 uM 72.0% @ 1.0 uM B-0666 0.17 uM 73.0% @ 1.0 uM B-0667 0.83 uM 75.0% @ 1.0 uM B-0668 0.27 uM 78.0% @ 1.0 uM B-0669 0.89 uM 34.0% @ 1.0 uM B-0670 3.15 uM 32.0% @ 1.0 uM B-0671 6.38 uM 36.0% @ 1.0 uM B-0672 6.59 uM 32.0% @ 1.0 uM B-0673 8.54 uM 48.0% @ 1.0 uM B-0674 2.81 uM 42.0% @ 1.0 uM B-0675 5.42 uM 3.0% @ 1.0 uM B-0676 2.09 uM 22.0% @ 1.0 uM B-0677 1.63 uM 25.0% @ 1.0 uM B-0678 0.38 uM 52.0% @ 1.0 uM B-0679 0.062 uM 45.0% @ 1.0 uM B-0680 0.42 uM 67.0% @ 1.0 uM B-0681 1.96 uM 17.0% @ 1.0 uM B-0682 0.76 uM 39.0% @ 1.0 uM B-0683 13.0 uM 32.0% @ 1.0 uM B-0684 0.54 uM 68.0% @ 1.0 uM B-0685 15.4 uM 33.0% @ 1.0 uM B-0686 0.42 uM 59.0% @ 1.0 uM B-0687 10.1 uM 15.0% @ 1.0 uM B-0688 0.66 uM 58.0% @ 1.0 uM B-0689 14.6 uM 27.0% @ 1.0 uM B-0690 27.1 uM 36.0% @ 1.0 uM B-0691 0.16 uM 48.0% @ 1.0 uM B-0692 0.38 uM 29.0% @ 1.0 uM B-0693 0.39 uM 28.0% @ 1.0 uM B-0694 0.62 uM 21.0% @ 1.0 uM B-0695 0.23 uM 32.0% @ 1.0 uM B-0696 0.085 uM 35.0% @ 1.0 uM B-0697 0.45 uM 44.0% @ 1.0 uM B-0698 2.33 uM 43.0% @ 1.0 uM B-0699 0.34 uM 31.0% @ 1.0 uM B-0700 0.24 uM 56.0% @ 1.0 uM B-0701 0.39 uM 45.0% @ 1.0 uM B-0702 0.036 uM 39.0% @ 1.0 uM B-0703 0.12 uM 39.0% @ 1.0 uM B-0704 2.19 uM 29.0% @ 1.0 uM B-0705 0.44 uM 21.0% @ 1.0 uM B-0706 0.44 uM 32.0% @ 1.0 uM B-0707 1.7 uM B-0708 2.1 uM B-0709 0.84 uM B-0710 1.99 uM B-0711 1.99 uM B-0712 2.9 uM B-0713 4.3 uM B-0714 3.7 uM B-0715 3.2 uM B-0716 4.6 uM B-0717 4.3 uM B-0718 1.4 uM B-0719 3.4 uM B-0720 1.3 uM B-0721 3.8 uM B-0722 0.07 uM >1.0 uM B-0723 0.47 uM B-0724 0.06 uM 17.0% @ 1.0 uM B-0725 9.7 uM B-0726 1.4 uM B-0727 0.51 uM B-0728 20.0 uM B-0729 0.87 uM B-0730 0.25 uM 11.0% @ 1.0 uM B-0731 0.87 uM >1.0 uM B-0732 14.0 uM B-0733 32.0 uM B-0734 0.92 uM B-0735 1.0 uM B-0736 26.0 uM B-0737 2.6 uM B-0738 2.7 uM B-0739 4.1 uM B-0740 4.4 uM B-0741 26.0 uM B-0742 2.2 uM B-0743 1.2 uM B-0744 23.0 uM B-0745 6.0 uM B-0746 0.01 uM 22.0% @ 1.0 uM B-0747 1.1 uM B-0748 1.2 uM B-0749 4.4 uM B-0750 0.92 uM B-0751 1.6 uM B-0752 0.33 uM B-0753 0.37 uM B-0754 0.55 uM B-0755 2.3 uM B-0756 0.94 uM B-0757 0.54 uM 16.0% @ 1.0 uM B-0758 1.5 uM B-0759 0.3 uM B-0760 0.01 uM 13.0% @ 1.0 uM B-0761 <0.1 uM B-0762 0.13 uM 5.0% @ 1.0 uM B-0763 0.015 uM 17.0% @ 1.0 uM B-0764 0.67 uM 26.0% @ 1.0 uM B-0765 0.3 uM 29.0% @ 1.0 uM B-0766 0.95 uM B-0767 0.08 uM B-0768 1.4 uM B-0769 12.7 uM B-0770 2.3 uM B-0771 0.5 uM B-0772 0.8 uM B-0773 14.0 uM B-0774 1.5 uM B-0775 0.6 uM >1.0 uM B-0776 0.9 uM >1.0 uM B-0777 21.0 uM B-0778 51.0 uM B-0779 0.5 uM B-0780 1.1 uM B-0781 48.0 uM B-0782 22.0 uM B-0783 8.0 uM B-0784 7.0 uM B-0785 23.0 uM B-0786 24.0 uM B-0787 1.5 uM B-0788 1.2 uM B-0789 33.0 uM B-0790 1.0 uM 4.0% @ 1.0 uM B-0791 0.3 uM >1.0 uM B-0792 1.1 uM B-0793 0.3 uM B-0794 2.9 uM 2.0% @ 1.0 uM B-0795 1.9 uM 11.0% @ 1.0 uM B-0796 1.4 uM B-0797 1.04 uM — B-0798 1.73 uM — B-0799 — >1.0 uM B-0800 1.01 uM >1.0 uM B-0801 0.67 uM >1.0 uM B-0802 — >1.0 uM B-0803 0.057 uM 53.0% @ 1.0 uM B-0804 0.3 uM 32.0% @ 1.0 uM B-0805 0.71 uM >1.0 uM B-0806 3.28 uM >1.0 uM B-0807 10.8 uM — B-0808 3.09 uM >1.0 uM B-0809 1.22 uM 7.0% @ 1.0 uM B-0810 1.11 uM >1.0 uM B-0811 2.79 uM 2.0% @ 1.0 uM B-0812 2.12 uM >1.0 uM B-0813 3.02 uM >1.0 uM B-0814 — >1.0 uM B-0815 2.11 uM >1.0 uM B-0816 3.46 uM >1.0 uM B-0817 3.07 uM 33.0% @ 1.0 uM B-0818 4.97 uM >1.0 uM B-0819 1.08 uM >1.0 uM B-0820 1.64 uM 3.0% @ 1.0 uM B-0821 1.44 uM — B-0822 1.33 uM — B-0823 2.39 uM >1.0 uM B-0824 3.41 uM — B-0825 — — B-0826 1.74 uM — B-0827 15.6 uM — B-0828 7.9 uM — B-0829 0.61 uM 65.0% @ 1.0 uM B-0830 0.54 uM 34.0% @ 1.0 uM B-0831 0.9 uM >1.0 uM B-0832 1.49 uM — B-0833 0.95 uM 23.0% @ 1.0 uM B-0834 1.25 uM — B-0835 — — B-0836 1.24 uM — B-0837 1.96 uM >1.0 uM B-0838 3.1 uM — B-0839 4.3 uM — B-0840 0.63 uM 47.0% @ 1.0 uM B-0841 0.32 uM 36.0% @ 1.0 uM B-0842 0.74 uM 63.0% @ 1.0 uM B-0843 0.61 uM >1.0 uM B-0844 0.4 uM 25.0% @ 1.0 uM B-0845 1.78 uM — B-0846 1.8 uM — B-0847 0.73 uM 21.0% @ 1.0 uM B-0848 1.56 uM — B-0849 1.25 uM — B-0850 1.81 uM — B-0851 0.91 uM 39.0% @ 1.0 uM B-0852 1.02 uM — B-0853 — 38.0% @ 1.0 uM B-0854 — 25.0% @ 1.0 uM B-0855 — 8.0% @ 1.0 uM B-0856 — 38.0% @ 1.0 uM B-0857 6.25 uM — B-0858 2.1 uM 48.0% @ 1.0 uM B-0859 39.5 uM — B-0860 38.1 uM — B-0861 1.32 uM 12.0% @ 1.0 uM B-0862 2.15 uM 4.0% @ 1.0 uM B-0863 0.81 uM 25.0% @ 1.0 uM B-0864 0.39 uM 40.% @ 1.0 uM B-0865 0.66 uM 46.0% @ 1.0 uM B-0866 1.38 uM 28.0% @ 1.0 uM B-0867 0.62 uM >1.0 uM B-0868 3.28 uM 8.0% @ 1.0 uM B-0869 4.19 uM >1.0 uM B-0870 3.13 uM >1.0 uM B-0871 1.9 uM >1.0 uM B-0872 3.13 uM 3.0% @ 1.0 uM B-0873 6.92 uM >1.0 uM B-0874 1.92 uM >1.0 uM B-0875 2.13 uM 8% @ 1.0 uM B-0876 0.89 uM >1.0 uM B-0877 1.17 uM 13.0% @ 1.0 uM B-0878 0.65 uM 19.0% @ 1.0 uM B-0879 0.87 uM 1.0% @ 1.0 uM B-0880 0.15 uM 40.0% @ 1.0 uM B-0881 1.36 uM >1.0 uM B-0882 1.48 uM 9% @ 1.0 uM B-0883 1.06 uM >1.0 uM B-0884 1.89 uM — B-0885 B-0886 B-0887 B-0888 B-0889 B-0890 B-0891 B-0892 B-0893 B-0894 B-0895 B-0896 B-0897 B-0898 B-0899 B-0900 B-0901 B-0902 B-0903 B-0904 B-0905 B-0906 B-0907 B-0908 B-0909 B-0910 B-0911 B-0912 B-0913 B-0914 B-0915 B-0916 B-0917 B-0918 B-0919 B-0920 B-0921 B-0922 B-0923 B-0924 B-0925 B-0926 B-0927 B-0928 B-0929 B-0930 B-0931 B-0932 B-0933 47.0% @ 1.0 uM 37.0% @ 1.0 uM B-0934 67.0% @ 1.0 uM 36.0% @ 1.0 uM B-0935 69.0% @ 1.0 uM 54.0% @ 1.0 uM B-0936 69.0% @ 1.0 uM >1.0 uM B-0937 64.0% @ 1.0 uM 1.74 uM B-0938 51.0% @ 1.0 uM 29.0% @ 1.0 uM B-0939 78.0% @ 1.0 uM 14.0% @ 1.0 uM B-0940 56.0% @ 1.0 uM 22.0% @ 1.0 uM B-0941 81.0% @ 1.0 uM 25.0% @ 1.0 uM B-0942 82.0% @ 1.0 uM 2.0% @ 1.0 uM B-0943 63.0% @ 10.0 uM 24.0% @ 1.0 uM B-0944 45.0% @ 1.0 uM 27.0% @ 1.0 uM B-0945 96.0% @ 1.0 uM 0.93 uM B-0946 76.0% @ 1.0 uM 31.0% @ 1.0 uM B-0947 69.0% @ 1.0 uM 34.0% @ 1.0 uM B-0948 68.0% @ 1.0 uM 1.81 uM B-0949 90.0% @ 1.0 uM 17.0% @ 1.0 uM B-0950 81.0% @ 1.0 uM 0.58 uM B-0951 82.0% @ 1.0 uM 20.0% @ 1.0 uM B-0952 44.0% @ 1.0 uM 21.0% @ 1.0 uM B-0953 63.0% @ 1.0 uM 25.0% @ 1.0 uM B-0954 62.0% @ 1.0 uM 0.52 uM B-0955 49.0% @ 1.0 uM 0.54 uM B-0956 56.0% @ 1.0 uM 1.33 uM B-0957 79.0% @ 1.0 uM 22.0% @ 1.0 uM B-0958 74.0% @ 1.0 uM 0.38 uM B-0959 83.0% @ 1.0 uM 39.0% @ 1.0 uM B-0960 48.0% @ 1.0 uM 4.0% @ 1.0 uM B-0961 79.0% @ 1.0 uM 23.0% @ 1.0 uM B-0962 85.0% @ 1.0 uM 2.71 uM B-0963 76.0% @ 1.0 uM 39.0% @ 1.0 uM B-0964 94.0% @ 1.0 uM 5.0 uM B-0965 74.0% @ 1.0 uM 1.1 uM B-0966 50.0% @ 1.0 uM 5.0% @ 1.0 uM B-0967 80.0% @ 1.0 uM 29.0% @ 1.0 uM B-0968 35.0% @ 1.0 uM 26.0% @ 1.0 uM B-0969 63.0% @ 1.0 uM 35.0% @ 1.0 uM B-0970 76.0% @ 10.0 uM 0.88 uM B-0971 61.0% @ 1.0 uM 39.0% @ 1.0 uM B-0972 85.0% @ 1.0 uM 2.0% @ 1.0 uM B-0973 66.0% @ 10.0 uM 48.0% @ 1.0 uM B-0974 57.0% @ 1.0 uM 47.0% @ 1.0 uM B-0975 82.0% @ 1.0 uM 32.0% @ 1.0 uM B-0976 79.0% @ 1.0 uM 36.0% @ 1.0 uM B-0977 60.0% @ 1.0 uM 26.0% @ 1.0 uM B-0978 59.0% @ 1.0 uM 36.0% @ 1.0 uM B-0979 56.0% @ 10.0 uM 23.0% @ 1.0 uM B-0980 68.0% @ 1.0 uM 31.0% @ 1.0 uM B-0981 62.0% @ 1.0 uM 57.0% @ 1.0 uM B-0982 65.0% @ 1.0 uM 23.0% @ 1.0 uM B-0983 75.0% @ 1.0 uM 0.8 uM B-0984 60.0% @ 1.0 uM 51.0% @ 1.0 uM B-0985 86.0% @ 1.0 uM 0.75 uM B-0986 70.0% @ 1.0 uM 71.0% @ 1.0 uM B-0987 78.0% @ 1.0 uM 79.0% @ 1.0 uM B-0988 72.0% @ 1.0 uM 65.0% @ 1.0 uM B-0989 85.0% @ 1.0 uM 0.85 uM B-0990 — 26.0% @ 1.0 uM B-0991 58.0% @ 1.0 uM 33.0% @ 1.0 uM B-0992 77.0% @ 1.0 uM 45.0% @ 1.0 uM B-0993 57.0% @ 1.0 uM 73.0% @ 1.0 uM B-0994 55.0% @ 1.0 uM 43.0% @ 1.0 uM B-0995 53.0% @ 1.0 uM 14.0% @ 1.0 uM B-0996 54.0% @ 1.0 uM 27.0% @ 1.0 uM B-0997 69.0% @ 1.0 uM 22.0% @ 1.0 uM B-0998 67.0% @ 1.0 uM 25.0% @ 1.0 uM B-0999 61.0% @ 1.0 uM 24.0% @ 1.0 uM B-1000 55.0% @ 1.0 uM 42.0% @ 1.0 uM B-1001 63.0% @ 1.0 uM 31.0% @ 1.0 uM B-1002 70.0% @ 1.0 uM 41.0% @ 1.0 uM B-1003 74.0% @ 1.0 uM 29.0% @ 1.0 uM B-1004 79.0% @ 1.0 uM 45.0% @ 1.0 uM B-1005 58.0% @ 1.0 uM 23.0% @ 1.0 uM B-1006 69.0% @ 1.0 uM 38.0% @ 1.0 uM B-1007 52.0% @ 1.0 uM 34.0% @ 1.0 uM B-1008 54.0% @ 1.0 uM 23.0% @ 1.0 uM B-1009 80.0% @ 1.0 uM 55.0% @ 1.0 uM B-1010 75.0% @ 1.0 uM 1.0 uM B-1011 72.0% 2 1.0 uM 17.0% @ 1.0 uM B-1012 — 20.0% @ 1.0 uM B-1013 85.0% @ 1.0 uM 7.0% @ 1.0 uM B-1014 88.0% @ 1.0 uM 20.0% @ 1.0 uM B-1015 77.0% @ 1.0 uM 34.0% @ 1.0 uM B-1016 58.0% @ 1.0 uM 10.0% @ 1.0 uM B-1017 96.0% @ 1.0 uM 58.0% @ 1.0 uM B-1018 88.0% @ 1.0 uM 34.0% @ 1.0 uM B-1019 82.0% @ 1.0 uM 66.0% @ 1.0 uM B-1020 87.0% @ 1.0 uM 36.0% @ 1.0 uM B-1021 82.0% @ 1.0 uM 35.0% @ 1.0 uM B-1022 84.0% @ 1.0 uM 53.0% @ 1.0 uM B-1023 93.0% @ 1.0 uM 70.0% @ 1.0 uM B-1024 89.0% @ 1.0 uM 57.0% @ 1.0 uM B-1025 61.0% @ 1.0 uM 23.0% @ 1.0 uM B-1026 87.0% @ 1.0 uM 53.0% @ 1.0 uM B-1027 58.0% @ 1.0 uM 18.0% @ 1.0 uM B-1028 70.0% @ 1.0 uM 17.0% @ 1.0 uM B-1029 69.0% @ 1.0 uM 54.0% @ 1.0 uM B-1030 76.0% @ 1.0 uM 60.0% @ 1.0 uM B-1031 69.0% @ 1.0 uM 42.0% @ 1.0 uM B-1032 76.0% @ 1.0 uM 37.0% @ 1.0 uM B-1033 86.0% @ 1.0 uM 34.0% @ 1.0 uM B-1034 66.0% @ 1.0 uM 39.0% @ 1.0 uM B-1035 75.0% @ 1.0 uM 52.0% @ 1.0 uM B-1036 68.0% @ 1.0 uM 68.0% @ 1.0 uM B-1037 — 41.0% @ 1.0 uM B-1038 57.0% @ 1.0 uM 0.57 uM B-1039 — 1.33 uM B-1040 72.0% @ 1.0 uM 0.38 uM B-1041 70.0% @ 1.0 uM 73.0% @ 1.0 uM B-1042 79.0% @ 1.0 uM 12.0% @ 1.0 uM B-1043 64.0% @ 1.0 uM 53.0% @ 1.0 uM B-1044 94.0% @ 1.0 uM 0.93 uM B-1045 78.0% @ 1.0 uM 25.0% @ 1.0 uM B-1046 72.0% @ 1.0 uM 66.0% @ 1.0 uM B-1047 72.0% @ 1.0 uM 58.0% @ 1.0 uM B-1048 67.0% @ 1.0 uM 19.0% @ 1.0 uM B-1049 67.0% @ 1.0 uM 65.0% @ 1.0 uM B-1050 — 0.54 uM B-1051 68.0% @ 1.0 uM 41% @ 1.0 uM B-1052 69.0% @ 1.0 uM 66% @ 1.0 uM B-1053 78.0% @ 1.0 uM 0.4 uM B-1054 79.0% @ 1.0 uM 55.0% @ 1.0 uM B-1055 89.0% @ 1.0 uM 63.0% @ 1.0 uM B-1056 89.0% @ 1.0 uM 0.76 uM B-1057 85.0% @ 1.0 uM 0.72 uM B-1058 0.66 uM 43.0% @ 1.0 uM B-1059 0.18 uM 24.0% @ 1.0 uM B-1060 0.11 uM 32.0% @ 1.0 uM B-1061 0.03 uM 19.0% @ 1.0 uM B-1062 <0.1 uM 26.0% @ 1.0 uM B-1063 0.16 uM 44.0% @ 1.0 uM B-1064 0.39 uM 50.0% @ 1.0 uM B-1065 0.56 uM 40.0% @ 1.0 uM B-1066 <0.1 uM 39.0% @ 1.0 uM B-1067 1.6 uM 32.0% @ 1.0 uM B-1068 0.48 uM 24.0% @ 1.0 uM B-1069 0.22 uM 27.0% @ 1.0 uM B-1070 <0.1 uM 44.0% @ 1.0 uM B-1071 <0.1 uM 48.0% @ 1.0 uM B-1072 0.38 uM 28.0% @ 1.0 uM B-1073 <0.1 uM 21.0% @ 1.0 uM B-1074 0.23 uM 33.0% @ 1.0 uM B-1075 0.03 uM 29.0% @ 1.0 uM B-1076 0.08 uM 31.0% @ 1.0 uM B-1077 <0.1 uM 38.0% @ 1.0 uM B-1078 0.26 uM 48.0% @ 1.0 uM B-1079 <0.1 uM 40.0% @ 1.0 uM B-1080 0.19 uM 28.0% @ 1.0 uM B-1081 <0.1 uM 37.0% @ 1.0 uM B-1082 <0.1 uM 54.0% @ 1.0 uM B-1083 <0.1 uM 23.0% @ 1.0 uM B-1084 0.43 uM 29.0% @ 1.0 uM B-1085 <0.1 uM 29.0% @ 1.0 uM B-1086 <0.1 uM 42.0% @ 1.0 uM B-1087 0.05 uM 32.0% @ 1.0 uM B-1088 0.73 uM 49.0% @ 1.0 uM B-1089 <0.1 uM 39.0% @ 1.p uM B-1090 <0.1 uM 90.0% @ 1.0 uM B-1091 <0.1 uM 73.0% @ 1.0 uM B-1092 0.27 uM 85.0% @ 1.0 uM B-1093 0.33 uM 36.0% @ 1.0 uM B-1094 0.013 uM 69.0% @ 1.0 uM B-1095 <0.1 uM 70.0% @ 1.0 uM B-1096 <0.1 uM 32.0% @ 1.0 uM B-1097 <0.1 uM 44.0% @ 1.07 uM B-1098 <0.1 uM 82.0% @ 1.0 uM B-1099 0.26 uM 74.0% @ 1.0 uM B-1100 0.22 uM 56.0% @ 1.0 uM B-1101 0.026 uM 82.0% @ 1.0 uM B-1102 0.035 uM 83.0% @ 1.0 uM B-1103 0.094 uM 90.0% @ 1.0 uM B-1104 0.12 uM 69.0% @ 1.0 uM B-1105 <0.1 uM 84.0% @ 1.0 uM B-1106 <0.1 uM 86.0% @ 1.0 uM B-1107 0.057 uM 84.0% @ 1.0 uM B-1108 0.22 uM 81.0% @ 1.0 uM B-1109 0.054 uM 80.0% @ 1.0 uM B-1110 0.47 uM 64.0% @ 1.0 uM B-1111 0.19 uM 64.0% @ 1.0 uM B-1112 0.58 uM 43.0% @ 1.0 uM B-1113 <0.1 uM 72.0% @ 1.0 uM B-1114 0.069 uM 51.0% @ 1.0 uM B-1115 0.024 uM 89.0% @ 1.0 uM B-1116 0.41 uM 81.0% @ 1.0 uM B-1117 0.13 uM 73.0% @ 1.0 uM B-1118 0.33 uM 91.0% @ 1.0 uM B-1119 0.35 uM 80.0% @ 1.0 uM B-1120 0.47 uM 9.0% @ 1.0 uM B-1121 3.58 uM 29.0% @ 1.0 uM B-1122 1.84 uM 32.0% @ 1.0 uM B-1123 2.93 uM 27.0% @ 1.0 uM B-1124 1.49 uM 52.0% @ 1.0 uM B-1125 0.56 uM 41.0% @ 1.0 uM B-1126 1.5 uM >1.0 uM B-1127 0.71 uM 7.0% @ 1.0 uM B-1128 2.55 uM 26.0% @ 1.0 uM B-1129 1.07 uM 46.0% @ 1.0 uM B-1130 0.5 uM 29.0% @ 1.0 uM B-1131 0.076 uM 34.0% @ 1.0 uM B-1132 0.72 uM 11.0% @ 1.0 uM B-1133 0.38 uM 33.0% @ 1.0 uM B-1134 1.71 uM 33.0% @ 1.0 uM B-1135 0.23 uM 38.0% @ 1.0 uM B-1136 1.17 uM 40.0% @ 1.0 uM B-1137 0.038 uM 35.0% @ 1.0 uM B-1138 1.82 uM >1.0 uM B-1139 0.041 uM 29.0% @ 1.0 uM B-1140 1.68 uM 39.0% @ 1.0 uM B-1141 2.47 uM 32.0% @ 1.0 uM B-1142 0.11 uM 37.0% @ 1.0 uM B-1143 0.17 uM 40.0% @ 1.0 uM B-1144 0.44 uM 72.0% @ 1.0 uM B-1145 1.07 uM 71.0% @ 1.0 uM B-1146 0.47 uM 61.0% @ 1.0 uM B-1147 0.095 uM 53.0% @ 1.0 uM B-1148 0.43 uM 61.0% @ 1.0 uM B-1149 1.55 uM 48.0% @ 1.0 uM B-1150 0.47 uM 75.0% @ 1.0 uM B-1151 0.32 uM 72.0% @ 1.0 uM B-1152 0.73 uM 53.0% @ 1.0 uM B-1153 2.22 uM 52.0% @ 1.0 uM B-1154 0.085 uM 46.0% @ 1.0 uM B-1155 3.22 uM 30.0% @ 1.0 uM B-1156 0.27 uM 78.0% @ 1.0 uM B-1157 0.26 uM 66.0% @ 1.0 uM B-1158 74% @ 1.0 uM 0.68 uM 53% @ 30 mpk @ −6 h B-1159 66.0% @ 1.0 uM 1.03 uM 60% @ 30 mpk @ −6 h B-1160 79.0% @ 1.0 uM 0.38 uM B-1161 64.0% 2 1.0 uM 0.93 uM 40% @ 30 mpk @ −6 h 45% @ 3 mpk @ −4 h B-1162 79.0% @ 1.0 uM 0.59 uM 40% @ 30 mpk @ −6 h B-1163 74.0% @ 1.0 uM 0.37 uM B-1164 — 0.35 uM B-1165 66.0% @ 1.0 uM 0.99 uM B-1166 77.0% @ 1.0 uM 0.39 uM 50% @ 30 mpk @ −6 h 50% @ 3 mpk @ −4 h B-1167 70.0% @ 1.0 uM 1.06 uM B-1168 66.0% @ 1.0 uM 0.63 uM B-1169 80.0% @ 1.0 uM 0.11 uM B-1170 82.0% @ 1.0 uM 0.57 uM B-1171 78.0% @ 1.0 uM 0.23 uM B-1172 68.0% @ 1.0 uM 1.95 uM B-1173 65.0% @ 1.0 uM 62% @ 1.0 uM B-1174 80.0% @ 1.0 uM 0.86 uM B-1175 72.0% @ 1.0 uM 1.83 uM B-1176 67.0% @ 1.0 uM 67.0% @ 1.0 uM B-1177 70.0% @ 1.0 uM 1.16 uM B-1178 92.0% @ 1.0 uM 1.61 uM B-1179 86.0% @ 1.0 uM 0.41 uM B-1180 78.0% @ 1.0 uM 0.53 uM B-1181 79.0% @ 1.0 uM 66% @ 1.0 uM B-1182 72.0% @ 1.0 uM 0.65 uM B-1183 77.0% @ 1.0 uM 0.2 uM B-1184 69.0% @ 1.0 uM 0.63 uM B-1185 71.0% @ 1.0 uM 0.79 uM B-1186 83.0% @ 1.0 uM 60% @ 1.0 uM B-1187 76.0% @ 1.0 uM 1.89 uM B-1188 — 36.0% @ 1.0 uM B-1189 68.0% @ 1.0 uM 0.83 uM B-1190 78.0% @ 1.0 uM 62.0% @ 1.0 uM B-1191 74.0% @ 1.0 uM 57.0% @ 1.0 uM B-1192 84.0% @ 1.0 uM 0.47 uM B-1193 69.0% @ 1.0 uM 65.0% @ 1.0 uM B-1194 87.0% @ 1.0 uM 0.58 uM B-1195 52.0% @ 1.0 uM 60.0% @ 1.0 uM B-1196 74.0% @ 1.0 uM 68.0% @ 1.0 uM B-1197 77.0% @ 1.0 uM 45.0% @ 1.0 uM B-1198 92.0% @ 1.0 uM 0.46 uM B-1199 87.0% @ 1.0 uM 49.0% @ 1.0 uM B-1200 95.0% @ 1.0 uM 0.64 uM B-1201 84.0% @ 1.0 uM 0.51 uM B-1202 71.0% @ 1.0 uM 58.0% @ 1.0 uM B-1203 84.0% @ 1.0 uM 58.0% @ 1.0 uM B-1204 68.0% @ 1.0 uM 59.0% @ 1.0 uM B-1205 74.0% @ 1.0 uM 46.0% @ 1.0 uM B-1206 81.0% @ 1.0 uM 0.34 uM B-1207 90.0% @ 1.0 uM 58.0% @ 1.0 uM B-1208 82.0% @ 1.0 uM 51.0% @ 1.0 uM B-1209 86.0% @ 1.0 uM 55.0% @ 1.0 uM B-1210 82.0% @ 1.0 uM 57.0% @ 1.0 uM B-1211 88.0% @ 1.0 uM 59.0% @ 1.0 uM B-1212 90.0% @ 1.0 uM 57.0% @ 1.0 uM B-1213 84.0% @ 1.0 uM 0.62 uM B-1214 76.0% @ 1.0 uM 58.0% @ 1.0 uM B-1215 86.0% @ 1.0 uM 0.23 uM B-1216 88.0% @ 1.0 uM 0.18 uM B-1217 87.0% @ 1.0 uM 0.46 uM B-1218 88.0% @ 1.0 uM 76.0% @ 1.0 uM B-1219 85.0% @ 1.0 uM 37.0% @ 1.0 uM B-1220 81.0% @ 1.0 uM 53.0% @ 1.0 uM B-1221 82.0% @ 1.0 uM 44.0% @ 1.0 uM B-1222 65.0% @ 1.0 uM 9.0% @ 1.0 uM B-1223 80.0% @ 1.0 uM 61.0% @ 1.0 uM B-1224 82.0% @ 1.0 uM 74.0% @ 1.0 uM B-1225 89.0% @ 1.0 uM 73.0% @ 1.0 uM B-1226 89.0% @ 1.0 uM 0.18 uM B-1227 83.0% @ 1.0 uM 0.22 uM B-1228 90.0% @ 1.0 uM 0.72 uM B-1229 87.0% @ 1.0 uM 0.65 uM B-1230 90.0% @ 1.0 uM 0.25 uM B-1231 94.0% @ 1.0 uM 0.56 uM B-1232 81.0% @ 1.0 uM 54.0% @ 1.0 uM B-1233 85.0% @ 1.0 uM 0.36 uM B-1234 89.0% @ 1.0 uM 0.49 uM B-1235 0.04 uM 76.0% @ 1.0 uM B-1236 0.1 uM 53.0% @ 1.0 uM B-1237 0.22 uM 39.0% @ 1.0 uM B-1238 0.14 uM 16.0% @ 1.0 uM B-1239 <0.1 uM 38.0% @ 1.0 uM B-1240 <0.1 uM 59.0% @ 1.0 uM B-1241 0.04 uM 81.0% @ 1.0 uM B-1242 0.08 uM 83.0% @ 1.0 uM B-1243 0.04 uM 47.0% @ 1.0 uM B-1244 0.26 uM 44.0% @ 1.0 uM B-1245 0.49 uM 42.0% @ 1.0 uM B-1246 0.27 uM 40.0% @ 1.0 uM B-1247 <0.1 uM 58.0% @ 1.0 uM B-1248 <0.1 uM 68.0% @ 1.0 uM B-1249 0.24 uM 60.0% @ 1.0 uM B-1250 0.14 uM 18.0% @ 1.0 uM B-1251 0.41 uM 38.0% @ 1.0 uM B-1252 0.17 uM 46.0% @ 1.0 uM B-1253 0.15 uM 57.0% @ 1.0 uM B-1254 0.16 uM 68.0% @ 1.0 uM B-1255 12.9 uM 75.0% @ 1.0 uM B-1256 0.12 uM 41.0% @ 1.0 uM B-1257 1.48 uM 40.0% @ 1.0 uM B-1258 0.07 uM 56.0% @ 1.0 uM B-1259 <0.1 uM 0.48 uM B-1260 0.11 uM 48.0% @ 1.0 uM B-1261 0.74 uM 44.0% @ 1.0 uM B-1262 <0.1 uM 63.0% @ 1.0 uM B-1263 1.05 uM 57.0% @ 1.0 uM B-1264 0.32 uM 47.0% @ 1.0 uM B-1265 0.43 uM 51.0% @ 1.0 uM B-1266 <0.1 uM 58.0% @ 1.0 uM B-1267 <0.1 uM 73.0% @ 1.0 uM B-1268 <0.1 uM 79.0% @ 1.0 uM B-1269 0.46 uM 84.0% @ 1.0 uM B-1270 0.47 uM 83.0% @ 1.0 uM B-1271 0.13 uM 74.0% @ 1.0 uM B-1272 0.014 uM 38.0% @ 1.0 uM B-1273 <0.1 uM 36.0% @ 1.0 uM B-1274 <0.1 uM 41.0% @ 1.0 uM B-1275 <0.1 uM 50.0% @ 1.0 uM B-1276 0.062 uM 11.0% @ 1.0 uM B-1277 <0.1 uM 47.0% @ 1.0 uM B-1278 0.12 uM 85.0% @ 1.0 uM B-1279 <0.1 uM 79.0% @ 1.0 uM B-1280 0.039 uM 83.0% @ 1.0 uM B-1281 <0.1 uM 85.0% @ 1.0 uM B-1282 <0.1 uM 75.0% @ 1.0 uM B-1283 <0.1 uM 64.0% @ 1.0 uM B-1284 <0.1 uM 75.0% @ 1.0 uM B-1285 0.057 uM 80.0% @ 1.0 uM B-1286 0.15 uM 78.0% 2 1.0 uM B-1287 0.25 uM 55.0% @ 1.0 uM B-1288 0.15 uM 74.0% @ 1.0 uM B-1289 0.73 uM 35.0% @ 1.0 uM B-1290 0.26 uM 75.0% @ 1.0 uM B-1291 0.097 uM 55.0% @ 1.0 uM B-1292 0.01 uM 74.0% @ 1.0 uM B-1293 0.31 uM 48.0% @ 1.0 uM B-1294 0.013 uM 54.0% @ 1.0 uM B-1295 0.079 uM 74.0% @ 1.0 uM B-1296 0.038 uM 48.0% @ 1.0 uM B-1297 0.02 uM >1.0 uM B-1298 0.055 uM 20.0% @ 1.0 uM B-1299 0.091 uM >1.0 uM B-1300 0.071 uM 18.0% @ 1.0 uM B-1301 0.12 uM 15.0% @ 1.0 uM B-1302 0.023 uM 11.0% @ 1.0 uM B-1303 0.08 uM >1.0 uM B-1304 0.11 uM 10.0% @ 1.0 uM B-1305 0.64 uM 9.0% @ 1.0 uM B-1306 0.11 uM >1.0 uM B-1307 0.009 uM 16.0% @ 1.0 uM B-1308 <0.1 uM >1.0 uM B-1309 0.045 uM >1.0 uM B-1310 0.12 uM 11.0% @ 1.0 uM B-1311 0.05 uM 57.0% @ 1.0 uM B-1312 0.35 uM >1.0 uM B-1313 0.035 uM 37.0% @ 1.0 uM B-1314 0.045 uM 24.0% @ 1.0 uM B-1315 0.055 uM 12.0% @ 1.0 uM B-1316 0.026 uM 36.0% @ 1.0 uM B-1317 0.019 uM 9.0% @ 1.0 uM B-1318 <0.1 uM 1.0% @ 1.0 uM B-1319 0.24 uM >1.0 uM B-1320 0.047 uM 43.0% @ 1.0 uM B-1321 0.47 uM 66.0% @ 1.0 uM B-1322 0.12 uM 87.0% @ 1.0 uM B-1323 0.013 uM 85.0% @ 1.0 uM B-1324 0.16 uM 83.0% @ 1.0 uM B-1325 0.27 uM 95.0% @ 1.0 uM B-1326 0.092 uM 84.0% @ 1.0 uM B-1327 0.13 uM 65.0% @ 1.0 uM B-1328 0.032 uM 86.0% @ 1.0 uM B-1329 0.66 uM 54.0% @ 1.0 uM B-1330 0.053 uM 85.0% @ 1.0 uM B-1331 0.004 uM 85.0% @ 1.0 uM B-1332 0.007 uM 81.0% @ 1.0 uM B-1333 0.45 uM 76.0% @ 1.0 uM B-1334 0.13 uM 73.0% @ 1.0 uM B-1335 0.097 uM 63.0% @ 1.0 uM B-1336 0.072 uM 83.0% @ 1.0 uM B-1337 0.4 uM 90.0% @ 1.0 uM B-1338 0.18 uM 73.0% @ 1.0 uM B-1339 0.12 uM 67.0% @ 1.0 uM B-1340 0.043 uM 63.0% @ 1.0 uM B-1341 0.42 uM 52.0% @ 1.0 uM B-1342 0.25 uM 59.0% @ 1.0 uM B-1343 0.065 uM 83.0% @ 1.0 uM B-1344 0.014 uM 86.0% @ 1.0 uM B-1345 0.27 uM 73.0% @ 1.0 uM B-1346 0.043 uM 86.0% @ 1.0 uM B-1347 0.021 uM 85.0% @ 1.0 uM B-1348 0.009 uM 69.0% @ 1.0 uM B-1349 0.037 uM 86.0% @ 1.0 uM B-1350 0.019 uM 78.0% @ 1.0 uM B-1351 0.068 uM 78.0% @ 1.0 uM B-1352 0.013 uM 76.0% @ 1.0 uM B-1353 0.062 uM 80.0% @ 1.0 uM B-1354 0.013 uM 83.0% @ 1.0 uM B-1355 0.07 uM 75.0% @ 1.0 uM B-1356 0.059 uM 91.0% @ 1.0 uM B-1357 0.18 uM 84.0% @ 1.0 uM B-1358 0.16 uM 76.0% @ 1.0 uM B-1359 0.005 84.0% @ 1.0 uM B-1360 0.11 0.15 uM 54% @ 3 mpk @ −4 h B-1361 0.03 0.29 uM B-1362 0.003 0.29 uM B-1363 0.009 0.28 uM 51.0% @ 30 pmk @ 53% @ 3 mpk @ −4 h −6 H B-1364 0.009 0.27 uM 53.0% @ 30 mpk @ 17% @ 3 mpk @ −4 h −6.0 H B-1365 0.17 88.0% @ 1.0 uM B-1366 0.04 0.27 uM B-1367 <0.1 0.22 uM B-1368 0.031 0.33 uM 44.0% @ 30 mpk @ - B-1369 <0.1 0.29 uM B-1370 <0.1 0.77 uM B-1371 0.06 83.0% @ 1.0 uM B-1372 <0.1 0.41 uM 48.0% @ 30 mpk @ - B-1373 0.016 0.17 uM B-1374 <0.1 0.28 uM B-1375 0.01 0.25 uM B-1376 0.009 0.26 uM 3.0% @ 30 mpk @ −6 H B-1377 0.12 5.0 uM B-1378 0.02 1.04 uM B-1379 <0.1 0.092 uM B-1380 <0.1 0.26 uM B-1381 0.055 0.73 uM B-1382 <0.1 0.44 uM B-1383 0.0012 0.15 uM B-1384 0.57 0.37 uM B-1385 <0.1 0.11 uM B-1386 <0.1 0.25 uM B-1387 <0.1 0.1 uM B-1388 0.57 1.38 uM B-1389 0.06 0.57 uM B-1390 <0.1 71.0% @ 1.0 uM B-1391 0.016 uM 82.0% @ 1.0 uM B-1392 0.059 uM 82.0% @ 1.0 uM B-1393 3.17 uM 80.0% @ 1.0 uM B-1394 0.32 uM 78.0% @ 1.0 uM B-1395 1.48 61.0% @ 1.0 uM B-1396 1.55 73.0% @ 1.0 uM B-1397 0.92 85.0% @ 1.0 uM B-1398 0.67 83.0% @ 1.0 uM B-1399 0.14 74.0% @ 1.0 uM B-1400 0.024 83.0% @ 1.0 uM B-1401 0.033 75.0% @ 1.0 uM B-1402 0.12 76.0% @ 1.0 uM B-1403 4.54 71% @ 1.0 uM B-1404 0.6 70% @ 1.0 uM B-1405 0.28 70% @ 1.0 uM B-1406 1.39 56.0% @ 1.0 uM B-1407 0.4 71.0% @ 1.0 uM B-1408 0.27 69.0% @ 1.0 uM B-1409 <0.1 72.0% @ 1.0 uM B-1410 <0.1 69% @ 1.0 uM B-1411 <0.1 81.0% @ 1.0 uM B-1412 0.097 80.0% @ 1.0 uM B-1413 0.016 78.0% @ 1.0 uM B-1414 0.025 83.0% @ 1.0 uM B-1415 1.41 79.0% @ 1.0 uM B-1416 0.14 81.0% @ 1.0 uM B-1417 0.069 69.0% @ 1.0 uM B-1418 1.01 82.0% @ 1.0 uM B-1419 0.3 84.0% @ 1.0 uM B-1420 <0.1 82.0% @ 1.0 uM B-1421 0.014 75.0% @ 1.0 uM B-1422 0.58 68.0% @ 1.0 uM B-1423 1.58 84.0% @ 1.0 uM B-1424 0.86 76.0% @ 1.0 uM B-1425 0.09 83.0% @ 1.0 uM B-1426 0.19 80.0% @ 1.0 uM B-1427 <0.1 84.0% @ 1.0 uM B-1428 <0.1 86.0% @ 1.0 uM B-1429 <0.1 87.0% @ 1.0 uM B-1430 0.75 uM 35.0% @ 1.0 uM B-1431 0.36 uM 58.0% @ 1.0 uM B-1432 0.11 uM 51.0% @ 1.0 uM B-1433 0.26 uM 21.0% @ 1.0 uM B-1434 0.19 uM 28.0% @ 1.0 uM B-1435 1.8 uM 45.0% @ 1.0 uM B-1436 1.0 uM 20.0% @ 1.0 uM B-1437 0.3 uM 23.0% @ 1.0 uM B-1438 2.01 uM 27.0% @ 1.0 uM B-1439 1.7 uM 17.0% @ 1.0 uM B-1440 0.87 uM 3.0% @ 1.0 uM B-1441 1.95 uM 66.0% @ 1.0 uM B-1442 1.54 uM 18.0% @ 1.0 uM B-1443 0.014 uM 83.0% @ 1.0 uM B-1444 0.3 uM 24.0% @ 1.0 uM B-1445 0.43 uM 27.0% @ 1.0 uM B-1446 0.77 uM 36.0% @ 1.0 uM B-1447 0.5 uM 34.0% @ 1.0 uM B-1448 1.43 uM 22.0% @ 1.0 uM B-1449 1.61 uM 50.0% @ 1.0 uM B-1450 2.1 uM 49.0% @ 1.0 uM B-1451 2.88 uM 50% @ 1.0 uM B-1452 2.41 uM 47.0% @ 1.0 uM B-1453 2.53 uM 49.0% @ 1.0 uM B-1454 1.6 uM 12.0% @ 1.0 uM B-1455 1.21 uM 8.0% @ 1.0 uM B-1456 1.29 uM >1.0 uM B-1457 0.43 uM 43.0% @ 1.0 uM B-1458 0.95 uM 65.0% @ 1.0 uM B-1459 0.67 uM 46.0% @ 1.0 uM B-1460 0.96 uM 29.0% @ 1.0 uM B-1461 0.4 uM 39.0% @ 1.0 uM B-1462 0.22 uM 50.0% @ 1.0 uM B-1463 2.34 uM 26.0% @ 1.0 uM B-1464 1.18 uM 27.0% @ 1.0 uM B-1465 3.23 uM 31.0% @ 1.0 uM B-1466 1.69 uM >1.0 uM B-1467 1.22 uM 1.0% @ 1.0 uM B-1468 1.61 uM 10.0% @ 1.0 uM B-1469 0.37 uM 14.0% @ 1.0 uM B-1470 0.6 uM 28.0% @ 1.0 uM B-1471 0.85 uM 25.0% @ 1.0 uM B-1472 0.93 uM 12.0% @ 1.0 uM B-1473 1.24 uM 14.0% @ 1.0 uM B-1474 1.23 uM 31.0% @ 1.0 uM B-1475 2.1 uM 24.0% @ 1.0 uM B-1476 0.047 uM 42.0% @ 1.0 uM B-1477 2.5 uM 34.0% @ 1.0 uM B-1478 B-1479 B-2270 0.72 uM 31% @ 10.0 uM B-2271 0.93 uM 38% @ 10.0 uM B-2272 0.26 uM 53.0% @ 10.0 uM B-2273 1.92 uM 39.0% @ 10.0 uM B-2274 0.26 uM 59.0% @ 10.0 uM B-2275 2.16 uM 53.0% @ 10.0 uM B-2276 11.5 uM 37.0% @ 10.0 uM B-2277 14.9 uM 44.0% @ 10.0 uM B-2278 0.8 uM 51.0% @ 10.0 uM B-2279 0.32 uM 36.0% @ 10.0 uM B-2280 0.4 uM 57.0% @ 10.0 uM B-2281 0.81 uM 60.0% @ 10.0 uM B-2282 0.91 uM 41.0% @ 10.0 uM B-2283 0.04 uM 53.0% @ 10.0 uM B-2284 4.61 uM 62.0% @ 10.0 uM B-2285 2.29 uM 49.0% @ 10.0 uM B-2286 0.017 uM 0.78 uM 25% @ 30 mpk @ −1 h B-2287 2.56 uM 61.0% @ 10.0 uM B-2288 6.51 uM 46.0% @ 10.0 uM B-2289 3.0 uM 30.0% @ 10.0 uM B-2290 2.37 uM 59.0% @ 10.0 uM B-2291 0.019 uM 41% @ 10.0 uM B-2292 8.82 uM 57.0% @ 10.0 uM B-2293 2.11 uM 56.0% @ 10.0 uM B-2294 1.68 uM 50.0% @ 10.0 uM B-2295 1.79 uM 56.0% @ 10.0 uM B-2296 17.3 uM 63.0% @ 10.0 uM B-2297 3.59 uM 57.0% @ 10.0 uM B-2298 0.29 uM 4.22 uM B-2299 1.97 uM 62.0% @ 10.0 uM B-2300 0.07 uM 43.0% @ 10.0 uM B-2301 0.18 uM 44.0% @ 10.0 uM B-2302 1.0 uM 58.0% @ 1.0 uM B-2303 0.011 uM 54.0% @ 10.0 uM B-2304 1.41 uM 50.0% @ 10.0 uM B-2305 0.54 uM 60.0% @ 10.0 uM B-2306 5.88 uM 39.0% @ 10.0 uM B-2307 2.29 uM 69.0% @ 10.0 uM B-2308 0.66 uM 56.0% @ 10.0 uM B-2309 0.29 uM 47.0% @ 10.0 uM B-2310 0.12 uM 1.2 uM 50% @ 30 mpk @ −6 h B-2311 7.18 uM 60% @ 10.0 uM B-2312 2.93 uM 43.0% @ 10.0 uM B-2313 42.3 uM 58.0% @ 10.0 uM B-2314 11.0 uM 66.0% @ 10.0 uM B-2315 0.49 uM 36.0% @ 10.0 uM B-2316 0.46 uM 58.0% @ 10.0 uM B-2317 1.0 uM 60.0% @ 10.0 uM B-2318 73.0% @ 10.0 uM 25.0% @ 10.0 uM B-2319 75.0% @ 10.0 uM 40.0% @ 10.0 uM B-2320 44.0% @ 10.0 uM 35.0% @ 10.0 uM B-2321 69.0% @ 10.0 uM 27.0% @ 10.0 uM B-2322 76.0% @ 10.0 uM 38.0% @ 10.0 uM B-2323 69.0% @ 10.0 uM 46.0% @ 10.0 uM B-2324 58.0% @ 10.0 uM 36.0% @ 10.0 uM B-2325 60.0% @ 10.0 uM 51.0% @ 10.0 uM B-2326 76.0% @ 10.0 uM 33.0% @ 10.0 uM B-2327 76.0% @ 10.0 uM 23.0% @ 10.0 uM B-2328 65.0% @ 10.0 uM 28.0% @ 10.0 uM B-2329 72.0% @ 10.0 uM 53.0% @ 10.0 uM B-2330 81.0% @ 10.0 uM 37.0% @ 10.0 uM B-2331 74.0% @ 10.0 uM 44.0% @ 10.0 uM B-2332 70.0% @ 10.0 uM 47.0% @ 10.0 uM B-2333 58.0% @ 10.0 uM 36.0% @ 10.0 uM B-2334 81.0% @ 10.0 uM 45.0% @ 10.0 uM B-2335 82.0% @ 10.0 uM 50.0% @ 10.0 uM B-2336 48.0% @ 10.0 uM 35.0% @ 10.0 uM B-2337 46.0% @ 10.0 uM 59.0% @ 10.0 uM B-2338 73.0% @ 10.0 uM 50.0% @ 10.0 uM B-2339 84.0% @ 10.0 uM >10.0 uM B-2340 35.0% @ 10.0 uM 12.0% @ 10.0 uM B-2341 75.0% @ 10.0 uM 50.0% @ 10.0 uM B-2342 83.0% @ 10.0 uM 46.0% @ 10.0 uM B-2343 43.0% @ 10.0 uM 27.0% @ 10.0 uM B-2344 71.0% @ 10.0 uM 50.0% @ 10.0 uM B-2345 64.0% @ 10.0 uM 38.0% @ 10.0 uM B-2346 45.0% @ 10.0 uM 48.0% @ 10.0 uM B-2347 49.0% @ 10.0 uM 50.0% @ 10.0 uM B-2348 76.0% @ 10.0 uM 48.0% @ 10.0 uM B-2349 75.0% @ 10.0 uM 27.0% @ 10.0 uM B-2350 38.0% @ 10.0 uM 56.0% @ 10.0 uM B-2351 77.0% @ 10.0 uM 1.0% @ 10.0 uM B-2352 37.0% @ 10.0 uM 19.0% @ 10.0 uM B-2353 38.0% @ 10.0 uM 33.0% @ 10.0 uM B-2354 65.0% @ 10.0 uM 25.0% @ 10.0 uM B-2355 84.0% @ 10.0 uM 50.0% @ 10.0 uM B-2356 77.0% @ 10.0 uM 45.0% @ 10.0 uM B-2357 47.0% @ 10.0 uM 41.0% @ 10.0 uM B-2358 17.0% @ 10.0 uM 52.0% @ 10.0 uM B-2359 76.0% @ 10.0 uM 35.0% @ 10.0 uM B-2360 45.0% @ 10.0 uM >10.0 uM B-2361 19.0% @ 10.0 uM 46.0% @ 10.0 uM B-2362 60% @ 100.0 uM 39.0% @ 10.0 uM B-2363 44.0% @ 10.0 uM 1.0% @ 10.0 uM B-2364 47.0% @ 10.0 uM 4.0% @ 10.0 uM B-2365 82.0% @ 10.0 uM 43.0% @ 10.0 uM B-2366 70.0% @ 10.0 uM 59.0% @ 10.0 uM B-2367 46.0% @ 10.0 uM 40.0% @ 1.0 uM B-2368 65.0% @ 10.0 uM 55.0% @ 10.0 uM B-2369 32.0% @ 10.0 uM >10.0 uM B-2370 73% @ 100.0 uM 20.0% @ 10.0 uM B-2371 54.0% @ 10.0 uM 36.0% @ 10.0 uM B-2372 55.0% @ 100.0 uM >10.0 uM B-2373 50.0% @ 100.0 uM 6% @ 10.0 uM B-2374 35.0% @ 10.0 uM 20.0% @ 10.0 uM B-2375 62.0% @ 100.0 uM >10.0 uM B-2376 32.0% @ 10.0 uM 17.0% @ 10.0 uM B-2377 34.0% @ 10.0 uM 17.0% @ 10.0 uM B-2378 48.0% @ 10.0 uM 61.0% @ 10.0 uM B-2379 73.0% @ 100.0 uM 45.0% @ 1.0 uM B-2380 81% @ 100.0 uM 53.0% @ 10.0 uM B-2381 68% @ 100.0 uM 2.0% @ 10.0 uM B-2382 51.0% @ 10.0 uM 24.0% @ 10.0 uM B-2383 63.0% @ 10.0 uM 35.0% @ 10.0 uM B-2384 49% @ 100.0 uM 10.0% @ 10.0 uM B-2385 79.0% @ 10.0 uM 19.0% @ 10.0 uM B-2386 38.0% @ 10.0 uM 19.0% @ 10.0 uM B-2387 50.0% @ 100.0 uM >10.0 uM B-2388 42.0% @ 10.0 uM 24.0% @ 10.0 uM B-2389 39.0% @ 10.0 uM 29.0% @ 10.0 uM B-2390 34.0% @ 10.0 uM 27.0% @ 1.0 uM B-2391 40.0% @ 10.0 uM 59.0% @ 10.0 uM B-2392 63.0% @ 10.0 uM 46.0% @ 10.0 uM B-2393 43.0% @ 10.0 uM >10.0 uM B-2394 37.0% @ 10.0 uM 22.0% @ 10.0 uM B-2395 32.0% @ 10.0 uM 28.0% @ 10.0 uM B-2396 75.0% @ 10.0 uM >10.0 uM B-2397 83.0% @ 10.0 uM 22.0% @ 10.0 uM B-2398 55% @ 100.0 uM 10.0% @ 10.0 uM B-2399 69.0% @ 10.0 uM 18.0% @ 10.0 uM B-2400 60.0% @ 10.0 uM 40.0% @ 10.0 uM B-2401 78.0% @ 10.0 uM 44.0% @ 10.0 uM B-2402 43.0% @ 10.0 uM 52.0% @ 10.0 uM B-2403 72% @ 100.0 uM 52.0% @ 10.0 uM B-2404 58% @ 100.0 uM 52.0% @ 10.0 uM B-2405 47% @ 100.0 uM >10.0 uM B-2406 45.0% @ 10.0 uM 24.0% @ 10.0 uM B-2407 47% @ 100.0 uM 27.0% @ 10.0 uM B-2408 39.0% @ 10.0 uM 10.0% @ 10.0 uM B-2409 78.0% @ 10.0 uM 26.0% @ 10.0 uM B-2410 33.0% @ 10.0 uM 32.0% @ 10.0 uM B-2411 26% @ 100.0 uM 13.0% @ 10.0 uM B-2412 40.0% @ 10.0 uM 31.0% @ 10.0 uM B-2413 75.0% @ 10.0 uM 37.0% @ 10.0 uM B-2414 86.0% @ 10.0 uM 38.0% @ 10.0 uM B-2415 94.0% @ 10.0 uM 50.0% @ 10.0 uM B-2416 85.0% @ 10.0 uM 43.0% @ 1.0 uM B-2417 83.0% @ 10.0 uM 18.0% @ 10.0 uM B-2418 88.0% @ 10.0 uM 34.0% @ 10.0 uM B-2419 86.0% @ 10.0 uM 66.0% @ 10.0 uM B-2420 70.0% @ 10.0 uM 34.0% @ 10.0 uM B-2421 89.0% 2 10.0 uM 38.0% @ 10.0 uM B-2422 90.0% @ 10.0 uM 17.0% @ 10.0 uM B-2423 85.0% @ 10.0 uM >10.0 uM B-2424 86.0% @ 10.0 uM 43.0% @ 10.0 uM B-2425 79.0% @ 10.0 uM 42.0% @ 10.0 uM B-2426 88.0% @ 10.0 uM 53.0% @ 10.0 uM B-2427 87.0% @ 10.0 uM 59.0% @ 10.0 uM B-2428 82.0% @ 10.0 uM 50.0% @ 10.0 uM B-2429 92.0% @ 10.0 uM 32.0% @ 10.0 uM B-2430 90.0% @ 10.0 uM 61.0% @ 10.0 uM B-2431 85.0% 2 10.0 uM 68.0% @ 10.0 uM B-2432 86.0% 2 10.0 uM 40.0% @ 10.0 uM B-2433 94.0% @ 10.0 uM 84.0% @ 10.0 uM B-2434 92.0% @ 10.0 uM 63.0% @ 10.0 uM B-2435 84.0% @ 10.0 uM 4.0% @ 10.0 uM B-2436 80.0% @ 10.0 uM 54.0% @ 10.0 uM B-2437 82.0% @ 10.0 uM 41.0% @ 10.0 uM B-2438 75.0% @ 10.0 uM 40.0% @ 10.0 uM B-2439 81.0% @ 10.0 uM 44.0% @ 10.0 uM B-2440 77.0% @ 10.0 uM 78.0% @ 10.0 uM B-2441 86.0% @ 10.0 uM 46.0% @ 10.0 uM B-2442 86.0% @ 10.0 uM >10.0 uM B-2443 84.0% @ 10.0 uM 44.0% @ 10.0 uM B-2444 89.0% @ 10.0 uM 7.0% @ 10.0 uM B-2445 94.0% @ 10.0 uM 15.0% @ 10.0 uM B-2446 90.0% @ 10.0 uM 28.0% @ 10.0 uM B-2447 94.0% @ 10.0 uM >10.0 uM B-2448 75.0% @ 10.0 uM 30.0% @ 10.0 uM B-2449 86.0% @ 10.0 uM 42.0% @ 10.0 uM B-2450 87.0% @ 10.0 uM 46.0% @ 1.0 uM B-2451 87.0% @ 10.0 uM 45.0% @ 10.0 uM B-2452 89.0% @ 10.0 uM 33.0% @ 10.0 uM B-2453 91.0% @ 10.0 uM >10.0 uM B-2454 88.0% @ 10.0 uM 40.0% @ 10.0 uM B-2455 87.0% @ 10.0 uM 54.0% @ 10.0 uM B-2456 86.0% @ 10.0 uM 53.0% @ 10.0 uM B-2457 90.0% @ 10.0 uM 18.0% @ 10.0 uM B-2458 83.0% @ 10.0 uM 36.0% @ 10.0 uM B-2459 82.0% @ 10.0 uM 81.0% @ 10.0 uM B-2460 80.0% @ 10.0 uM 79.0% @ 10.0 uM B-2461 67.0% @ 10.0 uM 59.0% @ 10.0 uM

Biological data from a number of compounds of Examples C-74 through C-139 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

-   -   “P38 alpha kinase IC50, μM”

In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as:

-   -   “Human Whole Blood IC50, μM or %Inhib@conc. (μM)”

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

-   -   “Rat LPS Model % Inhibition@dose@predose time”         wherein the dose is milligram per kilogram (mpk) administered by         oral gavage and the predose time indicates the number of hours         before LPS challenge when the compound is administered.

Human Whole Rat LPS Model P38 Blood IC50, % Inhibition @ alpha kinase μM or % dose @ predose Example # IC50, μM Inhib @ conc. (μM) time C-74 0.037 0.56 54% @ 5 mpk @ −4 h C-75 0.045 0.4 71% @ 5 mpk @ −4 h C-76 0.07 3.24 66% @ 5 mpk @ −4 h C-77 0.071 8.2 92% @ 5 mpk @ −4 h C-78 0.068 10.5 87% @ 5 mpk @ −4 h C-79 0.045 0.52 83% @ 5 mpk @ −4 h C-80 0.008 51% @ 5 μM C-81 0.037 40% @ 5 μM C-82 0.15 7.31 C-83 0.24 1.23 25% @ 5 mpk @ −4 h C-84 0.048 0.88 22% @ 5 mpk @ −4 h C-85 0.57 >25 C-86 0.007 0.19 66% @ 5 mpk @ −4 h C-87 0.027 0.34 C-88 0.012 0.3 59% @ 5 mpk @ −4 h C-89 0.039 0.12 27% @ 5 mpk @ −4 h C-90 0.037 0.48 C-91 0.054 2.31 63% @ 5 mpk @ −4 h C-92 0.024 0.28 66% @ 5 mpk @ −4 h C-93 0.009 0.38 50% @ 5 mpk @ −4 h C-94 0.02 0.27 73% @ 5 mpk @ −4 h C-95 0.13 3.91 32% @ 5 mpk @ −4 h C-96 0.077 2.1 38% @ 5 mpk @ −4 h C-97 0.025 3.83 21% @ 5 mpk @ −4 h C-98 0.016 0.64 78% @ 5 mpk @ −4 h C-99 0.062 0.38 36% @ 5 mpk @ −4 h C-100 0.027 0.27 44% @ 5 mpk @ −4 h C-101 0.083 3.71 52% @ 5 mpk @ −4 h C-102 0.29 7.56 72% @ 5 mpk @ −4 h C-105 0.033 0.13 46% @ 5 mpk @ −4 h C-106 0.026 0.44 23% @ 5 mpk @ −4 h C-107 0.014 0.38 11% @ 5 mpk @ −4 h C-108 0.02 0.73  0% @ 5 mpk @ −4 h C-111 0.21 6.05 39% @ 5 mpk @ −4 h C-112 0.54 6.36 89% @ 5 mpk @ −4 h C-113 0.082 2.72 77% @ 5 mpk @ −4 h C-114 0.11 1.73 39% @ 5 mpk @ −4 h C-115 0.042 10.2 39% @ 5 mpk @ −4 h C-116 0.429 0.50 53% @ 5 mpk @ −4 h C-117 3.42 7.26 71% @ 5 mpk @ −4 h C-118 0.298 >25 39% @ 5 mpk @ −4 h C-120 0.7 18.6 26% @ 5 mpk @ −4 h C-121 0.11 15.3 39% @ 5 mpk @ −4 h C-122 0.025 55% @ 5 mpk @ −4 h C-123 0.67 >25.0 C-124 0.17 4.56 51% @ 20 mpk @ −4 h C-125 7.22 >25.0 C-126 0.71 >25.0  6% @ 20 mpk @ −4 h C-127 0.038 0.27 53% @ 5 mpk @ −4 h C-128 0.09 2.22 63% @ 5 mpk @ −4 h C-132 0.086 44% @ 5 μM C-133 0.16 4.54 55% @ 5 mpk @ −4 h C-135 6.0 C-136 0.032 C-137 0.051 58% @ 5 mpk @ −4 h C-138 0.28 0.68 26% @ 5 mpk @ −4 h C-139 0.2 3.66 46% @ 5 mpk @ −4 h

Additional compounds of interest can be prepared as set forth above and as described below in Scheme D-1, wherein the R₁ and R₂ substituents are as defined previously.

The synthesis begins with the treatment of 4-methylpyrimidine 2 with a base such as LiHMDS, LDA or tBuOK in an organic solvent such as THF of ether which is cooled in an ice bath (0-10° C.). To the resulting 4-methylanion is added a solution of a suitably protected (Boc is shown) ethyl ester of isonipecotic acid 1 in THF or ether. The reaction is allowed to warm to room temperature and stirred for a period of 4 hours to 20 hours at which time the desired ketone 3 is isolated after aqueous work up. Condensation of the ketone 3 with tosylhydrazide in toluene or benzene as a solvent at refluxing temperatures for a period of 1 hour to 5 hours affords the hydrazone 4. The hydrazone 4 is reacted with a suitably substituted benzoyl chloride 5, in the presence of a base such as LiHMDS or LDA or tBuOK or triethylamine at temperatures ranging from 0° C. to 70° C. The reaction is stirred for a period of 3-6 hours. Acidic hydrolysis of the protecting groups with an aqueous acid such as HCl or H₂SO₄ and subsequent neutralization with an aqueous base such as NaOH or KOH affords the desired pyrazole 6. Treatment of the pyrazole 6 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBt or HATU and base such as N-methylmorpholine or diisopropylethylamine or triethylamine) affords the desired pyrazole amide 9. In most instance the desired products can be obtained pure by direct trituration with solvents such as methanol, ethyl acetate, acetonitrile or ether and/or recrystallization from suitable solvents.

The following examples contain detailed descriptions of the methods of preparation of these additional compounds that form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

EXAMPLE D-1 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

Step 1: A 5 L 4-necked round bottom flask fitted with an overhead mechanical stirrer, N₂ inlet and a thermocouple was charged with 600 g (2.75 mol) of di-tert-butyl-dicarbonate and 1.5 L of CH₂Cl₂. The solution was cooled to 0° C. and 428 g (2.73 mol) of ethyl isonipecotate was added dropwise via an addition funnel. The addition took 45 minutes and the temperature rose from 0° C. to 17.4° C. The reaction mixture was stirred for an additional 2 hours at ambient temperature. The solvent was removed in vacuo to afford 725 g of a yellow oil (residual solvent remained).

Step 2: A 3 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition funnel and a thermocouple was charged with 1850 mL (1.85 mol) of a 1.0 M solution of LiHMDS in THF. The flask was cooled to 5° C. and 68 mL (0.74 mol) of 4-methylpyrimidine was added (neat) to the stirred solution. To this solution was added 198 g (0.77 mol) of Ethyl-N-t-butylcarbonyl isonipecotate dissolved in 160 mL of THF. The ice bath was removed and the reaction was allowed to stir for 18 hours. The reaction was quenched with 500 mL of saturated NH₄Cl and was extracted with 500 mL of ethyl acetate. The organic phase was washed with 500 mL of brine, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to afford 235 g of a brown oil.

Step 3: A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a Dean-Stark trap and a thermocouple was charged with 1.5 L of toluene, 226 g (0.742 mol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone and 138.4 g (0.743 mol) of tosyl hydrazide. The mixture was warmed to reflux. The solution was allowed to reflux for 2 hours and was cooled to ambient temperature. The reaction was allowed to stand overnight. A fine precipitate formed and was removed by filtration. The filtrate was concentrated in vacuo to afford a brown solid. The solid was suspended in 500 mL of ethyl acetate and the resulting mixture was placed in a sonication bath for 5 hours. The mixture was cooled in an ice bath and was filtered to afford 310 g of a wet solid. The solid was dried in a vacuum oven (40° C., 5 mm) overnight to afford 248 g of the desired hydrazone (71%). ¹H NMR (CDCl₃) δ 9.03 (d, J=1.2 Hz, 1H), 8.72 (d, J=5.2 Hz, 2H), 7.89 (d, J=8.3 Hz, 2H), 7.32 (d, J=8.1 Hz, 2H), 7.26 (dd, J=5.2, 1.0 Hz, 1H), 4.03 (d, J=12.1 Hz, 2H), 3.76 (s, 2H), 2.71 (t, J=12.1 Hz, 2H), 2.43 (s, 3H), 2.34 (m, 1H), 1.66 (d, J=13.5 Hz, 2H), 1.47 (s, 9H), 1.38 (m, 2H); MS (M+H): 474 (base peak). Step 4:

Method A. A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition funnel and a thermocouple was charged with 400 mL (400 mmol) of a 1.0 M solution of LiHMDS in THF. The solution was cooled to −21.9° C. and a solution of 62 g (131 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 400 mL of THF was added slowly. The temperature never exceeded −11° C. throughout the addition. The solution was re-cooled to −19.6° C. and 23.0 g (131 mmol in 250 mL of THF) of p-chlorobenzoylchloride was added slowly. The temperature never exceeded −13° C. throughout the addition. The cooling bath was removed and the reaction was allowed to warm to ambient temperature. After 3 hours the reaction was quenched with 600 mL of 3 N HCl. The reaction was warmed to reflux and was held at reflux for 2 hours. The reaction was allowed to cool to ambient temperature overnight. The reaction mixture was washed with 1.4 L of Et₂O and the aqueous phase was neutralized with 1 L of 2.5 N NaOH. The aqueous phase was extracted with ethyl acetate (2×1000 mL). The combined organic phases were washed with brine (1×500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to afford 21 g of a yellow solid. The solid was suspended in 500 mL of 2:1 Et₂O/hexane. After sonication the solid was isolated by filtration to leave a wet solid. The solid was dried in a vacuum oven to afford 13.8 g of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole. ¹H NMR (DMSO-d₆) 9.18 (s, 1H), 8.65 (d, J=5.2, 1H), 7.44 (d, J=8.5, 2H), 7.37 (d, J=7.7 Hz, 2H), 7.15 (d, J=5.2 Hz, 1H), 3.16 (m, 1H), 3.00 (d, J=1.9 Hz, 2H), 2.52 (m, 2H), 1.69 (m, 4H); MS (M+H): 340 (base peak).

Method B: To a solution of 200 g (423 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 800 mL THF was added 70 mL (500 mmol) of triethylamine in a 3 L three necked flask. The solution was cooled in an ice/salt/water bath to 0-5° C. To this cold solution was added a solution of 4-chlorobenzoyl chloride (74 g, 423 mmol) in 100 mL THF dropwise, maintaining the temperature below 10° C. After the addition was complete the ice-bath was removed and replaced with a heating mantle. 4-N,N-dimethylaminopyridine (5 g, 40 mmol) was added and the reaction mixture was heated to 50° C. for 15-30 minutes. The reaction mixture was filtered and the residue washed with THF (100 mL). The combined filtrates were evaporated under reduced pressure to a semisolid.

The semisolid residue was dissolved in 450 mL THF and 180 mL of 12 N HCl was added to this solution rapidly. The reaction mixture was heated to 65° C. for 1.5-2 hours and transferred to a separatory funnel. The organic layer was discarded and the aqueous phase was washed twice with 200 mL of THF. The aqueous phase was transferred back to a 2 L flask and cooled to 0-10° C. in an ice bath. The pH of the solution was adjusted to between ˜9-10 by dropwise addition of 15 N ammonium hydroxide (˜180 mL). This mixture was transferred back to a separatory funnel and extracted with warm n-butanol (3×150 mL). The combined n-butanol phases were evaporated under reduced pressure to 15 dryness. The residue was then stirred with methanol (200 mL), filtered and dried to obtain 129 g (90%) of the desired 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole as a off-white solid. This material was identical in all respects to the material prepared by Method A.

Step 5: A 1 L round bottom flask was charged with 34.2 g (102 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole, 500 mL of CH₂Cl₂ and 26.6 mL (153 mmol) of Hunig's base. To this suspension was added 16.5 g (122 mmol) of 1-hydroxybenzotriazole and 8.1 g (106 mmol) of glycolic acid. The addition of glycolic acid was followed by the addition of 23.7 g (122 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The reaction was allowed to stir at ambient temperature overnight. The reaction was concentrated in vacuo to leave an oily residue. The residue was dissolved in 400 mL of methanol and 50 mL of 2.5 N NaOH. The reaction mixture was stirred at ambient temperature for 1 hour. The mixture was acidified to pH 5 with 2 N HCl and was extracted with CH₂Cl₂ (6×200 mL). The combined organic phases were filtered through phase paper and the filtrate was concentrated in vacuo to leave a yellow residue. The residue was treated with 75 mL of acetonitrile. A precipitate formed. The solid was filtered and washed with additional acetonitrile and Et₂O to afford 31.4 g of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole. ¹H NMR (DMSO-d₆) 9.20 (s, 1H), 8.67 (d, J=4.8, 1H), 7.40 (m, 4H), 7.17 (d, J=4.0, 1H), 4.53 (m, 2H), 4.13 (s, 2H), 3.77 (m, 1H), 3.05 (t, J=12.7 Hz, 1H), 2.69 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H); MS (M+H): 398 (base peak).

EXAMPLE D-2 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

A 25 mL round bottom flask was charged with 65 mg (0.164 mmol) of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole and 2.5 mL of dioxane. To this suspension was added 0.082 mL of 4 N HCl in dioxane. The mixture was stirred for 2 hours. The mixture was diluted with 5 mL of Et₂O and filtered. The solid was dried over solid CaSO₄ under vacuum for 12 h to afford 68 mg of N-(2-hydroxyacetyl)-S-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride. ¹H NMR (DMSO-d₆) 9.18 (s, 1H), 8.63 (d, J=5.37 Hz, 1H), 7.40 (d, J=8.59 Hz, 2H), 7.33 (d, J=8.59 Hz, 2H), 7.15 (m, 1H), 4.40 (m, 1H), 4.06 (m, 2H), 3.72 (m, 1H), 3.33 (m, 1H), 2.97 (m, 1H), 2.62 (m, 1H), 1.83 (m, 2H), 1.64 (m, 2H); MS (M+H): 398.

EXAMPLE D-3 N-(2-Methoxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole (fumarate salt)

To a suspension of 250 mg (0.74 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole (Example C-1, Step 3) and 180 mg (1.48 mmol) of N,N-dimethylamino pyridine in 20 mL of CH₂Cl₂ was added 88 mg (0.81 mmol) of 2-methoxyacetyl chloride. The reaction was stirred for 5 hours. The reaction was quenched with 20 mL of saturated NH₄Cl. The mixture was extracted with n-butyl alcohol and the organic layer was washed with brine. The solvent was removed to afford 72 mg of an oil. This oil was dissolved in 1 mL of warm MeOH. This solution was combined with a warm solution of 1 equivalent of fumaric acid in warm MeOH. The solution was cooled to ambient temperature and the reaction was allowed to stir for 1 hour. The solvent was removed in vacuo and the residue was triturated with Et₂O. The resulting solid was isolated by filtration to yield 56 mg of an off-white powder. ¹H NMR (DMSO-d₆) 13.23 (bs, 1H), 9.19 (d, J=1.2 Hz, 1H), 8.65 (d, J=5.1 Hz, 1H), 7.41 (n, 4H), 7.16 (dd, J=5.4, 1.2 Hz, 1H), 4.45 (bd, J=11.1 Hz, 1H), 4.11 (q_(AB), J=39.0, 13.8 Hz, 2H), 3.86 (bd, J=12.9 Hz, 1H), 3.32 (m, 4H), 3.04 (bt, J=12.3 Hz, 1H), 2.63 (bt, J=12.0 Hz, 1H), 1.77 (m, 4H); MS (M+H) 411 (base peak).

EXAMPLE D-4 N-(2-Hydroxy-2-methylpropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

Step 1: To a suspension of 2.05 g (6.1 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole (Example C-1, Step 3) and 3.7 g (30.5 mmol) of N,N-dimethylamino pyridine in 30 mL of CH₂C₂ was added 1.06 mL (7.3 mmol) of 2-acetoxy-2-methylpropionyl chloride. The reaction was allowed to stir overnight at ambient temperature. The reaction was quenched with saturated NH4Cl and water. The resulting aqueous phase was extracted with CH₂Cl₂. The combined organic layers were concentrated in vacuo to leave an oily solid. The residue was treated with CH₃CN and allowed to stand for 15 minutes. The resulting suspension was diluted with Et2O and was filtered to afford 2.2 g of a solid. Analysis by LC/MS indicated that the solid was a mixture of the hydroxy derivative and the acetoxy derivative. This solid was carried on to the next step without further purification.

Step 2: A solution of 1 g of the solid from step 1 in 10 mL of MeOH was treated with 500 mg of solid K₂CO₃. The mixture was allowed to stir overnight at ambient temperature. The suspension was treated with water and the resulting solution was extracted with ethyl acetate. The organic phase was filtered through phase separation paper (to remove the residual water) and was concentrated in vacuo to leave an oily solid. The solid was dried under vacuum and was treated with CH₃CN. The suspension was filtered to afford 825 mg of an off-white solid. This solid was suspended in 5 ml of dioxane and 0.5 mL of 4 N HCl in dioxane was added. The suspension was stirred for 1 hour and the suspension was filtered to leave a solid. The solid was washed with Et₂O and the resulting suspension was filtered to give 900 mg of the title compound. ¹H NMR (DMSO-d₆) 9.23 (s, 1H), 8.69 (s, 1H), 7.45 (m, 4H), 7.19 (s, 1H), 4.8 (br m, 4H), 3.85 (m, 2H), 3.38 (m, 1H), 1.89 (m, 2H), 1.72 (m, 2H), 1.37 (s, 6H); MS (M+H): 426 (base peak).

EXAMPLE D-5 (S)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

By following the method of Example C-1 and substituting (S)-lactic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 13.15 (s, br, 1H), 9.12 (d, J=1.07 Hz, 1H), 8.59 (d, J=5.37Hz, 1H), 7.39 (d, J=7.79Hz, 2H), 7.31 (d, J=8.33, 2H), 7.10 (dd, J=1.34, 5.1 Hz, 1H), 4.76 (m, 1H), 4.41 (m, 2H), 3.99 (m, 1H), 2.97 (m, 1H), 2.45 (m, 1H), 1.83 (m, 2H), 1.64 (m, 2H), 1.15 (m, 3H); MS (M+H): 412 (base peak).

EXAMPLE D-6 (R)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

By following the method of Example C-1 and substituting (R)-lactic acid for glycolic acid the title compound was prepared. ¹H NMR (CDCl₃) 9.24 (s, 1H), 8.52 (d, J=5.0 Hz, 1H), 7.32-7.36 (m, 4H), 6.98 (d, J=5.3 Hz, 1H), 4.72 (d, J=10.5 Hz, 1H), 4.55 (br, 1H), 3.88 (d, J=13.1 Hz, 1H), 3.66 (br, 1H), 3.19 (br, 1H), 2.82 (t, J=12.4 Hz, 1H), 2.10 (br, 2H), 1.37 (d, J=6.2 Hz, 3H), 1.81-1.90 (m, 2H); MS (M+H) 412 (base peak).

EXAMPLE D-7 (R)-N-(2-Hydroxy-2-phenylacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

By following the method of Example C-1 and substituting (R)-phenylacetic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-d₆) 9.15 (d, J=0.9 Hz, 1H), 8.63 (d, J=5.4 Hz, 1H), 7.40 (m, 9H), 7.13 (t, J=6.6 Hz, 1H), 5.43 (d, J=19.5 Hz, 1H), 4.51 (s, 1H), 4.04 (m, 1H), 3.33 (m, 4H), 2.8 (m, 2H), 1.68 (m, 3H); MS (M+H) 474 (base peak).

EXAMPLE D-8 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-fluorophenyl)pyrazole

By following the method of Example C-1 and substituting 4-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.48 (s, 1H), 9.40 (s, 1H), 8.86 (d, J=5.1 Hz, 1H), 7.71 (br, 2H), 7.42 (bd, J=5.2 Hz, 3H), 4.78 (br, 1H), 4.43 (s, 2H), 4.04 (br, 1H), 3.79 (br, 1H), 3.70 (s, 1H), 3.34 (t, J=12.2 Hz, 1H), 3.0 (br, 1H), 2.21 (d, J=10.9 Hz, 2H), 2.08 (br, 1H); MS (M+H): 382 (base peak).

EXAMPLE D-9 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethylphenyl)pyrazole

By following the method of Example C-1 and substituting 4-trifluoromethylbenzoyl chloride for 4chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.47 (s, 1H), 9.24 (s, 1H), 8.73 (d, J=4.0 Hz, 1H), 7.77 (bd, J=13.3 Hz, 4H), 7.34 (d, J=4.3 Hz, 1H), 4.61 (br, 1H), 4.26 (s, 2H), 3.87 (br, 1H), 3.52 (s, 2H), 3.17 (t, J=12.0 Hz, 1H), 2.8 (br, 1H), 2.02 (br, 2H), 1.91 (br, 1H); MS (M+H): 432 (base peak).

EXAMPLE D-10 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethoxyphenyl)pyrazole

By following the method of Example C-1 and substituting 4-trifluoromnethoxybenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.55 (s, 1H), 9.40 (s, 1H), 8.88 (d, J=4.6 Hz, 1H), 7.81Id, J=7.7 Hz, 2H), 7.64 (br, 2H), 7.47 (d, J=4.4 Hz, 1H), 4.75 (br, 1H), 4.42 (s, 2H), 4.04 (d, J=12.5 Hz, 1H), 3.69 (br, 2H), 3.34 (t, J=12.0 Hz, 1H), 3.0 (br, 1H), 2.20 (d, J=11.7 Hz, 2H), 2.05 (br, 1H); MS (M+H): 448 (base peak).

EXAMPLE D-11 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-chlorophenyl pyrazole

By following the method of Example C-1 and substituting 3-chlorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.41 (s, 1H), 9.24 (s, 1H), 8.73 (d, J=4.9 Hz, 1H), 7.56 (s, 1H), 7.49 (br, 2H), 7.41 (br, 1H), 7.32 (d, J=4.2 Hz, 1H), 4.60 (d, J=7 11.7 Hz, 1H), 4.25 (s, 2H), 3.87 (d, J=12.7 Hz, 1H), 3.52 (bs, 2H), 3.17 (t, J=12.1 Hz, 1H), 2.84 (d, J=12.5 Hz, 1H), 2.03 (d, J=11.9 Hz, 2H), 1.87 (br, 1H); MS (M+H): 398 (base peak).

EXAMPLE D-12 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-fluorophenyl)pyrazole

By following the method of Example C-1 and substituting 3-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.38 (s, 1H), 9.24 (s, 1H), 8.72 (d, J=5.2 Hz, 1H), 7.49 (dd, J=8.0 and 6.2 Hz, 1H), 7.24-7.32 (m, 4H), 4.60 (d, J=13.1 Hz, 1H), 4.25 (s, 2H), 3.87 (d, J=13.3 Hz, 1H), 3.55-3.60 (m, 1H), 3.52 (s, 1H), 3.17 (t, J=12.2 Hz, 1H), 2.82 (d, J=12.9 Hz, 1H), 2.03 (d, J=10.9 Hz, 2H), 1.83-1.96 (m, 1H); MS (M+H): 382 (base peak).

EXAMPLE D-13 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-trifluoromethylphenyl)pyrazole

By following the method of Example C-1 and substituting 3-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.76 (s, 1H), 9.41 (s, 1H), 8.91 (d, J=5.3 Hz, 1H), 8.02 (s, 1H), 7.95 (t, J=6.5 Hz, 2H), 7.85 (t, J=7.5 Hz, 1H), 7.53 (d, J=4.6 Hz, 1H), 4.78 (d, J=11.9 Hz, 1H), 4.45 (d, J=16.3 Hz, 2H), 4.06 (d, J=12.5 Hz, 1H), 3.69 (bs, 2H), 3.34 (t, J=11.3 Hz, 1H), 3.01 (d, J=13.1 Hz, 1H), 2.20 (d, J=11.1 Hz, 2H), 2.12 (br, 1H); MS (M+H): 432 (base peak).

The following examples can be prepared in a manner similar to that described above for the synthesis of Examples C1-C13.

EXAMPLE D-14 5-[4-N-(2-hydroxy-2-(2-chlorophenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-15 5-[4-N-(2-hydroxy-2-(3-chlorophenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-16 5-[4-N-(1-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-17 5-[4-N-(2-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-18 5-[4-N-(3-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-19 5-[4-N-(4-hydroxy-1-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-20 5-[4-N-(1-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-[4-chlorophenyl)pyrazole

EXAMPLE D-21 5-[4-N-(2-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-22 5-[4-N-(3-hydroxy-1-cyclopentylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-23 5-[4-N-(3-hydroxypropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-24 5-[4-N-(2-hydroxy-3,3,3-trifluoropropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-25 5-[4-N-(2-hydroxy-3-methylbutyryl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-26 5-[4-N-(2-hydroxyisocaproyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-27 5-[4-N-(2-hydroxy-2-cyclohexylacetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-28 5-[4-N-(2-hydroxy-2-(4-methoxyphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-29 5-[4-N-(2-hydroxy-2-(3-methoxyphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-30 5-[4-N-(2-hydroxy-2-(4-trifluoromethylphenyl)acetyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-31 5-[4-N-(2-hydroxy-3-phenylpropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-32 5-[4-N-(2-hydroxy-3-(4-hydroxyphenyl)propionyl)piperidyl]-4-(4-pyimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-33 5-[4-N-(2-hydroxy-3-imidazolpropionyl)piperidyl]-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

The synthesis of 2-substituted pyrimidinyl pyrazoles is shown in Scheme 2. Reaction of 2-methylmercapto-4-methyl pyrimidine 10 with N-Boc methyl ester of isonipecotic acid (1) under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether affords the desired ketone 11. Condensation of the ketone 11 with tosyl hydrazine under refluxing conditions in either toluene or benzene affords the hydrazone 12. The hydrazone 12 is deprotonated under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether and the anion is reacted in situ with a suitably substituted benzoyl chloride 5 to afford, after mild aqueous work up, the desired and fully protected pyrazole 13. Oxidation of the 2-mercaptomethyl group present in 13 with oxidants selected from but not limited to Oxone®, H₂O₂ or mCPBA in solvents such as dichloromethane, acetonitrile or tetrahyrofuran affords the 2-methane sulfonyl pyrazole 14. The 2-methanesulfone group in 14 is conveniently displaced with various amines, aryloxides or alkoxides in solvents such as tetrahydrofuran, dioxane, dimethylformamide or acetonitrile at temperatures ranging from 20° C. to 200° C. Under these reaction conditions the tosyl protecting group on the pyrazole is also simultaneously deprotected. Aqueous workup affords the desired tosyl deprotected, 2-alkoxy, or 2-aryloxy or 2-amino substituted pyrazoles 15. The alkoxides or aryloxides are generated from their respective alcohols or phenols with suitable bases such as LiHMDS, NaH, LDA or tBuOK in solvents such as tetrahydrofuran, dioxane or dimethylformamide. Deprotection of the remaining N-Boc group in 15 is accomplished with trifluoroacetic acid or hydrochloric acid in solvents such as dichloromethane or dioxane to afford the pyrazole 16. Treatment of the pyrazole 16 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBt or HATU and base such as N-methylmorpholine or diisopropyl ethylamine) affords the desired final products 17.

The following 2-substituted pyrimidine compounds can be prepared as set forth above, particularly in a manner similar to that outlined above in Scheme D-2.

EXAMPLE D-34 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-thiomethyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-35 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methanesulfonyl)pyrimidyl)-3-(4-chlorophenyl)pyrazole

EXAMPLE D-36 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-(4-(2-amino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-37 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-38 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-isopropylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-39 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-s-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-40 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-R-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-41 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methoxy)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-42 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(p-fluorophenoxy)pyrimidyl]-3-(4-chlorophenyl)pyrazole

EXAMPLE D-43 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(p-fluoroanilino)pyrimidyl]-3-(4-chlorophenyl)pyrazole

In a manner similar to that outlined above in Scheme D-1, for the synthesis of the piperidine analogs 6, the aminocyclohexane analogs are prepared by substitution of 1 in Scheme D-1 with a suitably protected (Boc is shown) methyl or ethyl ester of cis-aminocyclohexane carboxylic acid 10 or trans-aminocyclohexane carboxylic acid 11 or trans-aminomethylcyclohexane carboxylic acid 12, which affords the cis-aminocyclohexane 13, or trans-aminocyclohexane 14 or the trans-aminomethylcyclohexane 15 respectively (Scheme 3). Suitable reductive alkylations on 13, 14 or 15 with 1-1.5 equivalents of aldehydes or ketones in the presence of a reducing agent like sodium cyanoborohydride or sodium triacetoxyborohydride in solvents such as methanol, ethanol, acetic acid, tetrahydrofuran or dichloromethane lead to the desired mono-alkylated derivatives 16, 17 or 18 respectively.

The dimethyl derivatives 19, 20 or 21 can be prepared by heating a solution of the aminocyclohexanes 13, 14 or 15 respectively in a mixture of formaldehyde and formic acid at temperatures ranging from 40° C. to 110° C.

An additional group of compounds of interest includes the following:

Biological data for a number of compounds are shown in the following table. In vitro p38 alpha kinase inhibitory data are shown in the column identified as “p38 alpha IC₅₀ (μM)”. In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as: “HWB IC₅₀ (μM)”. In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF-release in the rat is shown in the column identified as: “ratLPS/%Inh@dose(mg/kg)”, wherein the dose is in milligram per kilogram (mg/kg) administered by oral gavage, 4 hours before LPS challenge.

HWB ratLPS/ ratLPS/ ratLPS/ Ex- p38 alpha IC₅₀ % Inh @ % Inh @ % Inh @ ample IC₅₀ (uM) (uM) 1.0 (mg/kg) 5.0 (mg/kg) 20.0 (mg/kg) D-1 0.17 83.0 D-2 0.084 1.79 89.0 95.0 D-3 0.095 0.46 69.0 88.0 91.0 D-4 0.91 1.55 42.3 83.0 99.0 D-5 0.14 4.09 65.0 78.5 83.0 D-6 0.083 1.33 82.0 96.0 100 D-7 0.44 >25.0 0 D-8 0.18 1.3 65 85 D-9 1.63 15.8 5 86 D-10 3.95 14.8 80 D-11 0.16 1.5 43 86 D-12 0.82 7.06 71 91 D-13 0.33 8.36 53 87 

1. A compound, a tautomer of the compound, or a pharmaceutically-acceptable salt of the compound or tautomer, wherein: the compound corresponds in structure to Formula IB:

as to R¹: R¹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkylalkylene, cycloalkenylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, alkylcarbonyloxyarylene, and arylcarbonyloxyarylene, or R¹ corresponds in structure to formula (II):

i is an integer from zero to 9; and R²⁵ is selected from the group consisting of hydrogen, alkyl, aralkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl; alkylcarbonylalkylene, and arylcarbonylalkylene, and R²⁶ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and R²⁷ is selected from the group consisting of —CHR²⁸P²⁹, alkyl, cycloalkyl, alkynyl, aryl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, alkylarylene, alkylaralkyl, aralkylarylene, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyalkoxyarylene, arloxyarylene, aralkoxyarylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylalkoxylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, arylthioalklylarylene, arylsulfonylaminoalkylene, alkylsulfonylalkylene, and alkylaminosulfonylarylene, wherein: said alkyl, cycloalkyl, aryl, aralkyl, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, arylthioalklylarylene, and alkylsurfonylarylene may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; and R²⁸ is alkoxycarbonyl; and R²⁹ is selected from the group consisting of aralkyl, aralkoxyalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene, wherein: said aralkyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and nitro; and R² is piperidinyl substituted with: one or more substituents independently selected from the group consisting of hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl, wherein: said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and hydroxyacyl may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy, or one or more substituents independently selected from the group consisting of hydroxycycloalkyl and alkoxycycloalkyl, wherein: said hydroxycycloalkyl and alkoxycycloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R³ is pyridinyl optionally substituted with one or more substituents independently selected from the group consisting of hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy, wherein; said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R⁴ is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein: said haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy.
 2. A compound, tautomer, or salt of claim 1, wherein R² is piperidinyl substituted with one or more substituents independently selected from the group consisting of hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl, wherein: said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy.
 3. A compound, tautomer, or salt of claim 1, wherein: the compound corresponds in structure to Formula XB:

R¹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkylalkylene, cycloalkenylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, alkylcarbonyloxyarylene, and arylcarbonyloxyarylene; and R² is piperidinyl substituted with: one or more substituents independently selected from the group consisting of hydroxyalkyl, hydroxyalkenyl, alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl, wherein: said hydroxyalkyl, hydroxyalkanyl, alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl may be optionally substituted with one or more substituents independently selected from the groups consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy, or one or more substituents independently selected from the group consisting of hydroxycycloalkyl and hydroxycycloalkylcarbonyl, wherein: said hydroxycycloalkyl and hydroxycycloalkylcarbonyl may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R⁴ is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein: said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R⁵ represents one or more substituents independently selected from the group consisting of hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy, wherein: said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy.
 4. A compound, tautomer, or salt of claim 3, wherein R² is piperidinyl substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperdine ring.
 5. A compound, tautomer, or salt of claim 3, wherein R¹ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkynyl.
 6. A compound, tautomer, or salt of claim 3, wherein R¹ is hydrogen.
 7. A compound, tautomer, or salt of claim 3, wherein R² is piperidinyl substituted with at least one substituent selected from the group consisting of lower hydroxyalkyl, lower hydroxyalkylcarbonyl, and hydroxycycloalkylcarbonyl.
 8. A compound, tautomer, or salt of claim 3, wherein R⁴ is phenyl optionally substituted with one or more substituents independently selected from halo.
 9. A compound, tautomer, or salt of claim 3, wherein R⁴ is phenyl optionally substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, and iodo.
 10. A compound, tautomer, or salt of claim 3, wherein R⁴ is phenyl optionally substituted at the meta or para position with one or more chloro substituents.
 11. A compound, tautomer, or salt of claim 3, wherein R⁵ is hydrogen.
 12. A compound, tautomer, or salt of claim 1, wherein: the compound corresponds in structure of Formula XX:

as to R⁴⁰⁰: R⁴⁰⁰ is selected from group consisting of hydroxyalkyl, hydroxyalkylcarbonyl, and alkoxyalkylene, wherein: said hydroxyalkyl, hydroxyalkylcarbonyl, and alkoxyalkylene may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy, or R⁴⁰⁰ is hydroxycycloalkylcarbonyl optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl, wherein: said cycloalkyl, alkyl, aryl, arylalkyl, and haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R^(401a) and R^(401b) are independently selected from the group consisting of hydrogen, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein: said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl may be optionally substituted with one or more substituents independently selected from the group consisting of alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy; and R⁴⁰² is selected from the group consisting of hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy, wherein: said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, and aralkoxy may be optionally substituted with one of more substituents independently selected from the group consisting of alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, and aryloxy.
 13. A compound, tautomer, or salt of claim 12, wherein: as to R⁴⁰⁰: R⁴⁰⁰ is selected from the group consisting of lower hydroxyalkyl, lower hydroxyalkylcarbonyl, and lower alkoxyalkylene, wherein: said lower hydroxyalkyl, lower hydroxyalkylcarbonyl, and lower alkoxyalkylene may be optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, and lower haloalkyl, wherein: said cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, and lower haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of lower alkylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, and phenyloxy; or R⁴⁰⁰ is hydroxycycloalkylcarbonyl optionally substituted with one or more substituents independently selected from the group consisting of cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, and lower haloalkyl, wherein: said cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, and lower haloalkyl may be optionally substituted with one or more substituents independently selected from the group consisting of lower alkylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, and aryloxy; and R^(401a) and R^(401b) are independently selected from the group consisting of hydrogen, halo, lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl, wherein: said lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl may be optionally substituted with one or more substituents independently selected from the group consisting of lower alkylene, lower alkenylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, and phenyloxy; and R⁴⁰² is selected from the group consisting of hydrogen, phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy, wherein: said phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of lower alkylene, lower alkenylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, and phenyloxy.
 14. A compound, tautomer, or salt of claim 12, wherein R⁴⁰⁰ is optionally-substituted hydroxyalkylcarbonyl.
 15. A compound, tautomer, or salt of claim 12, wherein R⁴⁰⁰ is optionally-substituted hydroxycycloalkylcarbonyl.
 16. A compound, tautomer, or salt of claim 12, wherein R⁴⁰⁰ is optionally-substituted alkoxyalkylene.
 17. A compound, tautomer, or salt of claim 12, wherein R⁴⁰⁰ is optionally-substituted hydroxyalkyl.
 18. A compound, tautomer, or salt of claim 12, wherein R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo.
 19. A compound, tautomer, or salt of claim 12, wherein R^(401a) is selected from the group consisting of meta-chloro and para-chloro.
 20. A compound, tautomer, or salt of claim 12, wherein R⁴⁰² is hydrogen.
 21. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is optionally substituted lower hydroxyalkylcarbonyl; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 22. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is selected from to group consisting of optionally substituted 2-hydroxyacetyl, 2-hydroxy-proprionyl, 2-hydroxy-2-methylpropionyl, 2-hydroxy-2-phenylacetyl, 3-hydroxyproprionyl, 2-hydroxy-3-methylbutryl, 2-hydroxyisocapropyl, and 2-hydroxy-3-phenylproprionyl; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 23. A compound, tautomer, or salt of claim 22, wherein R^(401a) is selected from the group consisting of meta-chloro and para-chloro.
 24. A compound, tautomer, or salt of claim 22, wherein: R^(401a) is para-chloro, and R^(401b) is hydrogen.
 25. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is optionally substituted lower hydroxycycloalkylcarbonyl; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 26. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is selected from the group consisting of optionally substituted 1-hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclohexylacetyl, 3-hydroxy-1-cyclohexylacetyl, 4-hydroxy-1-cyclohexylacetyl, 1-hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclopentylacetyl, and 3-hydroxy-1-cyclopentylacetyl, 2-hydroxy-2-cyclohexylacetyl; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 27. A compound, tautomer, or salt of claim 26, wherein R^(401a) is selected from the group consisting of meta-chloro and para-chloro.
 28. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is optionally substituted lower hydroxyalkyl; and R⁴⁰¹ is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 29. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is selected from the group consisting of optionally substituted hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxylisopropyl; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 30. A compound, tautomer, or salt of claim 29, wherein R^(401a) is selected from the group consisting of meta-chloro and para-chloro.
 31. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is optionally substituted lower alkoxyalkylene; and R^(401a) selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 32. A compound, tautomer, or salt of claim 12, wherein: R⁴⁰⁰ is selected from the group consisting of optionally substituted methoxymethylene, methoxyethylene, methoxypropylene, methoxyisopropylene, ethoxymethylene, ethoxyethylene, ethoxypropylene, and ethoxyisopropylene; and R^(401a) is selected from the group consisting of chloro, fluoro, bromo, and iodo; and R⁴⁰² is hydrogen.
 33. A compound, tautomer, or salt of claim 32, wherein R^(401a) is selected from the group consisting of meta-chloro and para-chloro.
 34. A pharmaceutical composition, wherein: the pharmaceutical composition comprises a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt or the compound; and said compound is selected from the group consisting of compounds recited in claim
 1. 35. A method for treating a tumor necrosis factor mediated disorder, wherein: said method comprises treating a subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 1. 36. A method for treating a p38 kinase mediated disorder, wherein: said method comprises treating a subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof; and said compound is selected from the group of compounds recited in claim
 1. 37. The method of claim 36, wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthrits, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease and cachexia.
 38. The method of claim 36, wherein the p38 kinase mediated disorder is inflammation.
 39. The method of claim 36, wherein the p38 kinase mediated disorder is arthritis.
 40. The method of claim 36, wherein the p38 kinase mediated disorder is asthma.
 41. A method for treating inflammation, wherein: said method comprises treating a subject having or susceptible to inflammation with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof; and said compound is selected from the group of compounds recited in claim
 1. 42. A method for treating arthritis, wherein: said method comprises treating a subject having or susceptible to arthritis with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 1. 43. A pharmaceutical composition, wherein: the pharmaceutical composition comprises a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt of the compound; and said compound is selected from the group consisting of compounds recited in claim
 3. 44. A method for treating a tumor necrosis factor mediated disorder, wherein: said method comprises treating a subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof; and said compound is selected born to group of compounds recited in claim
 3. 45. A method for treating a p38 kinase mediated disorder, wherein: said method comprises frosting a subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or a therapeutically-acceptable salt thereof; and said compound is selected from the group of compounds recited in claim
 3. 46. The method of claim 45, wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthrits, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cachexia.
 47. The method of claim 45, wherein the p38 kinase mediated disorder is inflammation.
 48. The method of claim 45, wherein the p38 kinase mediated disorder is arthritis.
 49. The method of claim 45, wherein the p38 kinase mediated disorder is asthma.
 50. A method for testing inflammation, wherein: said method comprises treating a subject having or susceptible to inflammation with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 3. 51. A method for treating arthritis, wherein: said method comprises testing a subject having or susceptible to arthritis with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compound recited in claim
 3. 52. A pharmaceutical composition, wherein: the pharmaceutical composition comprises a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt of the compound; and said compound is selected from the group consisting of compounds recited in claim
 12. 53. A method for treating a tumor necrosis factor mediated disorder, wherein: said method comprises treating a subject having or susceptible to such disorder with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 12. 54. A method for treating a p38 kinase mediated disorder, wherein: said method comprises treating a subject having or susceptible to such disorder with a therapeutically-effective of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 12. 55. The method of claim 54, wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthrits, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cachexia.
 56. The method of claim 54, wherein the p38 kinase mediated disorder is inflammation.
 57. The method of claim 54, wherein the p38 kinase mediated disorder is arthritis.
 58. The method of claim 54, wherein the p38 kinase mediated disorder is asthma.
 59. A method for treating inflammation, wherein: said method comprises treating a subject having or susceptible to inflammation with a therapeutically-effective of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 12. 60. A method for treating arthritis, wherein: said method comprises treating a subject having or susceptible to arthritis with a therapeutically-effective amount of a compound or a pharmaceutically-acceptable salt thereof, and said compound is selected from the group of compounds recited in claim
 12. 61. A process for making a compound, tautomer, or salt melted in claim 1, wherein: the process comprises cyclizing an acyl hydrazone to form a compound corresponding in structure to Formula IB; and the acyl hydrazone corresponds in structure to the following formula:

Formula IB, R¹, R², R³, and R⁴ are as defined in claim
 1. 62. The process according to claim 61, wherein: the acyl hydrazone is farmed by a process comprising reacting a ketone with an acyl hydrazide; and the ketone corresponds in structure to the following formula:

the acyl hydrazide corresponds in structure to the following formula:

R¹, R², R³ and R⁴ are as defined in claim
 61. 63. The process according to claim 61, wherein: the acyl hydrazone is formed by a process comprising: reacting a ketone with a hydrazine to form a substituted hydrazide, and reacting the substituted hydrazide with an acyl halide; and the ketone corresponds in structure to the following formula:

the hydrazine corresponds in structure to the following formula:

the substituted hydrazide corresponds in structure to the following formula:

the acyl halide corresponds in structure to the following formula:

X is halogen; and R¹, R², R³ and R⁴ are as defined in claim
 61. 